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RESUMO
 
Com o aumento do tempo de vida da população humana muitas 
modalidades médicas, incluindo a dermatologia, deparam-se com uma revolução 
na forma de garantir saúde e qualidade de vida aos pacientes. Em contato com o 
ambiente externo, a pele representa um órgão no qual as mudanças com o 
envelhecimento causam danos funcionais, além de potencial impacto estético e 
psicossocial. A epiderme, camada mais externa da pele, constitui uma barreira 
seletiva com destacada capacidade de renovação e manutenção da homeostasia 
corporal. Entretanto, o entendimento de diversos mecanismos associados à 
fisiologia e envelhecimento da epiderme permanece como desafio para a 
comunidade científica. Com base nesse cenário, o objetivo do presente trabalho 
foi compreender o atual estado da arte no tema de envelhecimento da epiderme e 
realizar experimentos voltados para lacunas existentes, com foco na integração de 
aspectos clínicos, fisiológicos, morfológicos, celulares e moleculares. O capítulo 
de abertura descreve uma avaliação global de transcritos associados ao 
envelhecimento da epiderme humana, com a técnica de microarranjos de DNA e 
coleta não invasiva com fitas adesivas. O estudo indica características 
moleculares específicas do fotoenvelhecimento epidermal, com alterações 
relevantes e complementares a dados clínicos e morfológicos prévios, como 
modulação das vias de organização do citoesqueleto de actina e sinalização de 
cálcio, expressão gênica alterada de proteínas do envelope córneo, e avaliação de 
um painel segmentado por décadas de vida que sugere aspectos inéditos de 
regulação homeostática da epiderme, além de genes com modulação contínua ao 
longo das idades. O segundo capítulo compara o envelhecimento nas regiões 
folicular e interfolicular da epiderme. Como um sistema biológico de simples 
obtenção e fácil manuseio, os bulbos dos folículos pilosos representam uma fonte 
rica de material epidermal distinto, conforme evidencias na ampla modulação 
gênica diferenciada. O terceiro capítulo inclui uma avaliação in vitro do 
envelhecimento da epiderme, com queratinócitos de indivíduos de diferentes 
idades cultivados em monocamada e no modelo de pele equivalente. Os 
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resultados evidenciam diferenças na expressão de marcadores moleculares de 
proliferação e diferenciação entre queratinócitos neonatais e adultos, mas não 
entre adultos de diferentes idades. Não houve diferença nas populações de 
células tronco, entretanto, observou-se aumento de células na fase proliferativa do 
ciclo celular em neonatos, assim como predominância de células na fase 
estacionária do ciclo celular em adultos mais velhos. Concluindo, os resultados 
obtidos no presente trabalho contribuem de forma significativa para o avanço do 
entendimento dos mecanismos moleculares afetados pelo avanço da idade da 
epiderme, possilitando a busca de novas alternativas no tratamento do 
envelhecimento cutâneo. 
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ABSTRACT 
 
With the increase in lifetime of the human population many medical 
disciplines, including dermatology, are facing a revolution in the approaches to 
ensure healthcare and quality of life for patients. In contact with the external 
environment, the skin is an organ in which the changes of aging cause functional 
damage, in addition to potential aesthetic and psychosocial impact. Epidermis, the 
outermost skin layer, is a selective barrier with outstanding capacity for renewal 
and maintenance of the body homeostasis. However, the understanding of several 
mechanisms associated with skin physiology and aging remains a challenge for the 
scientific community. Considering this scenario, the objective of this work was to 
evaluate the state of the art knowledge on epidermal aging and to conduct 
experimental approaches to cover gaps that still exist on that theme, focusing on 
the integration of clinical, physiological, morphological, cellular and molecular 
aspects of epidermis aging. The opening chapter describes a study based on 
global transcriptional evaluation associated with aging of the human epidermis, 
using DNA microarrays and noninvasive tape stripping. This study reveals 
molecular characteristics specific of epidermal photoaging, with relevant findings 
complementary to previous clinical and morphological data, such as modulation of 
the actin cytoskeleton and calcium signaling pathways;  altered gene expression of 
proteins of the cornified envelope; and evaluation of a segmented panel structured 
by decades of life, which suggests new aspects of homeostatic regulation in the 
epidermis and unvails genes with continuous modulation throughout different ages. 
The second chapter compares the gene expression patterns of the follicular and 
interfollicular regions of epidermis undergoing aging. As a biological system easily 
sampled and handled, the bulbs of plucked hair follicles represent a rich source of 
distinct epidermal material, as evidenced by the wide differential gene modulation 
that was detected. The third chapter includes an experimental in vitro evaluation of 
skin aging using keratinocytes isolated from individuals of different ages and 
cultured in monolayer and in skin equivalent models. Differences in the expression 
of proliferation and differentiation molecular markers between neonatal and adult 
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keratinocytes were observed. No differences were found regarding the stem cell 
populations, however, neonates showed an increased percentage of cells in the 
proliferative phase of cell cycle, while older adults presented a predominance of 
cells in the stationary phase of cell cycle. The results herein presented provide 
novel insights on the molecular mechanisms affected by epidermal aging, enabling 
the search of new alternatives in the treatment of aging skin. 
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1. INTRODUÇÃO 
 
1.1. Conceituação do envelhecimento humano 
 
A complexidade do envelhecimento humano pode ser analisada a partir de 
diferentes abordagens conceituais e teóricas. Segundo Santin (2010), a questão 
do envelhecimento se estende em todos os níveis das ciências humanas, das 
ciências econômicas, das ciências jurídicas e das políticas sociais. O termo 
envelhecimento conota movimento, remetendo a um processo de chegar à 
velhice, ou de se tornar velho. Em relação aos seres vivos, envelhecimento 
significa aproximar-se do fim da vida. De acordo com Del-Masso (2010), 
envelhecer é chegar pouco a pouco a um período mais avançado da vida ou 
perder a jovialidade e a beleza, além das possíveis perdas das habilidades 
cognitivas. É inquestionável que o processo de envelhecimento provoca no 
organismo modificações biológicas, psicológicas e sociais. Entretanto, é nas 
idades mais avançadas que esse processo torna-se mais evidente, o que faz com 
que a própria velhice seja mais notada do que o processo de envelhecimento. Por 
isso é mais fácil reconhecer o estágio final do envelhecimento, normalmente com 
base nas aparências físicas (Santin, 2010). 
A constituição do envelhecimento humano, como um objeto distinto de 
estudo é relativamente recente, incluído como uma parte importante da 
gerontologia e da geriatria. A gerontologia não trata apenas do velho ou da 
velhice, ela inclui os fenômenos que levam à velhice. A geriatria, por sua vez, não 
trata apenas das doenças dos idosos, mas se preocupa, também, com as 
prevenções destas doenças (Santin, 2010). Do ponto de vista biológico, o 
envelhecimento é um processo complexo e contínuo que se caracteriza por 
alterações celulares e moleculares, com diminuição progressiva da capacidade de 
homeostase do organismo (Bagatin, 2008). Os fatores que interferem no 
envelhecimento podem ser intrínsecos (determinados pela constituição genética 
individual) e extrínsecos (exposições ambientais). Embora os mecanismos 
fundamentais envolvidos na patogênese do envelhecimento ainda necessitem de 
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mais estudos, uma massa crescente de evidências aponta para o fato de que 
múltiplas vias e vários elementos estão envolvidos no processo de envelhecimento 
celular e molecular (Makrantonaki e Zouboulis, 2007; Zouboulis e Makrantonaki, 
2011). Sabe-se que o acúmulo de radicais livres e o estresse oxidativo que ocorre 
com a idade, contribuem para o fenótipo senil provocando alterações no 
organismo como desenvolvimento de tumores malignos, arteriosclerose, doenças 
neurodegenerativas e artrite reumatóide (Dröge, 2002). Outra causa descrita para 
o envelhecimento é o aumento da atividade inflamatória crônica, com o acúmulo 
de substâncias que desencadeiam uma série de danos teciduais (Caruso et al., 
2004). 
No que se refere às descrições de processos moleculares associados ao 
envelhecimento, alguns mecanismos relacionados são: encurtamento e ruptura 
dos telômeros (Buckingham e Klingelhutz, 2011), perda de metilação no DNA com 
alteração na taxa de proliferação celular (Richardson, 2003; Bollati, 2009), 
acúmulo de mutações genéticas (como no gene de p53), alterações hormonais e 
alterações inflamatórias (Giacomoni, 2005). Johnson (2006) relata marcadores 
biológicos do envelhecimento que, mesmo na ausência de quadro patológico, 
representam indicativos da perda de capacidade funcional do organismo. O 
aumento de citocinas pró-inflamatórias (IL-1, IL-6 e TNF-α), diminuição da 
testosterona sérica, antioxidantes, alelos da apolipoproteína E, deleções no DNA e 
sinalizadores de resposta ao estresse são alguns exemplos destes marcadores. 
 
1.2. Envelhecimento populacional 
 
O tempo médio de sobrevida humana tem aumentado consideravelmente 
nas últimas décadas, sendo que os idosos passam a representar uma parcela 
significativa da população e o surgimento de indivíduos centenários não 
representa mais uma raridade (Farage et al., 2010). De acordo com a Organização 
das Nações Unidas (ONU) (www.onu.org.br), uma transição única e irreversível do 
processo demográfico deve resultar em populações mais velhas em todos os 
lugares, sendo que a proporção de pessoas com 60 anos ou mais deve triplicar, e 
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o número de pessoas acima dos 80 anos deve quadruplicar na maior parte dos 
países até 2050. As estimativas do Fundo de População das Nações Unidas 
(UNFPA) (www.unfpa.org.br) também apontam que em 2050 80% das pessoas 
mais velhas do mundo viverão em países em desenvolvimento e a população com 
mais de 60 anos de idade será maior que a população com menos de 15. 
No Brasil esta não é uma realidade distinta. O envelhecimento da 
população brasileira apresenta características de um processo acelerado, em 
ritmo significativamente maior se comparado com aquele já observado em 
diversos países europeus (Carvalho e Garcia, 2003). Com um perfil estável até os 
anos 60, o Brasil apresentava uma população jovem: 52% abaixo de 20 anos, e 
menos de 3% acima dos 65. A partir de então, um rápido e generalizado declínio 
da fecundidade foi o principal fator responsável pelo com estreitamento contínuo 
da base da pirâmide etária, que torna os grupos etários mais velhos 
proporcionalmente maiores em relação a toda a população (Carvalho e Garcia, 
2003). Embora a menor fecundidade seja a principal responsável pelo 
envelhecimento populacional, o aumento da longevidade também contribui, de 
forma secundária, para esse fenômeno. Segundo dados publicados pelo Instituto 
Brasileiro de Geografia e Estatística (IBGE) em 29 de agosto de 2013 
(www.ibge.gov.br/home/estatistica/populacao/projecao_da_populacao/2013/defaul
t.shtm), a esperança de vida ao nascer, que em 2013 chegou a 71,3 anos para 
homens e 78,5 anos para mulheres, em 2060, deve atingir 78,0 e 84,4 anos, 
respectivamente, o que representa um ganho de 6,7 anos médios de vida para os 
homens e 5,9 anos para as mulheres. 
Além de representar uma mudança significativa em termos 
socioeconômicos, o novo perfil populacional impacta na atuação de diversas 
modalidades médicas, visando promover a saúde e bem-estar de todos. Buscando 
alternativas multidisciplinares para combater o problema, profissionais de 
diferentes modalidades agrupam-se, como na Sociedade Brasileira para o Estudo 
do Envelhecimento (SOBRAE) (www.sobrae.com.br), que inclui dermatologistas, 
médicos esteticistas, do trabalho, do exercício e do esporte. De fato, os cuidados 
geriátricos tem se tornado uma questão de saúde mundial (Thapa et al., 2012). 
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1.3. Dermatologia e o envelhecimento cutâneo 
 
A dermatologia representa uma das áreas médicas mais impactadas pelo 
envelhecimento populacional, uma vez que o envelhecimento cutâneo pode 
causar danos funcionais, além de potencial impacto estético e psicossocial. A pele 
representa um sistema complexo e dinâmico, no qual alguns sinais do processo 
de envelhecimento natural são notados visivelmente.  
Diversas doenças da pele associadas ao envelhecimento não representam 
condições letais, mas podem comprometer a qualidade de vida dos indivíduos 
afetados. As erupções pruriginosas crônicas, por exemplo, podem diminuir a 
autoestima, deixar o portador em situações constrangedoras, interferir no sono, e 
muitas vezes, provocar depressão, isolamento social e deterioração da aparência, 
além de representar uma condição desconfortável e, não menos importante, 
possuir elevado custo de tratamento. Outras características observadas na pele 
envelhecida são a capacidade reduzida de cicatrização, o enfraquecimento da 
imunidade local que aumenta o risco de infecções, uma maior lentidão na resposta 
a tratamentos e um aumento na predisposição a reações adversas (Farage et al., 
2010). De impacto mais drástico, a pele envelhecida apresenta maior disposição 
para o desenvolvimento de tumores, exigindo maiores cuidados principalmente 
quanto à exposição solar (Tsatsou et al., 2012). 
Com o envelhecimento da população mundial, a elevação da qualidade de 
vida e, portanto, o prolongamento do período ativo e produtivo dos indivíduos, a 
aparência da pele toma cada vez mais importância para garantir a segurança e 
confiança dos indivíduos no convívio social. Muitas vezes, a aceitação do 
envelhecimento humano não é uma das tarefas simples, já que os indivíduos 
costumam acreditar que só os outros envelhecem e que eles devem permanecer 
eternamente jovens ou maduros (Del-Masso, 2010). Dessa forma, a busca por 
tratamentos estéticos para reverter os sinais do envelhecimento cutâneo, como a 
formação de rugas ou o aparecimento de manchas, tem aumentado muito em 
consultórios dermatológicos ou mesmo no mercado cosmético (Wollina et al., 
2008). Entretanto, apesar das diversas opções terapêuticas disponíveis, muitas 
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delas carecem de legitimidade científica, levando ao questionamento sobre a real 
fundamentação da abordagem dermatológica anti-idade (Kreyden, 2005). 
 
1.4. Funções, estrutura e tipos de pele 
 
A pele é o maior órgão do corpo humano, representando 15% do peso total, 
e responsável por seu revestimento e proteção. Apesar de amplamente descrita, a 
estrutura básica da pele foi revisada no Anexo 1 devido à sua importância no tema 
central deste trabalho. Além disso, uma revisão detalhada abrangendo diversos 
aspectos anatômicos, histológicos e imunohistoquímicos da pele humana normal 
pode ser conferida no trabalho de Kanitakis (2002). Em decorrência de sua 
arquitetura e propriedades físicas, químicas e biológicas, a pele é responsável por 
diversas atividades, tais como proteção imunológica, termorregulação, percepção 
sensorial, secreção e proteção contra radiação solar (Mota, 2006). 
A estrutura da pele é formada por duas camadas principais: epiderme e 
derme. Adjacente, encontra-se o tecido subcutâneo ou tecido adiposo, algumas 
vezes descrito na literatura como uma terceira camada cutânea (Figura 1). 
 
  
Figura 1. Estrutura morfológica da pele, indicando suas camadas e os principais elementos 
presentes em cada uma delas. 
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 A epiderme representa a porção mais externa da pele, formada por diversas 
camadas celulares justapostas e organizadas em uma estrutura multilamelar. 
Compondo uma verdadeira barreira seletiva, a epiderme controla as trocas de 
moléculas entre o interior do corpo e o ambiente externo. Majoritariamente 
formada por queratinócitos (~85% das células totais), possui também melanócitos, 
células de Langerhans e células de Merkel. Por sofrer um constante processo de 
descamação, a epiderme precisa ser renovada continuamente (Milstone, 2004). A 
renovação inicia-se com a multiplicação de células proliferativas (epidermopoiese) 
na porção mais interna da epiderme, a camada basal, originando os queratinócitos 
que passam por um processo de diferenciação à medida que são empurrados 
para a superfície epidermal pela ocorrência de novas divisões celulares na 
camada basal, em um processo que leva em torno de quatro semanas para se 
completar (Figura 2) (Fuchs e Raghavan, 2002). A diferenciação dos 
queratinócitos é marcada por mudanças de cunho molecular, estrutural e 
funcional, dando origem a uma epiderme estratificada do interior à superfície 
corporal, composta por camada basal, camada espinhosa, camada granulosa e 
estrato córneo (Fuchs e Raghavan, 2002; Simpson et al., 2011). Em algumas 
áreas, como palmas das mãos e solas dos pés, é possível observar uma camada 
extra, conhecida como estrato lúcido, entre a camada granulosa e o estrato córneo 
(Brohem et al., 2011). No estrato córneo, os queratinócitos atingem seu ponto 
máximo de diferenciação, podendo ser chamados de corneócitos: células mortas, 
anucleadas e de morfologia achatada, que representam blocos de proteínas e 
lipídios, unidos entre si e mergulhados em uma matriz lipídica (Eckhart et al., 
2013). Muito mais que um elemento de proteção mecânica, a epiderme representa 
um tecido metabolicamente ativo que passa periodicamente por ciclos de 
renovação completa, em constante equilíbrio dinâmico (Fuchs e Raghavan, 2002). 
Alguns autores consideram o funcionamento da epiderme como paradoxal, 
exibindo grande estabilidade para proteção do organismo contra agressões 
externas ao mesmo tempo em que mantém considerável flexibilidade de seus 
componentes celulares para garantir regeneração tecidual e capacidade de 
resposta a diferentes estímulos (Simpson et al., 2011). Devido a tal capacidade, a 
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epiderme representa um componente decisivo na manutenção da homeostasia 
corporal, com funções de: 1) barreira de proteção contra insultos mecânicos e 
químicos (Lulevich et al., 2010; Kirschner et al., 2013), 2) manutenção do equilíbrio 
hidro-iônico do organismo (Proksch et al., 2008; Kirschner et al., 2013), 3) defesa 
imunológica contra patógenos e eliminação de toxinas (Geusau et al., 2001; 
Baroni et al., 2012; Polak et al., 2013), e 4) proteção contra radiação solar e 
atividade antioxidante (Shindo et al., 1994; Yamaguchi et al., 2006). 
 
 
Figura 2. Esquema representativo do processo de renovação epidermal. 
 
A derme representa a porção interna da pele, cuja estrutura é rica em 
elementos de matriz extracelular, como as fibras de colágeno e elastina, 
apresentando também vasos sanguíneos, vasos linfáticos e terminações 
nervosas. Basicamente, a derme é responsável por todo o tipo de sustentação da 
pele, em termos físicos e nutricionais, representando cerca de 90% da espessura 
cutânea. A derme apresenta espessura variável de acordo com a região do corpo 
observada, apresentando duas regiões distintas: a papilar (superficial, delgada e 
composta de tecido conjuntivo frouxo com fibras mais esparsas) e a reticular (mais 
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profunda, espessa e composta de tecido conjuntivo denso com estrutura fibrilar 
mais compactas). Os fribroblastos representam o principal tipo celular residente na 
derme, responsáveis pela síntese de diversos componentes da matriz extracelular, 
incluindo proteínas e outros elementos da substância fundamental amorfa (tais 
como fluido intersticial e complexos de glicosaminoglicanos e proteínas, 
denominados proteoglicanos e glicoproteínas). Além disso, a derme também 
apresenta células relacionadas à defesa imunológica, incluindo células dendríticas 
e diversos outros tipos celulares não permanentes que migram para derme a partir 
dos vasos sanguíneos em situações específicas como no caso das respostas 
inflamatórias (incluindo macrófagos e neutrófilos) (Farage et al., 2010). 
Para uma correta funcionalidade da pele, a comunicação entre suas duas 
principais camadas é essencial. Ao captar sinais do ambiente externo, a epiderme 
aciona mecanismos específicos, como no caso da produção de citocinas frente à 
radiação ultravioleta, que atingem a derme e estimulam uma resposta biológica. A 
ativação desta cascata de sinalizações intra e intercelulares, pode gerar estímulos 
em feedback para a epiderme, formando um ciclo de interações contínuas e 
regulação mútua entre as camadas (Brohem e Lorencini, 2014). Ainda, a derme 
com sua rica estruturação fibrosa e a presença de vasos sanguíneos, fornece 
constante suporte e garante o abastecimento de nutrientes para manutenção 
viável da epiderme. A manutenção do equilíbrio hidro-iônico é mais um exemplo 
funcional das interações entre epiderme e derme. As trocas de água entre os 
diferentes compartimentos da pele e o meio externo, dependem de três fatores: 1) 
umidade do meio externo, 2) capacidade de substituir a perda de água por 
evaporação (movimento de água de dentro para fora, a partir dos vasos 
sanguíneos) e 3) habilidade intrínseca do estrato córneo de impedir ou reduzir a 
perda de água transepidérmica (Bouwstra et al., 2008). Para que tudo isso ocorra, 
são estabelecidas redes de sinalizações complexas formadas entre os dois 
componentes celulares principais da pele: queratinócitos e fibroblastos. Essas 
interações têm se demonstrado fundamentais para inúmeros processos, tais como 
crescimento e diferenciação de células, reparação tecidual, cicatrização de feridas, 
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além do desenvolvimento e tratamento de diversas doenças (Brohem e Lorencini, 
2014). 
Complementando as atribuições funcionais da epiderme e derme, o tecido 
subcutâneo ou adiposo representa uma camada de células com elevada 
capacidade de armazenamento energético na forma de lipídeos, além de exercer 
papel de proteção mecânica e auxílio no controle da temperatura. Além das 
camadas, a pele também apresenta seus anexos, como as glândulas sudoríparas 
e os folículos pilossebáceos (unidades compostas pela associação de folículos 
pilosos e glândulas sebáceas) (Farage et al., 2010). 
A pele pode ser classificada em diferentes tipos com base em critérios 
como: 1) produção de sebo e hidratação ou 2) coloração. Considerando a 
produção de sebo e hidratação, a Sociedade Brasileira de Dermatologia (SBD) 
(www.sbd.org.br) define quatro tipos de pele: 
 Normal, tipo de pele menos frequente com textura saudável e aveludada, 
elasticidade ideal e quantidade adequada de gordura natural, aspecto rosado, com 
poros pequenos e pouco visíveis, pouco propensa ao desenvolvimento de 
espinhas e manchas; 
 Seca, caracterizada pela perda de água em excesso, normalmente com 
poros poucos visíveis, pouca luminosidade e mais propensa à descamação e 
vermelhidão, maior tendência ao aparecimento de pequenas rugas e fissuras, 
podendo ser causada por fatores genéticos e hormonais, assim como condições 
ambientais (tempo frio ou seco, vento, radiação ultravioleta ou até mesmo banhos 
demorados e com água quente); 
 Oleosa, com aspecto mais brilhante, úmido e espesso por causa da 
produção de sebo maior do que o normal, poros dilatados e maior tendência à 
formação de acne, cravos e espinhas, podendo ser causada por fatores genéticos, 
alterações hormonais, excesso de sol, estresse e dieta rica em alimentos com alto 
teor de gordura; 
 Mista, tipo de pele mais frequente, com aspecto oleoso e poros dilatados na 
“zona T” (testa, nariz e queixo) e seco nas bochechas e extremidades, tem 
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espessura mais fina, com tendência à descamação e ao surgimento de rugas finas 
e precoces. 
A coloração da pele resulta de uma combinação de fatores como a 
espessura das camadas celulares e a quantidade de pigmentos, com destaque 
para a melanina produzida pelos melanócitos da epiderme. A quantidade de 
melanina sintetizada tem forte influência de componentes genéticos, mas também 
pode ser modulada por fatores como idade, ocorrência de resposta inflamatória, 
variações hormonais e influências ambientais como tabagismo, alcoolismo, 
poluição e exposição à radiação solar. Além disso, a produção de melanina pode 
ser regulada em diferentes estágios biomoleculares como o nível de atividade da 
tirosinase nos melanócitos (principal enzima envolvida na síntese de melanina), 
mudanças na rota biossintética (podendo originar pigmentos mais claros de 
feomelanina ou pigmentos mais escuros de eumelanina) e na transferência de 
pigmentos produzidos para os queratinócitos (Mota, 2006). Com base na 
coloração da pele e sua reação à exposição solar, a SBD adota a escala 
Fitzpatrick (Figura 3) para classificação dos fototipos cutâneos, criada em 1976 
pelo dermatologista e diretor do departamento de Dermatologia da Escola de 
Medicina de Harvard: Thomas B. Fitzpatrick. Tal escala considera seis fototipos 
cutâneos, sendo eles: 
 Fototipo I, com pele branca que sempre queima, nunca bronzeia e é muito 
sensível ao sol; 
 Fototipo II, com pele branca que sempre queima, bronzeia muito pouco e é 
sensível ao sol; 
 Fototipo III, com pele morena clara que queima (moderadamente), bronzeia 
(moderadamente) e tem sensibilidade normal ao sol; 
 Fototipo IV, com pele morena moderada que queima (pouco), sempre 
bronzeia e tem sensibilidade normal ao sol; 
 Fototipo V, com pele morena escura que queima (raramente), sempre 
bronzeia e é pouco sensível ao sol; 
 Fototipo VI, com pele negra que nunca queima, totalmente pigmentada e é 
insensível ao sol. 
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Figura 3. Escala de Fitzpatrick para classificação dos seis fototipos cutâneos. Adaptado de 
www.laserdocs.co.uk. 
 
1.5. Mudanças cutâneas com o envelhecimento 
 
Por representar um órgão em contato direto com o ambiente externo, a pele 
está frequentemente exposta à ação de agentes agressores. Essa exposição ao 
longo do tempo pode refletir diretamente na velocidade de envelhecimento 
cutâneo, caracterizado pela formação de rugas e além de perda de resistência e 
elasticidade. Em pessoas com exposição constante à radiação solar, por exemplo, 
tais efeitos tendem a ser mais pronunciados ou acelerados (Scharffetter-Kochanek 
et al., 2000). Waller e Maibach (2005 e 2006) fizeram um compilado das principais 
modificações que afetam a estrutura da pele com o avanço da idade, incluindo 
tendência de diminuição do fluxo sanguíneo, redução da espessura de derme e 
epiderme, alterações na organização das fibras colagênicas e elásticas, 
diminuição na atividade de enzimas que atuam em processos de modificação pós-
traducional, formação de agregados proteicos, modificações na deposição de 
glicosaminoglicanos que tendem a interagir menos com moléculas de água e 
mudanças no conteúdo lipídico. 
Quanto aos aspectos clínicos, o envelhecimento da pele é caracterizado por 
atrofia tecidual e rugas finas, com comprometimento de fibras elásticas e 
surgimento de elastose na derme reticular. A exposição constante à radiação solar 
promove o aparecimento de sinais intensificados, ocorrendo formação de rugas 
mais profundas, espessamento da pele, amarelamento, ressecamento, surgimento 
de melanoses, telangiectasias, poiquilodermia, queratoses actínicas e aumento da 
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probabilidade de ocorrência de câncer. Ainda, as rugas derivadas de efeito direto 
da ação excessiva da radiação solar podem corresponder a até 85% daquelas 
presentes na pele envelhecida (Bagatin, 2008). Intrinsicamente, ao longo dos 
anos, a pele também apresenta mudanças que podem ser observadas em suas 
diferentes camadas (Figura 4). Ocorrem alterações como redução de gordura no 
tecido subcutâneo, aumento de substância elastolítica na derme superior, 
destruição da estrutura fibrilar, aumento da quantidade de substância intercelular e 
infiltrado inflamatório moderado. Em um trabalho amplo, que avaliou 45 amostras 
de pele distintas de homens e mulheres com idades entre 17 e 81 anos, foi 
observado que, com o envelhecimento há uma diminuição na espessura e na 
quantidade de camadas de células viáveis na epiderme, aumento na quantidade 
de grânulos querato-hialinos, achatamento da junção dermo-epidermal, maior 
presença de material elastolítico na derme, aumento de infiltrado inflamatório com 
presença de trabéculas fibrosas mais espessas e atrofia da hipoderme. O 
envelhecimento cronológico também afeta o metabolismo de fibroblastos, 
reduzindo seu tempo de vida, capacidade de divisão celular e potencial de 
produção de colágeno. Ainda, durante o envelhecimento, o aumento da espessura 
das fibrilas de colágeno diminui a elasticidade da pele (Levakov et al., 2012).  
 
 
Figura 4. Análise histológica do envelhecimento cutâneo, com destaque para características como 
redução da espessura epidermal, achatamento da junção dermo-epidermal e desestruturação de 
fibras na derme. (A) Pele jovem (indivíduo de aproximadamente 30 anos). (B) Pele envelhecida 
(indivíduo de aproximadamente 60 anos). 
A B 
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Trabalhos relacionados ao estudo de síndromes de envelhecimento 
precoce ou síndromes progeróides também têm contribuído com o entendimento 
da importância de alguns genes no avanço do envelhecimento cutâneo, como no 
caso das síndromes de Hutchinson-Gilford, Werner, Bloom, Cockayne etc. Estes 
estudos, particularmente no caso da síndrome de Hutchinson-Gilford, que 
representa a forma mais dramática de envelhecimento prematuro, têm apontado 
para processos chave no avanço do envelhecimento cutâneo, incluindo 
mecanismos de transcrição, replicação e reparo do DNA, instabilidade genômica, 
senescência celular, ciclo celular, apoptose, função mitocondrial, proteólise 
mediada por ubiquitina, matriz extracelular, síntese de lipídeos, metabolismo 
celular e diferenciação de células-tronco (Makrantonaki e Zouboulis, 2007; Capell 
et al., 2009; Zouboulis e Makrantonaki, 2011). 
Apesar das diversas descrições de efeitos do envelhecimento sobre a pele, 
a maioria dos trabalhos permanece focada na derme e na desorganização de sua 
estrutura rica em matriz extracelular (Luebberding et al., 2012). 
 
1.6. Mudanças funcionais e moleculares da epiderme com o 
envelhecimento 
 
Há diversas mudanças que acometem a função de barreira da epiderme 
com o envelhecimento (Ramos-e-Silva et al., 2012). Um estudo recente realizado 
com 150 mulheres entre 18 e 80 anos observou que, com o aumento da idade, há 
uma queda contínua na produção de sebo e diminuição no valor de pH, com 
significativo aumento detectado em mulheres de 50 a 60 anos, período típico da 
ocorrência de menopausa, mas sem mudanças na perda de água transepidermal 
ou no nível de hidratação do estrato córneo (Luebberding et al., 2012). Alguns 
trabalhos apontam a redução da espessura da epiderme que surge com o 
envelhecimento como decorrente da diminuição da quantidade e/ou atividade de 
células tronco na camada basal ou na região dos folículos pilosos. Este tema é 
bastante discutido na comunidade científica e há concordância quanto ao fato de 
que a homeostase das células-tronco da epiderme pode mudar com o 
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envelhecimento, embora os mecanismos específicos relacionados a este processo 
ainda não sejam bem esclarecidos. No trabalho de Lock-Andersen et al. (1997) é 
evidenciado que a espessura do estrato córneo não varia entre grupos de jovens e 
idosos, mas há uma redução na chamada epiderme celular, formada pelos 
estratos que apresentam células viáveis. Outros trabalhos também apontam 
evidências de um aumento no número de células-tronco com a idade, embora 
descrevam a ocorrência, em paralelo, de um decréscimo na função e atividade 
metabólica das mesmas. Um estudo demonstrou que há um desequilíbrio na via 
de sinalização Jak-Stat e na produção de citocinas das células-tronco epidermais, 
de forma que o declínio em sua funcionalidade poderia ser compreendido como 
um mecanismo para a supressão de tumores que poderiam surgir com o avanço 
da idade (Doles et al., 2012). Outros trabalhos evidenciam o afinamento da 
epiderme com o avanço da idade associado à redução na capacidade proliferativa 
das células e ao aumento na taxa de apoptose, sendo este último mecanismo 
reforçado pela observação do aumento na expressão de Fas (Gilhar et al., 2004; 
El-Aal et al., 2012). Ainda, há observações demonstrando que, com a idade, não 
há alterações na atividade das células-tronco da epiderme, sendo que as mesmas 
mantêm suas características ao longo do envelhecimento cutâneo, diferentemente 
do que ocorre com as chamadas células amplificadoras transientes. Neste caso, o 
aumento da quantidade destas células pode ser interpretado como um mecanismo 
compensatório para a queda de sua atividade, buscando uma manutenção das 
funções da epiderme (Liang et al., 2004; Stern e Bickenbach, 2007; Charruyer et 
al., 2009). 
Um estudo desenvolvido por Schmuth et al. (2005) demonstrou que existem 
diferenças na produção de proteínas transportadoras de ácidos graxos na 
epiderme quando comparados tecidos de origem embrionária e adulta, indicando 
uma regulação dinâmica destes constituintes ao longo do desenvolvimento. A 
atividade de esfingomielinase também é reduzida, sendo que indivíduos de 80 
anos apresentam 25% da atividade encontrada em indivíduos de 20 anos, 
reforçando como o envelhecimento compromete o metabolismo de lipídeos na 
epiderme (Yamamura e Tezuka, 1990). Como um elemento essencial para a 
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diferenciação dos queratinócitos e manutenção da homeostase da barreira 
cutânea, a distribuição de cálcio entre as camadas da epiderme na face também 
parece variar com a idade. Na pele jovem e saudável, há um gradiente de cálcio 
caracterizado por uma baixa concentração nas camadas mais internas (camada 
basal e estrato espinhoso) com um aumento na disponibilidade extra e intracelular 
de cálcio que atinge um pico de maior concentração no estrato granuloso. Em 
amostras de pele de indivíduos mais velhos, entretanto, o cálcio apresenta-se 
distribuído igualmente entre todas as camadas da epiderme, sem a formação do 
gradiente observado na pele jovem, sugerindo uma disfunção em bombas ou 
canais iônicos que pode culminar com as alterações morfológicas tipicamente 
observadas com o avanço do envelhecimento cutâneo (Denda et al., 2003). 
Outros achados apontam para diferenças na eliminação de danos 
provocados por radiação na epiderme quando amostras de indivíduos de 
diferentes idades são comparadas. No estudo de Yamada et al. (2006) foi 
verificado por imunohistoquímica e immunoblotting que a remoção de dímeros de 
pirimidina induzidos por UVB acontece de forma mais lenta na epiderme de 
indivíduos mais velhos. No grupo de 22 a 26 anos, o tempo de remoção completa 
dos dímeros foi de 4 dias, frente a 14 dias no grupo de 70 a 78 anos. Os 
resultados indicaram que a idade é um fator mais importante que a dose de 
radiação para a remoção dos dímeros de pirimidina da epiderme. Além das 
modificações que acometem os queratinócitos, estudos também apontam para 
mudanças associadas ao envelhecimento que afetam outros tipos celulares 
presentes na epiderme, como uma redução no número de melanócitos (com 
redução de 10 a 20% a cada década depois dos 25-30 anos) e células de 
Langerhans, comprometendo as funções de proteção contra radiação ou 
imunológica da pele (Ortonne, 1990; Wulf et al., 2004). Assim como em outros 
tecidos ou outras doenças, os estudos baseados em biologia molecular e 
expressão dos genes ainda precisam ser mais bem explorados para explicar os 
fenômenos que acometem a epiderme ao longo do envelhecimento. Sabe-se, por 
exemplo, que o nível de detecção da filagrina por imunohistoquímica diminui em 
amostras de epiderme com idades mais avançadas. Entretanto, o nível de 
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expressão gênica da filagrina não parece ser afetado pela idade. Ainda, avaliando 
a disponibilidade de aminoácidos derivados da degradação enzimática da filagrina 
para a formação dos fatores naturais de hidratação (NMF), foi verificado que a 
quantidade total de aminoácidos no estrato córneo de indivíduos mais velhos foi 
maior que nos jovens, sugerindo que a redução na disponibilidade de filagrina 
preconizada pelo avanço da idade pode ser derivada de sua proteólise nas 
camadas superiores do estrato espinhoso e não de alterações referentes à 
diminuição na expressão gênica (Takahashi e Tezuka, 2004). Este exemplo ilustra 
bem a necessidade de se esclarecer mecanismos moleculares para a melhor 
compreensão e talvez até para o desenvolvimento de terapias específicas para o 
tratamento da epiderme. 
 
1.7. Evolução contínua em biologia molecular impacta na dermatologia 
 
Com a conclusão do Projeto Genoma Humano, novas perspectivas foram 
abertas para ajudar as gerações futuras a viver melhor e atingir idades superiores 
aos 100 anos com a dignidade almejada. Assim como nas outras áreas, a 
dermatologia também foi impactada pelos avanços científicos da revolução 
genética. Nos últimos anos o número de publicações científicas abordando o tema 
“expressão gênica” aplicado aos cuidados da pele aumentou consideravelmente. 
Além disso, a biologia molecular tem estado mais presente na abordagem do 
envelhecimento cutâneo, que, como um processo altamente complexo, envolve a 
ação simultânea e contínua de diversos fatores que desencadeiam uma 
diminuição progressiva da capacidade homeostática da pele. Considerando tudo 
isso associado à própria complexidade histológica da pele, os estudos nesta área 
vêm sendo muito favorecidos pela aplicação de tecnologias de avaliação global 
dos fenômenos biológicos. A utilização destas tecnologias deu origem ao termo 
“skinomics”, referindo-se à avaliação global de moléculas biológicas associadas ao 
desenvolvimento e funcionalidade cutânea (Blumenberg, 2005). 
Aliada ao avanço dos estudos da pele e suas alterações, a biologia 
molecular também oferece vantagens para o desenvolvimento de tratamentos 
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mais eficazes no combate ao envelhecimento cutâneo. A farmacogenômica 
representa uma nova área que surgiu a partir destes conceitos, envolvendo a 
aplicação de tecnologias como o sequenciamento de DNA, análise da expressão 
gênica e técnicas estatísticas em pesquisas e testes relacionados a fármacos ou 
ingredientes. Um dos princípios defendidos pela farmacogenômica é o 
desenvolvimento da chamada medicina personalizada, onde fármacos e suas 
combinações são otimizados em uma composição única para cada indivíduo 
(Squassina et al., 2010). Esta nova perspectiva permite levar em consideração as 
variações individuais tanto na identificação das necessidades, como na escolha 
dos ativos e acompanhamento da resposta de um indivíduo ao tratamento 
escolhido na busca da máxima assertividade e eficácia. Mais uma vez, as 
tecnologias inovadoras derivadas da revolução genética têm favorecido ainda 
mais o avanço e detalhamento dos conceitos de farmacogenômica aplicados à 
dermatologia (Rizzo e Maibach, 2012). 
 
1.8. Justificativa e estrutura do trabalho 
 
De fato, as mudanças nas propriedades físicas de diversos tecidos do corpo 
humano com o avanço da idade vêm sendo descritas há algumas décadas. Muitos 
trabalhos já avaliaram as mudanças que acometem a organização da matriz 
extracelular dérmica, associando a perda da integridade da pele a tais fenômenos. 
A importância destes estudos é indiscutível uma vez que a perda da configuração 
estrutural original da matriz extracelular pode ter impactos diretos na função 
dérmica (Bailey, 2001). De acordo com Cristofalo e Pignolo (1996), embora 
alterações na natureza dos contatos de células senescentes sejam normalmente 
atribuídas a mudanças na composição da matriz extracelular, ainda permanecem 
dúvidas quanto à produção de proteínas específicas não relacionadas à matriz ou 
de moléculas associadas à membrana. Paralelo a isso, diversas dúvidas 
permanecem com relação às mudanças provocadas pelo envelhecimento que 
podem afetar os queratinócitos na epiderme. Poucos trabalhos têm sido 
desenvolvidos no que se refere especificamente à avaliação dos efeitos do 
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envelhecimento na epiderme, mesmo em termos de avaliação de sinais clínicos da 
função de barreira (Luebberding et al., 2012). Tendo em vista a falta de 
conhecimento científico específico sobre o envelhecimento da epiderme humana, 
alguns estudos começam a surgir focados em biologia molecular, embora não 
focados na compreensão global dos mecanismos associados ao envelhecimento 
da epiderme e, geralmente, baseados em ensaios de cultivo celular in vitro 
(Gilchrest et al., 1994; Baek et al., 2003; Brégégère et al., 2003; Perera et al., 
2006). Gromov et al. (2003) desenvolveram um trabalho bastante interessante e 
complementar o que está sendo proposto na abordagem deste estudo, porém com 
análise global de proteínas associadas ao envelhecimento da epiderme. Além de 
seus achados interessantes, os autores concordam quanto às limitações 
encontradas na literatura atual para mecanismos moleculares associados ao 
envelhecimento cutâneo: a maioria dos estudos globais está concentrada em 
análises de fibroblastos, a complexidade do tecido cutâneo dificulta a interpretação 
de estudos globais (como os já realizados para tecido muscular, cerebral e 
hepático) e muitas vezes há utilização de modelos animais com baixa 
reprodutibilidade para tecido correspondente humano. 
O entendimento dos mecanismos moleculares de envelhecimento cutâneo 
pode abrir novas estratégias para o tratamento de diversas doenças que surgem 
com o avanço da idade, incluindo câncer (Makrantonaki e Zouboulis, 2007), além 
de auxiliar na busca de tratamentos estéticos intensamente procurados nas 
clínicas dermatológicas atualmente, como no caso da eliminação de rugas sem a 
necessidade de procedimentos cirúrgicos ou altamente invasivos. Apesar da 
maioria dos estudos apontar para a derme e a composição de sua matriz 
extracelular como o principal componente na determinação do envelhecimento 
cutâneo, uma redução na hidratação do estrato córneo da epiderme pode 
contribuir com a formação de rugas de 25 a 85% maiores (Flynn e Mccormack, 
2010). Além disso, uma grande parte das doenças que acometem a pele estão 
associadas a células específicas da epiderme, como no caso dos melanomas. 
Estas características fazem da epiderme um alvo rico para novos estudos 
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moleculares de espectro global, visando elucidar aspectos ainda pouco explorados 
sobre a biologia desta camada cutânea. 
O presente trabalho contém três capítulos no formato de artigos científicos 
elaborados no tema de envelhecimento epidermal. O primeiro capítulo descreve 
uma avaliação global de transcritos modulados de acordo com o envelhecimento 
da epiderme humana, utilizando a técnica de microarranjos de DNA e coleta não 
invasiva da epiderme com fitas adesivas. O segundo capítulo contém uma 
comparação dos estudos realizados sobre o envelhecimento nas regiões folicular 
e interfolicular da epiderme. O terceiro capítulo inclui uma avaliação in vitro do 
envelhecimento da epiderme, com queratinócitos de indivíduos de diferentes 
idades cultivados em monocamada e no modelo de pele equivalente. Nos 
documentos anexos, são apresentados também dois trabalhos de revisão da 
literatura, um deles representando uma análise aprofundada e abrangente, 
descrevendo os recentes avanços em biologia celular e molecular com modelos 
tradicionais da função e envelhecimento da epiderme. O outro trabalho apresenta 
uma revisão de ordem prática no tema, contemplando as alternativas terapêuticas 
possíveis para tratamento do envelhecimento epidermal. 
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2. OBJETIVOS 
 
2.1. Objetivo geral 
 
Realizar avaliação global de transcritos da epiderme humana utilizando a 
técnica de microarranjo de DNA, e buscando identificar marcadores moleculares, 
vias metabólicas ou agrupamentos gênicos diferencialmente expressos com o 
avanço da idade. 
 
2.2. Objetivos específicos 
 
 A partir de coletas de amostras de epiderme humana de mulheres de 
diferentes faixas etárias, avaliar a expressão gênica associada ao envelhecimento 
utilizando microarranjos de DNA; 
 Identificar os principais conjuntos de genes diferencialmente expressos, 
associados a processos biológicos ou a vias metabólicas moduladas pelo 
envelhecimento da epiderme; 
 Realizar análise comparativa da expressão gênica com o envelhecimento 
da epiderme obtida por técnicas distintas de coleta: fita adesiva e pelos de 
sobrancelha; 
 Estabelecer modelos experimentais in vitro com o cultivo de células 
epidermais para avaliar o efeito da idade do doador. 
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Abstract 
 
Skin is a complex system formed by the dermis and epidermis, which both 
comprise a variety of cell types. As the outer layer of skin, the epidermis forms a 
barrier on the surface of the body to protect against external aggressions and 
maintain its balance of fluids and ions. In addition to the action of external factors, 
the skin undergoes the intrinsic aging process, which governs the entire body of an 
organism. Single-target and large-scale studies have been used extensively to try 
to understand the mechanisms that underlie the skin damage caused by intrinsic 
and extrinsic factors. Nevertheless, most molecular processes remain to be 
understood. In this study, we assessed human epidermal aging in sun-exposed 
skin using non-invasive tape stripping and DNA microarrays analysis for ~20,000 
genes. To better understand the mechanisms of aging as a continuous and gradual 
process, traditional young versus old analysis was complemented by different 
strategies to evaluate a broad panel of volunteers from each decade of life 
between 20 and 80 years old, representing an unprecedented approach for 
epidermal aging evaluation. By adopting a minimal fold change (FC) value of 1.5 
and a p-value cut-off of 0.05, statistically significant differences were observed for 
3,247 distinct human genes, with 4,146 up-regulated and 717 down-regulated.  
Although the number of up-regulated genes was higher than down-regulated 
genes, 63 gene ontology (GO) terms were associated with down-regulation, and 
only 24 were associated with up-regulation. Down-regulated genes were 
predominant at FC 3.0 with a 0.05 p-value cut-off, indicating that in terms of 
significant biological process enrichment and the intensity of FC expression, down-
regulation is a critical condition for epidermal aging of sun-exposed skin. Relevant 
pathways comprising differentially expressed genes (DEGs) include the actin 
cytoskeleton (37 DEGs) and calcium signaling pathways (31 DEGs). Clustering 
analysis was performed using more stringent criteria (FC: 2.0, p-value cut-off: 0.01) 
to separate the young (20-40 years) and old groups (50-80 years). However, this 
clustering did not order the groups in a continuous and crescent sequence of ages, 
and the old group showed clear segregation into two distinct blocks, indicating that 
age-associated changes should not be interpreted as part of a linear process.  
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Analysis of specific gene expression profiles associated with each decade 
evidenced a dynamic and oscillating pattern of epidermal transcription with aging.  
A cluster with a single member, the SPRR2G gene, showed continuous increased 
expression, and a cluster with 20 members showed continuous reduced 
expression throughout a lifetime. In conclusion, the data presented in this article 
contribute to the understanding of the dramatic molecular changes that the 
epidermis experiences during aging.   
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Introduction 
 
Skinomics represents a set of global biological techniques that are applied 
to skin studies, such as genomics, transcriptomics, proteomics, and metabolomics 
(Blumenberg, 2005). Because of its accessibility, skin was one of the first targets 
analyzed by DNA microarrays, and dermatology embraced this approach early 
(Blumemberg, 2012 and 2013). Currently, several investigative strategies have 
been used to understand the molecular networks modulating skin function, 
covering aspects of health and disease and the occurrence of multifactorial 
processes such as aging (Robinson et al., 2009; Villaseñor-Park and Ortega-
Loayza, 2013). However, considering the inherent complexity of skin and the 
limitations of whole-tissue analysis, e.g., that it is not able to localize messenger 
RNAs to specific cell types, reducing the variables used in an experimental design 
may sometimes be recommended instead of extrapolating generalized conclusions 
(Mitsui et al., 2012). The epidermis and dermis are distinct skin layers in terms of 
their function, cellular and molecular composition, and even embryonic origin. This 
biological heterogeneity challenges the correct interpretation of skinomics because 
global analysis reflects a mixture of signaling pathways and molecular responses 
that occur simultaneously in different biological compartments. To avoid such 
complexity problems, some groups have worked with isolated skin layers or cells to 
achieve comprehensive results without traces of confounding material (Jansen and 
Schalkwijk, 2003; Mitsui et al., 2012). 
If skin biology studies have significant sophistication per se, the elucidation 
of skin aging-related mechanisms adds several pieces to this intricate research 
puzzle (Jansen and Schalkwijk, 2003). As a highly complex biological process 
involving cumulative deterioration, aging impairs homeostasis over a lifetime in 
different tissues and organs (Kirkwood, 2005). Although the impact of age on 
cutaneous functionality and organization has been extensively studied, little is 
known about the aging of the human epidermis, despite its essential role as the 
main functional barrier of the body where the symptoms of aging can be visually 
perceived with significant aesthetic and psychosocial implications (Farage et al., 
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2010; Sotoodian and Maibach, 2012). In fact, some “omics”-oriented studies have 
addressed the aspects of aging that affect the most abundant epidermal cell type, 
keratinocytes, by applying experimental in vitro models (Baek et al., 2003; Darbro 
et al., 2005; Perera et al., 2006; Sprenger et al., 2010). However, it is important to 
remember the differences between cultured cells and their in vivo counterparts. 
Cultured keratinocytes are less differentiated than those in vivo, and some points 
must be considered when comparing the cell biological mechanisms of in vitro 
senescence with those taking place in in vivo aging (Hwang et al., 2009; Mitsui et 
al., 2012). In addition, the dynamics of in vivo skin aging can be even more 
complex if the simultaneous influence of intrinsic factors (physiological components 
and genetic predisposition) and extrinsic factors (external insults, particularly from 
solar radiation) is considered (El-Domyati et al., 2002; Farage et al., 2008). 
Therefore, representative in vivo studies of epidermal aging are lacking, particularly 
those that employ “omics” approaches and include intrinsic and extrinsic age-
related components. 
In this study, we assessed the in vivo transcriptome of human epidermal 
aging in sun-exposed skin using non-invasive tape stripping and DNA microarrays 
analysis for ~20,000 genes. To better understand the mechanisms of aging as a 
continuous and gradual process, traditional young versus old analysis was 
complemented by different strategies to evaluate a broad panel of volunteers from 
each decade of life between 20 and 80 years old. This study represents an 
unprecedented approach for epidermal aging evaluation. 
 
Materials and methods 
 
Volunteers and samples 
 
The Research Ethics Committee institutional review board from 
Universidade Positivo, Curitiba, Brazil, approved this study, and written informed 
consent was obtained before enrolling volunteers for participation in this study, 
which was performed in compliance with the Declaration of Helsinki Principles. 
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Epidermal samples were obtained using Q-Squames Skin Sampling Discs 
(CuDerm, Dallas, TX, USA) applied to the back of the left or right hand (random 
choice) of women of different ages and skin phototype II or III according to the 
Fitzpatrick scale. Twenty-five adhesive tapes were collected from the same area of 
each volunteer; the first five were discarded, and the remaining 20 were stored in 
RNAlater solution (Ambion, Austin, TX, USA). Samples from 62 healthy women 
were used for microarray analysis (Table S1), and an independent panel of 20 
healthy women was used for real-time qPCR validation (Table S3). 
 
RNA extraction and processing 
 
RNA extraction was performed using the RNeasy Mini Kit (Qiagen, Hilden, 
Germany). Tape strips, two at a time, were agitated in Tissuelyser LT (Qiagen) for 
5 minutes at 50 Hz with lysis buffer and two 7-mm magnetic beads (Qiagen). The 
procedure was repeated until all 20 tape strips from each volunteer were 
processed, followed by the subsequent steps for total RNA extraction. Purified 
RNAs were quantified with a 2000c NanoDrop spectrometer (Thermo Scientific, 
Wilmington, NC, USA), and the quality was checked using a 2100 Bioanalyzer 
(Agilent Technologies, Santa Clara, CA, USA) and a Agilent RNA 6000 Pico Kit 
(Agilent Technologies). Because of the low total RNA yields, the samples were 
amplified with the Arcturus RiboAmp PLUS HS Kit (Applied Biosystems, Carlsbad, 
CA, USA) and SuperScript III Reverse Transcriptase (Applied Biosystems). All 
procedures were performed according to manufacturers’ instructions. 
 
RNA labeling, hybridization and microarray scanning 
 
Amplified RNAs were processed using the Turbo Arcturus Labelling Kit 
(Applied Biosystems), and samples were labeled with Cy5. Universal Human 
Reference RNA (Agilent Technologies) from a unique batch was labeled with Cy3 
for use in the data normalization of different arrays (Novoradovskaya et al., 2004). 
The use of exogenous RNA from the Agilent RNA Spike-in Kit (Agilent 
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Technologies) was also used for the further calibration of the microarray 
measurements (Yang, 2006). After fragmentation with the Gene Expression 
Hybridization Kit (Agilent Technologies), 1:1 ratio mixtures of Cy5-labeled RNA 
from each volunteer and Cy3-labeled Universal Human Reference RNA (Agilent 
Technologies) were co-hybridized to two-color Agilent Whole Human Genome 
Oligo 44K microarrays (Agilent Technologies) to evaluate ~44,000 probe sets, 
which target 19,596 genes. Scanning and image analysis were performed using 
the Agilent DNA Microarray Scanner (Agilent Technologies). All procedures were 
performed according to manufacturers’ instructions. 
 
cDNA synthesis and real-time qPCR 
 
To validate the gene expression patterns in the RNA samples, cDNA was 
obtained using a ReverAid First Strand cDNA Synthesis Kit (Thermo Scientific). 
cDNA from three or four volunteers in the same age group was pooled in equal 
quantities, resulting in three samples for analysis for each group (young and old), 
and real-time qPCR was performed in duplicate for each sample using the ViiA 7 
Real Time PCR System (Applied Biosystems) with the TaqMan Fast Advanced 
Master Mix (Applied Biosystems) and TaqMan Gene Expression Assays (Applied 
Biosystems) for the following target genes: beta actin (ACTB, Hs99999903_m1); 
CCAAT/enhancer binding protein, alpha (CEBPA, Hs00269972_s1); fibroblast 
growth factor 5 (FGF5, Hs03676587_s1); forkhead box Q1 (FOXQ1, 
Hs00536425_s1); frizzled-related protein (FRZB, Hs00173503_m1); growth arrest-
specific 7 (GAS7, Hs00932959_m1); melanoma antigen family A, 10 (MAGEA10, 
Hs00253298_s1); olfactory receptor, family 11, subfamily G, member 2 (OR11G2, 
Hs02340403_s1); olfactory receptor, family 4, subfamily F, member 4 (OR4F4, 
Hs03406040_gH); and olfactory receptor, family 7, subfamily D, member 2 
(OR7D2, Hs01089409_s1). Glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH, Hs03929097_g1) was used as an endogenous control. All procedures 
were performed according to manufacturers’ instructions. 
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Data analysis 
 
Microarray raw data were extracted using the Agilent Feature Extraction 
v8.1 software (Agilent Technologies, Santa Clara, CA, USA). Data visualization 
and analysis were performed using the GeneSpring v12.5 software (Agilent 
Technologies). Data normalization was performed within and across the arrays 
using per gene, per chip normalization, according to Agilent’s recommendation. To 
detect the differentially expressed genes (DEGs) between experimental conditions, 
the following analyses were performed: 1) unpaired t-test with a corrected p-value 
(Benjamini Hochberg FDR) and a cut-off of 0.05 for young versus old comparisons; 
2) unpaired t-test with a corrected p-value (Benjamini Hochberg FDR) and a cut-off 
of 0.01 for segmentation according to different decades of life (each group 
compared to the immediately preceding younger group); and 3) one-way ANOVA 
with post-hoc Tukey’s HSD with a corrected p-value (Benjamini Hochberg FDR) 
and a cut-off of 0.01 for continuous gene expression analysis throughout aging (all 
groups compared to the youngest condition, i.e., ~20 years old). Hierarchical 
clustering was performed using the Euclidean distance metric and Ward’s linkage 
rule. K-means clustering analysis was used for DEGs identified when all groups 
were compared to the youngest condition (~20 years old). The minimal FC, p-
values and specific statistical tests were defined according to each analysis. For 
real-time qPCR experiments, the FC was calculated using the ddCt technique 
(Livak and Schmittgen, 2001). The DAVID database was used to conduct 
functional enrichment analysis (Huang et al., 2009a and 2009b). The human 
genome was used as a reference, and regulated GO terms were ranked according 
to their p-values (or called EASE score, a modified Fisher’s exact test) with a cut-
off of 0.01; Benjamini correction was also considered for ranking but not elimination 
(www.david.abcc.ncifcrf.gov). The KEGG database was used for the analysis of 
modulated pathways (Kanehisa and Goto, 2000; Kanehisa et al., 2014), 
considering the human genome as a reference and an adjusted p-value cut-off of 
0.01 (www.genome.jp/kegg). Network connectivity was analyzed using STRING 
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v9.1 (Franceschini et al., 2013), a database of known and predicted protein 
interactions (www.string-db.org). 
 
Results 
 
Panel of volunteers and sample considerations 
 
To cover a broad spectrum of the aging process, we recruited a panel of 
volunteers comprising 62 women who were distributed according to different 
decades of age i.e., 20 ± 1 years old (12 volunteers), 30 ± 1 years old (9 
volunteers), 40 ± 1 years old (9 volunteers), 50 ± 1 years old (9 volunteers), 60 ± 1 
years old (8 volunteers), 70 ± 1 years old (8 volunteers) and 80 ± 1 years old (7 
volunteers) (Table S1). Using non-invasive adhesive tape stripping, our analysis 
focused on the outer viable layers of epidermis, including the granular (mainly) and 
spinous layers.  Most of the stratum corneum was discarded with the first five tapes 
collected because its dead cell components are not suitable for RNA extraction. 
The basal layer was likely not accessible due to its deeper position. Thus, 
epidermal differentiation and keratinocyte activity/structure are that biological 
processes that are most likely to be revealed by this approach. Moreover, tapes 
were collected from sun-exposed areas, providing samples with particular clinical 
and morphological interests with regards to epidermal aging.  
 
Young versus old epidermis microarray analysis and technical validation using 
real-time qPCR 
 
To establish comparisons with previous skin aging studies, young versus old 
analyses were initially performed by dividing the volunteers into two groups: 20-40 
years old (30 volunteers) and 50-80 years old (32 volunteers) (Table S1). By 
adopting a minimal fold change (FC) value of 1.5 and a p-value cut-off of 0.05, 
statistically significant differences were observed for 4,863 probe sets (3,416 
recognized HGNC mapped probe sets representing 3,247 distinct human genes), 
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with 4,146 up-regulated and 717 down-regulated (Table S2). Technical validation 
of the microarray results was performed using real-time qPCR in an independent 
young versus old panel including 10 volunteers who were 25 ± 3 years old and 10 
volunteers who were 55 ± 4 years old (Table S3). Similar results were found for the 
expression of 10 randomly selected genes (up-, down- or non-regulated) (Figure 
1).  
 
Figure 1. Real-time qPCR validation of microarray results. These qPCR results represent the 
median (± SD) of triplicate analyses using an independent secondary panel of volunteers (10 
young, 10 old). GAPDH was used as an endogenous control. A complete list of regulated genes 
can be found in Table S2. 
 
Separate lists of the up- and down-regulated genes (Table S2) were 
analyzed in the DAVID database to identify significantly up- and down-modulated 
biological processes, respectively, ranked according to p-value (cut-off 0.01) (Table 
1). Although the number of up-regulated genes was higher than that of down-
regulated genes, the opposite trend was found for biological processes, i.e., 63 
gene ontology (GO) terms were associated with down-regulated gene expression, 
and 24 were associated with up-regulated gene expression. Filtering data with 
distinct FC values of 1.5, 2.0 and 3.0 and maintaining the p-value cut-off of 0.05 
demonstrated that the ratio between the up- and down-regulated genes decreased 
with an increase in FC criteria (Table S4). Notably, the down-regulated genes were 
predominant in the 3.0 FC dataset. Therefore, one may conclude that despite the 
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higher number of up-regulated genes in terms of significant biological processes 
enrichment and FC expression intensity, the down-regulation of gene expression is 
critical for the epidermal aging of sun-exposed skin. 
 
Table 1. Gene ontology (GO) terms associated with sun-exposed epidermal aging. 
GO term GO code 
Number 
of DEGs
1
 
p-value 
Up-regulated biological processes 
   
Translational elongation GO:0006414 30 0.000160 
Negative regulation of protein metabolic process GO:0051248 44 0.001159 
Negative regulation of protein modification process GO:0031400 31 0.001371 
Multi-organism process GO:0051704 127 0.001785 
Negative regulation of cellular protein metabolic process GO:0032269 42 0.001801 
Interspecies interaction between organisms GO:0044419 60 0.002109 
Induction of apoptosis by extracellular signals GO:0008624 29 0.002222 
Negative regulation of response to stimulus GO:0048585 26 0.003719 
Positive regulation of programmed cell death GO:0043068 84 0.003956 
Positive regulation of cell death GO:0010942 84 0.004483 
Positive regulation of apoptosis GO:0043065 83 0.004805 
Carbohydrate transport GO:0008643 18 0.004839 
Glucose transport GO:0015758 11 0.005714 
Regulation of apoptosis GO:0042981 143 0.005774 
Regulation of programmed cell death GO:0043067 144 0.006142 
Regulation of glucose transport GO:0010827 12 0.006592 
Positive regulation of cellular process GO:0048522 304 0.006815 
Response to peptide hormone stimulus GO:0043434 35 0.007001 
Regulation of cell death GO:0010941 144 0.007087 
Hexose transport GO:0008645 11 0.007479 
Cellular protein metabolic process GO:0044267 380 0.007861 
Regulation of synaptic plasticity GO:0048167 18 0.008135 
Protein metabolic process GO:0019538 449 0.008462 
Monosaccharide transport GO:0015749 11 0.009636 
Down-regulated biological processes 
   
Organ development GO:0048513 69 0.000001 
System development GO:0048731 81 0.000019 
Anatomical structure development GO:0048856 84 0.000066 
Multicellular organismal development GO:0007275 92 0.000090 
Cell fate commitment GO:0045165 12 0.000254 
Cell differentiation GO:0030154 58 0.000289 
Regulation of transcription from RNA polymerase II promoter GO:0006357 32 0.000331 
Keratinization GO:0031424 7 0.000334 
Negative regulation of programmed cell death GO:0043069 20 0.000391 
Developmental process GO:0032502 96 0.000403 
Negative regulation of cell death GO:0060548 20 0.000404 
Regulation of programmed cell death GO:0043067 34 0.000502 
Regulation of system process GO:0044057 18 0.000511 
Epithelium development GO:0060429 15 0.000518 
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Regulation of cell death GO:0010941 34 0.000540 
Tissue development GO:0009888 29 0.000790 
Cellular developmental process GO:0048869 58 0.000810 
Epithelial cell differentiation GO:0030855 11 0.000907 
Anatomical structure morphogenesis GO:0009653 44 0.000957 
Positive regulation of cellular process GO:0048522 61 0.001163 
Regulation of cellular process GO:0050794 178 0.001284 
Regulation of biological process GO:0050789 184 0.001431 
Ectoderm development GO:0007398 13 0.001545 
Organ morphogenesis GO:0009887 25 0.001610 
Regulation of apoptosis GO:0042981 32 0.001746 
Negative regulation of biological process GO:0048519 59 0.002009 
Regulation of RNA metabolic process GO:0051252 59 0.002035 
Regulation of neurological system process GO:0031644 11 0.002087 
Negative regulation of apoptosis GO:0043066 18 0.002244 
Biological regulation GO:0065007 191 0.002249 
Epidermis development GO:0008544 12 0.002574 
Positive regulation of biological process GO:0048518 64 0.002744 
Multicellular organismal process GO:0032501 118 0.003216 
Regulation of transcription, DNA-dependent GO:0006355 57 0.003250 
Keratinocyte differentiation GO:0030216 7 0.003266 
Regulation of gene expression GO:0010468 84 0.003317 
Regulation of metabolic process GO:0019222 102 0.003860 
Regulation of primary metabolic process GO:0080090 94 0.004054 
Regulation of localization GO:0032879 25 0.004503 
Epidermal cell differentiation GO:0009913 7 0.005033 
Regulation of transmission of nerve impulse GO:0051969 10 0.005283 
Angiogenesis GO:0001525 10 0.005520 
Notch signaling pathway GO:0007219 6 0.005603 
Cell fate determination GO:0001709 5 0.005715 
Myeloid leukocyte differentiation GO:0002573 5 0.006366 
Regulation of macromolecule metabolic process GO:0060255 92 0.006416 
Regulation of transcription GO:0045449 76 0.006710 
Positive regulation of apoptosis GO:0043065 19 0.007115 
Regulation of nucleobase, nucleoside, nucleotide and nucleic acid 
metabolic process 
GO:0019219 81 0.007177 
Positive regulation of programmed cell death GO:0043068 19 0.007589 
Regulation of cellular biosynthetic process GO:0031326 84 0.007758 
Positive regulation of cell death GO:0010942 19 0.008003 
Immune system development GO:0002520 14 0.008370 
Leukocyte differentiation GO:0002521 9 0.008471 
Negative regulation of cellular process GO:0048523 52 0.008553 
Regulation of cellular metabolic process GO:0031323 96 0.008743 
Regulation of nitrogen compound metabolic process GO:0051171 81 0.008975 
Cell death GO:0008219 27 0.009011 
Regulation of multicellular organismal process GO:0051239 33 0.009012 
Signal transduction GO:0007165 81 0.009054 
Regulation of biosynthetic process GO:0009889 84 0.009157 
Regulation of anatomical structure morphogenesis GO:0022603 12 0.009370 
Death GO:0016265 27 0.009837 
1. DEGs, differentially expressed genes. 
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To identify the modulated pathways, the complete list of modulated genes 
was analyzed using the KEGG database (Table S2). Forty pathways showed 
significant modulation and were ranked according to their p-values (cut-off: 0.01) 
(Table S5). In addition to statistical significance, biological interpretation is 
essential for meaningful pathway analysis. Of the identified pathways, ~50% were 
associated with human diseases and organismal systems not necessarily related 
to skin. Other pathways could be linked to key aspects of epidermal aging, such as 
focal adhesion, cytokine-cytokine receptor interaction, Wnt signaling pathway, 
MAPK signaling pathway, cell adhesion molecules, Jak-STAT signaling pathway 
and Hedgehog signaling pathway, which helps explain the clinical, morphological 
and/or functional alterations of aged epidermis. The actin cytoskeleton pathway 
has 37 DEGs in common with our results, and 32 of these genes are up-regulated, 
which corresponds to significant ACTB up-regulation according to the microarray 
and qPCR techniques and might help explain the clinical observations of solar 
keratosis in sun-exposed skin (Figure 2a). The calcium signaling pathway has 31 
DEGs in common with our results, which likely contribute to the impaired calcium 
gradient observed in aged epidermises (Figure 2b). 
 
Comparison to previous studies 
 
To verify the alignment of our findings with key previous aging-related 
studies, specific comparisons were established. A recent transcriptome analysis of 
intrinsic epidermal aging reported only 75 DEGs between five young and five old 
donors (18-24 and 70-75 years old, respectively) (Raddatz et al., 2013). Despite 
the noted biological and technical variations and population specificities, 15 
common DEGs were shared by our studies (Table S6), including cross-linked 
envelope proteins in keratinocytes, adhesion molecules and components of signal 
transduction pathways.  
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Figure 2. Biological pathways modulated by sun-exposed epidermal aging from the KEGG 
database. (A) Actin cytoskeleton pathway. (B) Calcium signaling pathway. A complete list of 
regulated genes can be found in Table S2. White boxes represent species independent genes from 
the reference pathway map that were not differentially expressed in our study; green boxes 
represent human genes from the pathway that were not differentially expressed in our study; blue 
and red boxes represent human genes from the pathway that were respectively up- or down-
regulated in our study. Graphic representations:  gene product;  other molecules (mostly 
chemical compounds);  another map;  activation;  inhibition; indirect effect; 
 indirect link to another map; +p phosphorylation; -p dephosphorylation. 
 
With a representative sample size for better analyzing intergroup changes 
despite intragroup variability, an elegant study was performed by Glass et al. 
(2013) as part of the MuTHER (Multiple Tissue Human Expression Resource) 
project. Using a linear mixed model and a large panel of 856 female twins ranging 
in age from 39 to 85 years old, 1,672 probe sets were differentially expressed in 
photo-protected skin throughout a lifetime, of which 273 were also detected in our 
analysis (Table S7). Yan et al. (2013) conducted a skin photoaging evaluation with 
paired analysis of sun-exposed and sun-protected samples from 21 Chinese 
women ranging from 34-55 years old. A total of 1,621 modulated probe sets were 
identified, and 250 also present in our data (Table S8). If considered together, the 
Glass et al. (2013) and Yan et al. (2013) studies had 42 DEGs in common with our 
results, including significant epidermal markers such as keratins and keratin 
associated proteins. To determine broader aging aspects, we checked whether 
known aging-related genes from Human Ageing Genomic Resources (HAGR) were 
present in our dataset (de Magalhães et al., 2009; Tacutu et al., 2013). GenAge is 
a database within HAGR that consists of 298 genes potentially associated with 
human aging, and 43 of these genes are correlated with our study (Table S9), 
including markers of actin filament organization, regulation of cell growth and 
progression through the cell cycle as well as genes related to protein modification 
and apoptosis. The two lists of ~40 shared DEGs, which were obtained from the 
comparison of our results with those of Glass and Yan or the HAGR data, were 
evaluated using the DAVID and STRING databases and revealed distinct profiles 
(Figure 3), which are detailed in the discussion section. 
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B A 
Figure 3. Associations between modulated biomarkers of sun-exposed epidermal aging. Analyses were performed with differentially expressed genes 
(DEGs) by comparing our dataset with other studies. (A) DEGs in common with Glass et al. (2013) and Yan et al. (2013), sun-protected and sun-
exposed skin aging studies, respectively, showing genes mainly related to tissue-specific biological processes and only one association. (B) DEGs in 
common with Human Ageing Genomic Resources (HAGR), a study of aging not restricted to skin, showing genes related to broad biological processes 
and many molecular associations. Complete lists of genes are found in Tables S7-S9. Different node colors are used only as a visual aid. Big nodes 
indicate proteins with available structural information. Stronger associations are represented by thicker lines. 
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Epidermal aging transcriptome segmentation according to different decades of life  
 
As previously stated, our panel of volunteers whose DNA was used for 
microarray analysis comprised women distributed across different age decades. 
Because the number of volunteers per experimental group was significantly 
reduced by panel segmentation, more restrictive criteria were adopted for the 
selection of DEGs, i.e., considering a minimal FC of 2.0 and a p-value cut-off of 
0.01. Clustering analysis was performed to evaluate the consistency of traditional 
grouping, i.e., young versus old, in reflecting the evolution of epidermal aging 
(Figure 4a). Indeed, the young (20-40 years) and old groups (50-80 years) were 
separated, but at least two specific observations are notable from the analysis. 
First, clustering did not order the groups into a continuous and crescent sequence 
of ages, indicating that the age-associated changes should not be interpreted as 
part of a linear process. Second, the old group showed clear segregation into two 
distinct blocks. Together, these findings exposed critical limitations of the traditional 
young versus old polarizing analyses, based on a single comparison of extreme 
phenotypic aging conditions. The next step was identifying DEGs in each decade 
of life by comparing each age group with the immediately preceding younger one. 
Following this rational, six lists of DEGs were generated to represent each decade 
of life between 20 and 80 years of age (Table S10). Though specific gene 
expression profiles are associated with each decade, one of the most interesting 
findings related to such an overall analysis is evidence of a dynamic and pattern of 
epidermal transcription that oscillates with age (Figure 4b).  
 
Continuous gene expression analysis throughout aging 
 
To better understand the continuous gene regulation in sun-exposed epidermal 
aging, each group was compared to the youngest group (~20 years old). 
Significant DEGs should present a minimal FC of 1.5 in at least four of the six total 
comparisons and a minimal FC of 3.0 between the 20- and 80-year-old groups. 
The p-value cut-off considered was 0.01. Genes complying with those criteria were 
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subjected to K-means clustering analysis. Several clusters were found, and the 
most representative clusters were selected for further evaluation, considering a 
continuous tendency toward an increase or decrease gene expression with age 
(Figure 5). One cluster evinced the isolated gene SPRR2G as an example of 
increased expression throughout life (Table S11). Regarding the continuous 
tendency to reduce gene expression with age, the selected cluster demonstrated 
20 modulated probe sets (11 HGNC identified genes), including the keratinization 
marker LCE1A and the transcription factor CEBPA (also identified in our young 
versus old analysis and confirmed by qPCR) (Table S11). 
 
 
Figure 4. Overall analysis of gene expression during sun-exposed epidermal aging using a 
segmented panel of different decades of life. (A) Hierarchical clustering analysis showing different 
age groups organized according to similarities in gene expression profile (branches at top). The 
colored boxes indicate a distribution of decades in preliminary young (blue) versus old (rose) 
classification. (B) Oscillating transcriptional profile along a lifetime, as indicated by a dashed line 
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(tendency in the difference between the numbers of up- and down-regulated genes). Each age 
group was compared to its preceding younger group. 
 
 
Figure 5. Clustering analysis of genes with similar expression profiles throughout life. (A) Genes 
with a tendency toward a continuous increase in sun-exposed epidermal aging. (B) Genes with 
tendency toward continuous decrease in sun-exposed epidermal aging. Each age group was 
compared with the youngest age group (~20 years old). A complete list of genes can be found in 
Table S11. 
 
Discussion 
 
In accordance with Rinnerthaler et al. (2013) and based on the adoption of 
different strategies for analysis, this study contributes to the understanding of the 
dramatic changes that occur in the epidermis during aging. As expected, the main 
findings were related to modifications in epidermal differentiation and keratinocyte 
activity/structure. Processes such as cell proliferation were not enriched in our 
data, possibly because cells from the basal epidermal layer were not likely to be 
sampled by tape stripping. Considering the fact that samples were collected from 
the back of hands, this report represents the first study focused on the 
transcriptome of sun-exposed human epidermal aging. 
A comparison of our data with skin-based transcriptome studies (Glass et 
al., 2013; Yan et al., 2013) indicated the regulation of tissue-specific biological 
processes, such as epidermis and ectoderm development. However, a comparison 
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with HAGR data predominantly demonstrated changes in broader biological 
processes, such as the regulation of cell death and response to chemical stimulus. 
The high level of interaction between the biomarkers of HAGR cross-analysis – 44 
in total – indicates the coordinated regulation of key genes that may simultaneously 
impact several processes (Figure 3b). Therefore, the epidermis appears to be 
affected by aging at different levels of molecular regulation, involving impaired 
broad and tissue-specific biological processes. Mitogen-activated protein kinase 8 
(MAPK8) represents a gene that affects the expression of other genes in a 
cascade effect. This gene responds to activation by environmental stress and pro-
inflammatory cytokines by phosphorylating a number of transcription factors. In 
addition to the MAPK8 gene, the MAPK signaling pathway was enriched in our 
analyses, suggesting an epidermal response to constant sun exposition. Akasaka 
et al. (2010) showed that MAPK8 protein accumulates in sunlight-exposed human 
epidermises, thereby promoting oxidative stress. Moreover, the MAPK signaling 
pathway has an indirect link with the Wnt signaling pathway, which was also 
enriched in our data. Aberrant Wnt signaling contributes to cancerous growth 
(Castilho et al., 2009), and our findings suggest that it could be related to increase 
predisposition to cancer development in photoaged skin (Mouret et al., 2011). 
It is important to note that several studies have evaluated the effects of 
aging on the entire skin, but most of these studies have proven to be difficult due to 
the heterogeneous nature of specimens (Gromov et al., 2003). The extensive list of 
DEGs presented here reflects our experimental composition (i.e., isolation of the 
epidermis plus a representative sample size) in association with the simultaneous 
effects of the intrinsic and extrinsic aging factors on the skin. Interestingly, despite 
the predominance of up-regulated genes in our data, down-regulated genes had 
the highest FC values and resulted in a higher number of significantly enriched 
biological processes (Table 1). Regarding the biological meaning of modulated 
processes in the comparison between young and old epidermises, seven of the top 
10 up-regulated GO terms were related to the deleterious effects on epidermal 
functions, such as the negative regulation of cellular protein metabolic process, 
negative regulation of response to stimulus and positive regulation of cell death 
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(including programmed cell death and apoptosis). The top 10 down-regulated GO 
terms included processes related to cell differentiation, keratinization and negative 
regulation of cell death. Some of these results complement or help elucidate the 
molecular mechanisms behind clinical or morphological epidermal changes. 
Moreover, establishing comprehensive parallels to other analyses adds significant 
insight to our data. Apoptosis induction in the photoaged epidermis was previously 
described as being marked by the presence of sunburn cells or apoptotic 
keratinocytes (Leyden, 2001; Van Laethem et al., 2005). Such an observation 
could be supported by our findings of either the induced positive regulation of cell 
death or the reduced negative regulation of cell death. 
According to López-Otín et al. (2013), the rate of aging is controlled, at least 
to some extent, by genetic pathways and biochemical processes that have been 
conserved throughout evolution, such as the nine emphasized mammalian 
hallmarks of aging: genomic instability, telomere attrition, epigenetic alterations, 
loss of proteostasis, deregulated nutrient sensing, mitochondrial dysfunction, 
cellular senescence, stem cell exhaustion, and altered intercellular communication. 
A study by Raddatz et al. (2013) highlighted the destabilization of the epigenome 
as a significant component of epidermal aging, but in contrast with our study, they 
found that young and old epidermis transcriptomes were similar overall. Because 
the results of this group were characterized by high expression levels of epidermis-
specific genes, we assumed that technical and/or biological limitations did not allow 
the authors to draw conclusions about broad and conserved regulatory processes. 
Our identification of DEGs shared with HAGR and the definitions López-Otín et al. 
(2013) suggest that the age-related modulation of epidermis-specific genes might 
be accompanied by overall impaired pathways that represent general hallmarks of 
aging in the entire organism. 
A recent study evaluated age-related changes in the composition of the 
cornified envelope (CE) in human skin (Rinnerthaler et al., 2013). Despite not 
applying an “omics”-related technique, the expression of 46 genes related to CE 
formation was evaluated in photo-protected epidermises that were isolated from 
nine individuals from each of the following age groups: 1-10, 17-44 and 59-74 
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years. Consistent with our findings, the authors observed no significant changes in 
the expression of the genes involved in the initial steps of CE assembly, including 
envoplakin, periplakin and involucrin. Of the five types of transglutaminases 
(TGMs), the authors identified only a slight increase in TGM1 expression, while we 
detected a similar result for TGM3. In both studies, the DEGs were mainly related 
to the processes occurring after scaffold formation, predominantly affecting loricrin 
(LOR) and the small proline-rich proteins (SPRRs), which correspond to 80% of the 
CE constitution (Kalinin et al., 2001). Rinnerthaler’s group verified the down-
regulation of LOR and the up-regulation of SPRRs, with the exception of SPRR2G. 
Increased SPPRs, which function as small bridges between LOR and themselves, 
were suggested to function in a compensatory mechanism for decreased LOR. In 
contrast, our data showed increased expression for LOR and some SPPRs, mainly 
SPPR2G, suggesting that LOR/SPRR expression has distinct patterns of 
regulation in photo-protected and photo-exposed skin. Nevertheless, inverse LOR 
regulation could be related to the presence of a thicker epidermis in photoaged 
skin (Leyden, 2001; El-Domyati et al., 2002), contrary to epidermal thinning in 
photo-protected areas (Lock-Andersen et al., 1997; Makrantonaki and Zouboulis, 
2007). The opposite regulation of LOR expression in photo-protected and photo-
exposed epidermises resembles elastin regulation in the dermis, whose production 
is reduced by aging in photo-protected skin, while it is over-expressed in 
photoaging conditions in the same tissue and leads to elastosis (Uitto, 2008). To 
date, there is no evidence for SPRR2G regulation with epidermal aging, but 
several studies have suggested that SPRRs are related to increased epithelial 
proliferation and the development of malignant processes (Carregaro et al., 2013). 
Our findings suggest a specific mechanism for epidermal photoaging related to 
impaired CE formation, which has not been previously described and has potential 
for further studies in the future. 
Because the ionic distribution of calcium drives keratinocytes into 
differentiation and is inevitable for CE synthesis, Rinnerthaler et al. (2013) also 
evaluated the influence of aging on this biological process and showed that the 
calcium distribution is different in aged skin, confirming a previous study performed 
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with facial sun-exposed epidermis (Denda et al., 2003). Our results showed a 
significant modulation of the calcium signaling pathway in aged epidermises, which 
is represented by 31 DEGs (Figure 2b). These results represent the first evidence 
of the molecular mechanisms that are involved in the impairment of the calcium 
gradient upon epidermal aging, which should be better explored in future studies. 
The effects of epidermal photoaging also appear to impair some aspects of 
the cellular structure, as demonstrated by our findings of modulation of the beta 
actin (ACTB) gene and the actin cytoskeleton pathway (Figure 2a). Interestingly, 
ACTB, which is widely used as an endogenous control gene, was up-regulated by 
epidermal aging in our microarray and qPCR analyses (Figure 1). ACTB 
modulation might be related to morphological changes in aged keratinocytes in 
photo-exposed skin areas in which the higher incidence of solar keratosis is 
associated with diffuse epidermal hyperplasia (Koehler et al., 2011). Previous 
reports have stated that senescent keratinocytes are irregularly shaped, enlarged 
and flattened (Soroka et al., 2008), strongly suggesting the impaired regulation of 
key cytoskeleton components, such as ACTB. Furthermore, actin microfilaments 
from keratinocytes were shown to be depolymerized by UV radiation (Provost et 
al., 2003); thus, increased ACTB gene expression could be interpreted as a 
compensatory mechanism or chronic attempt at damage repair. From a 
morphological perspective, the regulation of the actin cytoskeletal pathway could 
be related to the thicker epidermis observed in association with photoaging 
(Leyden, 2001; El-Domyati et al., 2002). 
The young versus old approach used in our study was important for 
obtaining interesting results and permitting comparisons with relevant previous 
findings in the literature. However, based on the proposition that aging is a 
continuous and cumulative process throughout life, we also performed analyses 
using a segmented panel of volunteers grouped according to different decades of 
life to understand the real dynamics of sun-exposed epidermal aging. Hierarchical 
clustering showed that epidermal aging does not appear to represent a linear 
biological process because different decades of life were not organized in a 
sequence of crescent age (Figure 4a). The group of 50-year-olds was allocated 
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closer to the 80-year-old group; however, menopause could help explain this 
phenomenon because it has already been noted as causing accelerated skin aging 
(Thornton, 2013). Moreover, the impaired gene expression at 50 years of age 
appears to be slightly recovered by 60 and 70 years of age, which likely occurs 
because these groups are clustered closer to the younger group, but they become 
impaired again at 80 years. Unfortunately, we could not identify clear reasons for 
this phenomenon, but it suggested an oscillatory pattern of gene expression in the 
epidermis throughout aging, which has likely been widely neglected because of the 
number of polarized young versus old analyses. By calculating the difference 
between the up-regulated and down-regulated genes in each decade, an intriguing 
profile was revealed, with alternate fluctuations throughout life (Figure 4b). In 
addition to being a barrier for mechanical protection, the epidermis has been 
described to be a metabolically active tissue in constant dynamic balance that 
periodically undergoes complete renewal cycles (Fuchs and Raghavan, 2002). The 
idea of a constant epidermal dynamic balance suggests the concept of a 
homeostasis that is characterized by fluctuations requiring readjustment (O'Neill, 
2004). López-Otín et al. (2013) stated that several critical questions have arisen in 
the field of aging regarding, among other factors, the compensatory responses that 
attempt to reestablish homeostasis. Thus, we have interpreted the molecular 
behavior of the epidermis throughout aging as a continuous attempt at homeostatic 
regulation based on successive rounds of feedback response. The highest 
oscillation in terms of gene expression occurs at approximately 30 years of age, 
which is in accordance with the publication of Kuwazuru et al. (2012), who stated 
that skin wrinkling morphology suddenly changes in the early 30s based on the 
evaluation of facial skin from 102 women aged 25–56 years. However, the 
amplitude of the fluctuation appears to decrease over a lifetime (which means a 
lower number of regulated genes), possibly suggesting that homeostatic 
mechanisms deteriorate with epidermal aging (O'Neill, 2004). According to 
Kirkwood (2005), aging involves cumulative changes that affect the ability to 
adaptively respond to stress. Notably, a ten-year interval between two sequential 
groups may be too large to infer causal relationships, which was not our intention. 
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Nevertheless, the use of segmented intervals appears to represent an advantage 
for the continuous evaluation of aging, thereby enriching data interpretation.  
An additional analysis, which used the panel of volunteers segregated by 
decades of age, was conducted to identify genes that tend to change continuously 
throughout life. SPPR2G represented the most significant up-regulated gene 
(Figure 5a). Because SPPR2G was not modulated in the study of Rinnerthaler et 
al. (2013), we believe that it represents a strong candidate for epidermal aging 
specifically associated with photoaged conditions. Additionally, the homologous 
family of SPRRs appears to have the greatest age-related changes in the CE 
occurring as a life-long process (Rinnerthaler et al., 2013). In the continuously 
down-regulated genes (Figure 5b), we identified the keratinization marker LCE1A. 
This gene represents a protein that is involved in the last step of CE assembly and 
was found to be down-regulated during epidermal aging in the study by 
Rinnerthaler et al. (2013). In this case, in addition to differences related to photo-
exposed or photo-protected areas, decreased levels of LCE1 members can be 
expected to be a result of reduced calcium levels in the aged epidermis. Another 
continuously down-regulated gene was the transcription factor CEBPA, which was 
also identified in the young versus old analysis and confirmed by qPCR. CEBPA is 
a basic leucine zipper transcription factor that is abundantly expressed in 
keratinocytes and whose function in skin is poorly characterized. Under UVB 
radiation, CEBPA is induced in keratinocytes, participates in cell cycle checkpoints 
that arrest cell cycle progression and prevents the replication of damaged DNA 
(Yoon K and Smart, 2004). Our evidences of gene expression reduction in the 
epidermis upon aging, using different analysis and techniques, suggests that 
CEBPA is an important element that is associated with an increased predisposition 
to cancer development in photoaged skin (Mouret et al., 2011). 
Given the functional importance of the epidermis to the homeostasis of an 
organism and the necessity of better understanding of the molecular mechanisms 
underlying epidermal aging, this study critically evaluated the changes affecting the 
epidermis throughout life, including intrinsic and extrinsic factors. With the main 
objective of this study being to open new perspectives for skin aging evaluation, we 
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presented alternative analyses that consider aging to be a continuous process. 
Future perspectives could include elucidating the specific mechanisms associated 
with epidermal aging to allow for the development of potential therapeutic 
approaches. 
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Supplemental material 
 
Table S1. Characterization of the main volunteer panel for microarray analyses. 
V o lunt eer N umber A ge ( Y ears Old ) Skin Phot o t ype
1
Skin Type
2
Et hnic Group
3
1 19 II Normal Italian/Portuguese
2 19 II Combinat ion Italian/Polish
3 19 II Combinat ion Indigenous/Italian/Japanese
4 20 II Oily Italian
5 20 III Oily German/Indigenous
6 20 II Oily Italian/Polish
7 20 II Oily Portuguese
8 21 III Oily Italian/Portuguese
9 21 III Oily German/Italian
10 21 III Oily European
11 21 III Oily European
12 21 II Normal Italian
13 29 II Combinat ion German/Italian
14 30 III Dry Asiat ic
15 30 II Combinat ion Indigenous/Spanish
16 30 III Combinat ion Indigenous
17 31 III Oily Italian
18 31 II Dry Indigenous
19 31 II Oily Ukrainian
20 31 III Combinat ion Lebanese/Portuguese
21 31 II Oily Italian/Spanish
22 40 II Combinat ion German
23 40 III Dry Not declared
24 40 III Combinat ion Not declared
25 40 II Combinat ion Italian
26 41 II Normal European
27 41 II Combinat ion German/Indigenous
28 41 II Combinat ion German
29 41 III Combinat ion Not declared
30 41 III Combinat ion Italian
31 49 III Combinat ion Japonese
32 49 III Dry Portuguese
33 50 II Dry Polish
34 50 III Combinat ion German/Italian
35 50 III Combinat ion German
36 51 II Combinat ion German/Russian
37 51 III Dry Portuguese
38 51 II Normal Italian
39 51 II Oily Portuguese
40 59 II Combinat ion Portuguese
41 59 II Dry Italian/Polish
42 59 II Oily Asiat ic
43 60 III Combinat ion Indigenous/Spanish
44 60 II Oily Polish
45 60 II Dry Italian
46 61 II Dry Spanish
47 61 II Normal Italian
48 69 II Normal Italian
49 69 II Dry Ukrainian
50 69 II Oily German
51 71 II Normal Indigenous/Russian
52 71 II Combinat ion German
53 71 III Oily
Dutch/Indigenous/Portugues
e/Swiss
54 71 II Dry Danish/Portuguese
55 71 II Combinat ion Not declared
56 79 II Not declared Caucasian
57 79 II Dry Ukrainian
58 79 II Combinat ion Japonese
59 81 II Not declared Polish
60 81 II Normal Portuguese
61 81 II Dry Italian
62 81 II Combinat ion German/Portuguese
1. Classif icat ion according to Fitzpatrick phototyping scale
2. Personal declarat ion of predominant skin type in the body according to sebum product ion
3. Personal declarat ion of ethnic groups  
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Table S2. Probe sets modulated in the epidermis of young versus old volunteers with a minimal fold 
change of 1.5 and a p-value cut-off of 0.05 (only one long list). 
HGN C  
A pproved  
Symbo l
1
HGN C  A pproved  N ame
1 FC R eg .
2
HGN C  
A pproved  
Symbo l
1
HGN C  A pproved  N ame
1 FC R eg .
2
RBFOX1 RNA binding protein, fox-1 homolog (C. elegans) 1 1,52 Up AFG3L1P AFG3-like AAA ATPase 1, pseudogene 1,92 Up
A4GALT alpha 1,4-galactosyltransferase 2,09 Down AGBL2 ATP/GTP binding protein-like 2 1,68 Up
NCEH1 neutral cholesterol ester hydrolase 1 1,52 Up AGBL4 ATP/GTP binding protein-like 4 1,66 Down
AATF apoptosis antagonizing transcript ion factor 1,98 Up AGBL5 ATP/GTP binding protein-like 5 1,85 Up
AATK apoptosis-associated tyrosine kinase 1,51 Down AGPAT4 1-acylglycerol-3-phosphate O-acyltransferase 4 1,53 Up
ABAT 4-aminobutyrate aminotransferase 2,15 Up PHYKPL 5-phosphohydroxy-L-lysine phospho-lyase 1,92 Up
M TSS1L metastasis suppressor 1-like 1,95 Up AHI1 Abelson helper integrat ion site 1 1,78 Up
M TSS1L metastasis suppressor 1-like 1,91 Down AIM 1L absent in melanoma 1-like 1,66 Up
ABCC2
ATP-binding cassette, sub-family C (CFTR/M RP), 
member 2
1,62 Up AIRE autoimmune regulator 1,50 Down
ABCC6
ATP-binding cassette, sub-family C (CFTR/M RP), 
member 6
1,68 Up AK5 adenylate kinase 5 1,64 Up
ABCD3
ATP-binding cassette, sub-family D (ALD), member 
3
1,61 Up AK7 adenylate kinase 7 1,60 Up
ABCE1
ATP-binding cassette, sub-family E (OABP), 
member 1
1,85 Up AKAP14 A kinase (PRKA) anchor protein 14 1,57 Up
ABCF2
ATP-binding cassette, sub-family F (GCN20), 
member 2
1,52 Up AKAP5 A kinase (PRKA) anchor protein 5 1,68 Up
ABCG1
ATP-binding cassette, sub-family G (WHITE), 
member 1
1,73 Up AKAP8L A kinase (PRKA) anchor protein 8-like 1,51 Up
ABCG5
ATP-binding cassette, sub-family G (WHITE), 
member 5
1,52 Up AKT1S1 AKT1 substrate 1 (proline-rich) 1,80 Up
ABHD1 abhydrolase domain containing 1 1,70 Up AKTIP AKT interact ing protein 1,67 Up
ABHD2 abhydrolase domain containing 2 1,93 Up ALAS2 aminolevulinate, delta-, synthase 2 1,62 Up
ABHD4 abhydrolase domain containing 4 1,75 Up ALCAM activated leukocyte cell adhesion molecule 1,60 Down
ABI3BP ABI family, member 3 (NESH) binding protein 1,65 Up ALDH18A1 aldehyde dehydrogenase 18 family, member A1 1,61 Up
ABI3BP ABI family, member 3 (NESH) binding protein 1,69 Up ALDH1A3 aldehyde dehydrogenase 1 family, member A3 1,51 Up
ABLIM 2 act in binding LIM  protein family, member 2 1,58 Up ALDH1B1 aldehyde dehydrogenase 1 family, member B1 1,54 Up
ABR active BCR-related 1,67 Up ALDH2 aldehyde dehydrogenase 2 family (mitochondrial) 2,00 Up
ACAD9 acyl-CoA dehydrogenase family, member 9 1,86 Up ALDH8A1 aldehyde dehydrogenase 8 family, member A1 1,62 Up
ACAT1 acetyl-CoA acetyltransferase 1 1,55 Up ALDOA aldolase A, fructose-bisphosphate 1,68 Down
ACBD4 acyl-CoA binding domain containing 4 3,06 Down ALG3 ALG3, alpha-1,3- mannosyltransferase 1,93 Up
ACN9 ACN9 homolog (S. cerevisiae) 1,54 Up ALG3 ALG3, alpha-1,3- mannosyltransferase 1,60 Up
ACOT11 acyl-CoA thioesterase 11 1,67 Up ALKBH8 alkB, alkylat ion repair homolog 8 (E. coli) 1,54 Up
ACOT12 acyl-CoA thioesterase 12 1,57 Up ALOX12 arachidonate 12-lipoxygenase 1,72 Up
ACOX2 acyl-CoA oxidase 2, branched chain 1,51 Up ALOX15B arachidonate 15-lipoxygenase, type B 2,74 Up
ACP6 acid phosphatase 6, lysophosphat idic 1,56 Up ALOX5AP arachidonate 5-lipoxygenase-act ivat ing protein 3,85 Down
ACR acrosin 1,63 Up FAM 117B family with sequence similarity 117, member B 2,09 Up
ACTA1 act in, alpha 1, skeletal muscle 1,95 Up TM EM 237 transmembrane protein 237 1,62 Up
ACTB act in, beta 4,39 Up ALX4 ALX homeobox 4 1,74 Up
ACTG1 act in, gamma 1 2,23 Up AM DHD1 amidohydrolase domain containing 1 1,80 Up
ACTG1 act in, gamma 1 3,13 Up AM FR
autocrine motility factor receptor, E3 ubiquit in 
protein ligase
1,81 Up
ACTL8 act in-like 8 2,23 Down AM M ECR1L AM M ECR1-like 1,60 Up
ACTR1B
ARP1 act in-related protein 1 homolog B, centract in 
beta (yeast)
1,76 Down AM N amnion associated transmembrane protein 1,70 Up
ADA adenosine deaminase 1,69 Up AM N amnion associated transmembrane protein 2,28 Down
ADAM 12 ADAM  metallopept idase domain 12 1,91 Up AM PH amphiphysin 1,71 Up
ADAM 20 ADAM  metallopept idase domain 20 1,64 Up ANAPC10 anaphase promoting complex subunit  10 1,67 Up
ADAM 22 ADAM  metallopept idase domain 22 1,54 Up ANAPC4 anaphase promoting complex subunit  4 1,51 Up
ADAM 22 ADAM  metallopept idase domain 22 1,78 Up ANAPC5 anaphase promoting complex subunit  5 1,69 Up
ADAM 33 ADAM  metallopept idase domain 33 1,55 Up ANGPT2 angiopoiet in 2 1,53 Down
ADAM TS10
ADAM  metallopept idase with thrombospondin type 
1 motif , 10
1,65 Down ANGPTL2 angiopoiet in-like 2 1,58 Up
ADAM TS2
ADAM  metallopept idase with thrombospondin type 
1 motif , 2
1,58 Up ANK2 ankyrin 2, neuronal 1,62 Up
ADAM TS7
ADAM  metallopept idase with thrombospondin type 
1 motif , 7
2,45 Down ANKFY1 ankyrin repeat and FYVE domain containing 1 1,67 Up
ADAR adenosine deaminase, RNA-specif ic 1,52 Up ANKM Y2 ankyrin repeat and M YND domain containing 2 1,80 Up
ADCYAP1R1
adenylate cyclase act ivat ing polypept ide 1 (pituitary) 
receptor type I
1,53 Up ANKRD23 ankyrin repeat domain 23 1,65 Up
ADD1 adducin 1 (alpha) 1,74 Up ANKRD27 ankyrin repeat domain 27 (VPS9 domain) 1,90 Up
ADD2 adducin 2 (beta) 1,81 Up ANKRD53 ankyrin repeat domain 53 1,79 Down
ADD3 adducin 3 (gamma) 1,76 Up ANKRD7 ankyrin repeat domain 7 1,74 Up
ADH1A
alcohol dehydrogenase 1A (class I), alpha 
polypept ide
1,54 Up ANKRD9 ankyrin repeat domain 9 1,53 Down
ADH1C
alcohol dehydrogenase 1C (class I), gamma 
polypept ide
1,92 Up ANPEP alanyl (membrane) aminopept idase 1,65 Up
ADHFE1 alcohol dehydrogenase, iron containing, 1 1,51 Up ANXA13 annexin A13 1,85 Up
ADIPOQ adiponect in, C1Q and collagen domain containing 1,57 Up ANXA3 annexin A3 1,65 Up
ADIPOR1 adiponect in receptor 1 1,75 Up ANXA8 annexin A8 1,71 Up
ADNP activity-dependent neuroprotector homeobox 2,27 Up KDM 1A lysine (K)-specif ic demethylase 1A 1,69 Up
ADPRH ADP-ribosylarginine hydrolase 1,69 Up AP1G2 adaptor-related protein complex 1, gamma 2 subunit 1,62 Up
ADRBK1 adrenergic, beta, receptor kinase 1 1,76 Up AP1S1 adaptor-related protein complex 1, sigma 1 subunit 1,51 Up
ADRBK2 adrenergic, beta, receptor kinase 2 1,52 Up AP2A2 adaptor-related protein complex 2, alpha 2 subunit 1,69 Up
AEBP1 AE binding protein 1 1,61 Up AP3S1 adaptor-related protein complex 3, sigma 1 subunit 1,56 Up
AES amino-terminal enhancer of split 1,83 Up NECAB3 N-terminal EF-hand calcium binding protein 3 1,86 Up
AKR7L aldo-keto reductase family 7-like 1,65 Up APBB1
amyloid beta (A4) precursor protein-binding, family 
B, member 1 (Fe65)
2,39 Down
AFF1 AF4/FM R2 family, member 1 1,51 Up APC adenomatous polyposis coli 2,10 Up  
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APC2 adenomatosis polyposis coli 2 2,23 Down ATXN1 ataxin 1 1,77 Up
APCS amyloid P component, serum 1,82 Up ATXN7L1 ataxin 7-like 1 1,54 Up
APH1B APH1B gamma secretase subunit 1,67 Up AURKB aurora kinase B 2,32 Up
API5 apoptosis inhibitor 5 1,63 Up AUTS2 autism suscept ibility candidate 2 1,77 Up
APLP2 amyloid beta (A4) precursor-like protein 2 1,56 Up AVPR1A arginine vasopressin receptor 1A 1,53 Up
APOBEC3F
apolipoprotein B mRNA edit ing enzyme, catalyt ic 
polypept ide-like 3F
1,63 Up AVPR2 arginine vasopressin receptor 2 1,92 Up
APOL1 apolipoprotein L, 1 4,06 Down LPCAT2 lysophosphat idylcholine acyltransferase 2 1,54 Up
APOL1 apolipoprotein L, 1 1,60 Down B2M beta-2-microglobulin 1,61 Up
APPBP2
amyloid beta precursor protein (cytoplasmic tail) 
binding protein 2
1,69 Up B3GALT1
UDP-Gal:betaGlcNAc beta 1,3-
galactosyltransferase, polypept ide 1
1,52 Up
AQP10 aquaporin 10 1,85 Up B3GALT2
UDP-Gal:betaGlcNAc beta 1,3-
galactosyltransferase, polypept ide 2
1,59 Up
AQP2 aquaporin 2 (collect ing duct) 1,76 Down B3GALT4
UDP-Gal:betaGlcNAc beta 1,3-
galactosyltransferase, polypept ide 4
1,73 Up
AQP5 aquaporin 5 1,67 Up B3GAT1
beta-1,3-glucuronyltransferase 1 
(glucuronosyltransferase P)
1,68 Up
ARC activity-regulated cytoskeleton-associated protein 1,59 Up B3GNT2
UDP-GlcNAc:betaGal beta-1,3-N-
acetylglucosaminyltransferase 2
1,50 Up
ARCN1 archain 1 1,71 Up B3GNT4
UDP-GlcNAc:betaGal beta-1,3-N-
acetylglucosaminyltransferase 4
2,13 Up
NAA11 N(alpha)-acetylt ransferase 11, NatA catalyt ic subunit 1,64 Up B3GNTL1
UDP-GlcNAc:betaGal beta-1,3-N-
acetylglucosaminyltransferase-like 1
1,64 Up
ARF1 ADP-ribosylat ion factor 1 2,06 Up BACE2 beta-site APP-cleaving enzyme 2 1,73 Up
ARF3 ADP-ribosylat ion factor 3 1,62 Up BACE2 beta-site APP-cleaving enzyme 2 1,87 Up
ARHGAP17 Rho GTPase act ivat ing protein 17 1,53 Up BACH2
BTB and CNC homology 1, basic leucine zipper 
transcript ion factor 2
1,51 Up
ARHGAP19 Rho GTPase act ivat ing protein 19 1,56 Up BAG1 BCL2-associated athanogene 1,58 Up
ARHGAP26 Rho GTPase act ivat ing protein 26 1,69 Up BAGE4 B melanoma ant igen family, member 4 1,58 Up
ARHGEF10 Rho guanine nucleot ide exchange factor (GEF) 10 1,58 Up BAK1 BCL2-antagonist /killer 1 2,06 Down
ARHGEF16 Rho guanine nucleot ide exchange factor (GEF) 16 1,57 Up BAM BI BM P and act ivin membrane-bound inhibitor 1,77 Up
ARHGEF18
Rho/Rac guanine nucleot ide exchange factor (GEF) 
18
1,51 Up BASP1 brain abundant, membrane attached signal protein 1 1,63 Up
ARHGEF19 Rho guanine nucleot ide exchange factor (GEF) 19 1,99 Up DDX39B DEAD (Asp-Glu-Ala-Asp) box polypept ide 39B 1,50 Up
ARHGEF3 Rho guanine nucleot ide exchange factor (GEF) 3 1,61 Up PRRC2A proline-rich coiled-coil 2A 1,55 Down
ARID4B AT rich interact ive domain 4B (RBP1-like) 1,76 Up BBS1 Bardet-Biedl syndrome 1 1,51 Down
ARID5B AT rich interact ive domain 5B (M RF1-like) 1,77 Up BCAM basal cell adhesion molecule (Lutheran blood group) 1,54 Down
ARIH1 ariadne RBR E3 ubiquit in protein ligase 1 1,58 Up BCAN brevican 1,64 Up
ARIH2 ariadne RBR E3 ubiquit in protein ligase 2 2,40 Down BCAR3 breast cancer ant i-estrogen resistance 3 2,41 Up
ARL3 ADP-ribosylat ion factor-like 3 1,61 Up BCAS4 breast carcinoma amplif ied sequence 4 1,78 Up
ARL6IP1 ADP-ribosylat ion factor-like 6 interact ing protein 1 1,53 Up BCAT1 branched chain amino-acid transaminase 1, cytosolic 1,91 Up
ARL6IP4 ADP-ribosylat ion-like factor 6 interact ing protein 4 1,58 Up BCKDK branched chain ketoacid dehydrogenase kinase 1,60 Up
ARL6IP6 ADP-ribosylat ion-like factor 6 interact ing protein 6 1,51 Up BCL11A B-cell CLL/ lymphoma 11A (zinc f inger protein) 1,50 Up
ARM C5 armadillo repeat containing 5 1,58 Down BCL11B B-cell CLL/ lymphoma 11B (zinc f inger protein) 1,63 Up
ARM C6 armadillo repeat containing 6 1,53 Down BCL2L14 BCL2-like 14 (apoptosis facilitator) 1,81 Up
ARPC5 act in related protein 2/3 complex, subunit  5, 16kDa 2,13 Up BCL7A B-cell CLL/ lymphoma 7A 1,77 Up
ARRDC1 arrest in domain containing 1 2,06 Up BCORL1 BCL6 corepressor-like 1 1,51 Up
ARV1 ARV1 homolog (S. cerevisiae) 1,59 Up BDH2 3-hydroxybutyrate dehydrogenase, type 2 2,04 Down
ARV1 ARV1 homolog (S. cerevisiae) 1,52 Up BDKRB1 bradykinin receptor B1 1,62 Up
ACER1 alkaline ceramidase 1 1,69 Up BEX2 brain expressed X-linked 2 1,84 Up
ASB2 ankyrin repeat and SOCS box containing 2 1,50 Up BFSP1 beaded f ilament structural protein 1, f ilensin 1,97 Up
ASB8 ankyrin repeat and SOCS box containing 8 1,57 Up BFSP2 beaded f ilament structural protein 2, phakinin 1,57 Up
ASCC3 act ivat ing signal cointegrator 1 complex subunit  3 1,80 Up BHLHE23 basic helix-loop-helix family, member e23 1,98 Down
ATM IN ATM  interactor 1,66 Up BICD2 bicaudal D homolog 2 (Drosophila) 1,79 Up
ASGR1 asialoglycoprotein receptor 1 1,57 Up BID BH3 interact ing domain death agonist 1,65 Up
ASM TL acetylserotonin O-methyltransferase-like 1,53 Up BIVM basic, immunoglobulin-like variable motif  containing 1,67 Up
ASNS asparagine synthetase (glutamine-hydrolyzing) 1,84 Up BLCAP bladder cancer associated protein 1,59 Up
ASXL3 addit ional sex combs like 3 (Drosophila) 1,50 Up BLM H bleomycin hydrolase 1,88 Up
ATCAY ataxia, cerebellar, Cayman type 3,93 Down BLOC1S2
biogenesis of lysosomal organelles complex-1, 
subunit  2
1,51 Up
ATF5 act ivat ing transcript ion factor 5 1,67 Up BLVRA biliverdin reductase A 1,65 Up
ATF7IP act ivat ing transcript ion factor 7 interact ing protein 1,55 Up BM P1 bone morphogenet ic protein 1 1,78 Up
ATG16L1 autophagy related 16-like 1 (S. cerevisiae) 1,70 Up BM P7 bone morphogenet ic protein 7 1,63 Up
ATG9B autophagy related 9B 1,76 Up BM P8A bone morphogenet ic protein 8a 1,52 Up
ATOH7 atonal homolog 7 (Drosophila) 1,90 Up BM P8A bone morphogenet ic protein 8a 1,91 Down
ATP11A ATPase, class VI, type 11A 1,58 Down BNIP3 BCL2/adenovirus E1B 19kDa interact ing protein 3 1,90 Up
ATP13A1 ATPase type 13A1 1,72 Up BNIP3L
BCL2/adenovirus E1B 19kDa interact ing protein 3-
like
1,55 Up
ATP13A2 ATPase type 13A2 1,51 Up BOLA1 bolA family member 1 1,76 Up
ATP13A3 ATPase type 13A3 1,67 Up BOLA2B bolA family member 2B 1,77 Up
ATP1A4 ATPase, Na+/K+ transport ing, alpha 4 polypept ide 1,81 Up BPI bactericidal/permeability-increasing protein 1,91 Up
ATP2B4 ATPase, Ca++ transport ing, plasma membrane 4 1,63 Up BPIFC BPI fold containing family C 1,60 Up
ATP5H
ATP synthase, H+ transport ing, mitochondrial Fo 
complex, subunit  d
2,05 Up BPTF bromodomain PHD f inger transcript ion factor 1,53 Up
ATP5L
ATP synthase, H+ transport ing, mitochondrial Fo 
complex, subunit  G
2,17 Up M PC1 mitochondrial pyruvate carrier 1 1,54 Up
ATP6V0A1 ATPase, H+ transport ing, lysosomal V0 subunit  a1 1,58 Up BRS3 bombesin-like receptor 3 1,50 Up
ATP6V0A2 ATPase, H+ transport ing, lysosomal V0 subunit  a2 1,52 Up CELF4 CUGBP, Elav-like family member 4 1,83 Up
ATP6V0C
ATPase, H+ transport ing, lysosomal 16kDa, V0 
subunit  c
1,78 Up BRWD1 bromodomain and WD repeat domain containing 1 1,60 Down
ATP6V1A
ATPase, H+ transport ing, lysosomal 70kDa, V1 
subunit  A
1,65 Up BTBD9 BTB (POZ) domain containing 9 2,02 Up
ATP6V1B2
ATPase, H+ transport ing, lysosomal 56/58kDa, V1 
subunit  B2
1,58 Up BTF3 basic transcript ion factor 3 1,94 Up
ATP6V1D
ATPase, H+ transport ing, lysosomal 34kDa, V1 
subunit  D
1,55 Up BTG1 B-cell t ranslocat ion gene 1, ant i-proliferat ive 2,13 Up
ATP7B ATPase, Cu++ transport ing, beta polypept ide 1,75 Down BTG2 BTG family, member 2 2,01 Up
DPH6 diphthamine biosynthesis 6 1,78 Up BTNL9 butyrophilin-like 9 1,53 Down  
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BZW2 basic leucine zipper and W2 domains 2 1,79 Up C19orf33 chromosome 19 open reading frame 33 2,11 Up
C10orf11 chromosome 10 open reading frame 11 1,93 Up C19orf44 chromosome 19 open reading frame 44 4,15 Down
WBP1L WW domain binding protein 1-like 1,74 Up C19orf47 chromosome 19 open reading frame 47 1,57 Up
BEND7 BEN domain containing 7 1,52 Down KXD1 KxDL motif  containing 1 1,63 Up
JAKM IP3 Janus kinase and microtubule interact ing protein 3 1,62 Up WDR83OS WD repeat domain 83 opposite strand 1,65 Up
FRA10AC1
fragile site, folic acid type, rare, f ra(10)(q23.3) or 
f ra(10)(q24.2) candidate 1
1,78 Up DDA1 DET1 and DDB1 associated 1 1,78 Up
C10orf62 chromosome 10 open reading frame 62 1,67 Up C19orf59 chromosome 19 open reading frame 59 1,95 Up
M ORN4 M ORN repeat containing 4 1,59 Up SM G9 SM G9 nonsense mediated mRNA decay factor 1,52 Up
FAM 204A family with sequence similarity 204, member A 1,69 Up ZC3H4 zinc f inger CCCH-type containing 4 2,05 Up
C11orf16 chromosome 11 open reading frame 16 3,55 Down C1orf100 chromosome 1 open reading frame 100 1,95 Up
C11orf21 chromosome 11 open reading frame 21 1,55 Down C1orf101 chromosome 1 open reading frame 101 1,59 Up
KIAA1549L KIAA1549-like 2,43 Down C1orf106 chromosome 1 open reading frame 106 1,59 Up
DNHD1 dynein heavy chain domain 1 1,70 Up DIEXF
digest ive organ expansion factor homolog 
(zebraf ish)
2,17 Up
C11orf49 chromosome 11 open reading frame 49 1,73 Up SH3D21 SH3 domain containing 21 1,52 Up
ANAPC15 anaphase promoting complex subunit  15 1,51 Down CCDC181 coiled-coil domain containing 181 1,90 Up
C11orf57 chromosome 11 open reading frame 57 1,63 Up CCDC181 coiled-coil domain containing 181 1,51 Up
IFT46
intraf lagellar t ransport  46 homolog 
(Chlamydomonas)
1,52 Up C1orf116 chromosome 1 open reading frame 116 1,51 Up
M SANTD2 M yb/SANT-like DNA-binding domain containing 2 1,70 Up TM EM 167B transmembrane protein 167B 1,82 Up
LINC00301 long intergenic non-protein coding RNA 301 1,51 Up DESI2 desumoylat ing isopept idase 2 1,55 Up
C11orf70 chromosome 11 open reading frame 70 1,86 Up AUNIP aurora kinase A and ninein interact ing protein 1,56 Up
C11orf72 chromosome 11 open reading frame 72 2,20 Up SNAP47 synaptosomal-associated protein, 47kDa 1,93 Up
C11orf72 chromosome 11 open reading frame 72 1,91 Up M AB21L3 mab-21-like 3 (C. elegans) 2,26 Up
SHANK2-AS3 SHANK2 ant isense RNA 3 2,42 Down RNF220 ring f inger protein 220 1,51 Up
SDHAF2 succinate dehydrogenase complex assembly factor 2 1,57 Up RNF220 ring f inger protein 220 1,53 Up
HNF1A-AS1 HNF1A ant isense RNA 1 1,58 Up TSACC TSSK6 act ivat ing co-chaperone 3,17 Up
C12orf29 chromosome 12 open reading frame 29 1,82 Up C1orf198 chromosome 1 open reading frame 198 2,74 Up
RHNO1 RAD9-HUS1-RAD1 interact ing nuclear orphan 1 1,73 Up FAM 189B family with sequence similarity 189, member B 1,51 Up
C12orf5 chromosome 12 open reading frame 5 1,96 Up C1orf204 chromosome 1 open reading frame 204 1,51 Down
LACC1
laccase (mult icopper oxidoreductase) domain 
containing 1
1,66 Up C1orf210 chromosome 1 open reading frame 210 1,57 Down
M EDAG mesenteric estrogen-dependent adipogenesis 1,53 Up STM N1 stathmin 1 1,64 Up
C14orf1 chromosome 14 open reading frame 1 1,68 Up TRM T1L
tRNA methyltransferase 1 homolog (S. cerevisiae)-
like
2,02 Up
JKAM P JNK1/M APK8-associated membrane protein 1,70 Up C1orf43 chromosome 1 open reading frame 43 1,81 Up
C14orf113~with
drawn
entry withdrawn 1,97 Up C1orf53 chromosome 1 open reading frame 53 1,61 Up
DTD2 D-tyrosyl-tRNA deacylase 2 (putat ive) 1,52 Up C1orf63 chromosome 1 open reading frame 63 1,61 Up
GSKIP GSK3B interact ing protein 1,62 Up SZT2 seizure threshold 2 homolog (mouse) 1,59 Up
ZNF839 zinc f inger protein 839 1,64 Up RSG1 REM 2 and RAB-like small GTPase 1 1,88 Up
ZC2HC1C zinc f inger, C2HC-type containing 1C 1,69 Up C1orf95 chromosome 1 open reading frame 95 2,91 Down
C14orf144 chromosome 14 open reading frame 144 1,54 Up C1QTNF2 C1q and tumor necrosis factor related protein 2 1,62 Up
CEP128 centrosomal protein 128kDa 1,74 Up C1QTNF2 C1q and tumor necrosis factor related protein 2 1,79 Up
INF2 inverted formin, FH2 and WH2 domain containing 1,68 Up C1R complement component 1, r subcomponent 1,99 Up
NOP9 NOP9 nucleolar protein 1,57 Up C2 complement component 2 1,58 Up
ELM SAN1 ELM 2 and M yb/SANT-like domain containing 1 2,71 Down C2 complement component 2 1,78 Up
CCDC176 coiled-coil domain containing 176 1,58 Up C2 complement component 2 1,75 Up
HM GN2P46
high mobility group nucleosomal binding domain 2 
pseudogene 46
1,72 Up VSTM 2L V-set and transmembrane domain containing 2 like 1,64 Up
ANP32A-IT1 ANP32A intronic transcript  1 (non-protein coding) 1,85 Up SOGA1 suppressor of glucose, autophagy associated 1 1,64 Up
KATNBL1 katanin p80 subunit  B-like 1 2,02 Up SOGA1 suppressor of glucose, autophagy associated 1 1,61 Down
C15orf41 chromosome 15 open reading frame 41 1,61 Up PABPC1L poly(A) binding protein, cytoplasmic 1-like 1,61 Up
LINC00593 long intergenic non-protein coding RNA 593 2,14 Up PPDPF
pancreat ic progenitor cell dif ferent iat ion and 
proliferat ion factor
2,56 Up
FAM 195A family with sequence similarity 195, member A 1,89 Up C20orf195 chromosome 20 open reading frame 195 3,18 Down
C16orf3 chromosome 16 open reading frame 3 2,04 Down ZFAS1 ZNFX1 ant isense RNA 1 1,91 Up
C16orf45 chromosome 16 open reading frame 45 1,54 Up C20orf26 chromosome 20 open reading frame 26 1,58 Up
CM C2 C-x(9)-C motif  containing 2 1,59 Up AAR2 AAR2 splicing factor homolog (S. cerevisiae) 1,53 Up
C16orf70 chromosome 16 open reading frame 70 1,60 Up FERM T1 fermit in family member 1 1,54 Up
C16orf71 chromosome 16 open reading frame 71 1,74 Up RTFDC1 replicat ion terminat ion factor 2 domain containing 1 1,57 Up
C16orf74 chromosome 16 open reading frame 74 1,51 Up BPIFA3 BPI fold containing family A, member 3 1,89 Up
LINC00304 long intergenic non-protein coding RNA 304 2,51 Down ISM 1 isthmin 1, angiogenesis inhibitor 1,55 Up
TEFM transcript ion elongat ion factor, mitochondrial 1,95 Up C20orf85 chromosome 20 open reading frame 85 1,81 Up
SPATA32 spermatogenesis associated 32 1,84 Up ZNF295-AS1 ZNF295 ant isense RNA 1 1,52 Up
C17orf59 chromosome 17 open reading frame 59 1,72 Up CYP4F29P
cytochrome P450, family 4, subfamily F, polypept ide 
29, pseudogene
2,05 Up
TM EM 256 transmembrane protein 256 1,54 Up C21orf33 chromosome 21 open reading frame 33 1,72 Up
CTC1 CTS telomere maintenance complex component 1 1,52 Up M IS18A M IS18 kinetochore protein A 1,86 Up
C17orf75 chromosome 17 open reading frame 75 1,62 Up YBEY ybeY metallopept idase (putat ive) 1,55 Up
C17orf77 chromosome 17 open reading frame 77 1,57 Up C21orf58 chromosome 21 open reading frame 58 1,55 Down
COPRS coordinator of PRM T5, dif ferent iat ion st imulator 1,80 Up LINC00334 long intergenic non-protein coding RNA 334 1,84 Up
TPGS2 tubulin polyglutamylase complex subunit  2 1,77 Up GUCD1 guanylyl cyclase domain containing 1 1,53 Up
C18orf15 chromosome 18 open reading frame 15 1,57 Up C22orf29 chromosome 22 open reading frame 29 1,56 Down
RBFA ribosome binding factor A (putat ive) 1,99 Up SM DT1
single-pass membrane protein with aspartate-rich 
tail 1
1,97 Up
C18orf54 chromosome 18 open reading frame 54 1,73 Up TM EM 184B transmembrane protein 184B 1,76 Up
M FSD12 major facilitator superfamily domain containing 12 1,57 Up KIAA0930 KIAA0930 2,81 Up
C19orf31~withd
rawn
entry withdrawn 1,75 Up CNPPD1 cyclin Pas1/PHO80 domain containing 1 1,91 Up
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M M ADHC
methylmalonic aciduria (cobalamin def iciency) cblD 
type, with homocyst inuria
1,71 Up CA11 carbonic anhydrase XI 1,58 Up
DRC1
dynein regulatory complex subunit  1 homolog 
(Chlamydomonas)
1,64 Down CABIN1 calcineurin binding protein 1 2,85 Up
M AATS1 M YCBP-associated, test is expressed 1 1,80 Up CABLES2 Cdk5 and Abl enzyme substrate 2 1,73 Up
C3orf27 chromosome 3 open reading frame 27 1,74 Up CACNA1B
calcium channel, voltage-dependent, N type, alpha 1B 
subunit
1,80 Down
SSUH2 ssu-2 homolog (C. elegans) 1,78 Up CACNA1I
calcium channel, voltage-dependent, T type, alpha 1I 
subunit
2,48 Down
HM CES
5-hydroxymethylcytosine (hmC) binding, ES cell-
specif ic
1,65 Up CACNA2D1
calcium channel, voltage-dependent, alpha 2/delta 
subunit  1
1,65 Up
C3orf38 chromosome 3 open reading frame 38 1,78 Up CACNB1 calcium channel, voltage-dependent, beta 1 subunit 1,61 Up
FAM 194A family with sequence similarity 194, member A 1,96 Up CACNG7
calcium channel, voltage-dependent, gamma subunit  
7
1,74 Up
PP2D1 protein phosphatase 2C-like domain containing 1 1,59 Up CALCR calcitonin receptor 2,00 Down
C3orf58 chromosome 3 open reading frame 58 2,19 Down CALU calumenin 1,66 Up
M B21D2 M ab-21 domain containing 2 1,62 Up CAM K1D calcium/calmodulin-dependent protein kinase ID 1,99 Up
NDUFAF3
NADH dehydrogenase (ubiquinone) complex I, 
assembly factor 3
1,55 Up CAM K2D calcium/calmodulin-dependent protein kinase II delta 1,56 Up
C3orf62 chromosome 3 open reading frame 62 1,57 Up CAM K2G
calcium/calmodulin-dependent protein kinase II 
gamma
1,62 Up
WDFY3-AS2 WDFY3 ant isense RNA 2 1,59 Up CAM TA1 calmodulin binding transcript ion act ivator 1 1,96 Up
NOA1 nitric oxide associated 1 1,66 Up CAM TA1 calmodulin binding transcript ion act ivator 1 1,87 Up
C4orf17 chromosome 4 open reading frame 17 1,77 Up CANT1 calcium act ivated nucleot idase 1 1,59 Down
TRM T44 tRNA methyltransferase 44 homolog (S. cerevisiae) 1,50 Up CAPN3 calpain 3, (p94) 1,57 Up
PACRGL PARK2 co-regulated-like 1,51 Down CAPN6 calpain 6 1,51 Up
C5AR1 complement component 5a receptor 1 1,61 Up CAPN9 calpain 9 1,77 Up
C5orf20 chromosome 5 open reading frame 20 3,28 Down CAPRIN1 cell cycle associated protein 1 1,67 Up
FAM 172A family with sequence similarity 172, member A 1,52 Down CAPRIN1 cell cycle associated protein 1 1,90 Down
GAPT GRB2-binding adaptor protein, t ransmembrane 1,51 Up SHPK sedoheptulokinase 2,22 Up
SETD9 SET domain containing 9 1,50 Up CASD1 CAS1 domain containing 1 1,71 Up
FAM 13B family with sequence similarity 13, member B 1,75 Up CASKIN2 CASK interact ing protein 2 1,52 Down
C6orf106 chromosome 6 open reading frame 106 1,64 Up CASKIN2 CASK interact ing protein 2 1,98 Down
UHRF1BP1 UHRF1 binding protein 1 1,89 Up CASP10 caspase 10, apoptosis-related cysteine pept idase 1,51 Up
CCDC167 coiled-coil domain containing 167 1,50 Up CASP4 caspase 4, apoptosis-related cysteine pept idase 1,56 Up
OARD1 O-acyl-ADP-ribose deacylase 1 1,67 Up CASP4 caspase 4, apoptosis-related cysteine pept idase 4,11 Down
ATAT1 alpha tubulin acetylt ransferase 1 1,62 Up CASP5 caspase 5, apoptosis-related cysteine pept idase 1,85 Up
AKIRIN2 akirin 2 1,83 Up CASP8 caspase 8, apoptosis-related cysteine pept idase 3,85 Down
FAXC failed axon connect ions homolog (Drosophila) 1,57 Up CAV1 caveolin 1, caveolae protein, 22kDa 1,70 Up
SLC18B1 solute carrier family 18, subfamily B, member 1 1,74 Up CAV3 caveolin 3 1,68 Up
C6orf203 chromosome 6 open reading frame 203 1,52 Up CBS cystathionine-beta-synthase 2,13 Up
RSPH9 radial spoke head 9 homolog (Chlamydomonas) 1,61 Up CBX4 chromobox homolog 4 1,63 Up
VWA7 von Willebrand factor A domain containing 7 1,98 Down CCBE1 collagen and calcium binding EGF domains 1 1,60 Up
C6orf47 chromosome 6 open reading frame 47 2,31 Up CCDC102B coiled-coil domain containing 102B 2,05 Up
C6orf62 chromosome 6 open reading frame 62 1,87 Up CCDC108 coiled-coil domain containing 108 2,06 Down
BEND6 BEN domain containing 6 1,60 Up PRIM POL primase and polymerase (DNA-directed) 1,77 Up
GINM 1 glycoprotein integral membrane 1 1,82 Up CCDC114 coiled-coil domain containing 114 1,88 Up
BRAT1 BRCA1-associated ATM  act ivator 1 1,51 Up CCDC12 coiled-coil domain containing 12 1,71 Up
BRAT1 BRCA1-associated ATM  act ivator 1 1,67 Up CCDC13 coiled-coil domain containing 13 1,51 Up
C7orf34 chromosome 7 open reading frame 34 1,66 Up CCDC134 coiled-coil domain containing 134 1,79 Up
COA1
cytochrome c oxidase assembly factor 1 homolog (S. 
cerevisiae)
1,56 Up CCDC137 coiled-coil domain containing 137 1,55 Down
FAM 167A family with sequence similarity 167, member A 1,75 Down CCDC26 coiled-coil domain containing 26 1,76 Up
C8orf15~withdr
awn
entry withdrawn 1,64 Up CCDC50 coiled-coil domain containing 50 1,54 Down
C8orf31 chromosome 8 open reading frame 31 1,82 Up SPICE1 spindle and centriole associated protein 1 1,63 Up
C8orf34 chromosome 8 open reading frame 34 1,63 Up COA3 cytochrome c oxidase assembly factor 3 1,84 Up
UTP23
UTP23, small subunit  (SSU) processome 
component, homolog (yeast)
1,65 Up TM A7
translat ion machinery associated 7 homolog (S. 
cerevisiae)
1,83 Up
UTP23
UTP23, small subunit  (SSU) processome 
component, homolog (yeast)
1,54 Down CCDC79 coiled-coil domain containing 79 1,51 Up
FER1L6-AS1 FER1L6 ant isense RNA 1 1,77 Up CCDC86 coiled-coil domain containing 86 1,82 Up
C8orf60 chromosome 8 open reading frame 60 1,79 Up CCDC90B coiled-coil domain containing 90B 1,68 Up
ARHGEF39 Rho guanine nucleot ide exchange factor (GEF) 39 1,87 Up CCDC96 coiled-coil domain containing 96 1,54 Up
ERCC6L2
excision repair cross-complementing rodent repair 
def iciency, complementat ion group 6-like 2
1,89 Up CCIN calicin 1,71 Up
EQTN equatorin, sperm acrosome associated 1,51 Up CCKAR cholecystokinin A receptor 1,57 Up
C9orf114 chromosome 9 open reading frame 114 1,62 Up CCL2 chemokine (C-C motif ) ligand 2 1,55 Up
LINC00476 long intergenic non-protein coding RNA 476 1,70 Up CCL21 chemokine (C-C motif ) ligand 21 1,55 Up
C9orf135 chromosome 9 open reading frame 135 1,88 Up CCL3L3 chemokine (C-C motif ) ligand 3-like 3 1,58 Up
C9orf139 chromosome 9 open reading frame 139 1,63 Down CCL4 chemokine (C-C motif ) ligand 4 1,64 Up
M ORN5 M ORN repeat containing 5 1,73 Up CCNB1IP1
cyclin B1 interact ing protein 1, E3 ubiquit in protein 
ligase
1,70 Up
LINC00474 long intergenic non-protein coding RNA 474 1,54 Up CCND2 cyclin D2 1,99 Up
GSN-AS1 GSN ant isense RNA 1 1,55 Up CCND3 cyclin D3 1,99 Up
C9orf37 chromosome 9 open reading frame 37 1,60 Up CCPG1 cell cycle progression 1 1,73 Up
C9orf37 chromosome 9 open reading frame 37 1,84 Up ACKR4 atypical chemokine receptor 4 1,64 Up
C9orf53 chromosome 9 open reading frame 53 2,03 Up CCT2 chaperonin containing TCP1, subunit  2 (beta) 1,59 Up
C9orf57 chromosome 9 open reading frame 57 1,66 Up CCT4 chaperonin containing TCP1, subunit  4 (delta) 1,82 Up
AIF1L allograft  inf lammatory factor 1-like 1,86 Up CD109 CD109 molecule 1,65 Up
C9orf62 chromosome 9 open reading frame 62 1,99 Down CD151 CD151 molecule (Raph blood group) 1,68 Up
C9orf66 chromosome 9 open reading frame 66 1,82 Up CD163 CD163 molecule 1,84 Up
TM EM 252 transmembrane protein 252 1,66 Up CD177 CD177 molecule 1,81 Up
RABL6 RAB, member RAS oncogene family-like 6 1,52 Up CD177 CD177 molecule 1,88 Up  
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CD19 CD19 molecule 1,70 Up CHM L choroideremia-like (Rab escort  protein 2) 1,70 Up
CD1E CD1e molecule 1,65 Up CHM P4A charged mult ivesicular body protein 4A 1,53 Up
CD2 CD2 molecule 1,78 Up CHM P7 charged mult ivesicular body protein 7 1,56 Up
CD207 CD207 molecule, langerin 1,77 Up CHP1 calcineurin-like EF-hand protein 1 2,64 Up
CD244 CD244 molecule, natural killer cell receptor 2B4 1,85 Up CHRAC1 chromatin accessibility complex 1 1,75 Up
CD276 CD276 molecule 1,60 Down CHRDL1 chordin-like 1 6,09 Down
CD2AP CD2-associated protein 1,62 Up CHRM 2 cholinergic receptor, muscarinic 2 1,90 Up
CD302 CD302 molecule 1,53 Down CHRM 3 cholinergic receptor, muscarinic 3 1,60 Up
CD38 CD38 molecule 1,64 Up CHRNA1 cholinergic receptor, nicot inic, alpha 1 (muscle) 1,60 Up
CD46 CD46 molecule, complement regulatory protein 1,51 Up CHRNA4 cholinergic receptor, nicot inic, alpha 4 (neuronal) 2,25 Down
CD59 CD59 molecule, complement regulatory protein 1,63 Up CHST11 carbohydrate (chondroit in 4) sulfotransferase 11 1,51 Up
CD6 CD6 molecule 1,61 Up CHST13 carbohydrate (chondroit in 4) sulfotransferase 13 2,54 Down
CD63 CD63 molecule 2,56 Up CHST3 carbohydrate (chondroit in 6) sulfotransferase 3 1,64 Up
CD83 CD83 molecule 1,60 Up CHST4
carbohydrate (N-acetylglucosamine 6-O) 
sulfotransferase 4
1,74 Up
CDA cyt idine deaminase 1,52 Up CHTF18
CTF18, chromosome transmission f idelity factor 18 
homolog (S. cerevisiae)
1,77 Up
CDK11B cyclin-dependent kinase 11B 1,95 Up CHURC1 churchill domain containing 1 2,29 Up
CDK13 cyclin-dependent kinase 13 1,70 Up CIAO1 cytosolic iron-sulfur protein assembly 1 1,66 Up
CDC37 cell division cycle 37 1,53 Down CIB4 calcium and integrin binding family member 4 1,60 Up
CDC42 cell division cycle 42 1,87 Up CIDECP
cell death-inducing DFFA-like effector c 
pseudogene
1,79 Up
CDC42BPA CDC42 binding protein kinase alpha (DM PK-like) 1,66 Up CIDEB cell death-inducing DFFA-like effector b 1,91 Up
CDC42EP1 CDC42 effector protein (Rho GTPase binding) 1 3,50 Down CIITA
class II, major histocompatibility complex, 
t ransact ivator
2,09 Up
CDC42EP1 CDC42 effector protein (Rho GTPase binding) 1 1,60 Down CIRBP cold inducible RNA binding protein 1,84 Up
CDC42EP4 CDC42 effector protein (Rho GTPase binding) 4 1,70 Up CIRH1A cirrhosis, autosomal recessive 1A (cirhin) 1,57 Up
CDCA3 cell division cycle associated 3 1,53 Up CIZ1 CDKN1A interact ing zinc f inger protein 1 1,56 Up
CDCA7L cell division cycle associated 7-like 1,73 Up CKAP2 cytoskeleton associated protein 2 1,60 Up
CDCA8 cell division cycle associated 8 1,57 Up CKAP5 cytoskeleton associated protein 5 1,62 Up
CDH12 cadherin 12, type 2 (N-cadherin 2) 1,61 Up CKB creat ine kinase, brain 1,53 Down
CDH22 cadherin 22, type 2 2,51 Down CKLF chemokine-like factor 1,67 Up
CDH24 cadherin 24, type 2 1,75 Down CLCA4 chloride channel accessory 4 1,68 Up
CDH3 cadherin 3, type 1, P-cadherin (placental) 2,22 Up CLCC1 chloride channel CLIC-like 1 1,57 Up
CDH4 cadherin 4, type 1, R-cadherin (ret inal) 1,51 Up CLCF1 cardiotrophin-like cytokine factor 1 1,52 Down
CDIPT
CDP-diacylglycerol--inositol 3-
phosphat idyltransferase
1,64 Up CLDN11 claudin 11 3,09 Up
CDK2AP1 cyclin-dependent kinase 2 associated protein 1 1,70 Up CLDN12 claudin 12 1,69 Up
CDK5R2
cyclin-dependent kinase 5, regulatory subunit  2 
(p39)
1,80 Up CLDN12 claudin 12 1,74 Up
CDKAL1 CDK5 regulatory subunit  associated protein 1-like 1 1,64 Up CLEC14A C-type lect in domain family 14, member A 1,71 Up
CDR1 cerebellar degenerat ion-related protein 1, 34kDa 1,60 Up CLEC2B C-type lect in domain family 2, member B 2,08 Up
CDSN corneodesmosin 1,73 Up CLEC4G C-type lect in domain family 4, member G 1,52 Up
CEACAM 1
carcinoembryonic ant igen-related cell adhesion 
molecule 1 (biliary glycoprotein)
1,68 Up CLINT1 clathrin interactor 1 1,91 Up
CEACAM 4
carcinoembryonic ant igen-related cell adhesion 
molecule 4
1,79 Down CLN3 ceroid-lipofuscinosis, neuronal 3 1,73 Up
CEACAM 5
carcinoembryonic ant igen-related cell adhesion 
molecule 5
1,70 Up CLNS1A chloride channel, nucleot ide-sensit ive, 1A 1,53 Up
CEBPA CCAAT/enhancer binding protein (C/EBP), alpha 2,50 Down CLPTM 1
cleft  lip and palate associated transmembrane 
protein 1
1,56 Up
CEND1 cell cycle exit  and neuronal dif ferent iat ion 1 1,84 Up CLPTM 1L CLPTM 1-like 2,68 Down
CEND1 cell cycle exit  and neuronal dif ferent iat ion 1 1,58 Down CLTC clathrin, heavy chain (Hc) 1,52 Up
ADAP1 ArfGAP with dual PH domains 1 2,13 Up CM IP c-M af inducing protein 3,90 Down
AGAP3
ArfGAP with GTPase domain, ankyrin repeat and PH 
domain 3
2,47 Down CM TM 7
CKLF-like M ARVEL transmembrane domain 
containing 7
1,57 Up
CEP135 centrosomal protein 135kDa 1,74 Up XIRP1 xin act in-binding repeat containing 1 1,78 Up
CEP250 centrosomal protein 250kDa 1,91 Up XIRP2 xin act in-binding repeat containing 2 1,55 Up
CEP55 centrosomal protein 55kDa 1,62 Up CNDP2 CNDP dipept idase 2 (metallopept idase M 20 family) 1,53 Up
CEP57 centrosomal protein 57kDa 1,70 Up CNFN cornifelin 1,96 Up
CEP63 centrosomal protein 63kDa 1,51 Up CNNM 2 cyclin M 2 1,71 Up
CEP76 centrosomal protein 76kDa 1,65 Up CNNM 4 cyclin M 4 1,68 Up
CERK ceramide kinase 1,67 Up CNOT2 CCR4-NOT transcript ion complex, subunit  2 1,76 Up
CETP cholesteryl ester transfer protein, plasma 1,68 Up CNOT4 CCR4-NOT transcript ion complex, subunit  4 1,87 Up
CFL2 cof ilin 2 (muscle) 1,81 Up CNOT6 CCR4-NOT transcript ion complex, subunit  6 1,93 Up
CGA glycoprotein hormones, alpha polypept ide 1,89 Up CNR2 cannabinoid receptor 2 (macrophage) 1,56 Up
CGB1 chorionic gonadotropin, beta polypept ide 1 1,69 Down CNR2 cannabinoid receptor 2 (macrophage) 1,71 Up
TRM T6 tRNA methyltransferase 6 homolog (S. cerevisiae) 1,67 Up CNTN4 contact in 4 1,60 Up
CGN cingulin 1,99 Up CNTNAP5 contact in associated protein-like 5 1,52 Up
CHAC2 ChaC, cat ion transport  regulator homolog 2 (E. coli) 1,61 Up CNTROB centrobin, centrosomal BRCA2 interact ing protein 1,59 Up
CHAD chondroadherin 1,63 Up COG5 component of oligomeric golgi complex 5 1,70 Up
CHAF1B chromatin assembly factor 1, subunit  B (p60) 1,59 Up COG6 component of oligomeric golgi complex 6 1,55 Up
CHCHD5
coiled-coil-helix-coiled-coil-helix domain containing 
5
1,51 Up COIL coilin 1,97 Up
CHCHD5
coiled-coil-helix-coiled-coil-helix domain containing 
5
2,06 Up COL18A1 collagen, type XVIII, alpha 1 1,64 Down
CHCHD7
coiled-coil-helix-coiled-coil-helix domain containing 
7
1,69 Up COL21A1 collagen, type XXI, alpha 1 1,64 Up
CHD2 chromodomain helicase DNA binding protein 2 1,53 Up COL3A1 collagen, type III, alpha 1 1,63 Up
CHD6 chromodomain helicase DNA binding protein 6 1,79 Up COL4A2 collagen, type IV, alpha 2 1,76 Up
CHDH choline dehydrogenase 1,87 Up COL5A1 collagen, type V, alpha 1 1,70 Up
CHDH choline dehydrogenase 1,70 Up COL5A2 collagen, type V, alpha 2 1,82 Up
CHIA chit inase, acidic 1,64 Up COL6A1 collagen, type VI, alpha 1 1,82 Up
CHM choroideremia (Rab escort  protein 1) 1,67 Up COLEC10 collect in sub-family member 10 (C-type lect in) 1,51 Up  
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COM M D1 copper metabolism (M urr1) domain containing 1 1,62 Up CWF19L2 CWF19-like 2, cell cycle control (S. pombe) 1,78 Up
COM M D4 COM M  domain containing 4 2,68 Up CXCL12 chemokine (C-X-C motif ) ligand 12 1,53 Up
COM M D6 COM M  domain containing 6 2,41 Up TRM T2B tRNA methyltransferase 2 homolog B (S. cerevisiae) 1,65 Up
COPA coatomer protein complex, subunit  alpha 1,59 Up CXorf36 chromosome X open reading frame 36 2,23 Up
COPE coatomer protein complex, subunit  epsilon 1,59 Up CXorf36 chromosome X open reading frame 36 1,55 Up
COPS8 COP9 signalosome subunit  8 1,61 Up TET1 tet methylcytosine dioxygenase 1 1,62 Up
COQ7 coenzyme Q7 homolog, ubiquinone (yeast) 1,78 Up CYB5R2 cytochrome b5 reductase 2 1,60 Up
COQ9 coenzyme Q9 1,59 Up CYB5R3 cytochrome b5 reductase 3 1,75 Up
CORIN corin, serine pept idase 1,55 Up CYB5R3 cytochrome b5 reductase 3 1,83 Down
CORO2A coronin, act in binding protein, 2A 1,54 Up CYFIP1 cytoplasmic FM R1 interact ing protein 1 1,68 Up
CORO2A coronin, act in binding protein, 2A 1,53 Up CYFIP2 cytoplasmic FM R1 interact ing protein 2 2,33 Up
CORO2B coronin, act in binding protein, 2B 1,58 Up CYHR1 cysteine/hist idine-rich 1 1,50 Up
CORT cort istat in 2,31 Up FAM 197Y2
family with sequence similarity 197, Y-linked, member 
2
1,71 Up
COTL1 coactosin-like 1 (Dictyostelium) 1,51 Up CYP11B1
cytochrome P450, family 11, subfamily B, 
polypept ide 1
1,64 Up
COX4I1 cytochrome c oxidase subunit  IV isoform 1 1,61 Up CYP24A1
cytochrome P450, family 24, subfamily A, 
polypept ide 1
1,74 Up
COX7A2L
cytochrome c oxidase subunit  VIIa polypept ide 2 
like
1,65 Up CYP2A13
cytochrome P450, family 2, subfamily A, 
polypept ide 13
1,56 Up
CPAM D8
C3 and PZP-like, alpha-2-macroglobulin domain 
containing 8
1,89 Up CYP2B6
cytochrome P450, family 2, subfamily B, 
polypept ide 6
1,66 Up
CPLX3 complexin 3 1,99 Down CYP2C9
cytochrome P450, family 2, subfamily C, 
polypept ide 9
1,52 Up
CPN2 carboxypept idase N, polypept ide 2 1,69 Up CYP2F1
cytochrome P450, family 2, subfamily F, polypept ide 
1
2,10 Up
CPNE7 copine VII 1,53 Up CYP2S1
cytochrome P450, family 2, subfamily S, polypept ide 
1
1,75 Up
CPNE8 copine VIII 1,55 Down CYP3A7
cytochrome P450, family 3, subfamily A, 
polypept ide 7
1,51 Up
CPSF1
cleavage and polyadenylat ion specif ic factor 1, 
160kDa
1,57 Up CYP4F2
cytochrome P450, family 4, subfamily F, polypept ide 
2
1,59 Up
CPXM 2 carboxypept idase X (M 14 family), member 2 1,94 Up CYP4F2
cytochrome P450, family 4, subfamily F, polypept ide 
2
1,52 Down
CR1
complement component (3b/4b) receptor 1 (Knops 
blood group)
1,85 Up DAB2
Dab, mitogen-responsive phosphoprotein, homolog 
2 (Drosophila)
1,55 Up
CR2
complement component (3d/Epstein Barr virus) 
receptor 2
1,72 Up DAB2IP DAB2 interact ing protein 1,70 Up
CRABP1 cellular ret inoic acid binding protein 1 2,56 Down DACT3 dishevelled-binding antagonist  of  beta-catenin 3 2,14 Up
CRCT1 cysteine-rich C-terminal 1 3,76 Up DAD1 defender against cell death 1 1,79 Up
CRCT1 cysteine-rich C-terminal 1 1,67 Down DAP3 death associated protein 3 1,68 Up
CREB3L3 cAM P responsive element binding protein 3-like 3 1,55 Down DBI
diazepam binding inhibitor (GABA receptor 
modulator, acyl-CoA binding protein)
2,92 Up
CREB3L4 cAM P responsive element binding protein 3-like 4 1,75 Up DBN1 drebrin 1 1,50 Up
ATF6B act ivat ing transcript ion factor 6 beta 2,14 Up DBNDD2
dysbindin (dystrobrevin binding protein 1) domain 
containing 2
2,30 Up
CREG1 cellular repressor of E1A-st imulated genes 1 1,68 Up DBP
D site of albumin promoter (albumin D-box) binding 
protein
1,69 Up
CRELD2 cysteine-rich with EGF-like domains 2 1,75 Down DBR1 debranching RNA lariats 1 1,52 Up
CRHR1 cort icotropin releasing hormone receptor 1 2,47 Down DBT dihydrolipoamide branched chain transacylase E2 1,53 Up
CRIP1 cysteine-rich protein 1 (intest inal) 6,95 Down DCAKD dephospho-CoA kinase domain containing 1,57 Up
CRIP3 cysteine-rich protein 3 1,88 Up DCBLD1 discoidin, CUB and LCCL domain containing 1 1,53 Down
CRISPLD2
cysteine-rich secretory protein LCCL domain 
containing 2
1,67 Up DCBLD2 discoidin, CUB and LCCL domain containing 2 1,61 Up
CRTC1 CREB regulated transcript ion coact ivator 1 1,52 Up DCHS2 dachsous cadherin-related 2 1,81 Up
CRTC2 CREB regulated transcript ion coact ivator 2 1,60 Up DCST1 DC-STAM P domain containing 1 1,50 Up
CRYBB2 crystallin, beta B2 1,79 Up DCTN3 dynact in 3 (p22) 1,61 Up
CRYGD crystallin, gamma D 1,69 Up DCX doublecort in 1,70 Up
CRYL1 crystallin, lambda 1 1,58 Up DDAH2 dimethylarginine dimethylaminohydrolase 2 1,57 Down
CSAD cysteine sulf inic acid decarboxylase 1,80 Down DDB2 damage-specif ic DNA binding protein 2, 48kDa 1,58 Up
CSAG2 CSAG family, member 2 1,77 Up DDN dendrin 1,71 Up
CSF1R colony st imulat ing factor 1 receptor 1,67 Up DDOST
dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase subunit  (non-catalyt ic)
1,51 Up
CSF3R colony st imulat ing factor 3 receptor (granulocyte) 1,66 Up DDT D-dopachrome tautomerase 1,58 Down
CSK c-src tyrosine kinase 2,10 Up DDX19A DEAD (Asp-Glu-Ala-Asp) box polypept ide 19A 1,80 Down
CSM D3 CUB and Sushi mult iple domains 3 1,63 Up DDX47 DEAD (Asp-Glu-Ala-Asp) box polypept ide 47 1,71 Up
CSN2 casein beta 1,77 Up DDX56 DEAD (Asp-Glu-Ala-Asp) box helicase 56 1,67 Up
CSNK1G2 casein kinase 1, gamma 2 1,98 Up DDX56 DEAD (Asp-Glu-Ala-Asp) box helicase 56 1,94 Up
CSTA cystat in A (stef in A) 2,22 Up DEDD death effector domain containing 1,78 Up
CSTB cystat in B (stef in B) 1,87 Up DEFA4 defensin, alpha 4, cort icostat in 1,64 Up
CSTF1
cleavage st imulat ion factor, 3' pre-RNA, subunit  1, 
50kDa
1,58 Up DEFA6 defensin, alpha 6, Paneth cell-specif ic 1,75 Up
CSTL1 cystat in-like 1 1,51 Up DEFB106A defensin, beta 106A 1,72 Up
CTAGE1 cutaneous T-cell lymphoma-associated ant igen 1 1,59 Up DEFB123 defensin, beta 123 2,11 Up
CTCF CCCTC-binding factor (zinc f inger protein) 1,58 Up DEGS1 delta(4)-desaturase, sphingolipid 1 1,73 Up
CTDSP2
CTD (carboxy-terminal domain, RNA polymerase II, 
polypept ide A) small phosphatase 2
1,55 Up DENND1B DENN/M ADD domain containing 1B 1,62 Up
CTDSPL2
CTD (carboxy-terminal domain, RNA polymerase II, 
polypept ide A) small phosphatase like 2
1,54 Up DENND1C DENN/M ADD domain containing 1C 2,10 Up
CTF1 cardiotrophin 1 1,70 Up DENND2C DENN/M ADD domain containing 2C 1,85 Up
CTNNA3 catenin (cadherin-associated protein), alpha 3 1,71 Up DENND2C DENN/M ADD domain containing 2C 1,50 Up
CTNND2 catenin (cadherin-associated protein), delta 2 1,83 Up DENND3 DENN/M ADD domain containing 3 1,53 Up
CTPS2 CTP synthase 2 1,54 Up DENND4C DENN/M ADD domain containing 4C 1,67 Up
CTRB2 chymotrypsinogen B2 2,89 Down DFFA
DNA fragmentat ion factor, 45kDa, alpha 
polypept ide
2,01 Up
CTRL chymotrypsin-like 1,51 Up DFFB
DNA fragmentat ion factor, 40kDa, beta polypept ide 
(caspase-act ivated DNase)
1,66 Up
CTSB cathepsin B 1,57 Up DFNA5 deafness, autosomal dominant 5 2,08 Down
CTSF cathepsin F 1,59 Up DHRS3 dehydrogenase/reductase (SDR family) member 3 1,52 Up
CTSH cathepsin H 1,53 Up DHX34 DEAH (Asp-Glu-Ala-His) box polypept ide 34 1,52 Up
CTSK cathepsin K 2,05 Up DHX36 DEAH (Asp-Glu-Ala-His) box polypept ide 36 1,60 Up
CUL3 cullin 3 1,65 Up DHX37 DEAH (Asp-Glu-Ala-His) box polypept ide 37 1,59 Up
CUX1 cut-like homeobox 1 1,57 Up DHX38 DEAH (Asp-Glu-Ala-His) box polypept ide 38 1,73 Up  
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DIAPH1 diaphanous-related formin 1 1,67 Up DUX4 double homeobox 4 1,73 Down
DICER1 dicer 1, ribonuclease type III 1,57 Up DVL3 dishevelled segment polarity protein 3 2,38 Up
DIRAS3 DIRAS family, GTP-binding RAS-like 3 1,55 Up E2F6 E2F transcript ion factor 6 1,55 Up
DIRC2 disrupted in renal carcinoma 2 1,53 Up E2F6 E2F transcript ion factor 6 1,75 Up
DISP2 dispatched homolog 2 (Drosophila) 1,54 Up EBAG9
estrogen receptor binding site associated, ant igen, 
9
2,50 Up
STAG3L1 stromal ant igen 3-like 1 (pseudogene) 2,05 Up GPR183 G protein-coupled receptor 183 1,93 Up
POM 121L12 POM 121 transmembrane nucleoporin-like 12 1,82 Up EBNA1BP2 EBNA1 binding protein 2 1,59 Up
LRRC37BP1 leucine rich repeat containing 37B pseudogene 1 1,51 Up ECD ecdysoneless homolog (Drosophila) 1,87 Up
LINC01011 long intergenic non-protein coding RNA 1011 1,59 Up ECE2 endothelin convert ing enzyme 2 1,65 Up
NEURL1B neuralized E3 ubiquit in protein ligase 1B 1,89 Up ECHDC3 enoyl CoA hydratase domain containing 3 1,55 Up
DKK2 dickkopf WNT signaling pathway inhibitor 2 1,83 Up ECHS1 enoyl CoA hydratase, short  chain, 1, mitochondrial 1,85 Up
DLEU1
deleted in lymphocyt ic leukemia 1 (non-protein 
coding)
1,56 Up EDC3 enhancer of mRNA decapping 3 1,62 Down
DLEU2
deleted in lymphocyt ic leukemia 2 (non-protein 
coding)
1,73 Up EDEM 1 ER degradat ion enhancer, mannosidase alpha-like 1 1,51 Up
DLGAP3
discs, large (Drosophila) homolog-associated 
protein 3
2,02 Down LPAR1 lysophosphat idic acid receptor 1 1,60 Up
DLX1 distal-less homeobox 1 1,79 Up EEF1G eukaryot ic translat ion elongat ion factor 1 gamma 1,85 Up
DLX2 distal-less homeobox 2 1,74 Up EEF1G eukaryot ic translat ion elongat ion factor 1 gamma 2,09 Up
DLX3 distal-less homeobox 3 1,59 Up EEF2K eukaryot ic elongat ion factor-2 kinase 1,51 Up
DM AP1 DNA methyltransferase 1 associated protein 1 2,08 Up EEFSEC
eukaryot ic elongat ion factor, selenocysteine-tRNA-
specif ic
1,50 Up
DM BX1 diencephalon/mesencephalon homeobox 1 1,57 Up NECAB2 N-terminal EF-hand calcium binding protein 2 1,77 Up
DM C1 DNA meiot ic recombinase 1 1,65 Up EFHD1 EF-hand domain family, member D1 1,73 Up
DM RT1 doublesex and mab-3 related transcript ion factor 1 1,79 Up EFHD2 EF-hand domain family, member D2 1,76 Down
DM RTC1 DM RT-like family C1 1,88 Up EFNA5 ephrin-A5 3,15 Down
DNAH11 dynein, axonemal, heavy chain 11 1,57 Up EYS eyes shut homolog (Drosophila) 1,55 Up
DNAH11 dynein, axonemal, heavy chain 11 2,05 Up EGFLAM EGF-like, f ibronect in type III and laminin G domains 1,54 Up
DNAH17 dynein, axonemal, heavy chain 17 1,51 Up EHBP1 EH domain binding protein 1 1,59 Up
DNAH2 dynein, axonemal, heavy chain 2 1,59 Up EI24 etoposide induced 2.4 1,80 Up
DNAH3 dynein, axonemal, heavy chain 3 1,74 Up EIF1 eukaryot ic translat ion init iat ion factor 1 3,18 Up
DNAH7 dynein, axonemal, heavy chain 7 1,75 Up EIF1 eukaryot ic translat ion init iat ion factor 1 3,37 Up
DNAI1 dynein, axonemal, intermediate chain 1 1,64 Up EIF1AX eukaryot ic translat ion init iat ion factor 1A, X-linked 1,81 Up
DNAJA3 DnaJ (Hsp40) homolog, subfamily A, member 3 1,81 Up EIF2A eukaryot ic translat ion init iat ion factor 2A, 65kDa 1,71 Up
DNAJA4 DnaJ (Hsp40) homolog, subfamily A, member 4 1,50 Up EIF2AK3
eukaryot ic translat ion init iat ion factor 2-alpha kinase 
3
1,52 Down
DNAJB11 DnaJ (Hsp40) homolog, subfamily B, member 11 1,53 Up AGO1 argonaute RISC catalyt ic component 1 1,59 Up
DNAJB4 DnaJ (Hsp40) homolog, subfamily B, member 4 1,70 Up AGO3 argonaute RISC catalyt ic component 3 1,62 Up
DNAJC10 DnaJ (Hsp40) homolog, subfamily C, member 10 1,70 Up EIF3J eukaryot ic translat ion init iat ion factor 3, subunit  J 2,07 Up
DNAJC16 DnaJ (Hsp40) homolog, subfamily C, member 16 1,54 Up EIF3I eukaryot ic translat ion init iat ion factor 3, subunit  I 1,55 Up
DNASE1L2 deoxyribonuclease I-like 2 1,77 Up EIF3C eukaryot ic translat ion init iat ion factor 3, subunit  C 2,40 Up
DND1 DND microRNA-mediated repression inhibitor 1 1,52 Up EIF4EBP2
eukaryot ic translat ion init iat ion factor 4E binding 
protein 2
1,58 Up
DNHD1 dynein heavy chain domain 1 1,69 Up EIF5A2 eukaryot ic translat ion init iat ion factor 5A2 1,80 Up
DNM 1P35 DNM 1 pseudogene 35 1,67 Down CELA2B chymotrypsin-like elastase family, member 2B 1,78 Up
DOC2A double C2-like domains, alpha 1,68 Up ELAC2 elaC ribonuclease Z 2 1,68 Up
DOCK10 dedicator of cytokinesis 10 1,65 Up ELF1 E74-like factor 1 (ets domain transcript ion factor) 1,65 Up
DOCK10 dedicator of cytokinesis 10 1,87 Up ELF2 E74-like factor 2 (ets domain transcript ion factor) 1,84 Down
DOCK3 dedicator of cytokinesis 3 2,31 Down ELL3 elongat ion factor RNA polymerase II-like 3 1,62 Up
DOK3 docking protein 3 1,54 Down ELM O1 engulfment and cell mot ility 1 2,14 Up
DOK5 docking protein 5 2,09 Up ELM O1 engulfment and cell mot ility 1 1,75 Up
DXO decapping exoribonuclease 1,78 Up ELN elast in 1,53 Up
DPF2 D4, zinc and double PHD f ingers family 2 1,61 Up ELOVL6 ELOVL fatty acid elongase 6 1,66 Up
DPM 3
dolichyl-phosphate mannosyltransferase 
polypept ide 3
1,78 Up ELTD1
EGF, latrophilin and seven transmembrane domain 
containing 1
1,68 Up
DPP10 dipept idyl-pept idase 10 (non-funct ional) 1,69 Up EM CN endomucin 1,96 Up
DPY19L1 dpy-19-like 1 (C. elegans) 1,52 Up EM ILIN1 elast in microf ibril interfacer 1 2,97 Down
DPYSL2 dihydropyrimidinase-like 2 1,85 Up EM P2 epithelial membrane protein 2 1,68 Up
DQX1 DEAQ box RNA-dependent ATPase 1 1,79 Up EM R4P
egf-like module containing, mucin-like, hormone 
receptor-like 4 pseudogene
2,02 Up
RBM 45 RNA binding motif  protein 45 2,37 Up ENAH enabled homolog (Drosophila) 1,50 Up
CALY calcyon neuron-specif ic vesicular protein 1,54 Up ENC1 ectodermal-neural cortex 1 (with BTB domain) 1,64 Up
DRD4 dopamine receptor D4 1,71 Up ENG endoglin 1,55 Up
DRD5 dopamine receptor D5 1,53 Up ENPP1
ectonucleot ide 
pyrophosphatase/phosphodiesterase 1
1,66 Up
DRG2 developmentally regulated GTP binding protein 2 1,61 Up ENPP2
ectonucleot ide 
pyrophosphatase/phosphodiesterase 2
1,92 Up
DSC2 desmocollin 2 1,64 Up ENPP4
ectonucleot ide 
pyrophosphatase/phosphodiesterase 4 (putat ive)
1,64 Up
DSCAM Down syndrome cell adhesion molecule 1,59 Up ENPP6
ectonucleot ide 
pyrophosphatase/phosphodiesterase 6
1,67 Up
DSEL dermatan sulfate epimerase-like 1,51 Up ENSA endosulf ine alpha 1,84 Up
DSG4 desmoglein 4 1,99 Up EPAS1 endothelial PAS domain protein 1 1,58 Up
DTD1 D-tyrosyl-tRNA deacylase 1 1,75 Up EPB41L4B erythrocyte membrane protein band 4.1 like 4B 1,84 Up
DTNBP1 dystrobrevin binding protein 1 1,76 Up EPHA3 EPH receptor A3 1,82 Up
DTX3L deltex 3-like (Drosophila) 1,58 Up EPHA4 EPH receptor A4 1,60 Up
DUOX1 dual oxidase 1 1,59 Up EPHB6 EPH receptor B6 1,77 Up
DUSP16 dual specif icity phosphatase 16 1,87 Up EPN3 epsin 3 1,62 Up
DUSP3 dual specif icity phosphatase 3 1,94 Down B9D1 B9 protein domain 1 1,58 Down
DUSP4 dual specif icity phosphatase 4 1,59 Up ERG
v-ets avian erythroblastosis virus E26 oncogene 
homolog
1,50 Up
DUSP7 dual specif icity phosphatase 7 1,64 Up ERG
v-ets avian erythroblastosis virus E26 oncogene 
homolog
1,68 Up
DUX3 double homeobox 3 1,62 Up ERGIC1
endoplasmic ret iculum-golgi intermediate 
compartment (ERGIC) 1
1,69 Up
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ERGIC1
endoplasmic ret iculum-golgi intermediate 
compartment (ERGIC) 1
1,67 Down FASTKD1 FAST kinase domains 1 1,71 Up
ERGIC2 ERGIC and golgi 2 1,58 Up FAT2 FAT atypical cadherin 2 1,88 Up
ERN1 endoplasmic ret iculum to nucleus signaling 1 1,64 Down FBLIM 1 filamin binding LIM  protein 1 1,92 Up
ERP27 endoplasmic ret iculum protein 27 1,57 Up FBLN5 fibulin 5 1,73 Up
ESM 1 endothelial cell-specif ic molecule 1 1,67 Up FBXL12 F-box and leucine-rich repeat protein 12 2,08 Up
ESPNL espin-like 1,54 Up FBXL17 F-box and leucine-rich repeat protein 17 1,60 Down
ESR1 estrogen receptor 1 1,64 Up FBXL5 F-box and leucine-rich repeat protein 5 1,69 Up
ESR2 estrogen receptor 2 (ER beta) 1,57 Up FBXL7 F-box and leucine-rich repeat protein 7 1,76 Up
ESRRG estrogen-related receptor gamma 1,78 Up FBXL7 F-box and leucine-rich repeat protein 7 2,40 Up
ETNK2 ethanolamine kinase 2 1,76 Up FBXL8 F-box and leucine-rich repeat protein 8 1,57 Down
M ECOM M DS1 and EVI1 complex locus 1,64 Up FBXO16 F-box protein 16 1,63 Up
EVX1 even-skipped homeobox 1 2,49 Down FBXO17 F-box protein 17 1,97 Down
EXOC1 exocyst complex component 1 1,53 Up FBXO25 F-box protein 25 2,40 Down
EXOC2 exocyst complex component 2 1,67 Up FBXO3 F-box protein 3 1,53 Up
EXOC3L2 exocyst complex component 3-like 2 3,31 Down FBXO9 F-box protein 9 1,57 Up
ERI2 ERI1 exoribonuclease family member 2 1,52 Up FBXO9 F-box protein 9 1,90 Up
EXOSC1 exosome component 1 1,85 Up FBXW11 F-box and WD repeat domain containing 11 1,59 Up
EXOSC8 exosome component 8 1,55 Up FCAR Fc fragment of IgA, receptor for 1,71 Up
EYA3 eyes absent homolog 3 (Drosophila) 1,51 Up FCER1A
Fc fragment of IgE, high aff inity I, receptor for; alpha 
polypept ide
1,55 Up
F11R F11 receptor 1,56 Up FCF1 FCF1 rRNA-processing protein 1,51 Up
F2RL3 coagulat ion factor II (thrombin) receptor-like 3 1,54 Down FCGR2B Fc fragment of IgG, low aff inity IIb, receptor (CD32) 1,80 Up
FAAH fatty acid amide hydrolase 1,56 Up FCGR3A
Fc fragment of IgG, low aff inity IIIa, receptor 
(CD16a)
1,73 Up
FABP2 fatty acid binding protein 2, intest inal 1,80 Up FCGRT Fc fragment of IgG, receptor, t ransporter, alpha 1,86 Up
FABP3
fatty acid binding protein 3, muscle and heart  
(mammary-derived growth inhibitor)
1,56 Up FCN1 ficolin (collagen/f ibrinogen domain containing) 1 3,58 Down
FADD Fas (TNFRSF6)-associated via death domain 1,71 Up FCRL5 Fc receptor-like 5 1,68 Up
FADS2 fatty acid desaturase 2 1,70 Up FCRLA Fc receptor-like A 1,58 Up
FAIM 3 Fas apoptot ic inhibitory molecule 3 2,30 Down FCRLB Fc receptor-like B 1,54 Up
UBALD1 UBA-like domain containing 1 1,78 Up FDPSP2 farnesyl diphosphate synthase pseudogene 2 1,63 Up
FAM 101B family with sequence similarity 101, member B 1,58 Up FEM 1C fem-1 homolog c (C. elegans) 1,54 Up
FAM 104A family with sequence similarity 104, member A 1,51 Up FEN1 flap structure-specif ic endonuclease 1 1,52 Up
FAM 104B family with sequence similarity 104, member B 1,64 Up FETUB fetuin B 1,52 Up
FAM 110A family with sequence similarity 110, member A 1,80 Up FFAR2 free fatty acid receptor 2 1,99 Up
GTSF1L gametocyte specif ic factor 1-like 1,58 Up FGA fibrinogen alpha chain 1,60 Up
FAM 118A family with sequence similarity 118, member A 1,64 Up FGB fibrinogen beta chain 1,82 Up
FAM 122B family with sequence similarity 122B 2,00 Up FGD6 FYVE, RhoGEF and PH domain containing 6 1,86 Up
FAM 127B family with sequence similarity 127, member B 1,72 Up FGF19 fibroblast growth factor 19 1,60 Up
M ZT2B mitot ic spindle organizing protein 2B 1,68 Up FGF3 fibroblast growth factor 3 2,91 Down
FAM 129B family with sequence similarity 129, member B 1,65 Down FGF5 fibroblast growth factor 5 2,19 Up
FAM 129C family with sequence similarity 129, member C 1,85 Up FGL1 fibrinogen-like 1 2,13 Up
EDDM 3B epididymal protein 3B 1,89 Up FGR
feline Gardner-Rasheed sarcoma viral oncogene 
homolog
1,79 Up
FAM 133A family with sequence similarity 133, member A 1,64 Up FHIT fragile hist idine triad 1,55 Up
FAM 134B family with sequence similarity 134, member B 1,50 Up FIGF
c-fos induced growth factor (vascular endothelial 
growth factor D)
1,67 Up
FAM 13A family with sequence similarity 13, member A 1,66 Up FILIP1 f ilamin A interact ing protein 1 1,78 Up
IFI27L1 interferon, alpha-inducible protein 27-like 1 1,50 Up FKBP1A FK506 binding protein 1A, 12kDa 1,61 Up
FAM 21C family with sequence similarity 21, member C 1,75 Up FKBP4 FK506 binding protein 4, 59kDa 1,61 Up
FAM 32A family with sequence similarity 32, member A 1,68 Up FLAD1 flavin adenine dinucleot ide synthetase 1 1,57 Up
FAM 3B family with sequence similarity 3, member B 1,65 Up LRRC37A4P
leucine rich repeat containing 37, member A4, 
pseudogene
1,65 Up
BOD1L2 biorientat ion of chromosomes in cell division 1-like 2 1,64 Up M AGOHB mago-nashi homolog B (Drosophila) 1,85 Up
FAM 46C family with sequence similarity 46, member C 1,56 Up C19orf73 chromosome 19 open reading frame 73 1,81 Down
FAM 47A family with sequence similarity 47, member A 1,74 Up EPB41L4A-AS2 EPB41L4A ant isense RNA 2 (head to head) 1,99 Up
FAM 50A family with sequence similarity 50, member A 1,50 Up STAG3L4 stromal ant igen 3-like 4 (pseudogene) 1,62 Up
BRINP2
bone morphogenet ic protein/ret inoic acid inducible 
neural-specif ic 2
1,63 Up DNAJC22 DnaJ (Hsp40) homolog, subfamily C, member 22 2,28 Up
FAM 60A family with sequence similarity 60, member A 1,72 Up FAM 161A family with sequence similarity 161, member A 1,91 Up
ESYT1 extended synaptotagmin-like protein 1 1,56 Up VWDE von Willebrand factor D and EGF domains 1,61 Up
FAM 63A family with sequence similarity 63, member A 1,67 Up TM EM 209 transmembrane protein 209 1,55 Up
TM EM 255B transmembrane protein 255B 2,28 Down DENND1B DENN/M ADD domain containing 1B 1,63 Up
FAM 74A4 family with sequence similarity 74, member A4 1,53 Up TM EM 214 transmembrane protein 214 1,54 Up
RIM KLA
ribosomal modif icat ion protein rimK-like family 
member A
1,60 Up RBM 47 RNA binding motif  protein 47 1,81 Up
RM DN2 regulator of microtubule dynamics 2 1,53 Up ACSS3 acyl-CoA synthetase short-chain family member 3 1,65 Up
FAM 89B family with sequence similarity 89, member B 1,84 Up EFCAB6 EF-hand calcium binding domain 6 1,69 Up
FAM 8A1 family with sequence similarity 8, member A1 1,67 Up C16orf92 chromosome 16 open reading frame 92 1,63 Up
FAM 90A1 family with sequence similarity 90, member A1 1,60 Up TTC23L tetratricopept ide repeat domain 23-like 1,54 Up
FAM 91A1 family with sequence similarity 91, member A1 1,93 Up UBN2 ubinuclein 2 1,56 Up
FAM 98A family with sequence similarity 98, member A 1,52 Up LINC00889 long intergenic non-protein coding RNA 889 1,59 Up
FANCB Fanconi anemia, complementat ion group B 1,51 Up PUS10 pseudouridylate synthase 10 1,72 Up
FANCD2 Fanconi anemia, complementat ion group D2 1,74 Up LINC00896 long intergenic non-protein coding RNA 896 1,61 Up
FANCL Fanconi anemia, complementat ion group L 2,01 Up DLX6-AS1 DLX6 ant isense RNA 1 1,55 Up
FARSB phenylalanyl-tRNA synthetase, beta subunit 1,90 Up ADORA2A-AS1 ADORA2A ant isense RNA 1 1,60 Up
FARSB phenylalanyl-tRNA synthetase, beta subunit 4,77 Down LINC00094 long intergenic non-protein coding RNA 94 1,63 Up
FASLG Fas ligand (TNF superfamily, member 6) 1,73 Up C17orf104 chromosome 17 open reading frame 104 1,53 Up  
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KCNJ2-AS1 KCNJ2 ant isense RNA 1 (head to head) 1,64 Up GAS7 growth arrest-specif ic 7 1,63 Up
TAPT1-AS1 TAPT1 ant isense RNA 1 (head to head) 1,72 Up GCNT3 glucosaminyl (N-acetyl) t ransferase 3, mucin type 1,52 Up
CCDC168 coiled-coil domain containing 168 1,92 Up M OGS mannosyl-oligosaccharide glucosidase 4,35 Down
C2orf73 chromosome 2 open reading frame 73 1,77 Up GDA guanine deaminase 1,55 Up
ARHGEF37 Rho guanine nucleot ide exchange factor (GEF) 37 1,50 Up GDF3 growth dif ferent iat ion factor 3 1,66 Up
TM EM 232 transmembrane protein 232 1,52 Up GDNF glial cell derived neurotrophic factor 1,61 Down
C15orf52 chromosome 15 open reading frame 52 1,66 Up GDPD4
glycerophosphodiester phosphodiesterase domain 
containing 4
1,62 Up
M ROH5 maestro heat-like repeat family member 5 1,62 Up ARHGEF25 Rho guanine nucleot ide exchange factor (GEF) 25 1,57 Up
C1orf229 chromosome 1 open reading frame 229 1,69 Down GFOD1
glucose-fructose oxidoreductase domain containing 
1
1,55 Up
C11orf88 chromosome 11 open reading frame 88 1,56 Up GFRA3 GDNF family receptor alpha 3 1,89 Up
FLNB filamin B, beta 2,05 Down GGA2
golgi-associated, gamma adapt in ear containing, 
ARF binding protein 2
2,20 Up
FLRT1 fibronect in leucine rich transmembrane protein 1 1,90 Down GGCX gamma-glutamyl carboxylase 1,78 Up
FM O5 flavin containing monooxygenase 5 1,76 Up GGT1 gamma-glutamyltransferase 1 1,74 Up
FOXB1 forkhead box B1 1,54 Down GGT3P gamma-glutamyltransferase 3 pseudogene 2,02 Up
FOXC1 forkhead box C1 1,91 Up GGTLC2 gamma-glutamyltransferase light chain 2 1,76 Up
FOXC2 forkhead box C2 (M FH-1, mesenchyme forkhead 1) 1,76 Down GHITM growth hormone inducible transmembrane protein 1,72 Up
FOXD2 forkhead box D2 1,62 Up GHRHR growth hormone releasing hormone receptor 1,58 Up
FOXE1 forkhead box E1 (thyroid transcript ion factor 2) 2,43 Down GHRL ghrelin/obestat in prepropept ide 1,74 Up
FOXG1 forkhead box G1 1,57 Up GIP gastric inhibitory polypept ide 1,82 Up
FOXJ1 forkhead box J1 1,89 Up GIPC2 GIPC PDZ domain containing family, member 2 1,92 Up
FOXK2 forkhead box K2 1,70 Up GIT2
G protein-coupled receptor kinase interact ing 
ArfGAP 2
1,62 Up
FOXN3 forkhead box N3 1,94 Up GJC2 gap junct ion protein, gamma 2, 47kDa 1,51 Down
FOXN4 forkhead box N4 1,72 Up GJA3 gap junct ion protein, alpha 3, 46kDa 1,52 Up
FOXP1 forkhead box P1 1,57 Up GJA4 gap junct ion protein, alpha 4, 37kDa 1,91 Up
FOXP3 forkhead box P3 1,51 Up GJA5 gap junct ion protein, alpha 5, 40kDa 1,53 Up
FOXQ1 forkhead box Q1 2,52 Down GJB2 gap junct ion protein, beta 2, 26kDa 1,67 Up
FOXRED1 FAD-dependent oxidoreductase domain containing 1 1,59 Up GJE1 gap junct ion protein, epsilon 1, 23kDa 1,95 Up
FPR2 formyl pept ide receptor 2 1,53 Up GLDC glycine dehydrogenase (decarboxylat ing) 1,50 Up
ATAD5 ATPase family, AAA domain containing 5 1,72 Up GLIS3 GLIS family zinc f inger 3 1,64 Up
FRG1 FSHD region gene 1 1,76 Up GLRX glutaredoxin (thiolt ransferase) 1,83 Up
FRG2 FSHD region gene 2 1,52 Up GXYLT2 glucoside xylosyltransferase 2 1,55 Up
FRM D4A FERM  domain containing 4A 1,55 Up GLTP glycolipid transfer protein 1,71 Down
FRM D4A FERM  domain containing 4A 1,55 Down GLYAT glycine-N-acyltransferase 1,52 Up
FSCN1
fascin homolog 1, act in-bundling protein 
(Strongylocentrotus purpuratus)
1,77 Up GM 2A GM 2 ganglioside act ivator 1,62 Up
FSD1 fibronect in type III and SPRY domain containing 1 1,60 Up GNAS GNAS complex locus 2,00 Up
FSHR follicle st imulat ing hormone receptor 1,63 Up GNAZ
guanine nucleot ide binding protein (G protein), alpha 
z polypept ide
1,58 Down
FST follistat in 1,62 Down GNB4
guanine nucleot ide binding protein (G protein), beta 
polypept ide 4
1,79 Down
FSTL4 follistat in-like 4 1,78 Up GNG13
guanine nucleot ide binding protein (G protein), 
gamma 13
1,73 Down
FTCD formimidoyltransferase cyclodeaminase 1,52 Up GNG8
guanine nucleot ide binding protein (G protein), 
gamma 8
1,78 Up
FTH1 ferrit in, heavy polypept ide 1 3,63 Down GNGT2
guanine nucleot ide binding protein (G protein), 
gamma transducing act ivity polypept ide 2
1,54 Up
FTL ferrit in, light polypept ide 1,72 Up GNPDA2 glucosamine-6-phosphate deaminase 2 1,63 Up
FTM T ferrit in mitochondrial 1,66 Up GOLGA1 golgin A1 1,59 Up
FUBP3 far upstream element (FUSE) binding protein 3 1,67 Up GOLGA3 golgin A3 1,74 Up
FUBP3 far upstream element (FUSE) binding protein 3 1,97 Up GOLGA7 golgin A7 2,01 Down
FUNDC1 FUN14 domain containing 1 1,89 Up GOLGB1 golgin B1 1,59 Up
FUNDC2 FUN14 domain containing 2 1,55 Down GOLM 1 golgi membrane protein 1 1,53 Down
FUT10
fucosyltransferase 10 (alpha (1,3) 
fucosyltransferase)
1,51 Up GOLT1A golgi t ransport  1A 1,75 Up
FUT6 fucosyltransferase 6 (alpha (1,3) fucosyltransferase) 1,70 Up GOT2 glutamic-oxaloacet ic transaminase 2, mitochondrial 1,58 Up
FXN frataxin 2,26 Down GP1BA glycoprotein Ib (platelet), alpha polypept ide 2,13 Up
FYN FYN oncogene related to SRC, FGR, YES 1,87 Up GPBAR1 G protein-coupled bile acid receptor 1 1,86 Up
FZD10 frizzled family receptor 10 1,85 Up GPBP1L1 GC-rich promoter binding protein 1-like 1 1,61 Up
FZR1 fizzy/cell division cycle 20 related 1 (Drosophila) 1,62 Down GPC4 glypican 4 1,60 Up
GAB2 GRB2-associated binding protein 2 1,72 Up GPD1L glycerol-3-phosphate dehydrogenase 1-like 1,91 Up
GABARAPL3
GABA(A) receptors associated protein like 3, 
pseudogene
2,84 Up GPI glucose-6-phosphate isomerase 2,27 Down
GABPB2
GA binding protein transcript ion factor, beta 
subunit  2
1,53 Up GPM 6A glycoprotein M 6A 1,88 Down
GABRA1
gamma-aminobutyric acid (GABA) A receptor, alpha 
1
1,88 Up GPR112 G protein-coupled receptor 112 1,71 Up
GABRA2
gamma-aminobutyric acid (GABA) A receptor, alpha 
2
1,51 Up GPR115 G protein-coupled receptor 115 1,52 Up
GABRB1
gamma-aminobutyric acid (GABA) A receptor, beta 
1
1,66 Up GPR116 G protein-coupled receptor 116 1,78 Up
GAD2
glutamate decarboxylase 2 (pancreat ic islets and 
brain, 65kDa)
1,54 Up GPR150 G protein-coupled receptor 150 1,81 Down
GADD45B growth arrest and DNA-damage-inducible, beta 1,57 Up GPR153 G protein-coupled receptor 153 2,05 Down
GAL galanin/GM AP prepropept ide 1,61 Up GPR156 G protein-coupled receptor 156 2,49 Down
GAL3ST2 galactose-3-O-sulfotransferase 2 1,68 Up TPRA1 transmembrane protein, adipocyte asscociated 1 1,50 Up
CSGALNACT2
chondroit in sulfate N-
acetylgalactosaminyltransferase 2
1,62 Up GPR20 G protein-coupled receptor 20 1,56 Down
GALNT2
UDP-N-acetyl-alpha-D-galactosamine:polypept ide 
N-acetylgalactosaminyltransferase 2 (GalNAc-T2)
1,68 Up GPR35 G protein-coupled receptor 35 2,13 Down
GALNT6
UDP-N-acetyl-alpha-D-galactosamine:polypept ide 
N-acetylgalactosaminyltransferase 6 (GalNAc-T6)
1,79 Up GPR55 G protein-coupled receptor 55 1,94 Up
GALR3 galanin receptor 3 1,68 Down GPR61 G protein-coupled receptor 61 1,71 Up
GAM T guanidinoacetate N-methyltransferase 1,82 Up GPR62 G protein-coupled receptor 62 1,63 Up
GARNL3 GTPase act ivat ing Rap/RanGAP domain-like 3 2,12 Up GPR64 G protein-coupled receptor 64 1,84 Up
RAP1GAP2 RAP1 GTPase act ivat ing protein 2 1,76 Up GPR82 G protein-coupled receptor 82 1,74 Up
GART
phosphoribosylglycinamide formyltransferase, 
phosphoribosylglycinamide synthetase, 
phosphoribosylaminoimidazole synthetase
1,53 Up GPR89A G protein-coupled receptor 89A 1,78 Up
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GPRC5A
G protein-coupled receptor, family C, group 5, 
member A
1,71 Up HERC6
HECT and RLD domain containing E3 ubiquit in 
protein ligase family member 6
1,53 Up
GPRC5B
G protein-coupled receptor, family C, group 5, 
member B
1,79 Up HES7 hes family bHLH transcript ion factor 7 1,66 Down
GPRC5D
G protein-coupled receptor, family C, group 5, 
member D
1,93 Up HEXA hexosaminidase A (alpha polypept ide) 1,96 Up
GPS2 G protein pathway suppressor 2 1,85 Up HGD homogentisate 1,2-dioxygenase 1,74 Up
GPSM 1 G-protein signaling modulator 1 1,60 Up HGF
hepatocyte growth factor (hepapoiet in A; scatter 
factor)
1,66 Up
GPX2 glutathione peroxidase 2 (gastrointest inal) 1,63 Up HGFAC HGF act ivator 1,65 Up
GRAM D1A GRAM  domain containing 1A 1,51 Up HGS
hepatocyte growth factor-regulated tyrosine kinase 
substrate
1,65 Up
GRAM D3 GRAM  domain containing 3 1,58 Up HGS
hepatocyte growth factor-regulated tyrosine kinase 
substrate
1,81 Down
GREM 2 gremlin 2, DAN family BM P antagonist 1,62 Up HHIP hedgehog interact ing protein 1,63 Up
GRHL1 grainyhead-like 1 (Drosophila) 1,51 Up HIF3A hypoxia inducible factor 3, alpha subunit 1,53 Up
GRHL3 grainyhead-like 3 (Drosophila) 1,61 Up HINT2 hist idine triad nucleot ide binding protein 2 1,60 Up
GRIN1
glutamate receptor, ionotropic, N-methyl D-
aspartate 1
1,65 Down HIP1 hunt ingt in interact ing protein 1 1,54 Down
GRIN2A
glutamate receptor, ionotropic, N-methyl D-
aspartate 2A
1,72 Up HIPK1 homeodomain interact ing protein kinase 1 1,95 Up
GRIN2D
glutamate receptor, ionotropic, N-methyl D-
aspartate 2D
1,85 Down HIST1H2AH histone cluster 1, H2ah 2,19 Down
GRIN3A
glutamate receptor, ionotropic, N-methyl-D-
aspartate 3A
1,75 Up HIST1H2AJ histone cluster 1, H2aj 1,50 Up
GRINA
glutamate receptor, ionotropic, N-methyl D-
aspartate-associated protein 1 (glutamate binding)
1,75 Up HIST1H2AM histone cluster 1, H2am 1,53 Up
GRINA
glutamate receptor, ionotropic, N-methyl D-
aspartate-associated protein 1 (glutamate binding)
1,86 Up HIST1H2BD histone cluster 1, H2bd 1,65 Down
ARHGAP35 Rho GTPase act ivat ing protein 35 1,83 Up HIST1H2BE histone cluster 1, H2be 1,74 Up
GRM 5 glutamate receptor, metabotropic 5 1,51 Up HIST1H2BK histone cluster 1, H2bk 1,80 Up
GRWD1 glutamate-rich WD repeat containing 1 1,54 Up HIST1H3D histone cluster 1, H3d 1,56 Up
GSC2 goosecoid homeobox 2 1,55 Up HIST1H3J histone cluster 1, H3j 1,84 Up
GSDM A gasdermin A 1,74 Up HIST1H4A histone cluster 1, H4a 1,53 Up
GSG2 germ cell associated 2 (haspin) 2,31 Up HIST1H4B histone cluster 1, H4b 1,82 Up
GSK3A glycogen synthase kinase 3 alpha 2,02 Up HIST1H4E histone cluster 1, H4e 1,79 Up
GSK3B glycogen synthase kinase 3 beta 1,66 Up HIST1H4J histone cluster 1, H4j 1,63 Up
GSTM 3 glutathione S-transferase mu 3 (brain) 1,51 Up HIST2H2AA3 histone cluster 2, H2aa3 1,54 Up
GSTM 5 glutathione S-transferase mu 5 1,53 Up HIST3H2BB histone cluster 3, H2bb 1,61 Down
GSTO2 glutathione S-transferase omega 2 1,69 Up HIVEP3
human immunodeficiency virus type I enhancer 
binding protein 3
2,23 Up
GSTT2 glutathione S-transferase theta 2 2,16 Up HLA-B major histocompatibility complex, class I, B 1,51 Up
GTF3C4
general t ranscript ion factor IIIC, polypept ide 4, 
90kDa
1,64 Up HLA-DM A major histocompatibility complex, class II, DM  alpha 1,59 Up
GTPBP10 GTP-binding protein 10 (putat ive) 2,01 Up HLA-DOA major histocompatibility complex, class II, DO alpha 1,51 Up
OLA1 Obg-like ATPase 1 1,51 Up HLA-DOA major histocompatibility complex, class II, DO alpha 1,53 Up
GUCA1A guanylate cyclase act ivator 1A (ret ina) 1,79 Up HLA-DOB major histocompatibility complex, class II, DO beta 2,00 Up
GUCA2A guanylate cyclase act ivator 2A (guanylin) 1,73 Up HLA-DPA1 major histocompatibility complex, class II, DP alpha 1 2,86 Up
GUCY1A2 guanylate cyclase 1, soluble, alpha 2 1,57 Up HLA-DPB1 major histocompatibility complex, class II, DP beta 1 1,97 Up
GUCY1A3 guanylate cyclase 1, soluble, alpha 3 1,91 Up HLA-DPB2
major histocompatibility complex, class II, DP beta 2 
(pseudogene)
1,56 Up
GUK1 guanylate kinase 1 1,63 Up HLA-DQA1
major histocompatibility complex, class II, DQ alpha 
1
1,64 Up
GULP1 GULP, engulfment adaptor PTB domain containing 1 1,55 Up HLA-DQA1
major histocompatibility complex, class II, DQ alpha 
1
1,76 Up
GVINP1
GTPase, very large interferon inducible pseudogene 
1
1,86 Up HLA-DQB1 major histocompatibility complex, class II, DQ beta 1 1,56 Up
GYPC glycophorin C (Gerbich blood group) 1,69 Up HM CN1 hemicent in 1 1,60 Up
GYS2 glycogen synthase 2 (liver) 1,60 Up HM GXB4 HM G box domain containing 4 1,61 Up
H2AFJ H2A histone family, member J 2,03 Down HM GA1 high mobility group AT-hook 1 1,60 Up
H2AFY H2A histone family, member Y 1,80 Up HM GCLL1 3-hydroxymethyl-3-methylglutaryl-CoA lyase-like 1 2,08 Up
H2AFY2 H2A histone family, member Y2 1,86 Up HM GCS2
3-hydroxy-3-methylglutaryl-CoA synthase 2 
(mitochondrial)
1,83 Up
H2AFZ H2A histone family, member Z 1,57 Up HM GN1 high mobility group nucleosome binding domain 1 1,98 Up
H6PD
hexose-6-phosphate dehydrogenase (glucose 1-
dehydrogenase)
1,55 Up HM GN2 high mobility group nucleosomal binding domain 2 2,37 Up
HABP2 hyaluronan binding protein 2 1,57 Up HM GN2 high mobility group nucleosomal binding domain 2 1,94 Up
HADH hydroxyacyl-CoA dehydrogenase 1,70 Up HM HB1 histocompatibility (minor) HB-1 1,56 Up
HAGH hydroxyacylglutathione hydrolase 1,61 Up HM M R hyaluronan-mediated motility receptor (RHAM M ) 1,99 Up
HAGHL hydroxyacylglutathione hydrolase-like 1,71 Down HM OX1 heme oxygenase (decycling) 1 1,89 Down
HAPLN2 hyaluronan and proteoglycan link protein 2 1,50 Down HM X2 H6 family homeobox 2 1,67 Up
HAPLN4 hyaluronan and proteoglycan link protein 4 1,63 Up HNF4G hepatocyte nuclear factor 4, gamma 1,65 Up
HAS2 hyaluronan synthase 2 1,71 Up HNRNPC heterogeneous nuclear ribonucleoprotein C (C1/C2) 2,29 Down
HAVCR1 hepatit is A virus cellular receptor 1 1,72 Up HNRNPUL1 heterogeneous nuclear ribonucleoprotein U-like 1 2,64 Up
HAX1 HCLS1 associated protein X-1 1,66 Up HOM ER2 homer homolog 2 (Drosophila) 1,98 Up
HBE1 hemoglobin, epsilon 1 1,97 Up IFFO1 intermediate f ilament family orphan 1 2,37 Up
HCN4
hyperpolarizat ion act ivated cyclic nucleot ide-gated 
potassium channel 4
1,98 Down HOOK1 hook microtubule-tethering protein 1 1,58 Up
HCP5 HLA complex P5 (non-protein coding) 1,73 Up HOXA10 homeobox A10 1,89 Up
HTT huntingt in 2,06 Up HOXA6 homeobox A6 1,65 Up
HDAC5 histone deacetylase 5 1,59 Up HOXB3 homeobox B3 1,60 Up
HDAC7 histone deacetylase 7 1,86 Down HOXC10 homeobox C10 2,17 Up
HDAC9 histone deacetylase 9 1,53 Up HOXC11 homeobox C11 1,59 Up
HDAC9 histone deacetylase 9 2,10 Up HOXC5 homeobox C5 1,55 Up
HDDC2 HD domain containing 2 2,27 Up HOXD1 homeobox D1 1,67 Up
HDHD1
haloacid dehalogenase-like hydrolase domain 
containing 1
1,60 Up HOXD10 homeobox D10 1,61 Up
HEATR2 HEAT repeat containing 2 1,54 Up HOXD13 homeobox D13 1,51 Down
HECA headcase homolog (Drosophila) 1,91 Up HOXD8 homeobox D8 1,82 Up
HECTD3
HECT domain containing E3 ubiquit in protein ligase 
3
1,58 Up HPSE heparanase 1,89 Up
HEPACAM hepatic and glial cell adhesion molecule 1,84 Up HPSE2 heparanase 2 1,77 Up
HERC2
HECT and RLD domain containing E3 ubiquit in 
protein ligase 2
1,53 Up HRH3 histamine receptor H3 1,73 Up
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HRK
harakiri, BCL2 interact ing protein (contains only 
BH3 domain)
1,85 Down ILDR1 immunoglobulin-like domain containing receptor 1 1,60 Down
HS1BP3 HCLS1 binding protein 3 1,80 Up ILF2 interleukin enhancer binding factor 2 2,19 Up
HS2ST1 heparan sulfate 2-O-sulfotransferase 1 1,83 Up IM M P1L
IM P1 inner mitochondrial membrane pept idase-like 
(S. cerevisiae)
1,56 Up
HS3ST3B1
heparan sulfate (glucosamine) 3-O-sulfotransferase 
3B1
1,85 Up IM P4
IM P4, U3 small nucleolar ribonucleoprotein, 
homolog (yeast)
1,53 Up
HSD17B1 hydroxysteroid (17-beta) dehydrogenase 1 2,27 Down IM PA1 inositol(myo)-1(or 4)-monophosphatase 1 1,75 Up
HSD17B14 hydroxysteroid (17-beta) dehydrogenase 14 1,55 Down IM PA2 inositol(myo)-1(or 4)-monophosphatase 2 1,97 Up
HSD17B7P2
hydroxysteroid (17-beta) dehydrogenase 7 
pseudogene 2
1,68 Up ING2 inhibitor of  growth family, member 2 1,82 Up
HSD3B1
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and 
steroid delta-isomerase 1
1,91 Up INHBC inhibin, beta C 1,77 Up
HSDL2 hydroxysteroid dehydrogenase like 2 1,99 Up INS insulin 1,51 Up
HSFY2 heat shock transcript ion factor, Y linked 2 1,57 Up INSR insulin receptor 1,53 Up
HSH2D hematopoiet ic SH2 domain containing 1,85 Up INTS1 integrator complex subunit  1 1,52 Up
HSPA1A heat shock 70kDa protein 1A 1,60 Up INTS6 integrator complex subunit  6 1,67 Up
HSPA2 heat shock 70kDa protein 2 1,52 Up IQSEC1 IQ motif  and Sec7 domain 1 1,80 Up
HSPB6 heat shock protein, alpha-crystallin-related, B6 1,66 Up IQSEC2 IQ motif  and Sec7 domain 2 2,56 Down
HSPBP1
HSPA (heat shock 70kDa) binding protein, 
cytoplasmic cochaperone 1
2,14 Up IREB2 iron-responsive element binding protein 2 1,96 Up
CWC15
CWC15 spliceosome-associated protein homolog 
(S. cerevisiae)
3,02 Down IRF5 interferon regulatory factor 5 1,67 Up
TRM T112 tRNA methyltransferase 11-2 homolog (S. cerevisiae) 1,88 Up IRX4 iroquois homeobox 4 1,54 Down
TRM T2A tRNA methyltransferase 2 homolog A (S. cerevisiae) 1,58 Down IRX6 iroquois homeobox 6 1,51 Up
HTR1A
5-hydroxytryptamine (serotonin) receptor 1A, G 
protein-coupled
1,83 Up IRX6 iroquois homeobox 6 1,61 Up
HTR3C
5-hydroxytryptamine (serotonin) receptor 3C, 
ionotropic
1,56 Up ISCA2 iron-sulfur cluster assembly 2 1,55 Up
HTR7
5-hydroxytryptamine (serotonin) receptor 7, 
adenylate cyclase-coupled
1,51 Up ISG15 ISG15 ubiquit in-like modif ier 1,56 Up
HTRA2 HtrA serine pept idase 2 1,70 Up ISG20 interferon st imulated exonuclease gene 20kDa 1,72 Up
HYDIN HYDIN, axonemal central pair apparatus protein 1,79 Up ISOC2 isochorismatase domain containing 2 1,50 Down
HYOU1 hypoxia up-regulated 1 1,82 Up ITGA2B
integrin, alpha 2b (platelet glycoprotein IIb of IIb/ IIIa 
complex, ant igen CD41)
1,53 Up
FICD FIC domain containing 1,57 Up ITGA5
integrin, alpha 5 (f ibronect in receptor, alpha 
polypept ide)
1,53 Up
ID4
inhibitor of  DNA binding 4, dominant negat ive helix-
loop-helix protein
1,54 Up ITGA7 integrin, alpha 7 2,04 Up
IDI2 isopentenyl-diphosphate delta isomerase 2 1,92 Up ITGA8 integrin, alpha 8 1,74 Up
IER5 immediate early response 5 2,37 Down ITGA9 integrin, alpha 9 2,17 Up
IFI27 interferon, alpha-inducible protein 27 1,57 Up ITGAL
integrin, alpha L (ant igen CD11A (p180), lymphocyte 
funct ion-associated ant igen 1; alpha polypept ide)
1,51 Up
IFI30 interferon, gamma-inducible protein 30 2,18 Up ITGAL
integrin, alpha L (ant igen CD11A (p180), lymphocyte 
funct ion-associated ant igen 1; alpha polypept ide)
1,62 Up
IFIT1
interferon-induced protein with tetratricopept ide 
repeats 1
1,85 Up ITGB4 integrin, beta 4 1,51 Up
IFIT5
interferon-induced protein with tetratricopept ide 
repeats 5
1,68 Up ITIH5
inter-alpha-trypsin inhibitor heavy chain family, 
member 5
1,76 Up
IFITM 3 interferon induced transmembrane protein 3 1,56 Up ITK IL2-inducible T-cell kinase 1,56 Down
IFITM 5 interferon induced transmembrane protein 5 3,21 Down ITPA
inosine triphosphatase (nucleoside triphosphate 
pyrophosphatase)
1,56 Up
IFT122
intraf lagellar t ransport  122 homolog 
(Chlamydomonas)
1,76 Up ITPKA inositol-t risphosphate 3-kinase A 1,53 Up
IFT80
intraf lagellar t ransport  80 homolog 
(Chlamydomonas)
1,77 Up ITSN1 intersect in 1 (SH3 domain protein) 1,52 Down
IGF2BP3 insulin-like growth factor 2 mRNA binding protein 3 1,68 Up M ED29 mediator complex subunit  29 1,62 Up
IGFBP3 insulin-like growth factor binding protein 3 1,63 Up JAG2 jagged 2 2,57 Down
IGFBP4 insulin-like growth factor binding protein 4 1,87 Up KDM 5D lysine (K)-specif ic demethylase 5D 2,04 Up
IGH immunoglobulin heavy locus 1,54 Up KDM 6B lysine (K)-specif ic demethylase 6B 1,56 Up
IGHA1 immunoglobulin heavy constant alpha 1 1,62 Up JOSD1 Josephin domain containing 1 1,69 Up
IGHV1-69 immunoglobulin heavy variable 1-69 2,24 Down JPH2 junctophilin 2 1,51 Up
IGKV1-5 immunoglobulin kappa variable 1-5 1,50 Down JPH2 junctophilin 2 1,99 Up
IGKV2-24 immunoglobulin kappa variable 2-24 1,75 Up JPH2 junctophilin 2 1,71 Up
IGSF11 immunoglobulin superfamily, member 11 1,61 Up JPH3 junctophilin 3 1,50 Up
IGSF11 immunoglobulin superfamily, member 11 1,90 Up KALRN kalirin, RhoGEF kinase 1,82 Up
IGSF21 immunoglobin superfamily, member 21 1,61 Up KATNAL1 katanin p60 subunit  A-like 1 1,62 Up
IGSF3 immunoglobulin superfamily, member 3 1,66 Up KBTBD2 kelch repeat and BTB (POZ) domain containing 2 1,61 Up
IGSF6 immunoglobulin superfamily, member 6 1,51 Up KBTBD2 kelch repeat and BTB (POZ) domain containing 2 1,74 Up
IGSF8 immunoglobulin superfamily, member 8 1,59 Up KBTBD4 kelch repeat and BTB (POZ) domain containing 4 1,63 Up
IKZF1 IKAROS family zinc f inger 1 (Ikaros) 1,92 Up KCM F1 potassium channel modulatory factor 1 1,56 Up
IL10 interleukin 10 1,54 Up KCNA10
potassium voltage-gated channel, shaker-related 
subfamily, member 10
1,94 Up
IL10RA interleukin 10 receptor, alpha 1,53 Up KCNA6
potassium voltage-gated channel, shaker-related 
subfamily, member 6
1,70 Up
IL15 interleukin 15 1,62 Up KCNAB1
potassium voltage-gated channel, shaker-related 
subfamily, beta member 1
1,50 Up
IL17A interleukin 17A 2,02 Up KCNAB1
potassium voltage-gated channel, shaker-related 
subfamily, beta member 1
1,54 Up
IL17RA interleukin 17 receptor A 1,62 Up KCNAB1
potassium voltage-gated channel, shaker-related 
subfamily, beta member 1
1,54 Up
IL18BP interleukin 18 binding protein 1,56 Up KCND3
potassium voltage-gated channel, Shal-related 
subfamily, member 3
1,65 Up
IL18BP interleukin 18 binding protein 1,73 Down KCNE1L KCNE1-like 1,60 Up
IL1B interleukin 1, beta 1,54 Up KCNG1
potassium voltage-gated channel, subfamily G, 
member 1
1,68 Up
IL36A interleukin 36, alpha 1,55 Up KCNG3
potassium voltage-gated channel, subfamily G, 
member 3
2,09 Up
IL36G interleukin 36, gamma 1,81 Up KCNG4
potassium voltage-gated channel, subfamily G, 
member 4
1,52 Up
IL1RAP interleukin 1 receptor accessory protein 1,51 Up KCNH1
potassium voltage-gated channel, subfamily H (eag-
related), member 1
1,55 Up
IL1RN interleukin 1 receptor antagonist 1,68 Up KCNH2
potassium voltage-gated channel, subfamily H (eag-
related), member 2
1,98 Up
IL2 interleukin 2 1,68 Up KCNH5
potassium voltage-gated channel, subfamily H (eag-
related), member 5
1,53 Up
IL23A interleukin 23, alpha subunit  p19 1,58 Down KCNIP2 Kv channel interact ing protein 2 1,50 Up
IL24 interleukin 24 1,51 Up KCNIP2 Kv channel interact ing protein 2 1,80 Up
IFNL2 interferon, lambda 2 1,87 Up KCNIP4 Kv channel interact ing protein 4 1,62 Up
IL2RG interleukin 2 receptor, gamma 1,79 Up KCNJ1
potassium inwardly-rect ifying channel, subfamily J, 
member 1
1,59 Up
IL3RA interleukin 3 receptor, alpha (low aff inity) 1,70 Up KCNJ12
potassium inwardly-rect ifying channel, subfamily J, 
member 12
1,56 Up
IL4I1 interleukin 4 induced 1 2,48 Up KCNK10 potassium channel, subfamily K, member 10 1,67 Up  
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KCNK7 potassium channel, subfamily K, member 7 2,39 Down KLF3 Kruppel-like factor 3 (basic) 1,60 Up
KCNM A1
potassium large conductance calcium-act ivated 
channel, subfamily M , alpha member 1
1,69 Up KLF8 Kruppel-like factor 8 1,57 Up
KCNM A1
potassium large conductance calcium-act ivated 
channel, subfamily M , alpha member 1
3,79 Down KLHDC1 kelch domain containing 1 1,52 Up
KCNN3
potassium intermediate/small conductance calcium-
act ivated channel, subfamily N, member 3
1,67 Up KLHDC3 kelch domain containing 3 1,67 Up
KCNQ2
potassium voltage-gated channel, KQT-like 
subfamily, member 2
1,54 Up KLHL12 kelch-like family member 12 1,54 Up
KCNQ5
potassium voltage-gated channel, KQT-like 
subfamily, member 5
1,99 Up KLHL15 kelch-like family member 15 1,53 Up
KCTD13
potassium channel tetramerizat ion domain containing 
13
1,77 Up KLHL18 kelch-like family member 18 2,33 Up
KCTD14
potassium channel tetramerizat ion domain containing 
14
1,61 Up KLHL20 kelch-like family member 20 1,52 Down
KCTD16
potassium channel tetramerizat ion domain containing 
16
1,59 Up KLHL24 kelch-like family member 24 1,61 Up
KCTD16
potassium channel tetramerizat ion domain containing 
16
1,65 Up KLHL5 kelch-like family member 5 1,53 Up
KCTD2
potassium channel tetramerizat ion domain containing 
2
1,86 Up KLHL9 kelch-like family member 9 1,58 Up
KCTD21
potassium channel tetramerizat ion domain containing 
21
1,68 Up KLK10 kallikrein-related pept idase 10 1,74 Up
KDELC2 KDEL (Lys-Asp-Glu-Leu) containing 2 1,62 Up KLK15 kallikrein-related pept idase 15 1,61 Up
KDELR3
KDEL (Lys-Asp-Glu-Leu) endoplasmic ret iculum 
protein retent ion receptor 3
1,81 Up KLK2 kallikrein-related pept idase 2 1,53 Up
KERA keratocan 1,79 Up KLK5 kallikrein-related pept idase 5 1,73 Up
KIAA0141 KIAA0141 1,66 Up KLK7 kallikrein-related pept idase 7 1,67 Up
M LEC malect in 1,53 Up KNG1 kininogen 1 1,94 Up
M LEC malect in 1,71 Up KRBA1 KRAB-A domain containing 1 1,50 Up
KIAA0247 KIAA0247 1,68 Up KREM EN1 kringle containing transmembrane protein 1 1,57 Up
TM EM 194A transmembrane protein 194A 1,56 Up KRT10 kerat in 10 2,57 Up
TTC37 tetratricopept ide repeat domain 37 1,54 Up KRT18P16 kerat in 18 pseudogene 16 2,02 Up
RPRD2 regulat ion of nuclear pre-mRNA domain containing 2 1,87 Up KRT18P21 kerat in 18 pseudogene 21 1,54 Up
SZT2 seizure threshold 2 homolog (mouse) 1,58 Up KRT23 kerat in 23 (histone deacetylase inducible) 2,49 Up
KIAA0513 KIAA0513 1,59 Up KRT27 kerat in 27 1,59 Up
KIAA0513 KIAA0513 1,87 Up KRT3 kerat in 3 1,90 Down
PRRC2B proline-rich coiled-coil 2B 1,56 Up KRT31 kerat in 31 3,90 Up
KIAA0586 KIAA0586 1,70 Up KRT32 kerat in 32 1,86 Up
KIAA0753 KIAA0753 1,61 Up KRT34 kerat in 34 4,58 Up
AHCYL2 adenosylhomocysteinase-like 2 1,62 Up KRT35 kerat in 35 1,99 Up
M AU2 M AU2 sister chromatid cohesion factor 1,65 Up KRT37 kerat in 37 1,81 Down
KIAA0907 KIAA0907 1,96 Up KRT38 kerat in 38 2,11 Up
ZSWIM 8 zinc f inger, SWIM -type containing 8 1,83 Down KRT5 kerat in 5 1,96 Up
FAM 149B1 family with sequence similarity 149, member B1 1,88 Down KRT76 kerat in 76 1,86 Up
SIK3 SIK family kinase 3 1,58 Up KRT8 kerat in 8 1,55 Up
KIAA1033 KIAA1033 1,82 Up KRT85 kerat in 85 2,02 Up
PALD1 phosphatase domain containing, paladin 1 1,83 Up KRT86 kerat in 86 3,43 Up
KIAA1328 KIAA1328 2,62 Down KRTAP1-3 kerat in associated protein 1-3 3,32 Up
KIAA1377 KIAA1377 1,54 Up KRTAP1-3 kerat in associated protein 1-3 1,69 Down
KIAA1462 KIAA1462 1,54 Up KRTAP13-2 kerat in associated protein 13-2 1,74 Up
ERV3-2 endogenous retrovirus group 3, member 2 2,14 Up KRTAP13-4 kerat in associated protein 13-4 2,20 Down
NYAP2
neuronal tyrosine-phosphorylated phosphoinosit ide-
3-kinase adaptor 2
1,76 Up KRTAP15-1 kerat in associated protein 15-1 2,00 Up
CCDC146 coiled-coil domain containing 146 1,56 Up KRTAP19-1 kerat in associated protein 19-1 2,14 Up
KIAA1524 KIAA1524 1,58 Up KRTAP2-4 kerat in associated protein 2-4 1,68 Up
FAM 214B family with sequence similarity 214, member B 1,72 Up KRTAP2-4 kerat in associated protein 2-4 2,28 Up
TLDC1 TBC/LysM -associated domain containing 1 1,60 Up KRTAP2-4 kerat in associated protein 2-4 2,21 Down
TLDC1 TBC/LysM -associated domain containing 1 2,25 Up KRTAP2-4 kerat in associated protein 2-4 1,83 Down
KIAA1614 KIAA1614 1,53 Up KRTAP3-1 kerat in associated protein 3-1 5,35 Up
EPG5
ectopic P-granules autophagy protein 5 homolog (C. 
elegans)
1,87 Up KRTAP3-2 kerat in associated protein 3-2 3,18 Up
ANKRD36B ankyrin repeat domain 36B 1,58 Up KRTAP4-1 kerat in associated protein 4-1 2,56 Up
KIAA1715 KIAA1715 2,33 Up KRTAP4-1 kerat in associated protein 4-1 1,84 Down
ZNF518B zinc f inger protein 518B 1,56 Down KRTAP4-2 kerat in associated protein 4-2 1,83 Up
KIAA1751 KIAA1751 1,53 Up KRTAP4-5 kerat in associated protein 4-5 4,40 Up
TNRC18 trinucleot ide repeat containing 18 1,69 Down KRTAP4-7 kerat in associated protein 4-7 3,02 Up
KIAA1875 KIAA1875 2,27 Down KRTAP4-8 kerat in associated protein 4-8 4,07 Up
TM EM 200A transmembrane protein 200A 1,54 Up KRTAP4-9 kerat in associated protein 4-9 3,38 Up
TM EM 200A transmembrane protein 200A 1,52 Up KRTAP5-9 kerat in associated protein 5-9 1,57 Down
KIAA1919 KIAA1919 1,62 Up KRTAP9-2 kerat in associated protein 9-2 3,86 Up
KIAA1919 KIAA1919 1,61 Up KRTAP9-3 kerat in associated protein 9-3 2,79 Up
PEAK1 pseudopodium-enriched atypical kinase 1 2,00 Up KRTAP9-4 kerat in associated protein 9-4 5,60 Up
KIAA2013 KIAA2013 1,69 Up KSR1 kinase suppressor of ras 1 1,61 Up
KIF1C kinesin family member 1C 2,14 Down POGLUT1 protein O-glucosyltransferase 1 1,60 Up
KIF23 kinesin family member 23 1,60 Up
TM EM 189-
UBE2V1
TM EM 189-UBE2V1 readthrough 1,83 Up
KIF24 kinesin family member 24 1,53 Up L1CAM L1 cell adhesion molecule 1,66 Down
KIF26B kinesin family member 26B 1,95 Up L2HGDH L-2-hydroxyglutarate dehydrogenase 1,73 Up
KIF5A kinesin family member 5A 1,94 Up L3M BTL1 l(3)mbt-like 1 (Drosophila) 1,50 Up
KIR2DS1
killer cell immunoglobulin-like receptor, two 
domains, short  cytoplasmic tail, 1
1,67 Up L3M BTL2 l(3)mbt-like 2 (Drosophila) 1,83 Up
KISS1R KISS1 receptor 1,66 Down LAGE3 L ant igen family, member 3 1,81 Up
KLC2 kinesin light chain 2 1,97 Up LAM A1 laminin, alpha 1 1,50 Up
KLC4 kinesin light chain 4 1,61 Up LANCL3
LanC lant ibiot ic synthetase component C-like 3 
(bacterial)
1,56 Up
KLF13 Kruppel-like factor 13 1,75 Up LAPTM 4B lysosomal protein transmembrane 4 beta 1,73 Up  
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LARP1B La ribonucleoprotein domain family, member 1B 1,54 Up LRRC34 leucine rich repeat containing 34 1,75 Up
LAT2 linker for act ivat ion of T cells family, member 2 1,60 Up LRRC39 leucine rich repeat containing 39 1,51 Up
LAT2 linker for act ivat ion of T cells family, member 2 1,70 Up LRRC41 leucine rich repeat containing 41 1,75 Up
LATS2 large tumor suppressor kinase 2 1,73 Up LRRC49 leucine rich repeat containing 49 1,70 Up
LAYN layilin 1,51 Up LRTOM T
leucine rich transmembrane and O-methyltransferase 
domain containing
1,57 Up
LBH limb bud and heart  development 1,81 Down CEP97 centrosomal protein 97kDa 1,51 Up
LBX2 ladybird homeobox 2 2,02 Up LSAM P limbic system-associated membrane protein 2,07 Up
LCE1A late cornif ied envelope 1A 2,70 Down PLIN5 perilipin 5 1,59 Up
LCE1C late cornif ied envelope 1C 3,42 Down LSG1 large 60S subunit  nuclear export  GTPase 1 1,75 Up
LCE1D late cornif ied envelope 1D 2,15 Down LSS
lanosterol synthase (2,3-oxidosqualene-lanosterol 
cyclase)
1,63 Up
LCE2B late cornif ied envelope 2B 2,95 Up LSS
lanosterol synthase (2,3-oxidosqualene-lanosterol 
cyclase)
1,93 Up
LCE2B late cornif ied envelope 2B 7,29 Up LSS
lanosterol synthase (2,3-oxidosqualene-lanosterol 
cyclase)
1,53 Up
LCE2C late cornif ied envelope 2C 4,35 Up LTBP3
latent transforming growth factor beta binding 
protein 3
1,63 Up
LCE2D late cornif ied envelope 2D 1,60 Down LRRC2-AS1 LRRC2 ant isense RNA 1 1,74 Up
LCE3D late cornif ied envelope 3D 2,26 Up LY6H lymphocyte ant igen 6 complex, locus H 1,51 Down
LCE3E late cornif ied envelope 3E 1,98 Down LY6K lymphocyte ant igen 6 complex, locus K 1,58 Up
LCN12 lipocalin 12 1,77 Up LYG2 lysozyme G-like 2 1,53 Up
LCN8 lipocalin 8 1,57 Up LYN
v-yes-1 Yamaguchi sarcoma viral related oncogene 
homolog
1,51 Up
LDB3 LIM  domain binding 3 1,77 Up LYNX1 Ly6/neurotoxin 1 2,34 Down
LDHA lactate dehydrogenase A 1,95 Up LYPD3 LY6/PLAUR domain containing 3 2,20 Up
LEM D2 LEM  domain containing 2 1,66 Up LYRM 1 LYR motif  containing 1 1,59 Up
M BOAT7
membrane bound O-acyltransferase domain 
containing 7
1,58 Up LYZL2 lysozyme-like 2 2,25 Up
LFNG
LFNG O-fucosylpept ide 3-beta-N-
acetylglucosaminyltransferase
2,21 Down SEC16B SEC16 homolog B (S. cerevisiae) 1,58 Up
LGALS1 lect in, galactoside-binding, soluble, 1 1,86 Up M AEA macrophage erythroblast at tacher 1,58 Up
LGALS14 lect in, galactoside-binding, soluble, 14 1,54 Up M AF
v-maf avian musculoaponeurot ic f ibrosarcoma 
oncogene homolog
2,04 Up
LGALS2 lect in, galactoside-binding, soluble, 2 2,42 Up M AFF
v-maf avian musculoaponeurot ic f ibrosarcoma 
oncogene homolog F
1,81 Up
LGALS3 lect in, galactoside-binding, soluble, 3 2,04 Up M AGEA10 melanoma ant igen family A, 10 1,66 Up
LGALS7 lect in, galactoside-binding, soluble, 7 1,51 Up M AGEA8 melanoma ant igen family A, 8 1,73 Up
LGALS8 lect in, galactoside-binding, soluble, 8 2,00 Down M AGEB1 melanoma ant igen family B, 1 1,65 Up
LGI4 leucine-rich repeat LGI family, member 4 1,84 Up M AGEC3 melanoma ant igen family C, 3 1,54 Up
LHCGR luteinizing hormone/choriogonadotropin receptor 1,51 Up M AGI3
membrane associated guanylate kinase, WW and 
PDZ domain containing 3
1,65 Up
LHX1 LIM  homeobox 1 1,70 Down M AK male germ cell-associated kinase 1,63 Up
LHX2 LIM  homeobox 2 2,12 Up M ALAT1
metastasis associated lung adenocarcinoma 
transcript  1 (non-protein coding)
2,00 Up
LIG3 ligase III, DNA, ATP-dependent 2,31 Down M AM L1 mastermind-like 1 (Drosophila) 1,71 Up
LIM D2 LIM  domain containing 2 1,51 Up M AN1A2 mannosidase, alpha, class 1A, member 2 2,06 Up
LIN7B lin-7 homolog B (C. elegans) 1,62 Up M AN2A1 mannosidase, alpha, class 2A, member 1 2,50 Up
LINGO4 leucine rich repeat and Ig domain containing 4 1,51 Down M AN2A2 mannosidase, alpha, class 2A, member 2 2,18 Up
LLGL2 lethal giant larvae homolog 2 (Drosophila) 1,80 Up M AN2A2 mannosidase, alpha, class 2A, member 2 1,79 Up
LM AN2 lect in, mannose-binding 2 1,81 Up M AN2C1 mannosidase, alpha, class 2C, member 1 1,63 Down
LM BRD1 LM BR1 domain containing 1 2,00 Up M AP1A microtubule-associated protein 1A 2,13 Up
LM O1 LIM  domain only 1 (rhombotin 1) 1,54 Up M AP1B microtubule-associated protein 1B 2,00 Up
LM O4 LIM  domain only 4 1,69 Up M AP2K1 mitogen-act ivated protein kinase kinase 1 1,72 Up
LM OD1 leiomodin 1 (smooth muscle) 1,61 Up M AP2K3 mitogen-act ivated protein kinase kinase 3 3,08 Up
LNX1
ligand of numb-protein X 1, E3 ubiquit in protein 
ligase
1,63 Up M AP2K4 mitogen-act ivated protein kinase kinase 4 1,52 Up
ZNF841 zinc f inger protein 841 1,76 Up M AP2K6 mitogen-act ivated protein kinase kinase 6 1,56 Up
C2orf74 chromosome 2 open reading frame 74 1,51 Down M AP2K6 mitogen-act ivated protein kinase kinase 6 1,51 Up
SM CO2
single-pass membrane protein with coiled-coil 
domains 2
1,76 Up M AP3K13 mitogen-act ivated protein kinase kinase kinase 13 1,59 Up
C19orf68 chromosome 19 open reading frame 68 1,80 Down M AP3K3 mitogen-act ivated protein kinase kinase kinase 3 1,53 Up
TRNP1 TM F1-regulated nuclear protein 1 1,52 Up M AP6D1 M AP6 domain containing 1 1,64 Up
NPIPB15
nuclear pore complex interact ing protein family, 
member B15
1,88 Up M AP7D1 M AP7 domain containing 1 1,55 Up
UBXN1 UBX domain protein 1 1,63 Up M AP7D2 M AP7 domain containing 2 1,63 Up
FAM 178B family with sequence similarity 178, member B 1,77 Up M APK15 mitogen-act ivated protein kinase 15 1,69 Up
VWA5A von Willebrand factor A domain containing 5A 1,52 Up M APK8 mitogen-act ivated protein kinase 8 1,72 Up
LONRF1 LON pept idase N-terminal domain and ring f inger 1 1,52 Up M APK8 mitogen-act ivated protein kinase 8 1,52 Down
LOR loricrin 3,57 Up M APK8IP1
mitogen-act ivated protein kinase 8 interact ing 
protein 1
1,61 Up
LOXL2 lysyl oxidase-like 2 1,56 Up M APKBP1 mitogen-act ivated protein kinase binding protein 1 1,71 Up
LPA lipoprotein, Lp(a) 1,55 Up M ARCKS myristoylated alanine-rich protein kinase C substrate 1,73 Up
LPAL2 lipoprotein, Lp(a)-like 2, pseudogene 1,93 Up M ARK4 M AP/microtubule aff inity-regulat ing kinase 4 1,54 Up
LRAT
lecithin ret inol acyltransferase (phosphat idylcholine--
ret inol O-acyltransferase)
1,95 Up M ARVELD2 M ARVEL domain containing 2 2,07 Down
LRCH2
leucine-rich repeats and calponin homology (CH) 
domain containing 2
1,94 Up M AST1 microtubule associated serine/threonine kinase 1 3,02 Down
LRCH3
leucine-rich repeats and calponin homology (CH) 
domain containing 3
1,84 Up M ATN1 matrilin 1, cart ilage matrix protein 1,58 Up
LRFN2
leucine rich repeat and f ibronect in type III domain 
containing 2
1,67 Up M BD5 methyl-CpG binding domain protein 5 1,66 Up
LRFN5
leucine rich repeat and f ibronect in type III domain 
containing 5
2,04 Up M BL2 mannose-binding lect in (protein C) 2, soluble 2,13 Up
LRP10 low density lipoprotein receptor-related protein 10 1,53 Up M C1R
melanocort in 1 receptor (alpha melanocyte 
st imulat ing hormone receptor)
1,50 Up
LRP10 low density lipoprotein receptor-related protein 10 1,65 Down M C3R melanocort in 3 receptor 1,74 Up
LRP3 low density lipoprotein receptor-related protein 3 1,70 Down M C5R melanocort in 5 receptor 1,60 Up
LRP5 low density lipoprotein receptor-related protein 5 1,94 Up M CAM melanoma cell adhesion molecule 1,69 Up
LRRC18 leucine rich repeat containing 18 1,94 Up M CAM melanoma cell adhesion molecule 1,51 Up
LRRC2 leucine rich repeat containing 2 1,55 Up SLC25A52 solute carrier family 25, member 52 1,60 Down
NRROS negative regulator of react ive oxygen species 1,83 Up M CF2L M CF.2 cell line derived transforming sequence-like 1,56 Up  
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M CFD2 mult iple coagulat ion factor def iciency 2 1,53 Up M ORF4 mortality factor 4 1,51 Up
M CL1 myeloid cell leukemia sequence 1 (BCL2-related) 1,53 Down M ORF4L2 mortality factor 4 like 2 1,78 Up
M CM 3AP-AS1 M CM 3AP ant isense RNA 1 2,49 Up M ARC2 mitochondrial amidoxime reducing component 2 1,66 Up
M CM 3AP-AS1 M CM 3AP ant isense RNA 1 1,61 Up M PDZ mult iple PDZ domain protein 2,47 Down
M CPH1 microcephalin 1 1,72 Up M PEG1 macrophage expressed 1 1,93 Up
M CTP2 mult iple C2 domains, t ransmembrane 2 1,60 Up M PHOSPH9 M -phase phosphoprotein 9 2,15 Up
M ECOM M DS1 and EVI1 complex locus 1,54 Up M PND M PN domain containing 1,60 Up
M E1 malic enzyme 1, NADP(+)-dependent, cytosolic 1,62 Up M PP7
membrane protein, palmitoylated 7 (M AGUK p55 
subfamily member 7)
1,60 Up
M EA1 male-enhanced ant igen 1 1,69 Up M PPE1 metallophosphoesterase 1 1,67 Up
M ECP2 methyl CpG binding protein 2 (Rett  syndrome) 1,82 Up M PV17 M pV17 mitochondrial inner membrane protein 2,06 Up
M EF2B myocyte enhancer factor 2B 3,39 Down M PV17L M PV17 mitochondrial membrane protein-like 1,54 Up
M EGF11 mult iple EGF-like-domains 11 1,52 Up M R1 major histocompatibility complex, class I-related 1,95 Up
M EP1A meprin A, alpha (PABA pept ide hydrolase) 1,62 Up M RAP melanocort in 2 receptor accessory protein 1,93 Up
M ETAP1 methionyl aminopept idase 1 1,96 Up M RGPRX1 M AS-related GPR, member X1 1,59 Up
M ETTL15 methyltransferase like 15 1,71 Up M PRIP myosin phosphatase Rho interact ing protein 1,70 Up
M ETTL4 methyltransferase like 4 2,33 Up M YL12B myosin, light chain 12B, regulatory 1,69 Up
M FAP1 microf ibrillar-associated protein 1 2,15 Up M RPL10 mitochondrial ribosomal protein L10 2,07 Up
M FHAS1 malignant f ibrous hist iocytoma amplif ied sequence 1 1,68 Up M RPL16 mitochondrial ribosomal protein L16 1,96 Up
M FI2
ant igen p97 (melanoma associated) ident if ied by 
monoclonal ant ibodies 133.2 and 96.5
1,54 Up M RPL24 mitochondrial ribosomal protein L24 1,68 Up
M FN1 mitofusin 1 1,58 Up M RPL35 mitochondrial ribosomal protein L35 1,50 Up
M FNG
M FNG O-fucosylpept ide 3-beta-N-
acetylglucosaminyltransferase
1,61 Up M RPL4 mitochondrial ribosomal protein L4 1,87 Up
M FSD3 major facilitator superfamily domain containing 3 1,55 Up M RPL42 mitochondrial ribosomal protein L42 1,89 Up
M FSD5 major facilitator superfamily domain containing 5 1,59 Up M RPS12 mitochondrial ribosomal protein S12 1,52 Up
M FSD8 major facilitator superfamily domain containing 8 1,61 Up M RPS18B mitochondrial ribosomal protein S18B 1,76 Up
M GA M GA, M AX dimerizat ion protein 1,58 Up M RPS24 mitochondrial ribosomal protein S24 2,00 Up
DLGAP1-AS2 DLGAP1 ant isense RNA 2 1,77 Up M RPS25 mitochondrial ribosomal protein S25 1,72 Up
TM EM 216 transmembrane protein 216 1,70 Up M RPS27 mitochondrial ribosomal protein S27 1,54 Up
M IR22HG M IR22 host gene (non-protein coding) 3,27 Down M RPS31 mitochondrial ribosomal protein S31 1,58 Up
M IR503HG M IR503 host gene (non-protein coding) 1,75 Up M RPS36 mitochondrial ribosomal protein S36 1,58 Up
C16orf62 chromosome 16 open reading frame 62 1,55 Up M RVI1 murine retrovirus integrat ion site 1 homolog 1,55 Up
C5orf46 chromosome 5 open reading frame 46 2,21 Up M S4A3
membrane-spanning 4-domains, subfamily A, 
member 3 (hematopoiet ic cell-specif ic)
1,84 Up
FNDC9 fibronect in type III domain containing 9 1,51 Up M S4A4A
membrane-spanning 4-domains, subfamily A, 
member 4A
1,82 Up
RPS2P32 ribosomal protein S2 pseudogene 32 1,54 Up M SH2 mutS homolog 2 1,54 Up
GABPB2
GA binding protein transcript ion factor, beta 
subunit  2
1,52 Down M SI2 musashi RNA-binding protein 2 1,65 Up
SLC22A24 solute carrier family 22, member 24 1,64 Up M SM B microseminoprotein, beta- 1,68 Up
CYP1B1-AS1 CYP1B1 ant isense RNA 1 1,51 Up M SRA methionine sulfoxide reductase A 2,93 Down
PRR18 proline rich 18 1,64 Down M SX1 msh homeobox 1 1,70 Down
LINC00663 long intergenic non-protein coding RNA 663 1,77 Down M SX2 msh homeobox 2 1,74 Up
LINC00626 long intergenic non-protein coding RNA 626 1,97 Up M T1JP metallothionein 1J, pseudogene 1,60 Up
C6orf223 chromosome 6 open reading frame 223 1,65 Up M TA1 metastasis associated 1 2,28 Down
COA5 cytochrome c oxidase assembly factor 5 1,57 Up M TA2 metastasis associated 1 family, member 2 1,94 Up
CCDC144NL
coiled-coil domain containing 144 family, N-terminal 
like
1,81 Up TC2N tandem C2 domains, nuclear 1,71 Up
M ICALL1 M ICAL-like 1 2,66 Down M TCH1 mitochondrial carrier 1 1,60 Up
M ICB M HC class I polypept ide-related sequence B 2,00 Up M TF1 metal-regulatory transcript ion factor 1 1,54 Up
M IDN midnolin 2,34 Up M TM R2 myotubularin related protein 2 1,63 Up
M INA M YC induced nuclear ant igen 1,72 Up M TM R6 myotubularin related protein 6 1,85 Up
M INK1 misshapen-like kinase 1 1,80 Up M TM R9 myotubularin related protein 9 1,81 Up
HINFP histone H4 transcript ion factor 1,55 Up M TM R9 myotubularin related protein 9 1,68 Up
M LANA melan-A 1,91 Up M TNR1A melatonin receptor 1A 1,63 Up
M LF1 myeloid leukemia factor 1 1,71 Up M TPN myotrophin 1,54 Up
KM T2C lysine (K)-specif ic methyltransferase 2C 1,77 Down M TRF1L mitochondrial t ranslat ional release factor 1-like 1,62 Up
M LLT6
myeloid/ lymphoid or mixed-lineage leukemia 
(trithorax homolog, Drosophila); t ranslocated to, 6
1,98 Up M TX1 metaxin 1 1,60 Up
M LLT6
myeloid/ lymphoid or mixed-lineage leukemia 
(trithorax homolog, Drosophila); t ranslocated to, 6
1,99 Up M UC16 mucin 16, cell surface associated 1,69 Up
M LN motilin 1,62 Up M UC20 mucin 20, cell surface associated 1,81 Up
M LNR motilin receptor 1,81 Up M UC4 mucin 4, cell surface associated 1,75 Up
M LPH melanophilin 1,65 Up M UC5AC mucin 5AC, oligomeric mucus/gel-forming 1,74 Up
M LXIP M LX interact ing protein 1,60 Up M UC5B mucin 5B, oligomeric mucus/gel-forming 1,51 Up
M LXIPL M LX interact ing protein-like 1,91 Down M UC5B mucin 5B, oligomeric mucus/gel-forming 1,56 Up
M LYCD malonyl-CoA decarboxylase 1,50 Down M US81 M US81 structure-specif ic endonuclease subunit 1,53 Up
M M AB
methylmalonic aciduria (cobalamin def iciency) cblB 
type
1,58 Up M X2 myxovirus (inf luenza virus) resistance 2 (mouse) 1,56 Up
M M AB
methylmalonic aciduria (cobalamin def iciency) cblB 
type
1,76 Up M XRA5 matrix-remodelling associated 5 1,66 Up
M M E membrane metallo-endopept idase 1,56 Up M XRA8 matrix-remodelling associated 8 1,59 Down
M M P17 matrix metallopept idase 17 (membrane-inserted) 3,29 Down M YADM myeloid-associated dif ferent iat ion marker 1,75 Up
M M RN1 mult imerin 1 1,65 Up M YADM myeloid-associated dif ferent iat ion marker 1,69 Up
M M RN2 mult imerin 2 1,78 Up M YBL1
v-myb avian myeloblastosis viral oncogene homolog-
like 1
1,52 Up
M OB1A M OB kinase act ivator 1A 1,67 Up M YBPC2 myosin binding protein C, fast type 1,69 Up
M OB3C M OB kinase act ivator 3C 1,56 Down M YCBP M YC binding protein 1,68 Up
M OCS1 molybdenum cofactor synthesis 1 1,95 Up M YCN
v-myc avian myelocytomatosis viral oncogene 
neuroblastoma derived homolog
1,60 Down
M OGAT1 monoacylglycerol O-acyltransferase 1 1,51 Up M YD88 myeloid dif ferent iat ion primary response 88 1,66 Up
M ON1B M ON1 secretory traf f icking family member B 1,93 Down M YH10 myosin, heavy chain 10, non-muscle 2,59 Up  
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M YL3 myosin, light chain 3, alkali; ventricular, skeletal, slow 1,65 Up NGB neuroglobin 1,73 Up
M YL4 myosin, light chain 4, alkali; atrial, embryonic 1,69 Up NGFRAP1
nerve growth factor receptor (TNFRSF16) 
associated protein 1
2,21 Up
M YL4 myosin, light chain 4, alkali; atrial, embryonic 1,52 Up BEX5 brain expressed, X-linked 5 1,83 Up
M YO10 myosin X 1,84 Up NGLY1 N-glycanase 1 1,74 Up
M YO15B myosin XVB pseudogene 1,59 Up NHP2L1
NHP2 non-histone chromosome protein 2-like 1 (S. 
cerevisiae)
1,63 Down
M YO15B myosin XVB pseudogene 1,51 Up NID1 nidogen 1 1,59 Up
M YO1B myosin IB 1,76 Up NIN ninein (GSK3B interact ing protein) 1,54 Up
M YO1C myosin IC 1,51 Up NKD1 naked cut icle homolog 1 (Drosophila) 1,54 Down
M YO1G myosin IG 1,59 Up NKD2 naked cut icle homolog 2 (Drosophila) 2,35 Down
M YO6 myosin VI 1,60 Up NKX1-2 NK1 homeobox 2 2,28 Down
M YO7A myosin VIIA 1,63 Up NKX2-8 NK2 homeobox 8 1,70 Down
M YOD1 myogenic dif ferent iat ion 1 1,55 Down NKX3-1 NK3 homeobox 1 1,91 Up
M YOG myogenin (myogenic factor 4) 1,81 Up NLRC3 NLR family, CARD domain containing 3 1,55 Up
M YOM 1 myomesin 1 1,59 Up NLRC4 NLR family, CARD domain containing 4 1,53 Up
M YRIP myosin VIIA and Rab interact ing protein 1,52 Up NLRP7 NLR family, pyrin domain containing 7 1,55 Up
KAT8 K(lysine) acetylt ransferase 8 1,71 Up NM D3 NM D3 ribosome export  adaptor 1,51 Up
N4BP3 NEDD4 binding protein 3 1,62 Down NM E2P1
NM E/NM 23 nucleoside diphosphate kinase 2 
pseudogene 1
1,79 Up
NADSYN1 NAD synthetase 1 1,70 Up NM E6 NM E/NM 23 nucleoside diphosphate kinase 6 1,98 Up
SND1-IT1 SND1 intronic transcript  1 (non-protein coding) 2,88 Up NM T1 N-myristoyltransferase 1 1,68 Up
NAGS N-acetylglutamate synthase 1,75 Up NM U neuromedin U 1,87 Up
NANOGP1 Nanog homeobox pseudogene 1 1,96 Up NM UR2 neuromedin U receptor 2 2,05 Up
NANP N-acetylneuraminic acid phosphatase 1,58 Up NOL11 nucleolar protein 11 1,52 Up
NAPSB napsin B aspart ic pept idase, pseudogene 1,53 Up NOP14 NOP14 nucleolar protein 1,72 Up
NARFL nuclear prelamin A recognit ion factor-like 1,68 Up NOL4 nucleolar protein 4 1,64 Up
NAT10 N-acetyltransferase 10 (GCN5-related) 1,71 Up NOL6 nucleolar protein 6 (RNA-associated) 1,65 Up
NAT6 N-acetyltransferase 6 (GCN5-related) 1,78 Up NONO non-POU domain containing, octamer-binding 1,76 Up
NAV2 neuron navigator 2 1,81 Up NOTCH2 notch 2 1,87 Down
NAV2 neuron navigator 2 1,57 Up NOTCH4 notch 4 1,58 Down
NBPF11 neuroblastoma breakpoint family, member 11 1,62 Up NOV nephroblastoma overexpressed 1,73 Up
NBR2 neighbor of BRCA1 gene 2 (non-protein coding) 1,89 Up NOVA1 neuro-oncological ventral ant igen 1 1,70 Up
NCKIPSD NCK interact ing protein with SH3 domain 1,52 Down NOX1 NADPH oxidase 1 1,70 Up
NCKIPSD NCK interact ing protein with SH3 domain 1,53 Down NPAS3 neuronal PAS domain protein 3 1,56 Down
NCL nucleolin 1,59 Up NPB neuropept ide B 1,51 Down
NCR3 natural cytotoxicity triggering receptor 3 1,53 Up NPC1L1 NPC1-like 1 1,60 Up
M T-ND3 mitochondrially encoded NADH dehydrogenase 3 6,46 Up NPFF neuropept ide FF-amide pept ide precursor 1,51 Up
NDFIP1 Nedd4 family interact ing protein 1 2,07 Up NPFFR2 neuropept ide FF receptor 2 2,01 Up
NDOR1 NADPH dependent dif lavin oxidoreductase 1 2,61 Down NPHP1 nephronophthisis 1 (juvenile) 1,71 Up
NDP Norrie disease (pseudoglioma) 1,57 Up NPHP3 nephronophthisis 3 (adolescent) 1,63 Up
NDRG1 N-myc downstream regulated 1 1,75 Up NPHS2 nephrosis 2, idiopathic, steroid-resistant (podocin) 1,66 Up
NDRG2 NDRG family member 2 1,52 Down NPIPA1
nuclear pore complex interact ing protein family, 
member A1
1,52 Up
NDST1
N-deacetylase/N-sulfotransferase (heparan 
glucosaminyl) 1
1,52 Up NPM 1
nucleophosmin (nucleolar phosphoprotein B23, 
numatrin)
3,18 Down
NDST2
N-deacetylase/N-sulfotransferase (heparan 
glucosaminyl) 2
1,62 Up NPTN neuroplast in 1,52 Up
NDST4
N-deacetylase/N-sulfotransferase (heparan 
glucosaminyl) 4
1,70 Up NPTXR neuronal pentraxin receptor 1,91 Up
NDUFA10
NADH dehydrogenase (ubiquinone) 1 alpha 
subcomplex, 10, 42kDa
1,56 Up NPVF neuropept ide VF precursor 1,53 Up
NDUFA13
NADH dehydrogenase (ubiquinone) 1 alpha 
subcomplex, 13
1,59 Up NR1H4 nuclear receptor subfamily 1, group H, member 4 1,92 Up
NDUFA3
NADH dehydrogenase (ubiquinone) 1 alpha 
subcomplex, 3, 9kDa
2,39 Down NR5A1 nuclear receptor subfamily 5, group A, member 1 1,81 Up
NDUFA8
NADH dehydrogenase (ubiquinone) 1 alpha 
subcomplex, 8, 19kDa
1,71 Up NR6A1 nuclear receptor subfamily 6, group A, member 1 1,61 Up
NDUFB2
NADH dehydrogenase (ubiquinone) 1 beta 
subcomplex, 2, 8kDa
1,61 Up NRAP nebulin-related anchoring protein 1,57 Down
NDUFB4
NADH dehydrogenase (ubiquinone) 1 beta 
subcomplex, 4, 15kDa
2,75 Up NRD1 nardilysin (N-arginine dibasic convertase) 1,58 Up
NDUFB7
NADH dehydrogenase (ubiquinone) 1 beta 
subcomplex, 7, 18kDa
3,47 Down NRG1 neuregulin 1 1,55 Up
NDUFB8
NADH dehydrogenase (ubiquinone) 1 beta 
subcomplex, 8, 19kDa
2,10 Up NRIP2 nuclear receptor interact ing protein 2 1,60 Up
NDUFS1
NADH dehydrogenase (ubiquinone) Fe-S protein 1, 
75kDa (NADH-coenzyme Q reductase)
1,73 Up NRN1L neurit in 1-like 1,58 Up
NDUFS7
NADH dehydrogenase (ubiquinone) Fe-S protein 7, 
20kDa (NADH-coenzyme Q reductase)
3,30 Down NRSN2 neurensin 2 2,32 Down
NDUFV2
NADH dehydrogenase (ubiquinone) f lavoprotein 2, 
24kDa
1,54 Up NSFL1C NSFL1 (p97) cofactor (p47) 1,58 Up
NDUFV3
NADH dehydrogenase (ubiquinone) f lavoprotein 3, 
10kDa
1,85 Up NSM CE1 non-SM C element 1 homolog (S. cerevisiae) 1,53 Up
NEFL neurof ilament, light polypept ide 1,57 Up NT5E 5'-nucleot idase, ecto (CD73) 1,50 Up
NEK9 NIM A-related kinase 9 1,50 Up NTRK2 neurotrophic tyrosine kinase, receptor, type 2 1,64 Up
NENF neudesin neurotrophic factor 1,54 Up NTRK3 neurotrophic tyrosine kinase, receptor, type 3 1,58 Up
NEO1 neogenin 1 2,74 Down NTSR1 neurotensin receptor 1 (high aff inity) 1,65 Up
NES nest in 1,69 Up NUCB2 nucleobindin 2 1,74 Up
NETO1 neuropilin (NRP) and tolloid (TLL)-like 1 2,13 Up NUCKS1
nuclear casein kinase and cyclin-dependent kinase 
substrate 1
1,80 Up
NEUROD2 neuronal dif ferent iat ion 2 1,54 Up NUCKS1
nuclear casein kinase and cyclin-dependent kinase 
substrate 1
2,07 Up
NEUROG1 neurogenin 1 2,72 Down NUDT16
nudix (nucleoside diphosphate linked moiety X)-type 
motif  16
1,78 Up
NEUROG3 neurogenin 3 1,70 Down NUP188 nucleoporin 188kDa 1,82 Up
NFATC2IP
nuclear factor of act ivated T-cells, cytoplasmic, 
calcineurin-dependent 2 interact ing protein
1,54 Up NUP210L nucleoporin 210kDa-like 1,52 Up
NFATC3
nuclear factor of act ivated T-cells, cytoplasmic, 
calcineurin-dependent 3
1,68 Up NUP98 nucleoporin 98kDa 1,75 Up
NFIA nuclear factor I/A 1,61 Up NUP98 nucleoporin 98kDa 1,55 Up
NFIB nuclear factor I/B 1,56 Up NUPL1 nucleoporin like 1 1,55 Up
NFIX
nuclear factor I/X (CCAAT-binding transcript ion 
factor)
1,92 Down NVL nuclear VCP-like 1,64 Up
NFKBIL1
nuclear factor of kappa light polypept ide gene 
enhancer in B-cells inhibitor-like 1
2,07 Down FAM 153A family with sequence similarity 153, member A 1,84 Up
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OAZ1 ornithine decarboxylase ant izyme 1 2,50 Up OSTM 1 osteopetrosis associated transmembrane protein 1 1,53 Up
OAZ1 ornithine decarboxylase ant izyme 1 1,55 Up OTOF otoferlin 1,95 Down
OBSCN
obscurin, cytoskeletal calmodulin and t it in-
interact ing RhoGEF
1,91 Up OTOP2 otopetrin 2 1,62 Up
OBSCN
obscurin, cytoskeletal calmodulin and t it in-
interact ing RhoGEF
1,55 Up OTUD1 OTU domain containing 1 1,69 Up
OCM oncomodulin 1,67 Up OTUD7A OTU domain containing 7A 1,58 Down
TENM 2 teneurin transmembrane protein 2 1,91 Up OXGR1 oxoglutarate (alpha-ketoglutarate) receptor 1 1,70 Up
TENM 3 teneurin transmembrane protein 3 1,85 Up OXR1 oxidat ion resistance 1 2,19 Up
OGFOD2
2-oxoglutarate and iron-dependent oxygenase 
domain containing 2
1,59 Up OXSM 3-oxoacyl-ACP synthase, mitochondrial 1,51 Up
OGFR opioid growth factor receptor 2,32 Down RPRD1A
regulat ion of nuclear pre-mRNA domain containing 
1A
1,91 Up
OGG1 8-oxoguanine DNA glycosylase 1,92 Up P2RX3 purinergic receptor P2X, ligand-gated ion channel, 3 1,69 Up
OGN osteoglycin 1,54 Up P2RX6 purinergic receptor P2X, ligand-gated ion channel, 6 1,94 Down
OLFM 1 olfactomedin 1 1,57 Up P4HB prolyl 4-hydroxylase, beta polypept ide 1,70 Up
OLFM 2 olfactomedin 2 1,55 Up TP53AIP1
tumor protein p53 regulated apoptosis inducing 
protein 1
1,79 Up
OLFM L2B olfactomedin-like 2B 1,58 Up PABPC1 poly(A) binding protein, cytoplasmic 1 1,59 Up
OLIG3 oligodendrocyte transcript ion factor 3 1,71 Down PACRG PARK2 co-regulated 1,81 Up
OM A1 OM A1 zinc metallopept idase 1,57 Up PACSIN3
protein kinase C and casein kinase substrate in 
neurons 3
1,50 Up
OPRK1 opioid receptor, kappa 1 1,97 Up PADI4 pept idyl arginine deiminase, type IV 1,90 Up
SIGM AR1 sigma non-opioid intracellular receptor 1 1,70 Up PAG1
phosphoprotein associated with glycosphingolipid 
microdomains 1
1,61 Up
OPTC opticin 1,54 Up PAIP1 poly(A) binding protein interact ing protein 1 1,79 Up
OR10A5 olfactory receptor, family 10, subfamily A, member 5 1,90 Up PAIP2B poly(A) binding protein interact ing protein 2B 1,79 Up
OR10H2 olfactory receptor, family 10, subfamily H, member 2 3,00 Down PANX3 pannexin 3 1,59 Up
OR10J1 olfactory receptor, family 10, subfamily J, member 1 1,70 Up PAPLN papilin, proteoglycan-like sulfated glycoprotein 1,66 Up
OR10J3 olfactory receptor, family 10, subfamily J, member 3 1,56 Up PAPSS2 3'-phosphoadenosine 5'-phosphosulfate synthase 2 1,76 Up
OR10P1 olfactory receptor, family 10, subfamily P, member 1 2,42 Up PAQR8 progest in and adipoQ receptor family member VIII 1,57 Up
OR11H12 olfactory receptor, family 11, subfamily H, member 12 1,51 Up PARD3B par-3 family cell polarity regulator beta 1,89 Up
OR12D3 olfactory receptor, family 12, subfamily D, member 3 1,65 Up PARG poly (ADP-ribose) glycohydrolase 1,84 Up
OR1A1 olfactory receptor, family 1, subfamily A, member 1 1,81 Up PARP1 poly (ADP-ribose) polymerase 1 1,81 Up
OR1A2 olfactory receptor, family 1, subfamily A, member 2 1,61 Up PARP10 poly (ADP-ribose) polymerase family, member 10 1,55 Down
OR1D2 olfactory receptor, family 1, subfamily D, member 2 1,78 Up PARP2 poly (ADP-ribose) polymerase 2 1,52 Up
OR1F2P olfactory receptor, family 1, subfamily F, member 2 1,54 Up PATE1 prostate and test is expressed 1 1,66 Up
OR1S2 olfactory receptor, family 1, subfamily S, member 2 2,17 Up PAX1 paired box 1 1,65 Up
OR2A9P
olfactory receptor, family 2, subfamily A, member 9 
pseudogene
1,99 Up PAX3 paired box 3 1,80 Up
OR2H1 olfactory receptor, family 2, subfamily H, member 1 1,95 Down PAX5 paired box 5 1,77 Up
OR2H2 olfactory receptor, family 2, subfamily H, member 2 1,94 Up PAX6 paired box 6 1,55 Up
OR2J2 olfactory receptor, family 2, subfamily J, member 2 1,52 Up PAX7 paired box 7 1,96 Up
OR2M 2 olfactory receptor, family 2, subfamily M , member 2 1,67 Up PBLD
phenazine biosynthesis-like protein domain 
containing
1,53 Up
OR4C46 olfactory receptor, family 4, subfamily C, member 46 1,53 Up PBX2 pre-B-cell leukemia homeobox 2 1,72 Up
OR4D2 olfactory receptor, family 4, subfamily D, member 2 3,01 Up PC pyruvate carboxylase 2,11 Down
OR4X2 olfactory receptor, family 4, subfamily X, member 2 1,64 Up PCBP4 poly(rC) binding protein 4 1,52 Up
OR51E1 olfactory receptor, family 51, subfamily E, member 1 1,55 Up PCDH10 protocadherin 10 1,81 Up
OR51G1 olfactory receptor, family 51, subfamily G, member 1 1,65 Up PCDH7 protocadherin 7 1,75 Up
OR52A1 olfactory receptor, family 52, subfamily A, member 1 2,04 Up PCDHA1 protocadherin alpha 1 1,51 Down
OR52B2 olfactory receptor, family 52, subfamily B, member 2 1,64 Up PCDHB12 protocadherin beta 12 1,77 Up
OR52K2 olfactory receptor, family 52, subfamily K, member 2 1,51 Up PCDHB9 protocadherin beta 9 1,87 Up
OR5AP2 olfactory receptor, family 5, subfamily AP, member 2 1,61 Up PCDHGA7 protocadherin gamma subfamily A, 7 2,14 Down
OR5F1 olfactory receptor, family 5, subfamily F, member 1 1,79 Up PCDHGA8 protocadherin gamma subfamily A, 8 2,50 Up
OR5T2 olfactory receptor, family 5, subfamily T, member 2 1,83 Up PCDHGA9 protocadherin gamma subfamily A, 9 1,57 Up
OR6K2 olfactory receptor, family 6, subfamily K, member 2 2,34 Up PCDHGB1 protocadherin gamma subfamily B, 1 2,12 Up
OR6M 1 olfactory receptor, family 6, subfamily M , member 1 1,93 Up PCDHGC4 protocadherin gamma subfamily C, 4 1,56 Up
OR6N1 olfactory receptor, family 6, subfamily N, member 1 1,59 Up PCGF1 polycomb group ring f inger 1 2,26 Up
OR6W1P
olfactory receptor, family 6, subfamily W, member 1 
pseudogene
1,75 Up PCGF5 polycomb group ring f inger 5 1,96 Up
OR6Y1 olfactory receptor, family 6, subfamily Y, member 1 2,41 Up PCK2
phosphoenolpyruvate carboxykinase 2 
(mitochondrial)
1,63 Up
OR7D2 olfactory receptor, family 7, subfamily D, member 2 1,57 Up PCLO piccolo presynapt ic cytomatrix protein 1,55 Up
OR7E13P
olfactory receptor, family 7, subfamily E, member 13 
pseudogene
2,13 Up PCM T1
protein-L-isoaspartate (D-aspartate) O-
methyltransferase
2,54 Up
OR7E156P
olfactory receptor, family 7, subfamily E, member 156 
pseudogene
1,84 Up PCNXL3 pecanex-like 3 (Drosophila) 2,18 Up
OR7E24 olfactory receptor, family 7, subfamily E, member 24 1,91 Up PCNXL3 pecanex-like 3 (Drosophila) 2,48 Down
OR7E91P
olfactory receptor, family 7, subfamily E, member 91 
pseudogene
1,66 Up PCOLCE procollagen C-endopept idase enhancer 1,61 Up
OR8H1 olfactory receptor, family 8, subfamily H, member 1 1,84 Up PCSK1N
proprotein convertase subt ilisin/kexin type 1 
inhibitor
1,62 Down
OR8U1 olfactory receptor, family 8, subfamily U, member 1 1,71 Up PCSK1N
proprotein convertase subt ilisin/kexin type 1 
inhibitor
2,34 Down
ORC2 origin recognit ion complex, subunit  2 1,63 Up PCSK6 proprotein convertase subt ilisin/kexin type 6 1,60 Up
ORM DL3 ORM 1-like 3 (S. cerevisiae) 2,21 Up CDK16 cyclin-dependent kinase 16 1,53 Up
OSBP oxysterol binding protein 1,73 Down PDCD1 programmed cell death 1 1,96 Up
OSBPL10 oxysterol binding protein-like 10 1,59 Up PDCD11 programmed cell death 11 1,71 Up
OSBPL10 oxysterol binding protein-like 10 2,19 Up PDCD4
programmed cell death 4 (neoplast ic transformation 
inhibitor)
1,98 Up
OSBPL1A oxysterol binding protein-like 1A 1,55 Up PDCL3 phosducin-like 3 1,75 Up
OSBPL8 oxysterol binding protein-like 8 1,75 Up PDE1B phosphodiesterase 1B, calmodulin-dependent 1,75 Up
OSBPL9 oxysterol binding protein-like 9 1,52 Up PDE1C phosphodiesterase 1C, calmodulin-dependent 70kDa 1,61 Up
OSM R oncostat in M  receptor 1,68 Up PDE4C phosphodiesterase 4C, cAM P-specif ic 2,08 Up
OSR2 odd-skipped related transcipt ion factor 2 1,66 Up PDE4D phosphodiesterase 4D, cAM P-specif ic 1,62 Up
OSTF1 osteoclast st imulat ing factor 1 1,99 Up PDE6B phosphodiesterase 6B, cGM P-specif ic, rod, beta 1,79 Up  
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PDIA3 protein disulf ide isomerase family A, member 3 1,63 Up PLA2G4C
phospholipase A2, group IVC (cytosolic, calcium-
independent)
1,99 Up
PDIA3 protein disulf ide isomerase family A, member 3 1,51 Up PLA2G4D phospholipase A2, group IVD (cytosolic) 1,83 Up
PDIA6 protein disulf ide isomerase family A, member 6 1,56 Up PLA2G4F phospholipase A2, group IVF 1,79 Up
PDK3 pyruvate dehydrogenase kinase, isozyme 3 1,54 Up PLA2R1 phospholipase A2 receptor 1, 180kDa 1,55 Up
PDPK1 3-phosphoinosit ide dependent protein kinase-1 1,53 Up PLAA phospholipase A2-act ivat ing protein 1,55 Up
PDRG1 p53 and DNA-damage regulated 1 1,63 Up PLAC1 placenta-specif ic 1 1,60 Up
PDXDC2P
pyridoxal-dependent decarboxylase domain 
containing 2, pseudogene
1,50 Up PLB1 phospholipase B1 1,80 Up
PDXK pyridoxal (pyridoxine, vitamin B6) kinase 1,89 Up PLCG2
phospholipase C, gamma 2 (phosphat idylinositol-
specif ic)
1,59 Down
PDZD11 PDZ domain containing 11 1,53 Up PLCH1 phospholipase C, eta 1 1,56 Up
PDZRN4 PDZ domain containing ring f inger 4 1,81 Up PLCH2 phospholipase C, eta 2 1,50 Down
ECI2 enoyl-CoA delta isomerase 2 1,87 Up PLD1 phospholipase D1, phosphat idylcholine-specif ic 1,81 Up
PELI2 pellino E3 ubiquit in protein ligase family member 2 1,95 Up PLEC plect in 1,53 Down
PENK proenkephalin 1,56 Down PLEKHA7
pleckstrin homology domain containing, family A 
member 7
1,56 Up
PER2 period circadian clock 2 1,72 Up PLEKHF1
pleckstrin homology domain containing, family F 
(with FYVE domain) member 1
1,86 Up
PES1 pescadillo ribosomal biogenesis factor 1 1,63 Up PLEKHG3
pleckstrin homology domain containing, family G 
(with RhoGef domain) member 3
1,65 Up
PEX10 peroxisomal biogenesis factor 10 1,68 Up PLEKHG3
pleckstrin homology domain containing, family G 
(with RhoGef domain) member 3
1,75 Up
PF4 platelet factor 4 1,76 Up PLEKHG5
pleckstrin homology domain containing, family G 
(with RhoGef domain) member 5
1,51 Up
PFKFB1
6-phosphofructo-2-kinase/fructose-2,6-
biphosphatase 1
1,57 Down PLEKHM 1
pleckstrin homology domain containing, family M  
(with RUN domain) member 1
1,63 Up
PFKFB2
6-phosphofructo-2-kinase/fructose-2,6-
biphosphatase 2
2,00 Up PLEKHO2
pleckstrin homology domain containing, family O 
member 2
1,75 Up
PFKL phosphofructokinase, liver 1,52 Down PLK1 polo-like kinase 1 1,69 Up
PFKL phosphofructokinase, liver 3,04 Down PLK3 polo-like kinase 3 1,97 Up
PFN1 prof ilin 1 1,51 Down PM L promyelocyt ic leukemia 1,55 Down
PFN3 prof ilin 3 1,58 Down PM S2
PM S2 postmeiot ic segregat ion increased 2 (S. 
cerevisiae)
1,58 Up
PGAM 5 phosphoglycerate mutase family member 5 1,72 Up PNM A1 paraneoplast ic M a ant igen 1 1,61 Up
PGAP1 post-GPI attachment to proteins 1 1,50 Up PNM A3 paraneoplast ic M a ant igen 3 1,57 Up
PGBD1 piggyBac transposable element derived 1 1,52 Down PNM T phenylethanolamine N-methyltransferase 1,59 Up
PGK1 phosphoglycerate kinase 1 1,59 Up PNPLA5 patat in-like phospholipase domain containing 5 1,86 Up
PGLYRP1 peptidoglycan recognit ion protein 1 1,59 Up PNPLA8 patat in-like phospholipase domain containing 8 1,88 Up
PGLYRP3 peptidoglycan recognit ion protein 3 1,54 Up PNPO pyridoxamine 5'-phosphate oxidase 1,68 Up
PGRM C2 progesterone receptor membrane component 2 1,84 Up POF1B premature ovarian failure, 1B 1,50 Up
PGRM C2 progesterone receptor membrane component 2 1,67 Up POFUT2 protein O-fucosyltransferase 2 1,79 Up
PHACTR4 phosphatase and act in regulator 4 2,01 Up PRSS53 protease, serine, 53 1,74 Up
PHF12 PHD f inger protein 12 1,78 Up POLDIP2
polymerase (DNA-directed), delta interact ing 
protein 2
1,52 Up
JADE1 jade family PHD f inger 1 1,53 Up POLE
polymerase (DNA directed), epsilon, catalyt ic 
subunit
1,98 Up
PHF20L1 PHD f inger protein 20-like 1 1,65 Up POLR1A polymerase (RNA) I polypept ide A, 194kDa 1,67 Up
PHF23 PHD f inger protein 23 1,53 Up POLR2C
polymerase (RNA) II (DNA directed) polypept ide C, 
33kDa
1,53 Up
PHF7 PHD f inger protein 7 2,60 Down POLR2L
polymerase (RNA) II (DNA directed) polypept ide L, 
7.6kDa
1,56 Up
PHKG2 phosphorylase kinase, gamma 2 (test is) 1,74 Up POLR3D
polymerase (RNA) III (DNA directed) polypept ide 
D, 44kDa
1,59 Up
PHLDB2 pleckstrin homology-like domain, family B, member 2 2,12 Up POLR3D
polymerase (RNA) III (DNA directed) polypept ide 
D, 44kDa
1,75 Up
PHLPP2
PH domain and leucine rich repeat protein 
phosphatase 2
2,01 Up POLRM T polymerase (RNA) mitochondrial (DNA directed) 1,73 Up
PHOX2A paired-like homeobox 2a 1,55 Down POM 121 POM 121 transmembrane nucleoporin 1,64 Up
PHYHD1 phytanoyl-CoA dioxygenase domain containing 1 1,58 Up POM P proteasome maturat ion protein 1,61 Up
PIAS4 protein inhibitor of  act ivated STAT, 4 1,67 Down POM T1 protein-O-mannosyltransferase 1 1,86 Up
INPP5J inositol polyphosphate-5-phosphatase J 1,62 Up PON3 paraoxonase 3 1,62 Up
PID1 phosphotyrosine interact ion domain containing 1 1,69 Up POP7
processing of precursor 7, ribonuclease P/M RP 
subunit  (S. cerevisiae)
2,10 Up
PIGG
phosphat idylinositol glycan anchor biosynthesis, 
class G
1,96 Up POU2F1 POU class 2 homeobox 1 1,66 Up
PIGN
phosphat idylinositol glycan anchor biosynthesis, 
class N
1,92 Up POU4F1 POU class 4 homeobox 1 1,67 Up
PIGR polymeric immunoglobulin receptor 1,97 Up POU5F1 POU class 5 homeobox 1 1,51 Up
PIGT
phosphat idylinositol glycan anchor biosynthesis, 
class T
1,60 Up POU6F2 POU class 6 homeobox 2 1,67 Up
PIGU
phosphat idylinositol glycan anchor biosynthesis, 
class U
1,70 Up PPAP2C phosphat idic acid phosphatase type 2C 1,70 Up
PIGX
phosphat idylinositol glycan anchor biosynthesis, 
class X
1,70 Up PPAPDC1B
phosphat idic acid phosphatase type 2 domain 
containing 1B
1,65 Up
PIGY
phosphat idylinositol glycan anchor biosynthesis, 
class Y
1,56 Up PPAT phosphoribosyl pyrophosphate amidotransferase 1,55 Up
PIK3CG
phosphat idylinositol-4,5-bisphosphate 3-kinase, 
catalyt ic subunit  gamma
1,85 Up PPBP
pro-platelet basic protein (chemokine (C-X-C motif ) 
ligand 7)
1,55 Up
PILRA paired immunoglobin-like type 2 receptor alpha 1,52 Up PPEF1
protein phosphatase, EF-hand calcium binding 
domain 1
1,71 Down
PIP5K1C
phosphat idylinositol-4-phosphate 5-kinase, type I, 
gamma
2,73 Down PPFIA1
protein tyrosine phosphatase, receptor type, f  
polypept ide (PTPRF), interact ing protein (liprin), 
alpha 1
1,59 Down
PIKFYVE phosphoinosit ide kinase, FYVE f inger containing 1,55 Up PPIA pept idylprolyl isomerase A (cyclophilin A) 1,61 Up
PIR pirin (iron-binding nuclear protein) 1,57 Up PPIA pept idylprolyl isomerase A (cyclophilin A) 1,61 Up
PISD phosphat idylserine decarboxylase 2,19 Up PPIF pept idylprolyl isomerase F 1,60 Up
PITPNM 2
phosphat idylinositol t ransfer protein, membrane-
associated 2
1,61 Up PPIL1 pept idylprolyl isomerase (cyclophilin)-like 1 1,75 Up
PITPNM 3 PITPNM  family member 3 1,89 Up PPIL2 pept idylprolyl isomerase (cyclophilin)-like 2 1,83 Up
PKD1L3 polycyst ic kidney disease 1-like 3 1,65 Up PPM 1F protein phosphatase, M g2+/M n2+ dependent, 1F 1,87 Down
PKD2L2 polycyst ic kidney disease 2-like 2 1,58 Up PPM E1 protein phosphatase methylesterase 1 1,71 Up
PKIA
protein kinase (cAM P-dependent, catalyt ic) inhibitor 
alpha
1,53 Up PPP1R11
protein phosphatase 1, regulatory (inhibitor) subunit  
11
3,98 Down
PKN2 protein kinase N2 1,56 Up PPP1R16B protein phosphatase 1, regulatory subunit  16B 1,62 Up
PKN2 protein kinase N2 1,87 Up PPP1R1C
protein phosphatase 1, regulatory (inhibitor) subunit  
1C
1,53 Up
PKN2 protein kinase N2 1,62 Down PPP1R3C protein phosphatase 1, regulatory subunit  3C 1,76 Up
PKNOX1 PBX/knotted 1 homeobox 1 1,58 Up PPP1R3E protein phosphatase 1, regulatory subunit  3E 1,63 Down
PKNOX1 PBX/knotted 1 homeobox 1 1,67 Up PPP1R3F protein phosphatase 1, regulatory subunit  3F 1,57 Up
PLA2G1B phospholipase A2, group IB (pancreas) 1,64 Up PPP1R3F protein phosphatase 1, regulatory subunit  3F 1,60 Down
PLA2G4C
phospholipase A2, group IVC (cytosolic, calcium-
independent)
1,95 Up PPP2CB
protein phosphatase 2, catalyt ic subunit , beta 
isozyme
1,56 Up
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PPP2R1B protein phosphatase 2, regulatory subunit  A, beta 1,94 Up PTPN7 protein tyrosine phosphatase, non-receptor type 7 1,51 Up
PPP2R2C protein phosphatase 2, regulatory subunit  B, gamma 1,51 Up PTPN9 protein tyrosine phosphatase, non-receptor type 9 1,65 Up
PPP2R3A protein phosphatase 2, regulatory subunit  B'', alpha 2,02 Up PTPRC protein tyrosine phosphatase, receptor type, C 1,58 Up
PPP2R5B protein phosphatase 2, regulatory subunit  B', beta 2,13 Up PTPRK protein tyrosine phosphatase, receptor type, K 1,64 Up
PPP2R5C
protein phosphatase 2, regulatory subunit  B', 
gamma
1,72 Up PTPRU protein tyrosine phosphatase, receptor type, U 1,51 Up
PPP2R5C
protein phosphatase 2, regulatory subunit  B', 
gamma
1,52 Up PTPRZ1
protein tyrosine phosphatase, receptor-type, Z 
polypept ide 1
1,52 Up
PRAF2 PRA1 domain family, member 2 1,70 Up PUM 2 pumilio RNA-binding family member 2 2,09 Up
PRB4 proline-rich protein BstNI subfamily 4 2,15 Down PVR poliovirus receptor 1,70 Up
PRC1 protein regulator of cytokinesis 1 1,91 Up PVRL1
poliovirus receptor-related 1 (herpesvirus entry 
mediator C)
1,68 Up
PRDM 11 PR domain containing 11 1,52 Up PXDNL peroxidasin homolog (Drosophila)-like 1,51 Up
PRDX4 peroxiredoxin 4 1,53 Up PEX2 peroxisomal biogenesis factor 2 1,84 Up
PREPL prolyl endopept idase-like 1,78 Up PXM P4 peroxisomal membrane protein 4, 24kDa 1,62 Up
PRKAG2
protein kinase, AM P-act ivated, gamma 2 non-
catalyt ic subunit
1,83 Up PYCARD PYD and CARD domain containing 1,79 Up
PRKCE protein kinase C, epsilon 1,56 Up PYGO1 pygopus family PHD f inger 1 1,83 Up
PRKCG protein kinase C, gamma 1,59 Up PYY2 peptide YY, 2 (pseudogene) 2,78 Down
PRKCH protein kinase C, eta 1,61 Up QPRT quinolinate phosphoribosyltransferase 1,73 Up
PRKCI protein kinase C, iota 1,65 Up QSOX2 quiescin Q6 sulfhydryl oxidase 2 1,84 Up
PRKD1 protein kinase D1 1,55 Up RAB10 RAB10, member RAS oncogene family 1,61 Up
PRKG1 protein kinase, cGM P-dependent, type I 1,52 Up RAB11A RAB11A, member RAS oncogene family 1,50 Down
PRL prolact in 1,53 Up RAB11FIP5 RAB11 family interact ing protein 5 (class I) 1,64 Up
PRLHR prolact in releasing hormone receptor 1,59 Down RAB15 RAB15, member RAS oncogene family 1,68 Up
PRM 1 protamine 1 1,70 Up RAB22A RAB22A, member RAS oncogene family 2,04 Up
PRM T2 protein arginine methyltransferase 2 1,64 Down RAB23 RAB23, member RAS oncogene family 1,86 Up
NDUFAF7
NADH dehydrogenase (ubiquinone) complex I, 
assembly factor 7
1,74 Up RAB27B RAB27B, member RAS oncogene family 1,69 Up
PROKR2 prokinet icin receptor 2 1,57 Up RAB3GAP2
RAB3 GTPase act ivat ing protein subunit  2 (non-
catalyt ic)
1,51 Down
PROL1 proline rich, lacrimal 1 1,73 Up RAB40C RAB40C, member RAS oncogene family 1,85 Up
PROP1 PROP paired-like homeobox 1 3,01 Down RAB43 RAB43, member RAS oncogene family 1,63 Up
PRPF18 pre-mRNA processing factor 18 1,65 Up RAB5C RAB5C, member RAS oncogene family 1,80 Up
PRPH peripherin 1,74 Up RAB7L1 RAB7, member RAS oncogene family-like 1 1,72 Up
PRPS1 phosphoribosyl pyrophosphate synthetase 1 1,67 Up RABIF RAB interact ing factor 1,53 Up
PRR12 proline rich 12 1,52 Up RABL3 RAB, member of RAS oncogene family-like 3 1,58 Up
PRR13 proline rich 13 2,06 Up RABL5 RAB, member RAS oncogene family-like 5 1,53 Up
PRR4 proline rich 4 (lacrimal) 1,62 Up RAC1
ras-related C3 botulinum toxin substrate 1 (rho 
family, small GTP binding protein Rac1)
1,80 Up
PRR5 proline rich 5 (renal) 2,46 Down RAD1 RAD1 homolog (S. pombe) 1,60 Up
PRR7 proline rich 7 (synapt ic) 1,61 Down RAD23B RAD23 homolog B (S. cerevisiae) 2,02 Up
PRRT2 proline-rich transmembrane protein 2 1,50 Down RAD51D RAD51 paralog D 1,55 Up
PRRT3 proline-rich transmembrane protein 3 1,68 Up RAD52 RAD52 homolog (S. cerevisiae) 1,98 Up
PRSS16 protease, serine, 16 (thymus) 1,57 Up RAD54B RAD54 homolog B (S. cerevisiae) 1,62 Up
PRSS21 protease, serine, 21 (test isin) 1,64 Up RAD9A RAD9 homolog A (S. pombe) 1,59 Up
PRTN3 proteinase 3 1,57 Up RAI14 ret inoic acid induced 14 1,52 Up
CYTH2 cytohesin 2 1,56 Up RALGPS2 Ral GEF with PH domain and SH3 binding motif  2 1,58 Up
CYTIP cytohesin 1 interact ing protein 1,51 Up RAM P2
receptor (G protein-coupled) act ivity modifying 
protein 2
1,53 Down
PSEN2 presenilin 2 (Alzheimer disease 4) 1,67 Down RAN RAN, member RAS oncogene family 2,22 Up
PSG11 pregnancy specif ic beta-1-glycoprotein 11 1,74 Up RANBP10 RAN binding protein 10 1,84 Up
PSG2 pregnancy specif ic beta-1-glycoprotein 2 1,56 Up RAP2C RAP2C, member of RAS oncogene family 1,86 Up
PSG4 pregnancy specif ic beta-1-glycoprotein 4 1,58 Up RAPGEF1 Rap guanine nucleot ide exchange factor (GEF) 1 1,98 Up
PSG7
pregnancy specif ic beta-1-glycoprotein 7 
(gene/pseudogene)
1,61 Up RAPGEF4 Rap guanine nucleot ide exchange factor (GEF) 4 1,71 Up
PSM A1
proteasome (prosome, macropain) subunit , alpha 
type, 1
1,64 Up RAPSN receptor-associated protein of the synapse 1,51 Up
PSM A6
proteasome (prosome, macropain) subunit , alpha 
type, 6
1,76 Up RARG ret inoic acid receptor, gamma 1,66 Up
PSM A6
proteasome (prosome, macropain) subunit , alpha 
type, 6
1,91 Up RARS arginyl-tRNA synthetase 1,51 Up
PSM B1
proteasome (prosome, macropain) subunit , beta 
type, 1
1,63 Up RASEF RAS and EF-hand domain containing 1,55 Up
PSM B9
proteasome (prosome, macropain) subunit , beta 
type, 9
1,53 Down RASGEF1A RasGEF domain family, member 1A 1,85 Up
PSM C1
proteasome (prosome, macropain) 26S subunit , 
ATPase, 1
1,53 Up RASGRP1
RAS guanyl releasing protein 1 (calcium and DAG-
regulated)
1,55 Up
PSM C1
proteasome (prosome, macropain) 26S subunit , 
ATPase, 1
1,53 Up RASGRP2
RAS guanyl releasing protein 2 (calcium and DAG-
regulated)
1,52 Up
PSM D10
proteasome (prosome, macropain) 26S subunit , non-
ATPase, 10
1,63 Up RASGRP4 RAS guanyl releasing protein 4 1,69 Up
PSM D2
proteasome (prosome, macropain) 26S subunit , non-
ATPase, 2
1,54 Up RASL11A RAS-like, family 11, member A 1,61 Up
PSM D5
proteasome (prosome, macropain) 26S subunit , non-
ATPase, 5
1,70 Up RAVER1 ribonucleoprotein, PTB-binding 1 1,93 Up
PSM D5
proteasome (prosome, macropain) 26S subunit , non-
ATPase, 5
2,14 Up RB1 ret inoblastoma 1 1,57 Up
PSM D6
proteasome (prosome, macropain) 26S subunit , non-
ATPase, 6
1,52 Up RBBP9 ret inoblastoma binding protein 9 1,67 Up
PSORS1C2 psoriasis suscept ibility 1 candidate 2 1,66 Up RBKS ribokinase 1,65 Up
PSORS1C2 psoriasis suscept ibility 1 candidate 2 2,83 Down RBM 15B RNA binding motif  protein 15B 1,92 Up
PSPH phosphoserine phosphatase 2,03 Up RBM 18 RNA binding motif  protein 18 1,65 Up
PTCD3 pentatricopept ide repeat domain 3 1,52 Down RBM 23 RNA binding motif  protein 23 1,51 Up
PTGER1 prostaglandin E receptor 1 (subtype EP1), 42kDa 1,64 Down ESRP2 epithelial splicing regulatory protein 2 2,42 Up
PTHLH parathyroid hormone-like hormone 1,55 Up RBM 38 RNA binding motif  protein 38 1,55 Up
PTK2B protein tyrosine kinase 2 beta 1,53 Down RBM 43 RNA binding motif  protein 43 1,56 Up
PTOV1 prostate tumor overexpressed 1 1,52 Up RBM S3
RNA binding motif , single stranded interact ing 
protein 3
1,73 Up
PTPLAD1
protein tyrosine phosphatase-like A domain 
containing 1
1,51 Up RBM XL1 RNA binding motif  protein, X-linked-like 1 1,63 Up
PTPN14 protein tyrosine phosphatase, non-receptor type 14 1,94 Up RBM Y2FP
RNA binding motif  protein, Y-linked, family 2, 
member F pseudogene
1,67 Up
PTPN23 protein tyrosine phosphatase, non-receptor type 23 1,92 Up RBPJ
recombinat ion signal binding protein for 
immunoglobulin kappa J region
1,71 Up
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RCC2 regulator of chromosome condensat ion 2 1,77 Up PTBP3 polypyrimidine tract binding protein 3 1,70 Up
RCL1 RNA terminal phosphate cyclase-like 1 2,50 Down ROR1 receptor tyrosine kinase-like orphan receptor 1 1,67 Up
CRCP CGRP receptor component 1,70 Up RORB RAR-related orphan receptor B 1,56 Up
RDH8 ret inol dehydrogenase 8 (all-t rans) 1,54 Up RORC RAR-related orphan receptor C 1,87 Up
REEP3 receptor accessory protein 3 1,65 Up RP2 ret init is pigmentosa 2 (X-linked recessive) 1,64 Up
REEP6 receptor accessory protein 6 1,56 Down RPH3AL rabphilin 3A-like (without C2 domains) 1,66 Up
REG1B regenerat ing islet-derived 1 beta 1,80 Up RPL10A ribosomal protein L10a 2,62 Up
RELA
v-rel avian ret iculoendotheliosis viral oncogene 
homolog A
1,58 Up RPL10L ribosomal protein L10-like 1,79 Up
REPIN1 replicat ion init iator 1 1,67 Up RPL13 ribosomal protein L13 2,47 Up
REPIN1 replicat ion init iator 1 1,76 Up RPL13A ribosomal protein L13a 1,52 Up
RETNLB resist in like beta 1,52 Up RPL14 ribosomal protein L14 1,52 Up
REXO1 REX1, RNA exonuclease 1 homolog (S. cerevisiae) 1,80 Up RPL22 ribosomal protein L22 1,91 Up
REXO2 RNA exonuclease 2 2,20 Up RPL22 ribosomal protein L22 1,84 Up
RFC3 replicat ion factor C (act ivator 1) 3, 38kDa 1,69 Up RPL22L1 ribosomal protein L22-like 1 1,59 Up
RFK ribof lavin kinase 1,91 Up RPL23 ribosomal protein L23 3,12 Up
RFX2
regulatory factor X, 2 (inf luences HLA class II 
expression)
1,72 Up RPL23A ribosomal protein L23a 3,77 Up
ARHGEF28 Rho guanine nucleot ide exchange factor (GEF) 28 1,80 Up RPL26L1 ribosomal protein L26-like 1 1,82 Up
RGPD1 RANBP2-like and GRIP domain containing 1 1,60 Up RPL28 ribosomal protein L28 1,84 Up
RGS11 regulator of G-protein signaling 11 2,08 Up RPL29 ribosomal protein L29 1,72 Up
RGS2 regulator of G-protein signaling 2, 24kDa 1,50 Up RPL29P2 ribosomal protein L29 pseudogene 2 1,62 Up
RGS20 regulator of G-protein signaling 20 1,51 Up RPL36A ribosomal protein L36a 2,85 Up
RGS4 regulator of G-protein signaling 4 1,64 Up RPL7A ribosomal protein L7a 1,69 Up
RGSL1 regulator of G-protein signaling like 1 1,81 Up RPLP2 ribosomal protein, large, P2 2,87 Up
RHBDD1 rhomboid domain containing 1 1,66 Up RPP21 ribonuclease P/M RP 21kDa subunit 1,63 Up
RHBDD3 rhomboid domain containing 3 1,58 Down RPP25 ribonuclease P/M RP 25kDa subunit 1,74 Down
RHBDL1 rhomboid, veinlet-like 1 (Drosophila) 2,53 Down RPS13 ribosomal protein S13 2,45 Up
RHBDL3 rhomboid, veinlet-like 3 (Drosophila) 1,54 Up RPS14 ribosomal protein S14 1,73 Up
RHCG Rh family, C glycoprotein 1,77 Up RPS15A ribosomal protein S15a 1,69 Up
RHEBL1 Ras homolog enriched in brain like 1 1,94 Up RPS19 ribosomal protein S19 1,62 Up
RHO rhodopsin 1,80 Up RPS19 ribosomal protein S19 1,84 Up
RHOA ras homolog family member A 1,67 Up RPS26 ribosomal protein S26 2,26 Up
RHOA ras homolog family member A 1,54 Up RPS27L ribosomal protein S27-like 1,54 Up
RHOC ras homolog family member C 1,94 Up RPS28 ribosomal protein S28 3,42 Up
RHOG ras homolog family member G 2,35 Up RPS28 ribosomal protein S28 2,40 Down
RHOT1 ras homolog family member T1 1,55 Up RPS29 ribosomal protein S29 2,64 Up
RHPN1 rhophilin, Rho GTPase binding protein 1 2,77 Down RPS3A ribosomal protein S3A 2,09 Up
RHPN2 rhophilin, Rho GTPase binding protein 2 1,53 Up RPS4X ribosomal protein S4, X-linked 1,72 Up
RIF1 RAP1 interact ing factor homolog (yeast) 1,56 Up RPS6 ribosomal protein S6 2,31 Up
RIM BP2 RIM S binding protein 2 1,92 Up RPS6KA1 ribosomal protein S6 kinase, 90kDa, polypept ide 1 1,72 Up
RIM S2 regulat ing synapt ic membrane exocytosis 2 1,76 Up RPSAP10 ribosomal protein SA pseudogene 10 1,56 Up
RING1 ring f inger protein 1 1,58 Up RPUSD2 RNA pseudouridylate synthase domain containing 2 2,24 Up
RIPK2 receptor-interact ing serine-threonine kinase 2 1,56 Up RRAD Ras-related associated with diabetes 1,57 Up
RIPK4 receptor-interact ing serine-threonine kinase 4 1,51 Up RRH
ret inal pigment epithelium-derived rhodopsin 
homolog
1,59 Up
DSTYK dual serine/threonine and tyrosine protein kinase 2,24 Up RRN3
RRN3 RNA polymerase I t ranscript ion factor 
homolog (S. cerevisiae)
1,92 Up
M EX3D mex-3 RNA binding family member D 2,01 Up RRP15
ribosomal RNA processing 15 homolog (S. 
cerevisiae)
1,73 Up
M EX3D mex-3 RNA binding family member D 2,55 Down RSF1 remodeling and spacing factor 1 1,57 Up
RNASE2
ribonuclease, RNase A family, 2 (liver, eosinophil-
derived neurotoxin)
1,55 Up RSL1D1 ribosomal L1 domain containing 1 1,73 Up
RNASE3 ribonuclease, RNase A family, 3 1,62 Up RSU1 Ras suppressor protein 1 1,79 Up
RND1 Rho family GTPase 1 1,66 Up RTF1
Rtf1, Paf1/RNA polymerase II complex component, 
homolog (S. cerevisiae)
1,99 Up
RND2 Rho family GTPase 2 1,59 Up RTP1 receptor (chemosensory) transporter protein 1 1,77 Up
RND3 Rho family GTPase 3 1,61 Up RUFY1 RUN and FYVE domain containing 1 1,59 Up
RNF111 ring f inger protein 111 1,58 Up SNX29P1 sort ing nexin 29 pseudogene 1 1,89 Up
RNF121 ring f inger protein 121 1,61 Up SGSM 1 small G protein signaling modulator 1 1,63 Up
RNF126 ring f inger protein 126 1,59 Up RXFP4 relaxin/ insulin-like family pept ide receptor 4 1,60 Up
RNF14 ring f inger protein 14 2,12 Up S100A1 S100 calcium binding protein A1 1,59 Down
RNF145 ring f inger protein 145 1,65 Up S100A2 S100 calcium binding protein A2 1,74 Up
RNF166 ring f inger protein 166 1,56 Up S100A3 S100 calcium binding protein A3 1,70 Up
RNF170 ring f inger protein 170 1,60 Up S100A7 S100 calcium binding protein A7 1,56 Up
RNF170 ring f inger protein 170 1,58 Up S100A7A S100 calcium binding protein A7A 1,54 Up
RNF175 ring f inger protein 175 1,59 Up S100A8 S100 calcium binding protein A8 1,89 Up
RNF187 ring f inger protein 187 1,60 Up S100PBP S100P binding protein 1,60 Up
RNF213 ring f inger protein 213 1,58 Up UBA2 ubiquit in-like modif ier act ivat ing enzyme 2 1,53 Up
RNF24 ring f inger protein 24 1,66 Up SALL2 spalt-like transcript ion factor 2 1,51 Up
RNF5 ring f inger protein 5, E3 ubiquit in protein ligase 1,68 Up SAM D10 sterile alpha motif  domain containing 10 1,53 Up
RNF8 ring f inger protein 8, E3 ubiquit in protein ligase 1,59 Up SAM D3 sterile alpha motif  domain containing 3 2,48 Down
RNH1 ribonuclease/angiogenin inhibitor 1 1,55 Up SAM D4A sterile alpha motif  domain containing 4A 2,23 Up
RNPC3 RNA-binding region (RNP1, RRM ) containing 3 1,67 Up SAM D4B sterile alpha motif  domain containing 4B 1,90 Up
RNPS1 RNA binding protein S1, serine-rich domain 1,61 Down SAM D4B sterile alpha motif  domain containing 4B 1,84 Down
ROBO1
roundabout, axon guidance receptor, homolog 1 
(Drosophila)
1,71 Up SAM M 50
SAM M 50 sort ing and assembly machinery 
component
1,51 Up
ROBO4
roundabout, axon guidance receptor, homolog 4 
(Drosophila)
1,74 Up PPP6R3 protein phosphatase 6, regulatory subunit  3 1,55 Down
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SASH1 SAM  and SH3 domain containing 1 1,69 Up SH2D4B SH2 domain containing 4B 1,57 Up
SC5D sterol-C5-desaturase 1,58 Up SH2D4B SH2 domain containing 4B 2,12 Up
LEPREL4 leprecan-like 4 1,72 Down SH2D6 SH2 domain containing 6 1,60 Up
SCAND2P SCAN domain containing 2 pseudogene 1,77 Up SH3BGRL SH3 domain binding glutamic acid-rich protein like 1,85 Up
SCARF2 scavenger receptor class F, member 2 1,86 Down SH3BP1 SH3-domain binding protein 1 1,64 Up
PDS5A
PDS5, regulator of cohesion maintenance, homolog 
A (S. cerevisiae)
2,05 Up SH3BP4 SH3-domain binding protein 4 1,55 Up
SCD stearoyl-CoA desaturase (delta-9-desaturase) 1,51 Up SH3BP5 SH3-domain binding protein 5 (BTK-associated) 1,68 Up
SCFD1 sec1 family domain containing 1 1,60 Up SH3GL2 SH3-domain GRB2-like 2 1,95 Up
SCFD2 sec1 family domain containing 2 1,77 Up SH3GL3 SH3-domain GRB2-like 3 1,86 Up
SCGB1D1 secretoglobin, family 1D, member 1 1,85 Up SHANK2 SH3 and mult iple ankyrin repeat domains 2 1,72 Up
SCGB1D2 secretoglobin, family 1D, member 2 1,59 Up SHANK3 SH3 and mult iple ankyrin repeat domains 3 1,51 Up
SCLY selenocysteine lyase 1,98 Up SHB
Src homology 2 domain containing adaptor protein 
B
1,95 Up
SCN3A sodium channel, voltage-gated, type III, alpha subunit 1,51 Up SHC1
SHC (Src homology 2 domain containing) 
transforming protein 1
1,58 Up
SCN5A sodium channel, voltage-gated, type V, alpha subunit 2,02 Up SHC2
SHC (Src homology 2 domain containing) 
transforming protein 2
1,86 Down
SHISA5 shisa family member 5 1,53 Up SHF Src homology 2 domain containing F 1,54 Up
SHISA5 shisa family member 5 2,83 Down SHOX2 short  stature homeobox 2 1,69 Down
SDCCAG3 serologically def ined colon cancer ant igen 3 1,69 Up SHROOM 1 shroom family member 1 1,70 Up
SDHD
succinate dehydrogenase complex, subunit  D, 
integral membrane protein
1,51 Up SIAE sialic acid acetylesterase 2,47 Up
SDK2 sidekick cell adhesion molecule 2 1,57 Down SIDT1 SID1 transmembrane family, member 1 1,53 Up
SDR9C7
short  chain dehydrogenase/reductase family 9C, 
member 7
1,76 Up SIDT2 SID1 transmembrane family, member 2 1,97 Up
SDSL serine dehydratase-like 1,52 Up SIGLEC11 sialic acid binding Ig-like lect in 11 1,70 Up
SEC22A
SEC22 vesicle traf f icking protein homolog A (S. 
cerevisiae)
1,65 Up SIPA1L1 signal-induced proliferat ion-associated 1 like 1 2,46 Up
SEC22A
SEC22 vesicle traf f icking protein homolog A (S. 
cerevisiae)
1,78 Up SIRPA signal-regulatory protein alpha 2,25 Down
SEC23B Sec23 homolog B (S. cerevisiae) 1,52 Up SIRPB1 signal-regulatory protein beta 1 1,63 Up
SEC61A2 Sec61 alpha 2 subunit  (S. cerevisiae) 1,57 Up SIT1
signaling threshold regulat ing transmembrane 
adaptor 1
1,58 Up
SEC61B Sec61 beta subunit 1,80 Up SKI v-ski avian sarcoma viral oncogene homolog 1,63 Up
VIM P VCP-interact ing membrane protein 1,59 Up SKIV2L2 superkiller viralicidic act ivity 2-like 2 (S. cerevisiae) 1,61 Up
SEM A3D
sema domain, immunoglobulin domain (Ig), short  
basic domain, secreted, (semaphorin) 3D
1,53 Up SKP1 S-phase kinase-associated protein 1 1,63 Up
SEM A4C
sema domain, immunoglobulin domain (Ig), 
t ransmembrane domain (TM ) and short  cytoplasmic 
domain, (semaphorin) 4C
1,72 Up SLAM F8 SLAM  family member 8 1,81 Up
SEM A4C
sema domain, immunoglobulin domain (Ig), 
t ransmembrane domain (TM ) and short  cytoplasmic 
domain, (semaphorin) 4C
1,78 Up SLC10A3 solute carrier family 10, member 3 2,07 Up
SEM A4G
sema domain, immunoglobulin domain (Ig), 
t ransmembrane domain (TM ) and short  cytoplasmic 
domain, (semaphorin) 4G
1,61 Up SLC11A2
solute carrier family 11 (proton-coupled divalent 
metal ion transporter), member 2
1,62 Up
SEM A5B
sema domain, seven thrombospondin repeats (type 1 
and type 1-like), t ransmembrane domain (TM ) and 
short  cytoplasmic domain, (semaphorin) 5B
1,53 Up SLC12A3
solute carrier family 12 (sodium/chloride 
transporter), member 3
1,55 Up
SEM A6D
sema domain, t ransmembrane domain (TM ), and 
cytoplasmic domain, (semaphorin) 6D
1,54 Up SLC15A1
solute carrier family 15 (oligopept ide transporter), 
member 1
1,52 Up
SENP5 SUM O1/sentrin specif ic pept idase 5 1,52 Up SLC15A4
solute carrier family 15 (oligopept ide transporter), 
member 4
1,63 Up
SEPN1 selenoprotein N, 1 1,72 Up SLC15A4
solute carrier family 15 (oligopept ide transporter), 
member 4
1,61 Up
SEPT12 sept in 12 2,01 Up SLC16A1
solute carrier family 16 (monocarboxylate 
transporter), member 1
1,83 Up
SEPT8 sept in 8 1,53 Up SLC16A11 solute carrier family 16, member 11 1,91 Up
M SRB1 methionine sulfoxide reductase B1 1,78 Up SLC16A14 solute carrier family 16, member 14 1,51 Up
SERF2 small EDRK-rich factor 2 2,07 Up SLC16A14 solute carrier family 16, member 14 2,13 Up
SERGEF
secret ion regulat ing guanine nucleot ide exchange 
factor
1,50 Up SLC16A5
solute carrier family 16 (monocarboxylate 
transporter), member 5
1,78 Up
SERINC1 serine incorporator 1 1,91 Up SLC17A1
solute carrier family 17 (organic anion transporter), 
member 1
1,80 Up
SERPINA11
serpin pept idase inhibitor, clade A (alpha-1 
ant iproteinase, ant it rypsin), member 11
1,93 Up SLC17A2 solute carrier family 17, member 2 2,12 Up
SERPINA4
serpin pept idase inhibitor, clade A (alpha-1 
ant iproteinase, ant it rypsin), member 4
1,58 Up SLC17A4 solute carrier family 17, member 4 1,57 Up
SERPINA7
serpin pept idase inhibitor, clade A (alpha-1 
ant iproteinase, ant it rypsin), member 7
1,62 Up SLC1A2
solute carrier family 1 (glial high aff inity glutamate 
transporter), member 2
1,91 Up
SERPINA9
serpin pept idase inhibitor, clade A (alpha-1 
ant iproteinase, ant it rypsin), member 9
1,98 Up SLC23A3 solute carrier family 23, member 3 1,52 Down
SERPINB10
serpin pept idase inhibitor, clade B (ovalbumin), 
member 10
1,57 Up SLC25A1
solute carrier family 25 (mitochondrial carrier; cit rate 
transporter), member 1
1,74 Up
SERPINB11
serpin pept idase inhibitor, clade B (ovalbumin), 
member 11 (gene/pseudogene)
1,69 Up SLC25A17
solute carrier family 25 (mitochondrial carrier; 
peroxisomal membrane protein, 34kDa), member 17
1,74 Up
SERPINB4
serpin pept idase inhibitor, clade B (ovalbumin), 
member 4
1,69 Up SLC25A27 solute carrier family 25, member 27 1,68 Up
SERPINB5
serpin pept idase inhibitor, clade B (ovalbumin), 
member 5
1,65 Up SLC25A33
solute carrier family 25 (pyrimidine nucleot ide 
carrier), member 33
1,51 Up
SERPINB8
serpin pept idase inhibitor, clade B (ovalbumin), 
member 8
2,32 Up SLC25A37
solute carrier family 25 (mitochondrial iron 
transporter), member 37
1,71 Up
SERPIND1
serpin pept idase inhibitor, clade D (heparin 
cofactor), member 1
1,58 Up SLC25A42 solute carrier family 25, member 42 1,72 Up
SERPINH1
serpin pept idase inhibitor, clade H (heat shock 
protein 47), member 1, (collagen binding protein 1)
1,51 Up SLC26A1 solute carrier family 26 (anion exchanger), member 1 1,83 Up
SERTAD1 SERTA domain containing 1 2,36 Up SLC29A1
solute carrier family 29 (equilibrat ive nucleoside 
transporter), member 1
1,55 Up
SERTAD2 SERTA domain containing 2 1,72 Up SLC2A10
solute carrier family 2 (facilitated glucose 
transporter), member 10
1,97 Up
SETBP1 SET binding protein 1 1,58 Up SLC2A2
solute carrier family 2 (facilitated glucose 
transporter), member 2
1,88 Up
SETD4 SET domain containing 4 1,76 Up SLC2A5
solute carrier family 2 (facilitated glucose/fructose 
transporter), member 5
1,67 Up
SETD5 SET domain containing 5 1,69 Up SLC2A8
solute carrier family 2 (facilitated glucose 
transporter), member 8
1,61 Up
SETD8 SET domain containing (lysine methyltransferase) 8 1,60 Up SLC30A3 solute carrier family 30 (zinc transporter), member 3 1,60 Up
SEZ6 seizure related 6 homolog (mouse) 1,97 Up SLC30A4 solute carrier family 30 (zinc transporter), member 4 1,70 Up
SF3A2 splicing factor 3a, subunit  2, 66kDa 2,02 Down SLC31A1
solute carrier family 31 (copper transporter), 
member 1
1,72 Up
SF3B5 splicing factor 3b, subunit  5, 10kDa 1,55 Up SLC32A1
solute carrier family 32 (GABA vesicular 
transporter), member 1
1,52 Up
SFRP5 secreted frizzled-related protein 5 2,09 Down SLC35A3
solute carrier family 35 (UDP-N-acetylglucosamine 
(UDP-GlcNAc) transporter), member A3
1,95 Up
SRSF11 serine/arginine-rich splicing factor 11 1,52 Up SLC35A5 solute carrier family 35, member A5 2,02 Up
SRSF6 serine/arginine-rich splicing factor 6 1,57 Up SLC35B1 solute carrier family 35, member B1 1,80 Up
SFTA2 surfactant associated 2 1,97 Up SLC35B2
solute carrier family 35 (adenosine 3'-phospho 5'-
phosphosulfate transporter), member B2
2,04 Down
SGK1 serum/glucocort icoid regulated kinase 1 1,51 Up SLC35B4
solute carrier family 35 (UDP-xylose/UDP-N-
acetylglucosamine transporter), member B4
1,86 Up
SGPP1 sphingosine-1-phosphate phosphatase 1 1,77 Up SLC35C1
solute carrier family 35 (GDP-fucose transporter), 
member C1
1,76 Up
SGPP2 sphingosine-1-phosphate phosphatase 2 1,53 Up SLC35D1
solute carrier family 35 (UDP-GlcA/UDP-GalNAc 
transporter), member D1
1,59 Up
SGTA
small glutamine-rich tetratricopept ide repeat (TPR)-
containing, alpha
1,68 Up SLC35E3 solute carrier family 35, member E3 2,10 Up
SH2B1 SH2B adaptor protein 1 2,10 Up SLC35F1 solute carrier family 35, member F1 1,66 Up  
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SH2D4B SH2 domain containing 4B 1,57 Up SLC36A1
solute carrier family 36 (proton/amino acid 
symporter), member 1
1,67 Up
SH2D4B SH2 domain containing 4B 2,12 Up SLC37A4
solute carrier family 37 (glucose-6-phosphate 
transporter), member 4
1,52 Up
SH2D6 SH2 domain containing 6 1,60 Up SLC38A3 solute carrier family 38, member 3 1,57 Up
SH3BGRL SH3 domain binding glutamic acid-rich protein like 1,85 Up SLC39A11 solute carrier family 39, member 11 1,59 Down
SH3BP1 SH3-domain binding protein 1 1,64 Up SLC39A12
solute carrier family 39 (zinc transporter), member 
12
1,90 Up
SH3BP4 SH3-domain binding protein 4 1,55 Up SLC3A1
solute carrier family 3 (amino acid transporter heavy 
chain), member 1
1,70 Up
SH3BP5 SH3-domain binding protein 5 (BTK-associated) 1,68 Up SLC41A1
solute carrier family 41 (magnesium transporter), 
member 1
1,66 Up
SH3GL2 SH3-domain GRB2-like 2 1,95 Up SLC43A3 solute carrier family 43, member 3 1,77 Up
SH3GL3 SH3-domain GRB2-like 3 1,86 Up SLC45A1 solute carrier family 45, member 1 1,72 Up
SHANK2 SH3 and mult iple ankyrin repeat domains 2 1,72 Up SLC45A2 solute carrier family 45, member 2 1,66 Up
SHANK3 SH3 and mult iple ankyrin repeat domains 3 1,51 Up SLC46A1
solute carrier family 46 (folate transporter), member 
1
1,75 Up
SHB
Src homology 2 domain containing adaptor protein 
B
1,95 Up SLC46A1
solute carrier family 46 (folate transporter), member 
1
1,61 Up
SHC1
SHC (Src homology 2 domain containing) 
transforming protein 1
1,58 Up SLC47A1
solute carrier family 47 (mult idrug and toxin 
extrusion), member 1
1,59 Up
SHC2
SHC (Src homology 2 domain containing) 
transforming protein 2
1,86 Down SLC4A8
solute carrier family 4, sodium bicarbonate 
cotransporter, member 8
1,54 Up
SHF Src homology 2 domain containing F 1,54 Up SLC5A1
solute carrier family 5 (sodium/glucose 
cotransporter), member 1
1,52 Up
SHOX2 short  stature homeobox 2 1,69 Down SLC5A2
solute carrier family 5 (sodium/glucose 
cotransporter), member 2
2,05 Down
SHROOM 1 shroom family member 1 1,70 Up SLC6A10P
solute carrier family 6 (neurotransmit ter 
t ransporter), member 10, pseudogene
1,59 Up
SIAE sialic acid acetylesterase 2,47 Up SLC6A2
solute carrier family 6 (neurotransmit ter 
t ransporter), member 2
1,58 Up
SIDT1 SID1 transmembrane family, member 1 1,53 Up SLC6A20
solute carrier family 6 (proline IM INO transporter), 
member 20
1,83 Up
SIDT2 SID1 transmembrane family, member 2 1,97 Up SLC6A6
solute carrier family 6 (neurotransmit ter 
t ransporter), member 6
2,06 Up
SIGLEC11 sialic acid binding Ig-like lect in 11 1,70 Up SLC7A1
solute carrier family 7 (cat ionic amino acid 
transporter, y+ system), member 1
1,69 Up
SIPA1L1 signal-induced proliferat ion-associated 1 like 1 2,46 Up SLC7A14 solute carrier family 7, member 14 1,63 Up
SIRPA signal-regulatory protein alpha 2,25 Down SLFN11 schlafen family member 11 1,60 Up
SIRPB1 signal-regulatory protein beta 1 1,63 Up SNX20 sort ing nexin 20 1,51 Up
SIT1
signaling threshold regulat ing transmembrane 
adaptor 1
1,58 Up SLM O1 slowmo homolog 1 (Drosophila) 1,70 Up
SKI v-ski avian sarcoma viral oncogene homolog 1,63 Up SLM O2 slowmo homolog 2 (Drosophila) 1,73 Up
SKIV2L2 superkiller viralicidic act ivity 2-like 2 (S. cerevisiae) 1,61 Up SM AD9 SM AD family member 9 1,69 Up
SKP1 S-phase kinase-associated protein 1 1,63 Up SM ARCC1
SWI/SNF related, matrix associated, act in 
dependent regulator of chromatin, subfamily c, 
member 1
1,69 Up
SLAM F8 SLAM  family member 8 1,81 Up SM ARCC1
SWI/SNF related, matrix associated, act in 
dependent regulator of chromatin, subfamily c, 
member 1
1,51 Up
SLC10A3 solute carrier family 10, member 3 2,07 Up SM ARCD1
SWI/SNF related, matrix associated, act in 
dependent regulator of chromatin, subfamily d, 
member 1
1,77 Up
SLC11A2
solute carrier family 11 (proton-coupled divalent 
metal ion transporter), member 2
1,62 Up SM ARCD2
SWI/SNF related, matrix associated, act in 
dependent regulator of chromatin, subfamily d, 
member 2
1,78 Up
SLC12A3
solute carrier family 12 (sodium/chloride 
transporter), member 3
1,55 Up SM C1A structural maintenance of chromosomes 1A 1,65 Up
SLC15A1
solute carrier family 15 (oligopept ide transporter), 
member 1
1,52 Up M IEF1 mitochondrial elongat ion factor 1 1,76 Up
SLC15A4
solute carrier family 15 (oligopept ide transporter), 
member 4
1,63 Up SM G1 SM G1 phosphat idylinositol 3-kinase-related kinase 2,12 Up
SLC15A4
solute carrier family 15 (oligopept ide transporter), 
member 4
1,61 Up SM PD2
sphingomyelin phosphodiesterase 2, neutral 
membrane (neutral sphingomyelinase)
1,75 Up
SLC16A1
solute carrier family 16 (monocarboxylate 
transporter), member 1
1,83 Up SM PD3
sphingomyelin phosphodiesterase 3, neutral 
membrane (neutral sphingomyelinase II)
1,68 Up
SLC16A11 solute carrier family 16, member 11 1,91 Up SM PD3
sphingomyelin phosphodiesterase 3, neutral 
membrane (neutral sphingomyelinase II)
1,53 Up
SLC16A14 solute carrier family 16, member 14 1,51 Up SM PDL3B sphingomyelin phosphodiesterase, acid-like 3B 1,79 Up
SLC16A14 solute carrier family 16, member 14 2,13 Up SM TN smoothelin 1,56 Up
SLC16A5
solute carrier family 16 (monocarboxylate 
transporter), member 5
1,78 Up SNCA
synuclein, alpha (non A4 component of amyloid 
precursor)
1,70 Up
SLC17A1
solute carrier family 17 (organic anion transporter), 
member 1
1,80 Up SND1
staphylococcal nuclease and tudor domain 
containing 1
1,78 Up
SLC17A2 solute carrier family 17, member 2 2,12 Up SIK1 salt-inducible kinase 1 1,61 Down
SLC17A4 solute carrier family 17, member 4 1,57 Up SNF8 SNF8, ESCRT-II complex subunit 1,85 Up
SLC1A2
solute carrier family 1 (glial high aff inity glutamate 
transporter), member 2
1,91 Up SNHG7
small nucleolar RNA host gene 7 (non-protein 
coding)
1,53 Up
SLC23A3 solute carrier family 23, member 3 1,52 Down SNORD22 small nucleolar RNA, C/D box 22 2,44 Up
SLC25A1
solute carrier family 25 (mitochondrial carrier; cit rate 
transporter), member 1
1,74 Up SNPH syntaphilin 2,60 Up
SLC25A17
solute carrier family 25 (mitochondrial carrier; 
peroxisomal membrane protein, 34kDa), member 17
1,74 Up SNRPA small nuclear ribonucleoprotein polypept ide A 1,66 Up
SLC25A27 solute carrier family 25, member 27 1,68 Up SNRPC small nuclear ribonucleoprotein polypept ide C 1,63 Up
SLC25A33
solute carrier family 25 (pyrimidine nucleot ide 
carrier), member 33
1,51 Up SNUPN snurport in 1 1,58 Down
SLC25A37
solute carrier family 25 (mitochondrial iron 
transporter), member 37
1,71 Up SNX10 sort ing nexin 10 1,70 Up
SLC25A42 solute carrier family 25, member 42 1,72 Up SNX13 sort ing nexin 13 1,72 Up
SLC26A1 solute carrier family 26 (anion exchanger), member 1 1,83 Up SNX14 sort ing nexin 14 1,90 Up
SLC29A1
solute carrier family 29 (equilibrat ive nucleoside 
transporter), member 1
1,55 Up SNX15 sort ing nexin 15 2,00 Up
SLC2A10
solute carrier family 2 (facilitated glucose 
transporter), member 10
1,97 Up ARHGAP33 Rho GTPase act ivat ing protein 33 2,08 Down
SLC2A2
solute carrier family 2 (facilitated glucose 
transporter), member 2
1,88 Up SNX4 sort ing nexin 4 1,55 Up
SLC2A5
solute carrier family 2 (facilitated glucose/fructose 
transporter), member 5
1,67 Up SNX5 sort ing nexin 5 1,54 Up
SLC2A8
solute carrier family 2 (facilitated glucose 
transporter), member 8
1,61 Up SNX5 sort ing nexin 5 1,71 Up
SLC30A3 solute carrier family 30 (zinc transporter), member 3 1,60 Up SOCS1 suppressor of cytokine signaling 1 1,76 Up
SLC30A4 solute carrier family 30 (zinc transporter), member 4 1,70 Up SOCS3 suppressor of cytokine signaling 3 1,64 Up
SLC31A1
solute carrier family 31 (copper transporter), 
member 1
1,72 Up SOCS4 suppressor of cytokine signaling 4 1,54 Up
SLC32A1
solute carrier family 32 (GABA vesicular 
transporter), member 1
1,52 Up SOCS6 suppressor of cytokine signaling 6 1,67 Up
SLC35A3
solute carrier family 35 (UDP-N-acetylglucosamine 
(UDP-GlcNAc) transporter), member A3
1,95 Up SOD1 superoxide dismutase 1, soluble 2,03 Up
SLC35A5 solute carrier family 35, member A5 2,02 Up SOHLH1
spermatogenesis and oogenesis specif ic basic helix-
loop-helix 1
1,51 Up
SLC35B1 solute carrier family 35, member B1 1,80 Up SOHLH2
spermatogenesis and oogenesis specif ic basic helix-
loop-helix 2
1,52 Up
SLC35B2
solute carrier family 35 (adenosine 3'-phospho 5'-
phosphosulfate transporter), member B2
2,04 Down SORBS1 sorbin and SH3 domain containing 1 1,57 Up
SLC35B4
solute carrier family 35 (UDP-xylose/UDP-N-
acetylglucosamine transporter), member B4
1,86 Up SORBS1 sorbin and SH3 domain containing 1 1,62 Up
SLC35C1
solute carrier family 35 (GDP-fucose transporter), 
member C1
1,76 Up SORCS1 sort ilin-related VPS10 domain containing receptor 1 1,62 Up
SLC35D1
solute carrier family 35 (UDP-GlcA/UDP-GalNAc 
transporter), member D1
1,59 Up SOST sclerost in 1,71 Up
SLC35E3 solute carrier family 35, member E3 2,10 Up SOX10 SRY (sex determining region Y)-box 10 1,50 Up
SLC35F1 solute carrier family 35, member F1 1,66 Up SOX12 SRY (sex determining region Y)-box 12 1,80 Up  
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SOX17 SRY (sex determining region Y)-box 17 1,61 Up STRN4 striat in, calmodulin binding protein 4 1,79 Up
SOX17 SRY (sex determining region Y)-box 17 1,53 Down STX12 syntaxin 12 1,62 Up
SOX3 SRY (sex determining region Y)-box 3 1,74 Up STXBP6 syntaxin binding protein 6 (amisyn) 1,65 Up
SOX3 SRY (sex determining region Y)-box 3 2,10 Down SUFU suppressor of fused homolog (Drosophila) 1,63 Up
SOX8 SRY (sex determining region Y)-box 8 1,94 Down ZNF280D zinc f inger protein 280D 1,79 Up
SP100 SP100 nuclear ant igen 1,53 Up SULT1A3
sulfotransferase family, cytosolic, 1A, phenol-
preferring, member 3
1,75 Up
SP100 SP100 nuclear ant igen 1,89 Down SULT1C2 sulfotransferase family, cytosolic, 1C, member 2 1,61 Up
SP5 Sp5 transcript ion factor 1,52 Down SULT4A1 sulfotransferase family 4A, member 1 1,75 Up
SPACA4 sperm acrosome associated 4 1,59 Up SUM O2 small ubiquit in-like modif ier 2 1,51 Up
SPAG9 sperm associated ant igen 9 1,65 Up SUM O2 small ubiquit in-like modif ier 2 1,87 Up
SPATA16 spermatogenesis associated 16 1,61 Up SUM O2 small ubiquit in-like modif ier 2 2,80 Down
SPATA18 spermatogenesis associated 18 2,27 Up SUPT16H suppressor of Ty 16 homolog (S. cerevisiae) 1,59 Up
SPATA2L spermatogenesis associated 2-like 1,66 Up SUPT5H suppressor of Ty 5 homolog (S. cerevisiae) 1,71 Up
SPECC1
sperm ant igen with calponin homology and coiled-
coil domains 1
2,00 Up SUSD2 sushi domain containing 2 1,88 Up
SPEN spen family transcript ional repressor 1,69 Up SUSD3 sushi domain containing 3 1,61 Up
SPG11 spast ic paraplegia 11 (autosomal recessive) 1,53 Up SVEP1
sushi, von Willebrand factor type A, EGF and 
pentraxin domain containing 1
1,63 Up
SPG21
spast ic paraplegia 21 (autosomal recessive, M ast 
syndrome)
1,85 Up SVOPL SVOP-like 1,77 Down
SPINK1 serine pept idase inhibitor, Kazal type 1 1,69 Up SYF2 SYF2 pre-mRNA-splicing factor 1,55 Up
SPINT2 serine pept idase inhibitor, Kunitz type, 2 1,77 Up SYN1 synapsin I 1,88 Down
SPOCK2
sparc/osteonect in, cwcv and kazal-like domains 
proteoglycan (test ican) 2
1,74 Up SYN3 synapsin III 1,59 Up
SPOP speckle-type POZ protein 2,30 Up SYNC syncoilin, intermediate f ilament protein 1,51 Up
SPPL2B signal pept ide pept idase like 2B 2,01 Down SYNGR1 synaptogyrin 1 1,94 Up
SPRED1 sprouty-related, EVH1 domain containing 1 1,55 Up SYNGR2 synaptogyrin 2 1,54 Up
SPRR1A small proline-rich protein 1A 3,13 Down SYNJ1 synaptojanin 1 1,57 Up
SPRR1B small proline-rich protein 1B 2,96 Up SYNPO synaptopodin 2,98 Down
SPRR2B small proline-rich protein 2B 2,96 Down SYT3 synaptotagmin III 1,52 Up
SPRR2D small proline-rich protein 2D 1,69 Up T T, brachyury homolog (mouse) 1,66 Up
SPRR2G small proline-rich protein 2G 21,17 Up TAC4 tachykinin 4 (hemokinin) 1,63 Down
SPRR3 small proline-rich protein 3 1,71 Up TACC1 transforming, acidic coiled-coil containing protein 1 1,73 Up
SPRYD3 SPRY domain containing 3 1,98 Up TACC1 transforming, acidic coiled-coil containing protein 1 2,40 Up
SPSB4
splA/ryanodine receptor domain and SOCS box 
containing 4
4,14 Down TACR1 tachykinin receptor 1 1,96 Up
SPTBN2 spectrin, beta, non-erythrocyt ic 2 1,56 Up TADA3 transcript ional adaptor 3 1,61 Up
SPTLC3
serine palmitoyltransferase, long chain base subunit  
3
1,68 Up TADA3 transcript ional adaptor 3 1,53 Up
SQRDL sulf ide quinone reductase-like (yeast) 1,58 Up TAF10
TAF10 RNA polymerase II, TATA box binding 
protein (TBP)-associated factor, 30kDa
1,96 Up
U2SURP U2 snRNP-associated SURP domain containing 1,55 Up TAF15
TAF15 RNA polymerase II, TATA box binding 
protein (TBP)-associated factor, 68kDa
1,58 Up
U2SURP U2 snRNP-associated SURP domain containing 1,59 Up TAGAP T-cell act ivat ion RhoGTPase act ivat ing protein 1,63 Up
SRBD1 S1 RNA binding domain 1 1,55 Up TANC1
tetratricopept ide repeat, ankyrin repeat and coiled-
coil containing 1
1,56 Up
SRCAP Snf2-related CREBBP act ivator protein 1,52 Down TAP1
transporter 1, ATP-binding cassette, sub-family B 
(M DR/TAP)
1,74 Up
SRCRB4D
scavenger receptor cysteine rich domain containing, 
group B (4 domains)
1,90 Up TAPT1 transmembrane anterior posterior t ransformation 1 1,57 Up
SRD5A3 steroid 5 alpha-reductase 3 2,01 Up TARDBP TAR DNA binding protein 1,67 Up
SREBF1
sterol regulatory element binding transcript ion 
factor 1
1,53 Up TAS2R16 taste receptor, type 2, member 16 2,11 Up
SRGAP1 SLIT-ROBO Rho GTPase act ivat ing protein 1 1,81 Up TAS2R43 taste receptor, type 2, member 43 1,76 Up
SRP68 signal recognit ion part icle 68kDa 1,62 Up TAS2R19 taste receptor, type 2, member 19 1,52 Up
SRXN1 sulf iredoxin 1 1,57 Up TASP1 taspase, threonine aspartase, 1 1,78 Up
SSB Sjogren syndrome ant igen B (autoant igen La) 1,60 Up TAT tyrosine aminotransferase 2,11 Up
SSBP2 single-stranded DNA binding protein 2 1,70 Up TAT tyrosine aminotransferase 2,01 Down
SSH3 slingshot protein phosphatase 3 1,63 Up TBC1D10A TBC1 domain family, member 10A 1,90 Up
SSPN sarcospan 1,92 Up TBC1D10B TBC1 domain family, member 10B 1,51 Up
SSRP1 structure specif ic recognit ion protein 1 1,50 Up TBC1D2 TBC1 domain family, member 2 1,85 Up
SSU72
SSU72 RNA polymerase II CTD phosphatase 
homolog (S. cerevisiae)
1,59 Up TBC1D20 TBC1 domain family, member 20 2,03 Up
ST3GAL5 ST3 beta-galactoside alpha-2,3-sialylt ransferase 5 1,56 Up TBC1D20 TBC1 domain family, member 20 1,58 Down
ST7L suppression of tumorigenicity 7 like 2,28 Up TBC1D25 TBC1 domain family, member 25 1,85 Up
STARD9
StAR-related lipid transfer (START) domain 
containing 9
1,89 Up TBC1D5 TBC1 domain family, member 5 1,60 Up
STAT1
signal t ransducer and act ivator of t ranscript ion 1, 
91kDa
2,12 Up TBL1Y transducin (beta)-like 1, Y-linked 1,66 Up
STAT2
signal t ransducer and act ivator of t ranscript ion 2, 
113kDa
1,68 Up TBL2 transducin (beta)-like 2 1,55 Up
STAT3
signal t ransducer and act ivator of t ranscript ion 3 
(acute-phase response factor)
1,58 Up TAF8
TAF8 RNA polymerase II, TATA box binding 
protein (TBP)-associated factor, 43kDa
1,53 Up
STAU2 staufen double-stranded RNA binding protein 2 1,64 Up TBRG1 transforming growth factor beta regulator 1 1,90 Up
STC1 stanniocalcin 1 1,67 Up TBX10 T-box 10 1,93 Up
HSPA13 heat shock protein 70kDa family, member 13 1,51 Up TCEA1 transcript ion elongat ion factor A (SII), 1 1,79 Up
STEAP3 STEAP family member 3, metalloreductase 1,63 Up TCEA3 transcript ion elongat ion factor A (SII), 3 1,73 Up
STEAP3 STEAP family member 3, metalloreductase 1,51 Up TCEAL3 transcript ion elongat ion factor A (SII)-like 3 1,72 Up
STK11 serine/threonine kinase 11 2,49 Down TCEAL4 transcript ion elongat ion factor A (SII)-like 4 1,78 Up
STK11IP serine/threonine kinase 11 interact ing protein 1,53 Up TCEB1
transcript ion elongat ion factor B (SIII), polypept ide 
1 (15kDa, elongin C)
1,66 Up
STK17B serine/threonine kinase 17b 2,18 Up TCEB2
transcript ion elongat ion factor B (SIII), polypept ide 
2 (18kDa, elongin B)
2,30 Up
STK31 serine/threonine kinase 31 1,54 Up HNF1A HNF1 homeobox A 2,68 Down
STK4 serine/threonine kinase 4 1,65 Up TCF20 transcript ion factor 20 (AR1) 1,70 Down
STOM stomatin 2,21 Up TCF23 transcript ion factor 23 1,84 Up
STOM L2 stomatin (EPB72)-like 2 1,75 Up TCF25 transcript ion factor 25 (basic helix-loop-helix) 1,84 Up
STRAP serine/threonine kinase receptor associated protein 2,20 Up TCL6 T-cell leukemia/ lymphoma 6 (non-protein coding) 1,50 Up
STRN striat in, calmodulin binding protein 1,65 Up TCN2 transcobalamin II 2,31 Up  
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TCTE3 t-complex-associated-test is-expressed 3 3,19 Down TM EM 175 transmembrane protein 175 2,90 Down
TDRD10 tudor domain containing 10 1,51 Up TM EM 178A transmembrane protein 178A 1,69 Up
TDRD10 tudor domain containing 10 1,67 Down TM EM 185A transmembrane protein 185A 1,57 Up
TEAD1
TEA domain family member 1 (SV40 transcript ional 
enhancer factor)
1,68 Up TM EM 25 transmembrane protein 25 1,68 Up
TM BIM 6 transmembrane BAX inhibitor motif  containing 6 1,55 Up TM EM 26 transmembrane protein 26 2,05 Up
TENC1
tensin like C1 domain containing phosphatase (tensin 
2)
1,51 Up TM EM 27 transmembrane protein 27 1,54 Up
TERF2IP telomeric repeat binding factor 2, interact ing protein 1,66 Up TM EM 30B transmembrane protein 30B 1,51 Up
TESK1 test is-specif ic kinase 1 1,59 Up TM EM 31 transmembrane protein 31 1,67 Up
TESK2 test is-specif ic kinase 2 1,55 Up TM EM 39B transmembrane protein 39B 1,80 Up
PRSS42 protease, serine, 42 1,74 Up NDC1 NDC1 transmembrane nucleoporin 1,69 Up
TEX13A test is expressed 13A 1,52 Up TM EM 50B transmembrane protein 50B 1,63 Up
TEX261 test is expressed 261 1,52 Up TM EM 55A transmembrane protein 55A 1,59 Up
TEX264 test is expressed 264 1,58 Up TM EM 62 transmembrane protein 62 2,05 Up
TFAM transcript ion factor A, mitochondrial 2,08 Up TM EM 63A transmembrane protein 63A 1,67 Up
TFAP2A
transcript ion factor AP-2 alpha (act ivat ing enhancer 
binding protein 2 alpha)
1,53 Up TM EM 71 transmembrane protein 71 1,70 Up
TFF1 trefoil factor 1 1,59 Up TM EM 86A transmembrane protein 86A 1,51 Up
TFF3 trefoil factor 3 (intest inal) 1,93 Up TM EM 86A transmembrane protein 86A 1,73 Up
TFPI
t issue factor pathway inhibitor (lipoprotein-
associated coagulat ion inhibitor)
1,75 Up TM EM 97 transmembrane protein 97 1,76 Up
TFR2 transferrin receptor 2 1,69 Up TM EM 97 transmembrane protein 97 2,44 Up
TGFBR2
transforming growth factor, beta receptor II 
(70/80kDa)
1,67 Up TM PRSS13 transmembrane protease, serine 13 1,77 Up
TGFBR2
transforming growth factor, beta receptor II 
(70/80kDa)
1,95 Up TM PRSS5 transmembrane protease, serine 5 1,63 Down
TGM 3 transglutaminase 3 1,66 Up TM PRSS6 transmembrane protease, serine 6 1,54 Up
TGOLN2 trans-golgi network protein 2 1,52 Up TM TC1
transmembrane and tetratricopept ide repeat 
containing 1
1,51 Up
THADA thyroid adenoma associated 1,65 Up TNF tumor necrosis factor 1,61 Down
THOC1 THO complex 1 2,07 Up TNFAIP8L1 tumor necrosis factor, alpha-induced protein 8-like 1 1,53 Down
THOC2 THO complex 2 1,54 Up TNFRSF11B
tumor necrosis factor receptor superfamily, member 
11b
1,65 Up
THRA thyroid hormone receptor, alpha 1,65 Up TNFRSF14
tumor necrosis factor receptor superfamily, member 
14
1,54 Up
M ED13L mediator complex subunit  13-like 2,84 Up TNFRSF21
tumor necrosis factor receptor superfamily, member 
21
1,76 Up
THRAP3 thyroid hormone receptor associated protein 3 1,71 Up TNFRSF25
tumor necrosis factor receptor superfamily, member 
25
2,06 Down
M ED24 mediator complex subunit  24 1,66 Up TNFRSF8
tumor necrosis factor receptor superfamily, member 
8
1,92 Up
THRB thyroid hormone receptor, beta 1,55 Up TNFRSF9
tumor necrosis factor receptor superfamily, member 
9
1,60 Up
ISM 2 isthmin 2 1,76 Up TNFSF18
tumor necrosis factor (ligand) superfamily, member 
18
1,53 Down
THSD4 thrombospondin, type I, domain containing 4 1,55 Up TNFSF8
tumor necrosis factor (ligand) superfamily, member 
8
1,62 Up
THSD7B thrombospondin, type I, domain containing 7B 1,55 Up TNNI1 troponin I type 1 (skeletal, slow) 1,77 Up
THY1 Thy-1 cell surface ant igen 2,71 Down TNS1 tensin 1 1,83 Up
TIA1
TIA1 cytotoxic granule-associated RNA binding 
protein
1,59 Up TNS3 tensin 3 1,53 Up
TIGD1 tigger transposable element derived 1 1,57 Up TNXB tenascin XB 1,58 Down
TIM M 17A
translocase of inner mitochondrial membrane 17 
homolog A (yeast)
1,63 Up TOM 1L1 target of myb1 (chicken)-like 1 2,11 Up
TIM M 44
translocase of inner mitochondrial membrane 44 
homolog (yeast)
1,50 Up TOM M 34 translocase of outer mitochondrial membrane 34 1,64 Up
TIM M 50
translocase of inner mitochondrial membrane 50 
homolog (S. cerevisiae)
1,68 Up TOP1P2 topoisomerase (DNA) I pseudogene 2 1,76 Up
TIM M 8A
translocase of inner mitochondrial membrane 8 
homolog A (yeast)
1,88 Up TOR1AIP1 torsin A interact ing protein 1 2,27 Up
TIM P2 TIM P metallopept idase inhibitor 2 1,66 Up TP53I11 tumor protein p53 inducible protein 11 1,56 Down
PTH2 parathyroid hormone 2 1,88 Down TPCN1 two pore segment channel 1 1,81 Up
TJAP1 tight junct ion associated protein 1 (peripheral) 1,68 Up TPD52 tumor protein D52 1,68 Up
TKTL1 transketolase-like 1 1,64 Up TPD52L1 tumor protein D52-like 1 1,70 Up
TLE6
transducin-like enhancer of split  6 (E(sp1) homolog, 
Drosophila)
1,66 Up TPM 1 tropomyosin 1 (alpha) 1,82 Up
TLK1 tousled-like kinase 1 1,50 Up TPSG1 tryptase gamma 1 1,83 Down
TLR1 toll-like receptor 1 1,54 Up TRABD TraB domain containing 2,33 Down
TLX1 T-cell leukemia homeobox 1 1,93 Up TRAF1 TNF receptor-associated factor 1 1,67 Up
TM 2D2 TM 2 domain containing 2 1,75 Up TRAF3IP3 TRAF3 interact ing protein 3 1,95 Up
TM 7SF3 transmembrane 7 superfamily member 3 2,00 Up TRAK1 traff icking protein, kinesin binding 1 1,61 Up
TM C2 transmembrane channel-like 2 1,67 Up TRAPPC1 traff icking protein part icle complex 1 1,53 Up
TM C2 transmembrane channel-like 2 1,63 Up TRAT1 T cell receptor associated transmembrane adaptor 1 1,76 Up
TM CO1 transmembrane and coiled-coil domains 1 1,58 Up TREM 2 triggering receptor expressed on myeloid cells 2 1,56 Up
TM ED1
transmembrane emp24 protein transport  domain 
containing 1
1,80 Up TREM L1 triggering receptor expressed on myeloid cells-like 1 1,52 Up
TM ED10
transmembrane emp24-like traf f icking protein 10 
(yeast)
1,85 Up TREM L2
triggering receptor expressed on myeloid cells-like 
2
1,92 Up
TM ED2 transmembrane emp24 domain traf f icking protein 2 1,71 Up TRIM 14 tripart ite motif  containing 14 1,69 Up
TM ED6
transmembrane emp24 protein transport  domain 
containing 6
1,78 Up TRIM 14 tripart ite motif  containing 14 1,58 Up
TM EM 108 transmembrane protein 108 2,06 Up TRIM 2 tripart ite motif  containing 2 2,07 Up
TM EM 108 transmembrane protein 108 1,83 Up TRIM 33 tripart ite motif  containing 33 1,85 Up
EM C3 ER membrane protein complex subunit  3 1,52 Up TRIM 35 tripart ite motif  containing 35 1,90 Up
TM EM 126B transmembrane protein 126B 1,58 Up TRIM 41 tripart ite motif  containing 41 1,62 Up
TM EM 127 transmembrane protein 127 1,81 Up TRIM 42 tripart ite motif  containing 42 1,74 Up
TM EM 131 transmembrane protein 131 2,15 Up TRIM 62 tripart ite motif  containing 62 1,55 Up
TM EM 141 transmembrane protein 141 1,65 Up TRIO trio Rho guanine nucleot ide exchange factor 1,54 Up
ORAI2 ORAI calcium release-act ivated calcium modulator 2 1,51 Up TRIP12 thyroid hormone receptor interactor 12 1,54 Up
CATSPERD catsper channel auxiliary subunit  delta 1,53 Up TRM T11 tRNA methyltransferase 11 homolog (S. cerevisiae) 1,69 Up
TM EM 155 transmembrane protein 155 2,16 Up TROAP trophinin associated protein 1,98 Down
TM EM 159 transmembrane protein 159 1,94 Up TRPC4
transient receptor potent ial cat ion channel, subfamily 
C, member 4
1,79 Up
TM EM 169 transmembrane protein 169 1,66 Up TRPV1
transient receptor potent ial cat ion channel, subfamily 
V, member 1
1,52 Up
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TRPV2
transient receptor potent ial cat ion channel, subfamily 
V, member 2
1,63 Up UM OD uromodulin 1,59 Up
TRPV6
transient receptor potent ial cat ion channel, subfamily 
V, member 6
2,57 Up UNC50 unc-50 homolog (C. elegans) 1,58 Up
TSC22D4 TSC22 domain family, member 4 1,65 Up UNC5C unc-5 homolog C (C. elegans) 1,68 Up
TSFM Ts translat ion elongat ion factor, mitochondrial 1,55 Up SUN2 Sad1 and UNC84 domain containing 2 1,68 Down
TSGA10IP test is specif ic, 10 interact ing protein 1,93 Up UNC93A unc-93 homolog A (C. elegans) 1,73 Up
TSHB thyroid st imulat ing hormone, beta 2,32 Up KRTDAP kerat inocyte dif ferent iat ion-associated protein 3,91 Up
TSPAN10 tetraspanin 10 2,21 Down C2orf66 chromosome 2 open reading frame 66 1,62 Up
TSPAN10 tetraspanin 10 3,46 Down FAM 150A family with sequence similarity 150, member A 1,51 Up
TSPAN18 tetraspanin 18 1,69 Up UPK2 uroplakin 2 1,77 Up
TSPAN4 tetraspanin 4 1,63 Up UPP2 uridine phosphorylase 2 2,07 Up
TSSK1B test is-specif ic serine kinase 1B 1,63 Up UQCR11
ubiquinol-cytochrome c reductase, complex III 
subunit  XI
1,88 Up
TTC14 tetratricopept ide repeat domain 14 1,79 Up UROS uroporphyrinogen III synthase 1,97 Up
TRAPPC12 traff icking protein part icle complex 12 1,57 Up USP13 ubiquit in specif ic pept idase 13 (isopept idase T-3) 1,54 Up
TTC18 tetratricopept ide repeat domain 18 1,52 Up USP28 ubiquit in specif ic pept idase 28 1,68 Up
TTC21B tetratricopept ide repeat domain 21B 1,78 Up USP32 ubiquit in specif ic pept idase 32 1,83 Up
TTC26 tetratricopept ide repeat domain 26 1,84 Up USP34 ubiquit in specif ic pept idase 34 1,87 Up
TTC27 tetratricopept ide repeat domain 27 1,55 Up USP34 ubiquit in specif ic pept idase 34 1,51 Up
TTC4 tetratricopept ide repeat domain 4 2,07 Up USP41 ubiquit in specif ic pept idase 41 1,71 Up
TTC7B tetratricopept ide repeat domain 7B 1,50 Up USP45 ubiquit in specif ic pept idase 45 1,67 Up
TTLL1 tubulin tyrosine ligase-like family, member 1 1,66 Up USP51 ubiquit in specif ic pept idase 51 1,65 Up
TTLL11 tubulin tyrosine ligase-like family, member 11 1,81 Up USP54 ubiquit in specif ic pept idase 54 1,71 Up
TTTY13
test is-specif ic t ranscript , Y-linked 13 (non-protein 
coding)
1,52 Up USP54 ubiquit in specif ic pept idase 54 2,32 Up
TTYH3 tweety family member 3 2,07 Up USP6 ubiquit in specif ic pept idase 6 (Tre-2 oncogene) 1,59 Up
TUBA1C tubulin, alpha 1c 1,50 Up USP6NL USP6 N-terminal like 1,79 Up
TUBB4B tubulin, beta 4B class IVb 3,46 Up USPL1 ubiquit in specif ic pept idase like 1 1,95 Up
TUBB4A tubulin, beta 4A class IVa 1,77 Up UTF1 undif ferent iated embryonic cell t ranscript ion factor 1 1,93 Down
TUBGCP6 tubulin, gamma complex associated protein 6 1,59 Up UTP14A
UTP14, U3 small nucleolar ribonucleoprotein, 
homolog A (yeast)
2,21 Up
TULP1 tubby like protein 1 1,60 Down UTS2R urotensin 2 receptor 2,47 Down
TUSC2 tumor suppressor candidate 2 1,61 Up VAC14 Vac14 homolog (S. cerevisiae) 1,63 Up
TWIST2 twist family bHLH transcript ion factor 2 1,60 Up VAM P2
vesicle-associated membrane protein 2 
(synaptobrevin 2)
1,52 Down
NM E9 NM E/NM 23 family member 9 1,55 Up VANGL1 VANGL planar cell polarity protein 1 1,51 Up
TXNL1 thioredoxin-like 1 1,52 Up VAV3 vav 3 guanine nucleot ide exchange factor 1,53 Up
GLRX3 glutaredoxin 3 1,59 Up VCX2 variable charge, X-linked 2 1,95 Down
TYR tyrosinase 1,87 Up VCY variable charge, Y-linked 2,03 Up
TYW3
tRNA-yW synthesizing protein 3 homolog (S. 
cerevisiae)
2,25 Up VEGFA vascular endothelial growth factor A 1,54 Up
U2AF1L4 U2 small nuclear RNA auxiliary factor 1-like 4 1,61 Up VGLL2 vest igial like 2 (Drosophila) 1,55 Up
UBA52
ubiquit in A-52 residue ribosomal protein fusion 
product 1
2,04 Up VGLL3 vest igial like 3 (Drosophila) 1,57 Up
UBAP1 ubiquit in associated protein 1 2,04 Up VIM vimentin 1,60 Up
UBB ubiquit in B 1,62 Up VIP vasoact ive intest inal pept ide 1,72 Up
UBC ubiquit in C 2,17 Up VIPR2 vasoact ive intest inal pept ide receptor 2 1,65 Up
UBC ubiquit in C 2,15 Up VM AC
vimentin-type intermediate f ilament associated 
coiled-coil protein
1,87 Up
UBA7 ubiquit in-like modif ier act ivat ing enzyme 7 1,68 Up VN1R5 vomeronasal 1 receptor 5 (gene/pseudogene) 1,94 Up
UBE2D3 ubiquit in-conjugat ing enzyme E2D 3 1,58 Up VPS11 vacuolar protein sort ing 11 homolog (S. cerevisiae) 1,84 Up
UBE2D3 ubiquit in-conjugat ing enzyme E2D 3 1,59 Up CHM P3 charged mult ivesicular body protein 3 1,60 Up
UBE2G1 ubiquit in-conjugat ing enzyme E2G 1 1,88 Up VPS28 vacuolar protein sort ing 28 homolog (S. cerevisiae) 1,97 Up
UBE2H ubiquit in-conjugat ing enzyme E2H 1,64 Up VRK2 vaccinia related kinase 2 2,04 Up
UBE2I ubiquit in-conjugat ing enzyme E2I 2,30 Down WAC WW domain containing adaptor with coiled-coil 1,60 Up
UBE2NL ubiquit in-conjugat ing enzyme E2N-like 1,55 Up WASF2 WAS protein family, member 2 2,11 Up
UBE2O ubiquit in-conjugat ing enzyme E2O 1,59 Up WBSCR16 Williams-Beuren syndrome chromosome region 16 1,57 Up
UBE2Q2 ubiquit in-conjugat ing enzyme E2Q family member 2 1,65 Up WDHD1 WD repeat and HM G-box DNA binding protein 1 1,86 Up
UBE2S ubiquit in-conjugat ing enzyme E2S 2,02 Up WDR12 WD repeat domain 12 1,81 Up
UBE2Z ubiquit in-conjugat ing enzyme E2Z 2,37 Down WDR18 WD repeat domain 18 2,18 Up
UBE3A ubiquit in protein ligase E3A 1,63 Up DCAF4 DDB1 and CUL4 associated factor 4 1,64 Up
UBL4B ubiquit in-like 4B 1,70 Up DCAF5 DDB1 and CUL4 associated factor 5 1,59 Up
UBOX5 U-box domain containing 5 1,83 Up WDR27 WD repeat domain 27 1,87 Up
UBQLN3 ubiquilin 3 1,64 Up DCAF8 DDB1 and CUL4 associated factor 8 1,53 Up
UBR1 ubiquit in protein ligase E3 component n-recognin 1 1,70 Up WDR45 WD repeat domain 45 1,60 Up
UBTD2 ubiquit in domain containing 2 1,53 Up WDR45B WD repeat domain 45B 1,52 Up
UCHL5 ubiquit in carboxyl-terminal hydrolase L5 1,59 Up POC1A POC1 centriolar protein A 1,56 Up
UCKL1 uridine-cyt idine kinase 1-like 1 1,64 Up DCAF7 DDB1 and CUL4 associated factor 7 1,50 Up
UCN urocort in 1,60 Down DAW1 dynein assembly factor with WDR repeat domains 1 1,51 Down
UCN2 urocort in 2 1,53 Down DPH7 diphthamide biosynthesis 7 1,87 Up
UQCR10
ubiquinol-cytochrome c reductase, complex III 
subunit  X
1,75 Up WDR90 WD repeat domain 90 1,62 Up
UQCR10
ubiquinol-cytochrome c reductase, complex III 
subunit  X
1,54 Up WFDC5 WAP four-disulf ide core domain 5 1,52 Up
UFD1L ubiquit in fusion degradat ion 1 like (yeast) 1,75 Up WHSC1 Wolf-Hirschhorn syndrome candidate 1 1,96 Up
UGDH UDP-glucose 6-dehydrogenase 1,72 Up WIBG within bgcn homolog (Drosophila) 1,56 Up
UGT3A1 UDP glycosyltransferase 3 family, polypept ide A1 1,82 Up WIPF1 WAS/WASL interact ing protein family, member 1 1,81 Up
UHM K1 U2AF homology motif  (UHM ) kinase 1 1,68 Up WIPF2 WAS/WASL interact ing protein family, member 2 2,01 Up
ULK1 unc-51 like autophagy act ivat ing kinase 1 1,77 Up WIPI1 WD repeat domain, phosphoinosit ide interact ing 1 1,66 Up
ULK1 unc-51 like autophagy act ivat ing kinase 1 1,52 Up WIPI2 WD repeat domain, phosphoinosit ide interact ing 2 1,94 Up  
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WNK4 WNK lysine def icient protein kinase 4 1,63 Down ZNF25 zinc f inger protein 25 1,53 Up
WNT10B
wingless-type M M TV integrat ion site family, 
member 10B
1,50 Up ZNF277 zinc f inger protein 277 1,51 Up
WNT5B
wingless-type M M TV integrat ion site family, 
member 5B
1,52 Up ZNF283 zinc f inger protein 283 1,58 Up
WNT6
wingless-type M M TV integrat ion site family, 
member 6
2,38 Down SCAPER S-phase cyclin A-associated protein in the ER 1,63 Up
WNT9A
wingless-type M M TV integrat ion site family, 
member 9A
1,50 Down ZBTB21 zinc f inger and BTB domain containing 21 1,54 Up
WRNIP1 Werner helicase interact ing protein 1 1,52 Up ZNF320 zinc f inger protein 320 1,50 Up
WWC3 WWC family member 3 2,38 Up ZNF326 zinc f inger protein 326 1,65 Up
WWP2 WW domain containing E3 ubiquit in protein ligase 2 1,85 Up ZNF333 zinc f inger protein 333 2,02 Up
WWP2 WW domain containing E3 ubiquit in protein ligase 2 1,88 Up ZNF296 zinc f inger protein 296 1,93 Up
WWP2 WW domain containing E3 ubiquit in protein ligase 2 1,54 Down ZNF346 zinc f inger protein 346 1,65 Up
WWTR1 WW domain containing transcript ion regulator 1 1,74 Up ZNF367 zinc f inger protein 367 1,55 Up
GPN1 GPN-loop GTPase 1 1,59 Up ZNF396 zinc f inger protein 396 1,94 Up
XCL2 chemokine (C motif ) ligand 2 1,61 Up ZFHX2 zinc f inger homeobox 2 1,52 Down
XKR6
XK, Kell blood group complex subunit-related 
family, member 6
2,03 Up ZNF410 zinc f inger protein 410 1,89 Up
XPNPEP3
X-prolyl aminopept idase (aminopept idase P) 3, 
putat ive
1,72 Up ZNF415 zinc f inger protein 415 1,52 Up
XPOT export in, tRNA 1,60 Up ZNF417 zinc f inger protein 417 1,71 Up
XRN1 5'-3' exoribonuclease 1 1,53 Up ZNF425 zinc f inger protein 425 1,68 Up
XYLB xylulokinase homolog (H. inf luenzae) 1,61 Up ZNF429 zinc f inger protein 429 1,68 Up
YBX1 Y box binding protein 1 1,57 Up ZNF440 zinc f inger protein 440 1,62 Up
YBX2 Y box binding protein 2 1,77 Up ZNF467 zinc f inger protein 467 1,81 Down
YPEL4 yippee-like 4 (Drosophila) 1,96 Up ZNF468 zinc f inger protein 468 1,67 Up
YTHDC1 YTH domain containing 1 1,81 Up ZNF501 zinc f inger protein 501 1,86 Up
YWHAB
tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase act ivat ion protein, beta
1,69 Up ZNF506 zinc f inger protein 506 1,93 Up
YWHAE
tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase act ivat ion protein, epsilon
1,83 Up ZNF518A zinc f inger protein 518A 1,65 Up
YWHAQ
tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase act ivat ion protein, theta
1,69 Up ZNF521 zinc f inger protein 521 1,70 Up
YWHAZ
tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase act ivat ion protein, zeta
1,52 Up ZNF525 zinc f inger protein 525 1,53 Up
ZBTB39 zinc f inger and BTB domain containing 39 1,73 Up ZNF532 zinc f inger protein 532 3,52 Up
ZBTB40 zinc f inger and BTB domain containing 40 1,56 Up ZNF546 zinc f inger protein 546 1,67 Up
ZBTB5 zinc f inger and BTB domain containing 5 1,86 Up ZNF551 zinc f inger protein 551 1,51 Down
ZC3H11A zinc f inger CCCH-type containing 11A 1,63 Up ZNF554 zinc f inger protein 554 1,51 Up
ZC3H13 zinc f inger CCCH-type containing 13 1,60 Up ZNF562 zinc f inger protein 562 1,51 Up
CISD1 CDGSH iron sulfur domain 1 2,12 Up ZNF578 zinc f inger protein 578 1,75 Up
ZDHHC2 zinc f inger, DHHC-type containing 2 1,80 Up ZNF579 zinc f inger protein 579 1,82 Down
ZDHHC21 zinc f inger, DHHC-type containing 21 1,63 Up ZNF581 zinc f inger protein 581 1,58 Up
ZDHHC21 zinc f inger, DHHC-type containing 21 1,66 Up ZNF589 zinc f inger protein 589 1,50 Up
ZDHHC24 zinc f inger, DHHC-type containing 24 2,07 Up ZNF607 zinc f inger protein 607 1,51 Up
ZDHHC4 zinc f inger, DHHC-type containing 4 1,88 Up ZNF616 zinc f inger protein 616 1,85 Up
ZDHHC5 zinc f inger, DHHC-type containing 5 1,56 Up ZNF618 zinc f inger protein 618 1,55 Up
ZDHHC8 zinc f inger, DHHC-type containing 8 1,63 Down ZNF618 zinc f inger protein 618 1,61 Up
ZFAND3 zinc f inger, AN1-type domain 3 1,77 Up ZNF619 zinc f inger protein 619 1,74 Down
ZFAND5 zinc f inger, AN1-type domain 5 1,60 Up ZNF625 zinc f inger protein 625 1,90 Up
ZFAND5 zinc f inger, AN1-type domain 5 1,53 Up ZNF644 zinc f inger protein 644 1,66 Up
ZFP36L1 ZFP36 ring f inger protein-like 1 1,98 Up UBR3
ubiquit in protein ligase E3 component n-recognin 3 
(putat ive)
1,51 Up
ZFP91 ZFP91 zinc f inger protein 1,64 Up ZNF655 zinc f inger protein 655 2,02 Up
ZFPL1 zinc f inger protein-like 1 1,84 Down ZNF681 zinc f inger protein 681 1,51 Up
ZFPM 1 zinc f inger protein, FOG family member 1 1,77 Down ZNF695 zinc f inger protein 695 1,62 Up
ZFR zinc f inger RNA binding protein 1,55 Up ZNF696 zinc f inger protein 696 1,79 Up
ZFY zinc f inger protein, Y-linked 1,54 Up ZNF697 zinc f inger protein 697 1,63 Down
ZFYVE20 zinc f inger, FYVE domain containing 20 1,76 Up ZNF704 zinc f inger protein 704 2,00 Up
ZFYVE26 zinc f inger, FYVE domain containing 26 1,59 Up ZNF761 zinc f inger protein 761 1,71 Up
ZFYVE27 zinc f inger, FYVE domain containing 27 1,56 Up ZNF764 zinc f inger protein 764 1,85 Up
ZG16 zymogen granule protein 16 1,54 Up ZNF767 zinc f inger family member 767 1,54 Up
ZIC4 Zic family member 4 1,99 Up ZNF772 zinc f inger protein 772 1,92 Up
ZIM 2 zinc f inger, imprinted 2 2,04 Up ZNF775 zinc f inger protein 775 2,23 Down
ZKSCAN2 zinc f inger with KRAB and SCAN domains 2 1,66 Up ZNF777 zinc f inger protein 777 2,17 Down
ZM AT2 zinc f inger, matrin-type 2 1,82 Up ZNF778 zinc f inger protein 778 1,76 Up
ZM AT5 zinc f inger, matrin-type 5 1,98 Up ZNF781 zinc f inger protein 781 1,57 Up
ZM YND12 zinc f inger, M YND-type containing 12 1,55 Up ZNF80 zinc f inger protein 80 1,70 Up
ZNF12 zinc f inger protein 12 1,76 Up ZNF818P zinc f inger protein 818, pseudogene 1,56 Up
ZNF133 zinc f inger protein 133 1,52 Up ZNF99 zinc f inger protein 99 1,64 Up
ZNF141 zinc f inger protein 141 1,60 Up ZNRD1 zinc ribbon domain containing 1 1,56 Up
ZNF174 zinc f inger protein 174 1,64 Down ZRANB1 zinc f inger, RAN-binding domain containing 1 1,64 Up
ZSCAN26 zinc f inger and SCAN domain containing 26 1,51 Up ZSCAN18 zinc f inger and SCAN domain containing 18 1,63 Up
ZNF213 zinc f inger protein 213 1,59 Down ZSCAN2 zinc f inger and SCAN domain containing 2 1,95 Up
ZNF219 zinc f inger protein 219 2,32 Up ZSCAN22 zinc f inger and SCAN domain containing 22 1,55 Up
ZNF226 zinc f inger protein 226 1,66 Up ZSWIM 6 zinc f inger, SWIM -type containing 6 1,72 Up
ZNF234 zinc f inger protein 234 1,84 Up ZW10 zw10 kinetochore protein 2,13 Up
ZNF235 zinc f inger protein 235 1,60 Up ZWILCH zwilch kinetochore protein 1,62 Up
ZNF236 zinc f inger protein 236 1,57 Up ZYG11B zyg-11 family member B, cell cycle regulator 2,01 Up
1. Information from HGNC (HUGO Gene Nomenclature Committee; www.genenames.org). 1. Information from HGNC (HUGO Gene Nomenclature Committee; www.genenames.org).
2. Type of regulat ion. 2. Type of regulat ion.  
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Table S3. Characterization of the secondary volunteer panel for real-time qPCR validation. 
V olunt eer N umber A ge ( Y ears Old ) Skin Phot o t ype
1
Skin Type
2
Et hnic Group
3
1 21 II Normal Polish
2 24 II Normal Germa/Italian
3 27 III Combinat ion Indigenous
4 22 II Oily Italian
5 27 II Not declared Not declared
6 54 II Oily Italian/Spanish
7 62 II Not declared Not declared
8 27 II Oily German/Polish/Portuguese/Spanish
9 24 II Combinat ion Portuguese
10 27 II Oily Polish
11 25 III Combinat ion African/German 
12 29 III Normal Italian/Libanese/Spanish
13 52 III Not declared Not declared
14 51 II Not declared Not declared
15 52 III Not declared Not declared
16 54 III Not declared Not declared
17 54 III Not declared Not declared
18 57 II Seca Italian
19 56 III Oily Spanish
20 62 II Normal Italian
1. Classif icat ion according to Fitzpatrick phototyping scale
2. Personal declarat ion of predominant skin type in the body according to sebum production
3. Personal declarat ion of ethnic groups  
 
 
Table S4. Number of differentially expressed probe sets in sun-exposed epidermal aging 
considering different fold-change values and a p-value cut-off of 0.05. 
1.5 2.0 3.0
Total 4,863 683 101
Up-regulated 4,146 419 36
Down-regulated 717 264 65
Ratio (up/down) 5.8 1.6 0.6
Fold change values
Probe sets account
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Table S5. KEGG pathways modulated in sun-exposed epidermal aging with p-value cut-off of 0.01. 
KEGG pathway name KEGG code Number of DEGs1 p-value
Systemic lupus erythematosus hsa05322 114 5.22E-91
Neuroactive ligand-receptor interaction hsa04080 69 1.91E-16
Ubiquitin mediated proteolysis hsa04120 34 1.28E-07
Ribosome hsa03010 24 2.34E-06
Fc gamma R-mediated phagocytosis hsa04666 25 6.54E-06
Focal adhesion hsa04510 40 6.54E-06
Cytokine-cytokine receptor interaction hsa04060 46 1.36E-05
Wnt signaling pathway hsa04310 32 2.38E-05
Type I diabetes mellitus hsa04940 15 2.80E-05
Chemokine signaling pathway hsa04062 36 3.19E-05
Neurotrophin signaling pathway hsa04722 27 5.73E-05
Regulation of actin cytoskeleton hsa04810 37 1.69E-04
Antigen processing and presentation hsa04612 21 1.69E-04
Alzheimer's disease hsa05010 31 1.73E-04
Endocytosis hsa04144 33 1.74E-04
Allograft rejection hsa05330 13 3.47E-04
MAPK signaling pathway hsa04010 42 4.04E-04
Vibrio cholerae infection hsa05110 15 4.09E-04
Cell adhesion molecules (CAMs) hsa04514 26 4.79E-04
Viral myocarditis hsa05416 18 4.79E-04
Calcium signaling pathway hsa04020 31 4.79E-04
Purine metabolism hsa00230 29 5.79E-04
Graft-versus-host disease hsa05332 13 6.45E-04
Asthma hsa05310 11 7.08E-04
Axon guidance hsa04360 24 8.78E-04
Epithelial cell signaling in Helicobacter pylori infection hsa05120 16 8.98E-04
Huntington's disease hsa05016 31 8.98E-04
Autoimmune thyroid disease hsa05320 14 1.28E-03
Riboflavin metabolism hsa00740 7 2.64E-03
Natural killer cell mediated cytotoxicity hsa04650 24 2.64E-03
Hematopoietic cell lineage hsa04640 17 2.83E-03
Fc epsilon RI signaling pathway hsa04664 16 3.34E-03
Intestinal immune network for IgA production hsa04672 12 3.34E-03
Type II diabetes mellitus hsa04930 12 3.34E-03
ECM-receptor interaction hsa04512 16 4.89E-03
Oocyte meiosis hsa04114 20 5.06E-03
Jak-STAT signaling pathway hsa04630 25 5.06E-03
Butanoate metabolism hsa00650 10 6.46E-03
Amyotrophic lateral sclerosis (ALS) hsa05014 12 6.86E-03
Hedgehog signaling pathway hsa04340 12 9.14E-03
1. DEGs, differentially expressed genes.  
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Table S6. Epidermal age-modulated genes shared with the study of Raddatz et al. (2013). 
HGNC Approved Symbol1 HGNC Approved Name1
ANXA3 annexin A3
CEACAM5 carcinoembryonic antigen-related cell adhesion molecule 5
FABP3 fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)
FBLIM1 filamin binding LIM protein 1
FZD10 frizzled family receptor 10
IFI27 interferon, alpha-inducible protein 27 
JPH2 junctophilin 2
MUC16 mucin 16, cell surface associated
OTOP2 otopetrin 2
SAMD4A sterile alpha motif domain containing 4A
SLC6A2 solute carrier family 6 (neurotransmitter transporter), member 2
SPRR1A small proline-rich protein 1A
SPRR1B small proline-rich protein 1B
TRIM2 tripartite motif containing 2
ZDHHC2 zinc finger, DHHC-type containing 2
1. Gene ontology terms identified with GeneSpring version 12.5 software (Agilent Technologies).  
 
 
Table S7. Epidermal age-modulated genes shared with the study of Glass et al. (2013). 
HGN C  A pproved  
Symbo l
1 HGN C  A pproved  N ame
1 HGN C  A pproved  
Symbo l
1 HGN C  A pproved  N ame
1
ABI3BP ABI family, member 3 (NESH) binding protein CHCHD5 coiled-coil-helix-coiled-coil-helix domain containing 5
ADA adenosine deaminase CIAO1 cytosolic iron-sulfur protein assembly 1
AKR7L aldo-keto reductase family 7-like CLCF1 cardiotrophin-like cytokine factor 1
ALOX15B arachidonate 15-lipoxygenase, type B CNDP2 CNDP dipept idase 2 (metallopept idase M 20 family)
ALOX5AP arachidonate 5-lipoxygenase-act ivat ing protein COL3A1 collagen, type III, alpha 1
ANAPC4 anaphase promoting complex subunit  4 COL5A2 collagen, type V, alpha 2
ANAPC5 anaphase promoting complex subunit  5 COM M D1 copper metabolism (M urr1) domain containing 1
ANGPTL2 angiopoiet in-like 2 CORIN corin, serine pept idase
ANKM Y2 ankyrin repeat and M YND domain containing 2 CREG1 cellular repressor of E1A-st imulated genes 1
AP1G2 adaptor-related protein complex 1, gamma 2 subunit CSAD cysteine sulf inic acid decarboxylase
APH1B APH1B gamma secretase subunit CSTB cystat in B (stef in B)
ARHGEF10 Rho guanine nucleot ide exchange factor (GEF) 10 CTSF cathepsin F
ARID4B AT rich interact ive domain 4B (RBP1-like) CTSK cathepsin K
ARM C6 armadillo repeat containing 6 DAB2 Dab, mitogen-responsive phosphoprotein, homolog 2 (Drosophila)
ASNS asparagine synthetase (glutamine-hydrolyzing) DAD1 defender against cell death 1
ATP6V0C ATPase, H+ transport ing, lysosomal 16kDa, V0 subunit  c DBN1 drebrin 1
ATP6V1D ATPase, H+ transport ing, lysosomal 34kDa, V1 subunit  D DCBLD2 discoidin, CUB and LCCL domain containing 2
AUTS2 autism suscept ibility candidate 2 DCST1 DC-STAM P domain containing 1
DDX39B DEAD (Asp-Glu-Ala-Asp) box polypept ide 39B DDB2 damage-specif ic DNA binding protein 2, 48kDa
BCAN brevican DFNA5 deafness, autosomal dominant 5
BCKDK branched chain ketoacid dehydrogenase kinase DIRAS3 DIRAS family, GTP-binding RAS-like 3
BCL11A B-cell CLL/ lymphoma 11A (zinc f inger protein) DM BX1 diencephalon/mesencephalon homeobox 1
BID BH3 interact ing domain death agonist DNAH17 dynein, axonemal, heavy chain 17
BLCAP bladder cancer associated protein DNASE1L2 deoxyribonuclease I-like 2
C11orf70 chromosome 11 open reading frame 70 DOCK3 dedicator of cytokinesis 3
M FSD12 major facilitator superfamily domain containing 12 DPM 3 dolichyl-phosphate mannosyltransferase polypept ide 3
C1orf63 chromosome 1 open reading frame 63 CALY calcyon neuron-specif ic vesicular protein
ZNF295-AS1 ZNF295 ant isense RNA 1 DUSP16 dual specif icity phosphatase 16
C21orf33 chromosome 21 open reading frame 33 DVL3 dishevelled segment polarity protein 3
M AATS1 M YCBP-associated, test is expressed 1 EEF2K eukaryot ic elongat ion factor-2 kinase
C6orf106 chromosome 6 open reading frame 106 EI24 etoposide induced 2.4
CCDC167 coiled-coil domain containing 167 ELM O1 engulfment and cell mot ility 1
CALU calumenin ERN1 endoplasmic ret iculum to nucleus signaling 1
CAM K2G calcium/calmodulin-dependent protein kinase II gamma FAM 129B family with sequence similarity 129, member B
COA3 cytochrome c oxidase assembly factor 3 FAM 46C family with sequence similarity 46, member C
CCDC86 coiled-coil domain containing 86 FAM 63A family with sequence similarity 63, member A
CCL2 chemokine (C-C motif ) ligand 2 FAM 89B family with sequence similarity 89, member B
CCL21 chemokine (C-C motif ) ligand 21 FANCD2 Fanconi anemia, complementat ion group D2
CDA cyt idine deaminase FAT2 FAT atypical cadherin 2
CDH12 cadherin 12, type 2 (N-cadherin 2) FCN1 ficolin (collagen/f ibrinogen domain containing) 1
CEBPA CCAAT/enhancer binding protein (C/EBP), alpha FETUB fetuin B
AGAP3 ArfGAP with GTPase domain, ankyrin repeat and PH domain 3 ARHGEF37 Rho guanine nucleot ide exchange factor (GEF) 37
CEP135 centrosomal protein 135kDa FOXQ1 forkhead box Q1
CEP63 centrosomal protein 63kDa GLDC glycine dehydrogenase (decarboxylat ing)
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HGN C  A pproved  
Symbo l
1 HGN C  A pproved  N ame
1 HGN C  A pproved  
Symbo l
1 HGN C  A pproved  N ame
1
GOLGB1 golgin B1 PTPRZ1 protein tyrosine phosphatase, receptor-type, Z polypept ide 1
GPI glucose-6-phosphate isomerase PXM P4 peroxisomal membrane protein 4, 24kDa
GPRC5D G protein-coupled receptor, family C, group 5, member D QPRT quinolinate phosphoribosyltransferase
GYPC glycophorin C (Gerbich blood group) RAB11FIP5 RAB11 family interact ing protein 5 (class I)
H2AFJ H2A histone family, member J RAD54B RAD54 homolog B (S. cerevisiae)
HADH hydroxyacyl-CoA dehydrogenase RANBP10 RAN binding protein 10
HCP5 HLA complex P5 (non-protein coding) RAPGEF1 Rap guanine nucleot ide exchange factor (GEF) 1
HIST1H2BD histone cluster 1, H2bd RASEF RAS and EF-hand domain containing
HIST1H2BK histone cluster 1, H2bk RBM 18 RNA binding motif  protein 18
HIVEP3 human immunodeficiency virus type I enhancer binding protein 3 REEP6 receptor accessory protein 6
HLA-DPA1 major histocompatibility complex, class II, DP alpha 1 REXO2 RNA exonuclease 2
HSD3B1
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid 
delta-isomerase 1
RHOG ras homolog family member G
HYOU1 hypoxia up-regulated 1 RIM BP2 RIM S binding protein 2
IGFBP4 insulin-like growth factor binding protein 4 RPL29 ribosomal protein L29
IL1B interleukin 1, beta RPP25 ribonuclease P/M RP 25kDa subunit
IRX6 iroquois homeobox 6 RPS29 ribosomal protein S29
ISG20 interferon st imulated exonuclease gene 20kDa S100A3 S100 calcium binding protein A3
ITGB4 integrin, beta 4 S100PBP S100P binding protein
JAG2 jagged 2 SAM M 50 SAM M 50 sort ing and assembly machinery component
KCNIP4 Kv channel interact ing protein 4 SC5D sterol-C5-desaturase
KCTD13 potassium channel tetramerizat ion domain containing 13 SDCCAG3 serologically def ined colon cancer ant igen 3
KDELR3
KDEL (Lys-Asp-Glu-Leu) endoplasmic ret iculum protein retent ion 
receptor 3
SDSL serine dehydratase-like
KIAA0513 KIAA0513 VIM P VCP-interact ing membrane protein
KIAA0586 KIAA0586 SEM A5B
sema domain, seven thrombospondin repeats (type 1 and type 1-like), 
t ransmembrane domain (TM ) and short  cytoplasmic domain, (semaphorin) 5B
KIAA0753 KIAA0753 M SRB1 methionine sulfoxide reductase B1
M AU2 M AU2 sister chromatid cohesion factor SERPINH1
serpin pept idase inhibitor, clade H (heat shock protein 47), member 1, (collagen 
binding protein 1)
KIAA0907 KIAA0907 SF3B5 splicing factor 3b, subunit  5, 10kDa
ZSWIM 8 zinc f inger, SWIM -type containing 8 SGPP2 sphingosine-1-phosphate phosphatase 2
KLHDC3 kelch domain containing 3 SHB Src homology 2 domain containing adaptor protein B
KRT27 kerat in 27 SHF Src homology 2 domain containing F
KRT32 kerat in 32 SIDT2 SID1 transmembrane family, member 2
KRT34 kerat in 34 SLC10A3 solute carrier family 10, member 3
KRT38 kerat in 38 SLC11A2 solute carrier family 11 (proton-coupled divalent metal ion transporter), member 2
KRT5 kerat in 5 SLC16A5 solute carrier family 16 (monocarboxylate transporter), member 5
KRT85 kerat in 85 SLC25A1 solute carrier family 25 (mitochondrial carrier; cit rate transporter), member 1
KRT86 kerat in 86 SLC25A42 solute carrier family 25, member 42
KRTAP19-1 kerat in associated protein 19-1 SLC2A5 solute carrier family 2 (facilitated glucose/fructose transporter), member 5
KRTAP4-2 kerat in associated protein 4-2 SLC35B1 solute carrier family 35, member B1
KRTAP4-5 kerat in associated protein 4-5 SLC35F1 solute carrier family 35, member F1
KRTAP9-3 kerat in associated protein 9-3 SLC37A4 solute carrier family 37 (glucose-6-phosphate transporter), member 4
KRTAP9-4 kerat in associated protein 9-4 SLC41A1 solute carrier family 41 (magnesium transporter), member 1
POGLUT1 protein O-glucosyltransferase 1 SLC45A2 solute carrier family 45, member 2
LFNG LFNG O-fucosylpept ide 3-beta-N-acetylglucosaminyltransferase SLC47A1 solute carrier family 47 (mult idrug and toxin extrusion), member 1
LGALS1 lect in, galactoside-binding, soluble, 1 SLC7A1 solute carrier family 7 (cat ionic amino acid transporter, y+ system), member 1
LGALS8 lect in, galactoside-binding, soluble, 8 SM G1 SM G1 phosphat idylinositol 3-kinase-related kinase
LRP3 low density lipoprotein receptor-related protein 3 SND1 staphylococcal nuclease and tudor domain containing 1
LRRC18 leucine rich repeat containing 18 ARHGAP33 Rho GTPase act ivat ing protein 33
NRROS negative regulator of react ive oxygen species SPEN spen family transcript ional repressor
LSS lanosterol synthase (2,3-oxidosqualene-lanosterol cyclase) SPG11 spast ic paraplegia 11 (autosomal recessive)
LYG2 lysozyme G-like 2 SPRR1A small proline-rich protein 1A
M AP1A microtubule-associated protein 1A SPTLC3 serine palmitoyltransferase, long chain base subunit  3
M APKBP1 mitogen-act ivated protein kinase binding protein 1 SREBF1 sterol regulatory element binding transcript ion factor 1
M C5R melanocort in 5 receptor SSH3 slingshot protein phosphatase 3
M E1 malic enzyme 1, NADP(+)-dependent, cytosolic STK31 serine/threonine kinase 31
M EA1 male-enhanced ant igen 1 SULT4A1 sulfotransferase family 4A, member 1
M FSD5 major facilitator superfamily domain containing 5 SYNGR1 synaptogyrin 1
M IR503HG M IR503 host gene (non-protein coding) TAF10
TAF10 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 
30kDa
M LANA melan-A TAP1 transporter 1, ATP-binding cassette, sub-family B (M DR/TAP)
M M RN1 mult imerin 1 TARDBP TAR DNA binding protein
M OCS1 molybdenum cofactor synthesis 1 TBC1D2 TBC1 domain family, member 2
M OGAT1 monoacylglycerol O-acyltransferase 1 TCN2 transcobalamin II
M RPS12 mitochondrial ribosomal protein S12 TEX264 test is expressed 264
M RPS24 mitochondrial ribosomal protein S24 TFF3 trefoil factor 3 (intest inal)
M RPS25 mitochondrial ribosomal protein S25 THOC1 THO complex 1
M SRA methionine sulfoxide reductase A THY1 Thy-1 cell surface ant igen
M SX1 msh homeobox 1 TJAP1 tight junct ion associated protein 1 (peripheral)
NAPSB napsin B aspart ic pept idase, pseudogene TM EM 141 transmembrane protein 141
NDUFA8 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 8, 19kDa TM EM 178A transmembrane protein 178A
NDUFB2 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 2, 8kDa TM EM 31 transmembrane protein 31
NKD2 naked cut icle homolog 2 (Drosophila) TM EM 50B transmembrane protein 50B
OAZ1 ornithine decarboxylase ant izyme 1 TM EM 71 transmembrane protein 71
OLFM L2B olfactomedin-like 2B TM EM 97 transmembrane protein 97
ORC2 origin recognit ion complex, subunit  2 TNFRSF21 tumor necrosis factor receptor superfamily, member 21
PADI4 pept idyl arginine deiminase, type IV TNFRSF25 tumor necrosis factor receptor superfamily, member 25
PAPLN papilin, proteoglycan-like sulfated glycoprotein TRAK1 traff icking protein, kinesin binding 1
PARP2 poly (ADP-ribose) polymerase 2 TRPV1 transient receptor potent ial cat ion channel, subfamily V, member 1
PC pyruvate carboxylase TRPV2 transient receptor potent ial cat ion channel, subfamily V, member 2
PCDH7 protocadherin 7 TTYH3 tweety family member 3
PCK2 phosphoenolpyruvate carboxykinase 2 (mitochondrial) TUBGCP6 tubulin, gamma complex associated protein 6
PDE4C phosphodiesterase 4C, cAM P-specif ic UCKL1 uridine-cyt idine kinase 1-like 1
PGAM 5 phosphoglycerate mutase family member 5 UCN2 urocort in 2
PHF12 PHD f inger protein 12 UQCR10 ubiquinol-cytochrome c reductase, complex III subunit  X
PHF7 PHD f inger protein 7 USPL1 ubiquit in specif ic pept idase like 1
PIGN phosphat idylinositol glycan anchor biosynthesis, class N VAV3 vav 3 guanine nucleot ide exchange factor
PISD phosphat idylserine decarboxylase YTHDC1 YTH domain containing 1
PLCH2 phospholipase C, eta 2 ZDHHC24 zinc f inger, DHHC-type containing 24
PNPLA5 patat in-like phospholipase domain containing 5 ZDHHC8 zinc f inger, DHHC-type containing 8
PON3 paraoxonase 3 ZFYVE20 zinc f inger, FYVE domain containing 20
PPP1R11 protein phosphatase 1, regulatory (inhibitor) subunit  11 ZFYVE26 zinc f inger, FYVE domain containing 26
PPP2R1B protein phosphatase 2, regulatory subunit  A, beta ZNF333 zinc f inger protein 333
PRM T2 protein arginine methyltransferase 2 ZNF525 zinc f inger protein 525
PRR4 proline rich 4 (lacrimal) ZNF581 zinc f inger protein 581
1. Information from HGNC (HUGO Gene Nomenclature Committee; www.genenames.org). 1. Information from HGNC (HUGO Gene Nomenclature Committee; www.genenames.org).  
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Table S8. Epidermal age-modulated genes shared with the study of Yan et al. (2013). 
HGN C  A pproved  
Symbo l
1 HGN C  A pproved  N ame
1 HGN C  A pproved  
Symbo l
1 HGN C  A pproved  N ame
1
A4GALT alpha 1,4-galactosyltransferase GCNT3 glucosaminyl (N-acetyl) t ransferase 3, mucin type
NCEH1 neutral cholesterol ester hydrolase 1 GJA3 gap junct ion protein, alpha 3, 46kDa
ACAD9 acyl-CoA dehydrogenase family, member 9 GLDC glycine dehydrogenase (decarboxylat ing)
ACOT11 acyl-CoA thioesterase 11 GNPDA2 glucosamine-6-phosphate deaminase 2
ACOX2 acyl-CoA oxidase 2, branched chain GPD1L glycerol-3-phosphate dehydrogenase 1-like
ADA adenosine deaminase GPR115 G protein-coupled receptor 115
ADH1A alcohol dehydrogenase 1A (class I), alpha polypept ide GPRC5D G protein-coupled receptor, family C, group 5, member D
ADHFE1 alcohol dehydrogenase, iron containing, 1 GREM 2 gremlin 2, DAN family BM P antagonist
ADNP act ivity-dependent neuroprotector homeobox GSTM 5 glutathione S-transferase mu 5
AES amino-terminal enhancer of split GUK1 guanylate kinase 1
AIM 1L absent in melanoma 1-like GULP1 GULP, engulfment adaptor PTB domain containing 1
ALDH2 aldehyde dehydrogenase 2 family (mitochondrial) HADH hydroxyacyl-CoA dehydrogenase
ALDOA aldolase A, fructose-bisphosphate HDHD1 haloacid dehalogenase-like hydrolase domain containing 1
ALKBH8 alkB, alkylat ion repair homolog 8 (E. coli) HIST1H2BD histone cluster 1, H2bd
ALOX12 arachidonate 12-lipoxygenase HOXB3 homeobox B3
ALOX15B arachidonate 15-lipoxygenase, type B HOXD10 homeobox D10
ANGPTL2 angiopoiet in-like 2 HPSE2 heparanase 2
ANPEP alanyl (membrane) aminopept idase HSD3B1 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1
AQP5 aquaporin 5 HYOU1 hypoxia up-regulated 1
ARM C6 armadillo repeat containing 6 IL10RA interleukin 10 receptor, alpha
ARV1 ARV1 homolog (S. cerevisiae) ITPKA inositol-t risphosphate 3-kinase A
ATG9B autophagy related 9B JPH2 junctophilin 2
ATP6V0C ATPase, H+ transport ing, lysosomal 16kDa, V0 subunit  c KATNAL1 katanin p60 subunit  A-like 1
BCAN brevican KCM F1 potassium channel modulatory factor 1
BLOC1S2 biogenesis of lysosomal organelles complex-1, subunit  2 KDELR3 KDEL (Lys-Asp-Glu-Leu) endoplasmic ret iculum protein retent ion receptor 3
DTD2 D-tyrosyl-tRNA deacylase 2 (putat ive) M LEC malect in
CCDC176 coiled-coil domain containing 176 KIAA0513 KIAA0513
CTC1 CTS telomere maintenance complex component 1 KIF23 kinesin family member 23
M FSD12 major facilitator superfamily domain containing 12 KRT27 kerat in 27
C1orf116 chromosome 1 open reading frame 116 KRT32 kerat in 32
AUNIP aurora kinase A and ninein interact ing protein KRT34 kerat in 34
C1orf53 chromosome 1 open reading frame 53 KRT8 kerat in 8
ISM 1 isthmin 1, angiogenesis inhibitor KRT85 kerat in 85
M M ADHC
methylmalonic aciduria (cobalamin def iciency) cblD type, with 
homocyst inuria
KRTAP13-2 kerat in associated protein 13-2
TRM T44 tRNA methyltransferase 44 homolog (S. cerevisiae) KRTAP19-1 kerat in associated protein 19-1
FAM 13B family with sequence similarity 13, member B KRTAP3-1 kerat in associated protein 3-1
ATAT1 alpha tubulin acetylt ransferase 1 KRTAP3-2 kerat in associated protein 3-2
FAM 167A family with sequence similarity 167, member A KRTAP4-5 kerat in associated protein 4-5
CAM K1D calcium/calmodulin-dependent protein kinase ID KRTAP4-7 kerat in associated protein 4-7
CCBE1 collagen and calcium binding EGF domains 1 KRTAP4-8 kerat in associated protein 4-8
CCL21 chemokine (C-C motif ) ligand 21 KRTAP9-3 kerat in associated protein 9-3
CCNB1IP1 cyclin B1 interact ing protein 1, E3 ubiquit in protein ligase KRTAP9-4 kerat in associated protein 9-4
CCND2 cyclin D2 LCE1A late cornif ied envelope 1A
CCT4 chaperonin containing TCP1, subunit  4 (delta) LCE1D late cornif ied envelope 1D
CD109 CD109 molecule LCE2B late cornif ied envelope 2B
CDH12 cadherin 12, type 2 (N-cadherin 2) LCE2C late cornif ied envelope 2C
CDH4 cadherin 4, type 1, R-cadherin (ret inal) LCE2D late cornif ied envelope 2D
CEACAM 1
carcinoembryonic ant igen-related cell adhesion molecule 1 
(biliary glycoprotein)
LHX2 LIM  homeobox 2
CEACAM 5 carcinoembryonic ant igen-related cell adhesion molecule 5 LNX1 ligand of numb-protein X 1, E3 ubiquit in protein ligase
CGA glycoprotein hormones, alpha polypept ide LRRC2 leucine rich repeat containing 2
CHAF1B chromatin assembly factor 1, subunit  B (p60) NRROS negative regulator of react ive oxygen species
CHCHD7 coiled-coil-helix-coiled-coil-helix domain containing 7 LYG2 lysozyme G-like 2
CKAP5 cytoskeleton associated protein 5 M AP2K1 mitogen-act ivated protein kinase kinase 1
CLN3 ceroid-lipofuscinosis, neuronal 3 M AP3K13 mitogen-act ivated protein kinase kinase kinase 13
CNNM 4 cyclin M 4 M ARCKS myristoylated alanine-rich protein kinase C substrate
CNOT4 CCR4-NOT transcript ion complex, subunit  4 M ETAP1 methionyl aminopept idase 1
CNTN4 contact in 4 M RAP melanocort in 2 receptor accessory protein
COL5A2 collagen, type V, alpha 2 M S4A4A membrane-spanning 4-domains, subfamily A, member 4A
COL6A1 collagen, type VI, alpha 1 M SI2 musashi RNA-binding protein 2
COQ9 coenzyme Q9 M XRA5 matrix-remodelling associated 5
CRABP1 cellular ret inoic acid binding protein 1 M YCN v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog
CRISPLD2 cysteine-rich secretory protein LCCL domain containing 2 M YH10 myosin, heavy chain 10, non-muscle
CSF1R colony st imulat ing factor 1 receptor M YL4 myosin, light chain 4, alkali; atrial, embryonic
CTDSPL2
CTD (carboxy-terminal domain, RNA polymerase II, polypept ide 
A) small phosphatase like 2
M YO7A myosin VIIA
CTNND2 catenin (cadherin-associated protein), delta 2 NDUFA3 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 3, 9kDa
CYFIP2 cytoplasmic FM R1 interact ing protein 2 NKD2 naked cut icle homolog 2 (Drosophila)
DENND3 DENN/M ADD domain containing 3 NOVA1 neuro-oncological ventral ant igen 1
DFNA5 deafness, autosomal dominant 5 NPFFR2 neuropept ide FF receptor 2
LRRC37BP1 leucine rich repeat containing 37B pseudogene 1 NSM CE1 non-SM C element 1 homolog (S. cerevisiae)
DLX1 distal-less homeobox 1 NTRK2 neurotrophic tyrosine kinase, receptor, type 2
DM C1 DNA meiot ic recombinase 1 OM A1 OM A1 zinc metallopept idase
DNAJA4 DnaJ (Hsp40) homolog, subfamily A, member 4 OXGR1 oxoglutarate (alpha-ketoglutarate) receptor 1
ECD ecdysoneless homolog (Drosophila) PCDH10 protocadherin 10
ELL3 elongat ion factor RNA polymerase II-like 3 PCDH7 protocadherin 7
ELM O1 engulfment and cell mot ility 1 PCSK1N proprotein convertase subt ilisin/kexin type 1 inhibitor
ENPP1 ectonucleot ide pyrophosphatase/phosphodiesterase 1 PDPK1 3-phosphoinosit ide dependent protein kinase-1
EPB41L4B erythrocyte membrane protein band 4.1 like 4B PDXK pyridoxal (pyridoxine, vitamin B6) kinase
EPHA3 EPH receptor A3 PELI2 pellino E3 ubiquit in protein ligase family member 2
ESRRG estrogen-related receptor gamma PENK proenkephalin
M ECOM M DS1 and EVI1 complex locus JADE1 jade family PHD f inger 1
FAM 101B family with sequence similarity 101, member B PIGT phosphat idylinositol glycan anchor biosynthesis, class T
FAM 91A1 family with sequence similarity 91, member A1 PLA2R1 phospholipase A2 receptor 1, 180kDa
FBXO3 F-box protein 3 PLEKHG3 pleckstrin homology domain containing, family G (with RhoGef domain) member 3
FCGR2B Fc fragment of IgG, low aff inity IIb, receptor (CD32) PNM A3 paraneoplast ic M a ant igen 3
FCGRT Fc fragment of IgG, receptor, t ransporter, alpha PNPO pyridoxamine 5'-phosphate oxidase
FEN1 flap structure-specif ic endonuclease 1 POLR2L polymerase (RNA) II (DNA directed) polypept ide L, 7.6kDa
FKBP4 FK506 binding protein 4, 59kDa PPAPDC1B phosphat idic acid phosphatase type 2 domain containing 1B
FM O5 flavin containing monooxygenase 5 PPP2R1B protein phosphatase 2, regulatory subunit  A, beta
FRM D4A FERM  domain containing 4A PRR4 proline rich 4 (lacrimal)
GAL galanin/GM AP prepropept ide PTHLH parathyroid hormone-like hormone  
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NKD2 naked cut icle homolog 2 (Drosophila) SHC1 SHC (Src homology 2 domain containing) transforming protein 1
NOVA1 neuro-oncological ventral ant igen 1 SIDT1 SID1 transmembrane family, member 1
NPFFR2 neuropept ide FF receptor 2 SLC41A1 solute carrier family 41 (magnesium transporter), member 1
NSM CE1 non-SM C element 1 homolog (S. cerevisiae) SLC6A6 solute carrier family 6 (neurotransmit ter t ransporter), member 6
NTRK2 neurotrophic tyrosine kinase, receptor, type 2 SLFN11 schlafen family member 11
OM A1 OM A1 zinc metallopept idase SM AD9 SM AD family member 9
OXGR1 oxoglutarate (alpha-ketoglutarate) receptor 1 SM PD3
sphingomyelin phosphodiesterase 3, neutral membrane (neutral sphingomyelinase 
II)
PCDH10 protocadherin 10 SNCA synuclein, alpha (non A4 component of amyloid precursor)
PCDH7 protocadherin 7 SOX8 SRY (sex determining region Y)-box 8
PCSK1N proprotein convertase subt ilisin/kexin type 1 inhibitor SPAG9 sperm associated ant igen 9
PDPK1 3-phosphoinosit ide dependent protein kinase-1 SPINK1 serine pept idase inhibitor, Kazal type 1
PDXK pyridoxal (pyridoxine, vitamin B6) kinase SPINT2 serine pept idase inhibitor, Kunitz type, 2
PELI2 pellino E3 ubiquit in protein ligase family member 2 SPRR2B small proline-rich protein 2B
PENK proenkephalin ST3GAL5 ST3 beta-galactoside alpha-2,3-sialylt ransferase 5
JADE1 jade family PHD f inger 1 STX12 syntaxin 12
PIGT phosphat idylinositol glycan anchor biosynthesis, class T SYNC syncoilin, intermediate f ilament protein
PLA2R1 phospholipase A2 receptor 1, 180kDa TASP1 taspase, threonine aspartase, 1
PLEKHG3
pleckstrin homology domain containing, family G (with RhoGef 
domain) member 3
TCN2 transcobalamin II
PNM A3 paraneoplast ic M a ant igen 3 TDRD10 tudor domain containing 10
PNPO pyridoxamine 5'-phosphate oxidase TENC1 tensin like C1 domain containing phosphatase (tensin 2)
POLR2L polymerase (RNA) II (DNA directed) polypept ide L, 7.6kDa TEX264 test is expressed 264
PPAPDC1B phosphat idic acid phosphatase type 2 domain containing 1B TGFBR2 transforming growth factor, beta receptor II (70/80kDa)
PPP2R1B protein phosphatase 2, regulatory subunit  A, beta THSD7B thrombospondin, type I, domain containing 7B
PRR4 proline rich 4 (lacrimal) TLE6 transducin-like enhancer of split  6 (E(sp1) homolog, Drosophila)
PTHLH parathyroid hormone-like hormone TM CO1 transmembrane and coiled-coil domains 1
QSOX2 quiescin Q6 sulfhydryl oxidase 2 TM PRSS6 transmembrane protease, serine 6
RAPGEF1 Rap guanine nucleot ide exchange factor (GEF) 1 TOM 1L1 target of myb1 (chicken)-like 1
RBM S3 RNA binding motif , single stranded interact ing protein 3 TPCN1 two pore segment channel 1
RBPJ
recombinat ion signal binding protein for immunoglobulin kappa 
J region
TPD52L1 tumor protein D52-like 1
RFC3 replicat ion factor C (act ivator 1) 3, 38kDa TPSG1 tryptase gamma 1
RGS4 regulator of G-protein signaling 4 TSPAN18 tetraspanin 18
RHBDL3 rhomboid, veinlet-like 3 (Drosophila) TWIST2 twist family bHLH transcript ion factor 2
RHPN2 rhophilin, Rho GTPase binding protein 2 UBE2Q2 ubiquit in-conjugat ing enzyme E2Q family member 2
RNF175 ring f inger protein 175 UBTD2 ubiquit in domain containing 2
RORB RAR-related orphan receptor B VANGL1 VANGL planar cell polarity protein 1
RPH3AL rabphilin 3A-like (without C2 domains) VEGFA vascular endothelial growth factor A
RSU1 Ras suppressor protein 1 VIP vasoact ive intest inal pept ide
S100A3 S100 calcium binding protein A3 DPH7 diphthamide biosynthesis 7
SAM D10 sterile alpha motif  domain containing 10 WFDC5 WAP four-disulf ide core domain 5
SCARF2 scavenger receptor class F, member 2 WNK4 WNK lysine def icient protein kinase 4
SCGB1D2 secretoglobin, family 1D, member 2 WNT5B wingless-type M M TV integrat ion site family, member 5B
SDSL serine dehydratase-like XYLB xylulokinase homolog (H. inf luenzae)
SEC23B Sec23 homolog B (S. cerevisiae) YBX2 Y box binding protein 2
VIM P VCP-interact ing membrane protein YTHDC1 YTH domain containing 1
SETBP1 SET binding protein 1 YWHAQ tyrosine 3-monooxygenase/tryptophan 5-monooxygenase act ivat ion protein, theta
SH3BGRL SH3 domain binding glutamic acid-rich protein like ZM YND12 zinc f inger, M YND-type containing 12
SH3GL3 SH3-domain GRB2-like 3 ZNF326 zinc f inger protein 326
1. Information from HGNC (HUGO Gene Nomenclature Committee; www.genenames.org). 1. Information from HGNC (HUGO Gene Nomenclature Committee; www.genenames.org).  
 
 
Table S9. Epidermal age-modulated genes shared with Human Ageing Genomic Resources 
(HAGR). 
HGN C  A pproved  
Symbol
1 HGN C  A pproved  N ame
1 HGN C  A pproved  
Symbol
1 HGN C  A pproved  N ame
1
BAK1 BCL2-antagonist/killer 1 NRG1 neuregulin 1
CDC42 cell division cycle 42 PARP1 poly (ADP-ribose) polymerase 1
CEBPA CCAAT/enhancer binding protein (C/EBP), alpha PCM T1 protein-L-isoaspartate (D-aspartate) O-methyltransferase
CETP cholesteryl ester transfer protein, plasma PDPK1 3-phosphoinosit ide dependent protein kinase-1
COQ7 coenzyme Q7 homolog, ubiquinone (yeast) PLCG2 phospholipase C, gamma 2 (phosphatidylinositol-specif ic)
DBN1 drebrin 1 PM L promyelocyt ic leukemia
EIF5A2 eukaryot ic translat ion init iat ion factor 5A2 PROP1 PROP paired-like homeobox 1
ELN elast in PTK2B protein tyrosine kinase 2 beta
ESR1 estrogen receptor 1 RAD52 RAD52 homolog (S. cerevisiae)
FEN1 flap structure-specif ic endonuclease 1 RB1 ret inoblastoma 1
GHRHR growth hormone releasing hormone receptor RELA v-rel avian ret iculoendotheliosis viral oncogene homolog A
GSK3A glycogen synthase kinase 3 alpha SHC1 SHC (Src homology 2 domain containing) transforming protein 1
GSK3B glycogen synthase kinase 3 beta SOD1 superoxide dismutase 1, soluble
HSPA1A heat shock 70kDa protein 1A STAT3 signal transducer and act ivator of transcript ion 3 (acute-phase response factor)
HTRA2 HtrA serine peptidase 2 STK11 serine/threonine kinase 11
IGFBP3 insulin-like growth factor binding protein 3 TFAP2A transcript ion factor AP-2 alpha (act ivat ing enhancer binding protein 2 alpha)
IL2 interleukin 2 TNF tumor necrosis factor
IL2RG interleukin 2 receptor, gamma UBB ubiquit in B
INS insulin UBE2I ubiquit in-conjugating enzyme E2I
INSR insulin receptor VEGFA vascular endothelial growth factor A
M APK8 mitogen-act ivated protein kinase 8 YWHAZ tyrosine 3-monooxygenase/tryptophan 5-monooxygenase act ivat ion protein, zeta
M SRA methionine sulfoxide reductase A
1. Information from HGNC (HUGO Gene Nomenclature Committee; www.genenames.org). 1. Information from HGNC (HUGO Gene Nomenclature Committee; www.genenames.org).
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Table S10. Modulated probe sets associated with epidermal aging in each decade of life. 
D own D own D own D own D own U p U p
AA188598 CAPN10 INHBC PLAC2 TRIM 41 AA627135 M LL3
AA884902 CCDC7 IRAK1 PLCH2 TRPV2 AA805504 M YO1C
ABCA7 CD6 ITGA5 PLD2 TSHB AA993531 NCAN
ABCE1 CDC2L1 ITGB1 PLEKHG2 TTLL3 AB016902 NECAP1
ACIN1 CDIPT ITGB4BP PLG TUBB8 AB019568 NEUROG3
ACOT11 CHAD ITIH5 PM L TXNL4B ACVR1B PDE3B
ADAM 17 CHCHD5 JPH2 PNM T UBE2L6 ADAM TS4 PDZD7
ADCY4 CHCHD5 KIAA0319L POLRM T UNC50 AF076205 PLGLB2
ADCYAP1R1 CHDH KIF21B PPAP2C VDP AK000809 PREI3
ADRM 1 CLDN15 KIT PPAT VEGFA AK022893 PRM T2
AF111848 CLDN6 KLF13 PPP1R15A VKORC1 AK093036 PRSS2
AF116624 CNTROB KLHDC7A PPP1R2 WARS AK093659 PSEN2
AF343666 COL14A1 KM O PPP2R5B WBSCR16 AK095986 PSPH
AFG3L1 CR606969 KRBA1 PPP2R5C WFDC5 AK127904 PXN
AHI1 CR748243 KRT18P16 PPY WNT10A AK128457 RAB11A
AI308948 CRYGS LAGE3 PRDM 11 WNT7A ANKRD17 RAM P2
AI650285 CSH1 LAIR1 PRELID2 X01147 ASB16 RORC
AJ399872 CX3CL1 LAPTM 5 PRKCG ZDHHC24 AVP S81524
AK001979 CYHR1 LBX2 PRKD2 ZDHHC5 AW138098 SCRT1
AK025975 CYP24A1 LENG9 PRM T1 ZFP36 AW979273 SCRT2
AK054756 D2HGDH LILRB5 PROKR2 ZIM 2 A_23_P393495 SH2B2
AK055960 DHRS1 LM OD1 PSM A6 ZM YND8 A_24_P110101 SH3BGRL2
AK090442 DIRAS1 LOC116143 PSM D10 ZNF410 A_24_P195749 SPINK7
AK123127 DKFZP434B0335 LOC146429 PTCH2 ZNF552 A_24_P255874 STK11
AK123302 DKFZp434B1231 LOC152663 RAM P3 ZNF607 A_24_P315885 TAF3
AK127156 DM AP1 LOC255783 RARG ZNF625 A_24_P560431 TH1L
AL036098 DPM 3 LOC284926 RARRES3 ZRSR2 A_32_P158543 THC2474831
AM DHD1 DTNB LOC286467 RASAL1 ZSCAN2 A_32_P80198 THC2482196
ANAPC5 DUX3 LOC348180 RENBP BC008341 THC2495469
ARD1B EM X1 LOC402176 REXO1 BC015588 THC2497143
ASPHD1 ENST00000262637 LOC441377 RIPK5 BC034792 THC2509970
ATG16L1 ENST00000299415 LOC441572 RNASE1 BC035669 THC2554498
ATP13A1 ENST00000301701 LOC441623 RPH3AL BC104421 THC2559651
ATP13A2 ENST00000308384 LOC442211 RPL10 BF436529 THC2563549
ATP5G1 ENST00000327574 LOC442336 RPL29 BQ310837 THC2567636
ATP5G2 ENST00000333131 LOC649375 RPS6KA1 BQ374929 THC2654949
ATP6V0C ENST00000355629 LOC652147 RPSAP10 BX344068 THC2655842
AW191706 ENST00000358618 LOC652411 SCARF2 C10orf130 THC2689802
AW511634 ENST00000375606 LOC728315 SCC-112 C19orf24 THC2753968
AW978845 ENST00000390596 LOC731183 SCT C1QTNF3 TM EM 142A
AY358103 ENY2 LOC731681 SDS C1orf172 TM EM 33
A_23_P135589 EPAS1 LRP5 SEZ6L2 C1orf210 YPEL1
A_23_P158868 EPN3 LYPD3 SGCA CACYBP ZC3H10
A_23_P213468 ETG09_48764 LYPLA1 SGK CB114618 ZDHHC6
A_23_P21882 ETG10_234183 M 6PRBP1 SHB CB305794 ZNF174
A_24_P247493 FAM 100A M 78233 SHBG CCDC137 ZNF483
A_24_P290214 FAM 109B M AGEA6 SHROOM 1 CCDC50
A_24_P332292 FAM 96B M AN2B1 SIRPB2 CD86
A_24_P481314 FBLIM 1 M AN2C1 SLC16A11 CRIP1
A_24_P486427 FFAR2 M APK8 SLC25A17 CTRC
A_24_P651129 FGD6 M ARK2 SLC25A45 CXorf42
A_24_P75856 FHL3 M CM 7 SLC26A6 CYP2B6
A_24_P903715 FLJ20273 M COLN1 SLC35C1 DHX9
A_24_P918926 FLJ20433 M CRS1 SLC37A2 DOCK8
A_24_P931554 FLJ30403 M FN1 SLC46A1 EDC3
A_24_P931583 FLJ31958 M FN1 SM EK1 ELOVL7
A_24_P932270 FLJ41603 M FSD5 SM G1 ENST00000269290
A_24_P940820 FOXC1 M GC27348 SOD1 ENST00000302932
A_32_P17615 FOXRED2 M IOX SPG21 EWSR1
A_32_P201785 FRM D1 M M P15 SRPK3 EXOC3L2
A_32_P27558 FUBP3 M M S19L SSR4 EXOC5
A_32_P74771 FXYD4 M OCOS STARD9 FAIM 3
BAIAP2 GAD1 M RPL4 STAT2 FAM 120C
BC009051 GBP4 M RPS18B STEAP3 FAM 18B2
BC010635 GEFT M UTYH STX11 FIP1L1
BC031973 GGN M YBL2 SYNGR1 FLJ11710
BC032451 GIPC3 NARFL TAAR2 FOS
BC036435 GOT1 NDOR1 TBXA2R GGT6
BC038749 GPR52 NDST4 TCEAL4 GLTSCR1
BC042649 GPRC5C NEURL TELO2 GNAZ
BCL2L1 GPX2 NGLY1 TFR2 GPR156
BE064950 GRB7 NOG TGFB1I1 H2AFJ
BF939434 GREM 2 NOS2A TGFBRAP1 HBZ
BI963219 GRHPR NOVA1 THC2509446 HDAC7A
BM 973223 GRWD1 NP414444 THC2518594 HIBCH
BOK GSCL NT5M THC2526647 HRH3
BQ773021 GTPBP5 NTHL1 THC2538882 HRK
BSPRY HAPLN4 NXF3 THC2559123 HSP90B1
BU616603 HAX1 OBSCN THC2597403 IGF1R
C10orf25 HDGFL1 OGG1 THC2643762 IL1R2
C10orf54 HEATR2 OPRK1 THC2654357 IRS1
C14orf162 HGS OR11A1 THC2661063 ITGB1BP2
C14orf24 HIST1H4E OR7E91P THC2681839 JAG2
C16orf14 HIVEP3 OTOP2 THC2693441 KCNK7
C17orf86 HLA-B PCNXL3 THC2703350 KIAA0974
C19orf16 HM BS PCSK6 THC2718406 KIAA1632
C19orf25 HM GN2 PDE4C THC2724111 KIR2DS4
C19orf33 HM OX2 PDGFRA THC2752750 KRT14
C1QB HNF4A PEAR1 THC2758091 LOC283174
C1orf104 HOXB5 PGM 1 TM 9SF4 LOC339352
C1orf88 HRC PGRM C2 TM ED1 LOC387895
C20orf85 HRNBP3 PHYHD1 TM ED10P LOC400604
C21orf89 IGF2BP3 PIAS3 TM SB4X LOC440353
C5AR1 IGH@ PIGU TOM M 40 LOC651746
C9orf130 IGHA1 PIK4CA TP73 LRDD
C9orf7 IGHD PKD1 TRAF1 M AP3K7
CABIN1 IKBKG PKD1L2 TREM L1 M ATN1
CACNB3 IL12RB1 PLA2G4D TREX2 M GC10814
2 0  versus 3 0  years o ld
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AB040974 ZFYVE28 ADAM 17 GPR52 THC2681839 AA158952 GDNF AF086321
ACVR2B ZNF483 ADAM TS2 GPR61 THC2752750 AA301508 GNAZ AK024824
AF060170 ZNF488 AF116624 GRWD1 THC2766373 AA372247 GPR52 AK093639
AF132206 AGBL5 H2AFY TIM M 44 AA464246 H64096 AKAP6
AF321778 AHSG HM G2L1 TM ED2 AA604115 HCRT AW445156
AK091357 AK022479 HTR7P TRABD AA627135 HRK A_23_P392897
AK091555 AK090827 IFITM 3 TREM 2 AA631847 HSD17B8 A_24_P932270
AL049321 AK091337 IFRD2 TREM L1 AA805504 IHPK2 A_32_P104995
ALG5 AK092942 IKBKG TRIM 41 AA854379 ILDR1 A_32_P206391
ANKK1 AK094447 IL2RG TSC2 AF086436 LOC157860 A_32_P42213
ANKRD17 AK123912 IRF5 TUBGCP6 AF116719 LOC391719 B3GNTL1
AQP2 ANXA2P1 ITIH5 UNQ9433 AF119895 LOC401357 BAX
ASXL1 APC KIAA1602 USP41 AF187554 LOC441743 BC040420
A_24_P160920 ARD1B KIAA1609 WDR81 AI206757 LOC442461 BC043527
A_24_P862251 ASTN1 KLF13 ZBTB7C AI267511 LOC649314 C20orf59
A_24_P943740 ATG16L1 KLF13 ZFAND5 AI652920 LOC728347 C6orf117
A_32_P215745 ATP13A2 KRBA1 ZIC5 AI752947 LOC85391 C6orf15
A_32_P230059 ATP1A4 KRT4 ZNF117 AK000809 LST1 CCND2
BC015588 ATP5G2 LAT2 ZNF226 AK054569 M ON1B CHTF18
BC031939 AT_ssH_PC_3 LOC255783 ZNF342 AK056855 M SRA COL27A1
BC070091 AY998685 LOC401357 AK057071 ND1 DERL1
BC104421 A_23_P111766 LOC646808 AK093659 NISCH DKFZP434A0131
BG009439 A_23_P65845 LOC652147 AK098360 NM _001018022 DNAH8
BQ374929 A_23_P89506 LOC652411 AK127378 NPAT ELN
C20orf117 A_24_P203814 LRAT AK127904 OR7A17 ELOVL4
C9orf122 A_24_P290214 M AGEC1 AK128457 OSCAR ENST00000285383
CCDC44 A_24_P467871 M AN2B1 AL517609 PAX4 ENST00000377711
CCDC50 A_24_P541213 M CF2L ALB PCDH20 ENST00000379392
CD82 A_24_P575267 M CL1 APC2 PDZD7 ESRRG
CD86 A_24_P632230 M ECP2 ATP11A PPP1R11 FAM 101B
CDKN2B A_24_P651129 M M P15 AW150698 PSM B8 GAD1
DDX52 A_24_P903715 M R1 AW178774 RAXL1 GPR3
DEAF1 A_24_P919340 M THFD1 AW378392 RGM A HPCAL1
DERL1 A_24_P931905 M YD88 AY090769 RPLP0 HYOU1
DIP2A A_24_P932270 NDOR1 AY239294 RPS2 IFI35
EFNA5 A_32_P27558 NDUFS4 AY239294 RPS9 ITGA7
EIF2AK3 A_32_P57247 NGLY1 A_23_P206568 RUNDC2B JPH2
EIF4B BC031973 NOVA1 A_23_P393495 SAP130 KLHL21
EXOC5 BC038747 NPY6R A_24_P195749 SCAND1 LM BR1L
FAM 120C BC070363 NRIP3 A_24_P54230 SP100 LOC440335
FBXL8 BCL2L12 NTRK3 A_24_P636834 SSSCA1 LOC51035
FOXQ1 BE064950 NUP98 A_24_P679997 STAT5A LOC51255
GFM 2 BF734670 NXF3 A_24_P753638 STC2 LRRC45
GPSM 3 BI963219 OR7A17 A_24_P831005 T19827 LYSM D4
GRPEL2 BRD4 OR7E91P A_32_P121234 TBC1D8 M AP7D2
IRS1 BX101288 OR8U1 A_32_P133402 THC2509970 M GC23985
KCND3 BX538250 OTOP2 A_32_P142407 THC2509970 M T1JP
KIAA0143 BX647075 PABPN1 A_32_P167723 THC2515611 NAP1L4
KLRC2 C11orf42 PCK2 A_32_P182246 THC2521188 NFKBIB
LHB C12orf32 PDK2 A_32_P64894 THC2524477 NIPBL
LHX1 C14orf144 PHACS BC001783 THC2532114 OTOP2
LM BR1L C16orf70 PIK4CA BC002470 THC2554100 PACSIN3
LOC339352 C19orf47 POLRM T BC002811 THC2556753 PGD
LOC387895 C1orf88 PPM 1D BC007606 THC2559651 PIP5K1A
LOC645431 C2orf25 PPM E1 BC008341 THC2563549 PITX2
LOC646161 C9orf16 PPP2R5C BC011398 THC2563568 PLD2
LOC646643 C9orf7 PPY BC013025 THC2564099 PLEC1
LOC650200 CA436847 PTDSS1 BC014023 THC2569209 PPP2CB
M AFA CABP5 PUM 2 BC014023 THC2572908 PRAM 1
M AP3K7 CAM K1D RBM 18 BC020341 THC2579654 PTCH2
M ATN1 CAPN10 REG1B BCAS4 THC2582065 RILP
M IZF CARS2 RGM A BI869933 THC2587750 RNF31
M PDZ CCDC49 RHOT2 BM 504117 THC2587773 RPSAP10
NEK9 CCDC7 RPL35 BM 975266 THC2591397 SASH1
NR4A2 CCND2 RUFY3 BQ233242 THC2597502 SEM A4C
NT5C CCPG1 RUVBL2 BQ310837 THC2658813 SIRPB1
NUDT14 CCRL1 S80864 BU622073 THC2678411 SLC29A3
PDZD8 CD3EAP SAP130 BU687083 THC2694215 SLC30A3
PEX11A CDC42EP4 SEC22A BX350880 THC2697162 SM EK1
PPIL6 CHODL SERPINA7 BX360933 THC2734788 SOCS3
PRAM E CHRAC1 SHC1 BX413319 THC2755341 SUPT4H1
PRM T2 CIAPIN1 SLC25A17 C10orf130 THY1 SYM PK
RAB11A COL14A1 SLC25A27 C9orf62 TM EM 142A TAAR2
RAD23B COL5A3 SLC25A45 CA306742 TRABD TBXAS1
RAM P2 CR2 SNTA1 CA414006 U01925 THC2612889
ROCK2 CRABP2 SNX12 CA431756 U22680 THC2722757
RORC CRYGA SOD1 CABP5 VHL THC2765833
RSU1 CYB5D2 SPRYD3 CB114618 W05707 TLL2
SCRT2 CYB5R2 SRPK3 CDV3 W81715 TNFRSF21
SENP7 CYP2S1 SSSCA1 CORO6 WBSCR19 TNRC4
SETD7 DQ680071 ST14 CV575560 ZNF777 TRM T12
SH3BP2 DSC2 ST8SIA3 DB348311 tcag7,1017 UCKL1
SHARPIN DYNC1H1 STAC2 DB356469 ZNF792
SLC27A1 E2F6 STARD9 DQ786272 ZSWIM 6
THC2538856 ELL2 STAT5A ENST00000269290
THC2648849 ENST00000355629 STC1 ENST00000328474
THC2650264 ENST00000360934 SYNGR1 ENST00000329385
THC2659646 EPN3 TCEAL4 ENST00000330598
THC2662468 FAM 129C TFAP2E ENST00000361567
TNXB FARSB TGFB1I1 ENST00000380231
TSPAN31 FAS THC2572376 EXOC3L2
TUBA3D FBF1 THC2617409 F7
TUBGCP2 FBRS THC2633920 FAIM 3
USHBP1 FLJ35700 THC2643762 FAM 18B2
X98562 FUT1 THC2646741 FAM 39B
YPEL1 FYN THC2666580 FLJ11710
ZC3H10 GPC4 THC2670523 FOXC2
ZDHHC6 GPR114 THC2672701 GAST
4 0  versus 50  years o ld3 0  versus 4 0  years o ld
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ACAT2 AA334114 SOX7 AANAT AA004800 PRNT ADAM TS13 ACD
BAALC AA631847 ST6GALNAC2 ABCC8 AA195394 RARRES3 ADAM TS7 ADAM 33
BC040420 AA714537 T19827 AK094323 ACTL7A RFC3 AF289566 AF343666
BI771091 ADAM TS13 THC2509970 ANKK1 AF086511 RND1 AI825645 ALDOC
CEP164 AF086335 THC2517184 APC2 AF130065 RREB1 APOL1 A_32_P192586
CRAT AF086436 THC2550620 AQP2 AK022109 RTF1 A_24_P471099 BAIAP2
DUSP3 AF116620 THC2556753 ASB16 AK023038 RUNX2 A_24_P862251 CD248
FAM 131B AF116719 THC2568627 ATP6V1C2 AK026155 SCN3A A_24_P941540 CDC25B
FAM 82C AI267511 THC2687042 AY927536 AK027150 SCYL2 A_32_P138933 CLEC10A
GLT25D1 AI754733 THC2697162 A_24_P110101 AK090442 SERTAD2 BC080624 CTLA4
IFI35 AI925475 THC2770735 A_24_P153363 AK092942 SIDT1 CASP8 DEPDC2
IL2RG AK023472 TM 7SF2 A_24_P494658 ARM C2 SLC13A1 CLPTM 1L DYRK1B
LOC51255 AK057071 TM EM 37 A_24_P922120 ASB2 SLC17A1 CREBL1 ENST00000215202
LYSM D4 AK094323 TUB A_32_P167577 A_23_P111766 SLC26A6 CRHR1 FXYD6
N75427 AK098360 U01925 A_32_P230059 A_24_P281285 SLC30A4 DLX3 HR
NCAPH AK127378 ZBTB45 A_32_P8971 A_24_P290214 SM C1A ENST00000318930 LOC147650
NUDT13 AK127904 BC002570 A_24_P464963 SNCA EPS8L2 M ASP2
POLR2J2 AL522622 BC015588 A_24_P698759 SOCS4 FRM D4A M GC4655
PP8961 AL540920 BC063381 A_24_P880176 SRPK3 GAST NT5DC1
PTPN5 AL567699 BC070091 A_32_P149461 ST3GAL6 KIAA0913 PIPOX
RABEP2 APC2 BC104421 A_32_P40348 SYT14 LBH PRIM A1
RKHD1 ATP6V1B1 BF089603 A_32_P47778 TAP2 LOC284889 RNF26
SLC34A3 ATP6V1C2 BF436529 A_32_P52948 TCFL5 LOC339352 RNF31
SLC8A1 AW858928 BM 054818 A_32_P63734 TESSP2 LOC644042 SIRT6
SM EK1 AY239294 BQ374929 BC013792 TFDP1 LOC651746 SORBS3
THC2645975 A_23_P108534 C1orf144 BC056907 TG LOC728449 SPTBN2
THC2778545 A_23_P11902 CSN1S2A BE835490 THC2488952 LOC728894 THAP8
TJP3 A_23_P141785 ENST00000302096 BQ017638 THC2548775 LOC90113
TM EM 35 A_24_P229438 ENST00000318930 BU733098 THC2612796 THC2760960
UBC A_24_P315885 ENST00000329385 BX105574 THC2618720 TUB
UCHL1 A_24_P392661 FAM 19A4 C1orf82 THC2655510
A_24_P831005 GPR150 C1orf88 THC2664350
A_24_P84268 HES4 C6orf166 THC2666580
A_32_P127454 HRASLS2 C8orf31 THC2679340
A_32_P138933 IRS1 CA436847 THC2694630
A_32_P142407 LHX1 CA437634 THC2697642
A_32_P142664 M AFA CABP5 THC2698970
A_32_P167577 M SRA CBX1 THC2721928
A_32_P182246 NEU1 CCNB1IP1 THC2778545
A_32_P227496 NFKBIB CD226 TNRC6A
A_32_P8971 PAK4 CD518214 TRIM 45
BC001783 PFKFB3 CENPJ TRPM 3
BC007809 PRR5 CES2 UBR1
BC008341 PRSS8 CHM L UBXD2
BC011398 REEP6 CIAPIN1 UNC50
BC070091 SASH1 CYP1B1 WBSCR16
BCAS4 SCARF2 DNAJC10 WIF1
BI035281 SCRT2 DOCK10 ZNF235
BI869933 SDK1 DQ680071 ZNF253
BM 975266 STK11 DYNLT3 ZNF595
BQ310837 THC2539554 ELF1 ZNF616
BQ339228 THC2657348 ENST00000311061 ZRANB1
BX362821 THC2719609 ENST00000366822
C10orf130 THC2722749 ERGIC1
CA420643 TK1 FAM 108A1
CA441361 TM EM 158 FAM 129C
CB528527 ZBTB45 FAM 57B
CCDC50 ZC3H10 FANCD2
CF528315 ZFPM 1 FARP1
COX19 ZNF2 FAS
CXCL3 ZNF467 FLJ22167
ENST00000302096 FSTL1
ENST00000320054 FUBP3
ENST00000328474 FYN
ENST00000329385 GRB7
ENST00000331096 GTF2F1
ENST00000361567 H2AFY2
ENST00000381924 HLA-DM A
EPS8L2 HOXC6
FAM 18B2 HSD17B7P2
FGFRL1 HTATIP2
FLJ11710 IFNA2
FRM D4A KCNH1
GALNT3 KCNN3
GAST KRT5
GPR89A LOC130728
HDAC7A LOC199882
KRT18 LOC646808
LFNG LRRC34
LOC387895 M FSD2
LOC402665 M GC13053
LOC643454 M SL2L1
LOC728044 M YADM
LOC728347 M YBL1
M ESDC1 NDOR1
NAG8 NDUFV3
NCAN NP186050
ND1 NUP210L
NM _001018022 PANX3
NM _001018022 PCDHB4
ODC1 PCNA
PDZD7 PER2
PNKP PGM 1
PSM D11 PHF12
RPS2 PIP5K1A
S100A4 PLB1
SEPHS2 POM GNT1
SHC2 PREPL
70  versus 8 0  years o ld50  versus 6 0  years o ld 6 0  versus 70  years o ld
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Table S11. Modulated genes demonstrating a continuous tendency to increase or decrease with 
epidermal aging. 
HGNC Approved Symbol1 HGNC Approved Name1
Continuous increase
SPRR2G small proline-rich protein 2G
Continuous decrease
CEBPA CCAAT/enhancer binding protein (C/EBP), alpha
EMILIN1 elastin microfibril  interfacer 1
FBXO17 F-box protein 17
FOXE1 forkhead box E1 (thyroid transcription factor 2)
IQSEC2 IQ motif and Sec7 domain 2
LCE1A late cornified envelope 1A
OGFR opioid growth factor receptor
OR2H1 olfactory receptor, family 2, subfamily H, member 1
PRB4 proline-rich protein BstNI subfamily 4
MEX3D mex-3 RNA binding family member D
SOX8 SRY (sex determining region Y)-box 8
1. Information from HGNC (HUGO Gene Nomenclature Committee; www.genenames.org).  
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Abstract 
 
Hair follicle (HF) is a unique system constituted of epithelial and 
mesenchymal compartments with the ability to cyclically regenerate during lifetime. 
Easy to be manipulated it represents an excellent model to study biological 
mechanisms, including aging. Follicular epidermis (the epidermal component of 
HF) is a tubular structure derivate from tissue invagination, continuous with the 
interfollicular epidermis (IFE). Despite constituting the same tissue, FE and IFE 
represent distinct biological niches with functional and morphological particularities, 
such as the presence of different stem-cell populations and expression of different 
types of keratins. As any other living tissue, epidermis suffers the effect of aging in 
all its extension, with cumulative deterioration and impaired homeostasis over the 
lifetime. Despite its critical role in the homeostasis maintenance, little is known 
about the aging of the human epidermis. In this work, we performed transcriptomic 
analyses of plucked hair shafts from a panel of 54 volunteer women of different 
ages to investigate the in vivo mechanisms of skin aging. These analyses revealed 
3,039 probe sets (2,024 recognized HGNC mapped probe sets representing 1,945 
distinct human genes), with 1,597 up-regulated and 1,442 down-regulated (fold 
change value of 1.5, p-value cut-off of 0.05). Hierarchical clustering showed a clear 
distinction between young and old groups with only three individuals of each group 
being not well classified. By comparing to the DAVID database, 33 gene ontology 
(GO) terms were associated with down-regulated gene expression, and 55 were 
associated with up-regulated gene expression. KEGG database comparisons 
identified thirty pathways with significant modulation (p-values cut-off: 0.01) 
Approximately 50% of these pathways are associated with human diseases and 
organismal systems, not necessarily related to skin. Interestingly, several 
significant pathways were related to signaling processes, such as the MAPK, 
chemokine, insulin, mTOR, Wnt, Notch and calcium signaling pathways. The 
results of this work were compared with those form our previous analysis of 
epidermal aging using tape stripping. The overall result of the comparison is quite 
surprising since both studies identified different biological processes and cellular 
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pathways. A total of 514 identified DEGs were common to the two studies, 
indicating a certain degree of similarity but with considerable differences between 
the materials. In summary, our results it indicate that IE and FE must be analyzed 
and interpreted as distinct epidermal niches, not just in relation to morphological 
localization, but also regarding molecular control.   
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Introduction 
 
Hair follicle (HF) is a complex and unique system with the ability to cyclically 
regenerate during lifetime, representing an excellent, easily manipulated and 
widely available model to the study of many biological mechanisms, including 
aging (Rompolas et al., 2012; Keyes et al., 2013). Most research is focused on the 
comprehension of HF cycling control because of the great clinical interest 
associated to hair loss or unwanted hair growth (Krause and Foitzik, 2006). 
Furthermore, special attention has been done to hair graying with age, mainly due 
to its aesthetical impact and the interest of cosmetic industry (Tobin, 2009; Trüeb, 
2005). However, potential application of HF in the studies of aging might not be 
restricted to the analysis of hair specific modifications. As a cutaneous appendage, 
HF is constituted of epithelial and mesenchymal compartments, undergoing 
changes throughout life that could reflect or complement aspects of overall skin 
aging (Keyes et al., 2013). 
Follicular epidermis (FE) – the epidermal component of HF – is a tubular 
structure derivate from tissue invagination, continuous with the interfollicular 
epidermis (IFE). Despite constituting the same tissue, FE and IFE represent 
distinct biological niches with functional and morphological particularities, such as 
the presence of different stem-cell populations and the expression of different 
types of keratin (Jiang et al., 2010; Mascré et al., 2012; Schweizer et al., 2007). 
IFE is responsible for skin barrier function against dehydration and external 
damage, composed of an inner basal layer of proliferative cells and suprabasal 
layers of differentiating progeny; while FE is responsible for hair fibers formation, 
with concentric layers of cells originated by proliferation activity at the base of HF 
(Blanpain and Fuchs, 2009). In case of damage to skin, HF stem cells can totally 
regenerate IFE, indicating the maintenance of a general epidermal programming 
(Ito et al., 2005; Solanas and Benitah, 2013). 
As any other living tissue, epidermis suffers the effect of aging in all its 
extension, with cumulative deterioration and impaired homeostasis over a lifetime 
(Kirkwood, 2005). Despite its critical role in the homeostasis maintenance, little is 
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known about the aging of the human epidermis. We have previously performed a 
study focused on transcriptomic analysis using a non-invasive technique to access 
IFE aging (Lorencini et al., unpublished results). The use of global techniques of 
analysis has been growing massively in the last years and the term skinomics has 
emerged as a tendency in the field of dermatology (Blumenberg, 2005). Since the 
skin represents a complex organ, some groups have been working with isolated 
skin layers or cells to achieve comprehensive results without traces of confounding 
material (Jansen and Schalkwijk, 2003; Mitsui et al., 2012). 
The plucked hair shaft has been used in medical research over the last 60 
years (Schembri et al., 2013), and gene expression studies have been done on 
such experimental model for many different purposes, such as the analysis of 
atopic dermatitis, stem cell behavior and hair cycle evaluation (Kim et al., 2006; 
Ohyama et al., 2006, Yoshikawa et al., 2013). Moreover, plucked hair represents 
an in vivo alternative that can be sampled easily without a major discomfort to the 
individual participating in the research with minimal (if not absent) harm potential 
(Schembri et al., 2013). Gho et al. (2004) demonstrated that typical break of 
mechanical plucking is located conically surrounding the dermal papilla, which 
remains unaffected inside the skin. Most of the HF epithelial structures remain 
attached to the plucked hair and only the epidermal constituents are involved in 
~90% of the cases (Bassukas and Horstein, 1989). Thus, the use of plucked hair 
shafts suggests a powerful tool with unprecedented application (except from hair 
graying analysis, of course) to the study of FE aging. 
 This study aimed to elucidate in vivo mechanisms of skin aging by applying 
the non-invasive plucked hair shafts collection from the eyebrows and a global 
analysis of transcriptome with DNA microarrays. It represents an innovative and 
relevant approach in the molecular evaluation of human epidermal aging, 
contributing to the expansion of dermatology knowledge in the era of skinomics. 
 
Material and methods 
 
Volunteers and samples 
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The Research Ethics Committee institutional review board from 
Universidade Positivo, Curitiba, Brazil, approved this study, and written informed 
consent was obtained before enrolling volunteers for participation in this study, 
which was performed in compliance with the Declaration of Helsinki Principles. 
Plucked hair shafts were obtained from the eyebrows of women of different ages 
and skin phototype II or III according to the Fitzpatrick scale. Twenty HFs were 
collected from the left and right sides of each volunteer. Samples from 54 healthy 
women were used for microarray analysis (Table S1), and an independent panel of 
22 healthy women was used for real-time qPCR validation (Table S3). 
 
RNA extraction and processing 
 
RNA extraction was performed using the RNeasy Mini Kit (Qiagen, Hilden, 
Germany). Hair follicles were agitated in Tissuelyser LT (Qiagen) for 5 minutes at 
50 Hz with lysis buffer and two 7-mm magnetic beads (Qiagen), followed by the 
subsequent steps for total RNA extraction. Purified RNAs were quantified with a 
2000c NanoDrop spectrometer (Thermo Scientific, Wilmington, NC, USA), and the 
quality was checked using a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, 
CA, USA) and a Agilent RNA 6000 Pico Kit (Agilent Technologies). Because of the 
low total RNA yields, the samples were amplified with the Arcturus RiboAmp PLUS 
HS Kit (Applied Biosystems) and SuperScript III Reverse Transcriptase (Applied 
Biosystems). All procedures were performed according to manufacturers’ 
instructions. 
 
RNA labeling, hybridization and microarray scanning 
 
Amplified RNAs were processed using the Turbo Arcturus Labelling Kit 
(Applied Biosystems), and samples were labeled with Cy5. Universal Human 
Reference RNA (Agilent Technologies) from a unique batch was labeled with Cy3 
for use in the data normalization of different arrays (Novoradovskaya et al., 2004). 
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The use of exogenous RNA from the Agilent RNA Spike-in Kit (Agilent 
Technologies) was also used for the further calibration of the microarray 
measurements (Yang, 2006). After fragmentation with the Gene Expression 
Hybridization Kit (Agilent Technologies), 1:1 ratio mixtures of Cy5-labeled RNA 
from each volunteer and Cy3-labeled Universal Human Reference RNA (Agilent 
Technologies) were co-hybridized to two-color Agilent Whole Human Genome 
Oligo 44K microarrays (Agilent Technologies) to evaluate ~44,000 probe sets, 
which target 19,596 genes. Scanning and image analysis were performed using 
the Agilent DNA Microarray Scanner (Agilent Technologies). All procedures were 
performed according to manufacturers’ instructions. 
 
cDNA synthesis and real-time qPCR 
 
To validate the gene expression patterns in the RNA samples, cDNA was 
obtained using a ReverAid First Strand cDNA Synthesis Kit (Thermo Scientific). 
cDNA from three or four volunteers in the same age group was pooled in equal 
quantities, resulting in three samples for analysis for each group (young and old), 
and real-time qPCR was performed in duplicate for each sample using the ViiA 7 
Real Time PCR System (Applied Biosystems) with the TaqMan Fast Advanced 
Master Mix (Applied Biosystems) and TaqMan Gene Expression Assays (Applied 
Biosystems) for the following target genes: aquaporin 9 (AQP9, Hs01035888_m1); 
caveolin 1 (CAV1, Hs00971716_m1); CCAAT/enhancer binding protein, alpha 
(CEBPA, Hs00269972_s1); collagen, type XXVII, alpha 1 (COL27A1, collagen, 
type XXVII, alpha 1); D site of albumin promoter (albumin D-box) binding protein 
(DBP, Hs00609747_m1); fibroblast growth factor receptor 1 (FGFR1, 
Hs00915142_m1); forkhead box Q1 (FOXQ1, Hs00536425_s1); heme oxygenase 
(decycling) 2 (HMOX, Hs01558390_m1); interleukin 10 receptor, alpha (IL10RA, 
Hs00155485_m1); and procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3 
(PLOD3, Hs01126617_m1). Beta actin (ACTB, Hs99999903_m1) and 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH, Hs03929097_g1) were 
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used as endogenous controls. All procedures were performed according to 
manufacturers’ instructions. 
 
Data analysis 
 
Microarray raw data were extracted using the Agilent Feature Extraction 
v8.1 software (Agilent Technologies, Santa Clara, CA, USA). Data visualization 
and analysis were performed using the GeneSpring v12.5 software (Agilent 
Technologies). Data normalization was performed within and across the arrays 
using per gene, per chip normalization, according to Agilent’s recommendation. To 
detect the differentially expressed genes (DEGs) between experimental conditions, 
unpaired t-test was performed with a p-value cut-off of 0.05, considering the 
minimal fold change (FC) of 1.5. Hierarchical clustering was performed using the 
Euclidean distance metric and Average rule. For real-time qPCR experiments, the 
FC was calculated using the ddCt technique (Livak and Schmittgen, 2001). The 
DAVID database was used to conduct functional enrichment analysis (Huang et al., 
2009a and 2009b). The human genome was used as a reference, and regulated 
GO terms were ranked according to their p-values (or called EASE score, a 
modified Fisher’s exact test) with a cut-off of 0.01; Benjamini correction was also 
considered for ranking but not elimination (www.david.abcc.ncifcrf.gov). The KEGG 
database was used for the analysis of modulated pathways (Kanehisa and Goto, 
2000; Kanehisa et al., 2014), considering the human genome as a reference and 
an adjusted p-value cut-off of 0.01 (www.genome.jp/kegg). 
 
Results 
 
Panel of volunteers and sample considerations 
 
We recruited a panel of volunteers comprising 54 women who were 
distributed into two groups of age i.e., 30 ± 8 years old (30 volunteers) and 64 ± 13 
years old (24 volunteers) (Table S1). Using non-invasive eyebrow plucked hair 
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shafts collection, our analysis focused on FE. Most of the epidermal material of the 
HF remains attached to the plucked hair and only the epidermal constituents are 
involved in ~90% of the cases, with no contaminant dermal material (Bassukas and 
Horstein, 1989). 
 
Microarray analysis and technical validation using real-time qPCR 
 
By adopting a minimal fold change (FC) value of 1.5 and a p-value cut-off of 
0.05, statistically significant differences were observed for 3,039 probe sets (2,024 
recognized HGNC mapped probe sets representing 1,945 distinct human genes), 
with 1,597 up-regulated and 1,442 down-regulated (Table S2). Technical validation 
of the microarray results was performed using real-time qPCR in an independent 
young versus old panel including 12 volunteers who were 25 ± 3 years old and 10 
volunteers who were 54 ± 2 years old (Table S3). Similar results were found for the 
expression of 10 randomly selected genes (up-, down- or non-regulated) (Figure 
1).  
 
 
Figure 1. Real-time qPCR validation of microarray results. These qPCR results represent the 
median (± SD) of triplicate analyses using an independent secondary panel of volunteers (12 
young, 10 old). GAPDH and ACTB were used as endogenous controls. A complete list of regulated 
genes can be found in Table S2. 
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A hierarchical clustering analysis was performed with the independent and 
consistently detected data of all volunteers, filtered according to a p-value cut-off of 
0.05. A clear distinction between pre-defined groups of young and old volunteers 
was observed with only three individuals of each group that were not well classified 
(Figure 2). 
 
 
Figure 2. Hierarchical clustering analysis of the complete panel of independent volunteers. 
Spontaneous hierarchical clustering evidenced that young and old groups defined were quite 
homogeneous. The ages in red, at the right side, indicate few volunteers that were not classified as 
expected a priori. 
 
Separate lists of the up- and down-regulated genes (Table S2) were 
analyzed in the DAVID database to identify significantly up- and down-modulated 
biological processes, respectively, ranked according to p-value (cut-off 0.01) (Table 
1). 33 gene ontology (GO) terms were associated with down-regulated gene 
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expression, and 55 were associated with up-regulated gene expression. However, 
it is important to note that, among the up-regulated GO, many have the description 
“negative regulation of”, which can reverse our interpretation of that result. 
 
Table 1. Gene ontology (GO) terms associated with sun-exposed epidermal aging. 
GO term GO code 
Number 
of DEGs
1
 
p-value 
Up-regulated biological processes 
   
Cellular process GO:0009987 672 0.00000004 
Cellular metabolic process GO:0044237 454 0.0000002 
Primary metabolic process GO:0044238 470 0.0000003 
Cellular macromolecule metabolic process GO:0044260 368 0.0000006 
Cellular biosynthetic process GO:0044249 255 0.000003 
Gene expression GO:0010467 227 0.000003 
Cellular macromolecule biosynthetic process GO:0034645 215 0.000003 
Biosynthetic process GO:0009058 261 0.000004 
Metabolic process GO:0008152 504 0.000004 
Macromolecule biosynthetic process GO:0009059 215 0.000007 
Macromolecule metabolic process GO:0043170 387 0.000020 
Regulation of metabolic process GO:0019222 260 0.000028 
Cellular nitrogen compound metabolic process GO:0034641 261 0.000055 
Regulation of macromolecule metabolic process GO:0060255 235 0.000069 
Nucleobase, nucleoside, nucleotide and nucleic acid metabolic 
process 
GO:0006139 244 0.000075 
Regulation of cellular biosynthetic process GO:0031326 215 0.000078 
Regulation of biosynthetic process GO:0009889 216 0.000086 
Regulation of primary metabolic process GO:0080090 236 0.000094 
Regulation of cellular metabolic process GO:0031323 246 0.000119 
Transcription GO:0006350 160 0.000125 
Regulation of gene expression GO:0010468 206 0.000236 
Nitrogen compound metabolic process GO:0006807 262 0.000320 
Negative regulation of cellular metabolic process GO:0031324 65 0.000352 
Negative regulation of macromolecule metabolic process GO:0010605 66 0.000353 
Negative regulation of nitrogen compound metabolic process GO:0051172 50 0.000451 
Negative regulation of cellular biosynthetic process GO:0031327 53 0.000471 
Negative regulation of metabolic process GO:0009892 68 0.000649 
Regulation of macromolecule biosynthetic process GO:0010556 201 0.000682 
Negative regulation of biosynthetic process GO:0009890 53 0.000755 
Regulation of nitrogen compound metabolic process GO:0051171 201 0.000805 
Interspecies interaction between organisms GO:0044419 31 0.000941 
Negative regulation of nucleobase, nucleoside, nucleotide and 
nucleic acid metabolic process 
GO:0045934 48 0.001067 
Negative regulation of transcription GO:0016481 44 0.001153 
Negative regulation of gene expression GO:0010629 47 0.001369 
Negative regulation of macromolecule biosynthetic process GO:0010558 50 0.001420 
Organelle organization GO:0006996 103 0.001674 
Negative regulation of RNA metabolic process GO:0051253 36 0.001914 
Translational elongation GO:0006414 15 0.001919 
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Regulation of nucleobase, nucleoside, nucleotide and nucleic acid 
metabolic process 
GO:0019219 196 0.002133 
Cellular component organization GO:0016043 176 0.002368 
Posttranscriptional regulation of gene expression GO:0010608 24 0.002477 
Regulation of transcription GO:0045449 182 0.002597 
Cellular protein metabolic process GO:0044267 166 0.003214 
Response to organic substance GO:0010033 60 0.004023 
Negative regulation of cellular process GO:0048523 121 0.004672 
Negative regulation of transcription, DNA-dependent GO:0045892 34 0.004781 
Regulation of transcription from RNA polymerase II promoter GO:0006357 60 0.004856 
Down-regulated biological processes 
   
Signal transduction GO:0007165 173 0.0006 
Developmental process GO:0032502 189 0.0006 
Cell development GO:0048468 51 0.0007 
System development GO:0048731 144 0.0011 
Multicellular organismal development GO:0007275 172 0.0013 
Anatomical structure development GO:0048856 154 0.0013 
Regulation of biological quality GO:0065008 97 0.0013 
Multicellular organismal process GO:0032501 243 0.0019 
Regulation of multicellular organismal process GO:0051239 66 0.0020 
Neurogenesis GO:0022008 46 0.0024 
Response to cold GO:0009409 6 0.0028 
Cell motion GO:0006928 38 0.0030 
Homeostatic process GO:0042592 54 0.0037 
Organ morphogenesis GO:0009887 43 0.0037 
Cell morphogenesis involved in differentiation GO:0000904 23 0.0038 
Positive regulation of molecular function GO:0044093 44 0.0044 
Response to external stimulus GO:0009605 63 0.0044 
Hormone metabolic process GO:0042445 13 0.0052 
Generation of neurons GO:0048699 42 0.0053 
Cell differentiation GO:0030154 102 0.0057 
Nervous system development GO:0007399 72 0.0058 
Cell adhesion GO:0007155 50 0.0060 
Biological adhesion GO:0022610 50 0.0061 
Regulation of hormone levels GO:0010817 16 0.0066 
Response to temperature stimulus GO:0009266 11 0.0067 
Cellular homeostasis GO:0019725 36 0.0068 
Cell communication GO:0007154 55 0.0073 
Protein kinase cascade GO:0007243 30 0.0074 
Regulation of oligodendrocyte differentiation GO:0048713 4 0.0076 
Neuron development GO:0048666 28 0.0078 
Positive regulation of cellular process GO:0048522 112 0.0084 
Anatomical structure morphogenesis GO:0009653 77 0.0086 
Cellular developmental process GO:0048869 104 0.0099 
Signal transduction GO:0007165 173 0.0006 
Developmental process GO:0032502 189 0.0006 
Cell development GO:0048468 51 0.0007 
System development GO:0048731 144 0.0011 
Multicellular organismal development GO:0007275 172 0.0013 
Anatomical structure development GO:0048856 154 0.0013 
Regulation of biological quality GO:0065008 97 0.0013 
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Multicellular organismal process GO:0032501 243 0.0019 
Regulation of multicellular organismal process GO:0051239 66 0.0020 
Neurogenesis GO:0022008 46 0.0024 
Response to cold GO:0009409 6 0.0028 
Cell motion GO:0006928 38 0.0030 
Homeostatic process GO:0042592 54 0.0037 
Organ morphogenesis GO:0009887 43 0.0037 
Cell morphogenesis involved in differentiation GO:0000904 23 0.0038 
Positive regulation of molecular function GO:0044093 44 0.0044 
Response to external stimulus GO:0009605 63 0.0044 
Hormone metabolic process GO:0042445 13 0.0052 
Generation of neurons GO:0048699 42 0.0053 
Cell differentiation GO:0030154 102 0.0057 
Nervous system development GO:0007399 72 0.0058 
Cell adhesion GO:0007155 50 0.0060 
Biological adhesion GO:0022610 50 0.0061 
Regulation of hormone levels GO:0010817 16 0.0066 
Response to temperature stimulus GO:0009266 11 0.0067 
Cellular homeostasis GO:0019725 36 0.0068 
Cell communication GO:0007154 55 0.0073 
Protein kinase cascade GO:0007243 30 0.0074 
Regulation of oligodendrocyte differentiation GO:0048713 4 0.0076 
Neuron development GO:0048666 28 0.0078 
1. DEGs, differentially expressed genes. 
 
To identify the modulated pathways, the complete list of modulated genes 
was analyzed using the KEGG database (Table S2). Thirty pathways showed 
significant modulation and were ranked according to their p-values (cut-off: 0.01) 
(Table S4). In addition to statistical significance, biological interpretation is 
essential for meaningful pathway analysis. Of the identified pathways, ~50% were 
associated with human diseases and organismal systems not necessarily related 
to skin. Interestingly, several significant pathways were related to signaling 
processes, such as the MAPK, chemokine, insulin, mTOR, Wnt, Notch and calcium 
signaling pathways. 
The results of this work were compared with those form our previous 
analysis of epidermal aging using tape stripping (Lorencini et al., unpublished 
results). A total of 514 identified DEGs were common to the two studies (Figure 3), 
indicating a certain degree of similarity but with considerable differences between 
the materials. 
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Figure 3. Comparison of gene expression modulation with aging in tape strip and plucked hair 
shaft. Numbers inside the circles represent the amount of differentially expressed genes (DEGs) 
observed in the young versus old comparison in the correspondent biological material. 
 
Discussion 
 
In this work, the analysis of aging was established by comparing adult 
women from two groups of age, representing the most common approach used by 
other groups in this field. Since menopause characterizes a typical age-associated 
systemic change with great impact on skin (Raine-Fenning et al.; 2003), it was 
adopted for the definition of young and old groups. Furthermore, spontaneous 
hierarchical clustering evidenced that pre- and post-menopause groups defined a 
priori were quite homogeneous, reinforcing the biological significance of our 
experimental approach. The epidermal material from plucked hair shaft 
demonstrated a better performance for the correct segregation of young versus old 
material in comparison to the use of tape strip (data not shown). These findings 
substantiate our choice and refuse any arbitrary decision, before continuing with 
global data analysis. 
The analysis of regulated GO terms in HF showed interesting results, but 
difficult to correlate with clinical or morphological aspects of epidermal aging. In 
fact, it was observed a prevalence of broad spectrum terms, such as cellular, 
metabolic or biosynthetic processes, and gene expression or transcription. In the 
up-regulated list, the same processes appear more than once and sometimes are 
preceded by the expression “negative regulation of”. It suggests that even the up-
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regulation associated with aging, which would be erroneous related to the 
interpretation of higher cellular metabolic activity, is linked to an inhibitory effect on 
those biological processes. Regarding the down-regulated GO terms, the 
processes of signal transduction and development were the most significant ones. 
Moreover, modulation of several signaling pathways was the most remarkable 
characteristic of aging in our results with HF, including several key genes such as 
an extensive representation of zinc finger proteins and associated elements (~70 
related DEGs).  
Accordingly to a recent work by Tevy et al. (2013), for unknown reasons, 
there is a decline in circadian rhythms with age, concomitant with declines in the 
overall metabolic tissue homeostasis. The timing of stem cells proliferation and 
differentiation in the epidermis of the HF occurs in a controlled manner through 
circadian rhythm. In a mice model presenting disturbed circadian rhythm, the 
epidermis is prematurely aged and predisposed to tumorigenesis (Janich et al., 
2011). So, considering all the findings of deregulated signaling transduction, our 
results might provide a link between disturbed circadian rhythm and the impaired 
regulation of stem cells behavior in the epidermal HF with age.  Several other 
mechanistic and corroborative analyses could be further performed to understand 
which factor is causing or being caused by a wide impairment in cellular epidermal 
signaling.   
The comparison of the HF results with that derived from tape indicates that, 
despite some similarities in gene expression, the two biological materials display 
very distinct profiles in the processes affected by aging. While tape analysis 
showed several processes associated to epidermal differentiation and 
keratinocytes regulation, results from HF indicated absolutely broader pathways, 
which is much more coherent to a tissue enriched in heterogeneous 
undifferentiated cells (Solanas et al., 2013). Clearly, our results indicate that IE and 
FE must be analyzed and interpreted as distinct epidermal niches, not just in 
relation to morphological localization, but also regarding molecular control.  
In conclusion, the use of plucked hair shaft represents a useful tool for the 
study of skin aging and, in particular, for the evaluation of age-related changes in 
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the FE. We have used eyebrow HF in our study, which can be a good alternative to 
study age-related changes in the face and could be a good tool for analyzing the 
effects of anti-aging products that are applied on the face. 
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Supplemental material  
 
Table S1. Characterization of the main volunteer panel for microarray analyses. 
 
V o lunt eer N umber A ge ( Y ears Old ) Skin Phot o t ype
1
Skin Type
2
Et hnic Group
3
1 19 II Normal Italian/Portuguese
2 19 II Combinat ion Italian/Polish
3 19 II Combinat ion Asian/Indigenous/Italian
4 20 II Oily Italian
5 20 III Oily German/Indigenous
6 20 II Oily Italian/Polish
7 20 II Oily Portuguese
8 21 III Oily Italian/Portuguese
9 21 III Oily German/Italian
10 21 III Oily African/Spanish
11 21 III Oily African/Portuguese
12 29 I Combinat ion German/Indigenous
13 29 II Combinat ion Portuguese
14 30 III Dry Asian
15 30 II Combinat ion Indigenour/Spanish
16 30 III Oily Indigenous
17 31 III Not declared African/Portuguese
18 31 III Oily Italian
19 31 II Oily Ukrainian
20 31 III Combinat ion Libanese/Portuguese
21 31 II Oily Italian/Spanish
22 38 III Oily African/Portuguese
23 40 II Combinat ion Italian
24 40 III Dry Not declared
25 40 III Combinat ion Not declared
26 41 II Normal Spanish 
27 41 II Combinat ion German/Indigenous
28 41 II Combinat ion German/Indigenous
29 41 III Combinat ion Indigenous/Portuguese
30 41 III Combinat ion Italian
31 49 III Oily Japanese
32 50 II Dry Polish
33 50 III Combinat ion German
34 51 II Combinat ion German/Russian
35 51 III Dry Portuguese
36 51 II Normal Italian
37 51 II Oily Portuguese
38 52 III Combinat ion Indigenous/Spanish
39 53 III Combinat ion Jewish
40 59 II Normal Indigenous/Spanish
41 59 II Dry Italian/Polish
42 59 II Oily Asian
43 60 II Dry Italian
44 61 II Dry Spanish
45 68 II Normal Portuguese
46 71 II Normal German
47 71 II Dry Danish/Portuguese
48 71 II Combinat ion Not declared
49 78 II Dry Polish
50 79 II Combinat ion Japanese
51 81 II Not declared Polish
52 83 III Dry Portuguese
53 83 II Dry Portuguese
54 90 II Dry German/Polish
1. Classif icat ion according to Fitzpatrick phototyping scale
2. Personal declarat ion of predominant skin type in the body according to sebum product ion
3. Personal declarat ion of ethnic groups  
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Table S2. Probe sets modulated in the epidermis of young versus old volunteers with a minimal fold 
change of 1.5 and a p-value cut-off of 0.05 (only one long list). 
HGN C  
A pproved  
Symbo l
1
HGN C  A pproved  N ame
1 FC R eg .
HGN C  
A pproved  
Symbo l
1
HGN C  A pproved  N ame
1 FC R eg .
37469 argonaute RISC catalyt ic component 2 2,09 up APBA3
amyloid beta (A4) precursor protein-binding, family 
A, member 3
1,83 down
AAAS achalasia, adrenocort ical insuff iciency, alacrimia 1,53 down APH1B APH1B gamma secretase subunit 1,76 up
AARS alanyl-tRNA synthetase 1,53 up APLP2 amyloid beta (A4) precursor-like protein 2 1,55 up
ABCB10 ATP-binding cassette, sub-family B (M DR/TAP), member 10 1,62 up APOA1 apolipoprotein A-I 1,50 down
ABCC6 ATP-binding cassette, sub-family C (CFTR/M RP), member 6 1,91 up APOBEC3B
apolipoprotein B mRNA edit ing enzyme, catalyt ic 
polypept ide-like 3B
1,64 down
ABCC8 ATP-binding cassette, sub-family C (CFTR/M RP), member 8 1,81 down APOC1 apolipoprotein C-I 1,56 up
ABCD1 ATP-binding cassette, sub-family D (ALD), member 1 1,64 up APOL3 apolipoprotein L, 3 2,11 down
ABCE1 ATP-binding cassette, sub-family E (OABP), member 1 2,09 up APOPT1 apoptogenic 1, mitochondrial 1,96 up
ABHD1 abhydrolase domain containing 1 1,55 up APPBP2
amyloid beta precursor protein (cytoplasmic tail) 
binding protein 2
1,92 up
ABHD10 abhydrolase domain containing 10 1,86 up AQP2 aquaporin 2 (collect ing duct) 1,73 down
ABHD11 abhydrolase domain containing 11 1,67 up AQP9 aquaporin 9 1,81 up
ABHD16B abhydrolase domain containing 16B 2,14 down ARF1 ADP-ribosylat ion factor 1 2,06 up
ABI3 ABI family, member 3 1,78 down ARHGAP27 Rho GTPase act ivat ing protein 27 1,96 down
ABL1 c-abl oncogene 1, non-receptor tyrosine kinase 1,62 down ARHGEF1 Rho guanine nucleot ide exchange factor (GEF) 1 2,30 down
ABTB1 ankyrin repeat and BTB (POZ) domain containing 1 1,53 down ARHGEF17 Rho guanine nucleot ide exchange factor (GEF) 17 1,52 down
ACAD10 acyl-CoA dehydrogenase family, member 10 1,93 down ARHGEF25 Rho guanine nucleot ide exchange factor (GEF) 25 1,68 down
ACAN aggrecan 1,50 up ARHGEF3 Rho guanine nucleot ide exchange factor (GEF) 3 1,73 up
ACAT2 acetyl-CoA acetyltransferase 2 1,62 up ARHGEF38 Rho guanine nucleot ide exchange factor (GEF) 38 2,42 down
ACBD3 acyl-CoA binding domain containing 3 1,81 up ARHGEF5 Rho guanine nucleot ide exchange factor (GEF) 5 1,51 up
ACBD4 acyl-CoA binding domain containing 4 1,56 down ARID1A AT rich interact ive domain 1A (SWI-like) 1,88 up
ACOT13 acyl-CoA thioesterase 13 1,88 up ARID1B AT rich interact ive domain 1B (SWI1-like) 3,24 down
ACP2 acid phosphatase 2, lysosomal 1,64 down ARID5B AT rich interact ive domain 5B (M RF1-like) 1,58 up
ACPT acid phosphatase, test icular 1,89 down ARL17B ADP-ribosylat ion factor-like 17B 1,64 down
ACSM 3 acyl-CoA synthetase medium-chain family member 3 1,81 up ARL3 ADP-ribosylat ion factor-like 3 2,28 up
ACSM 5 acyl-CoA synthetase medium-chain family member 5 6,14 down ARL6IP1 ADP-ribosylat ion factor-like 6 interact ing protein 1 1,79 up
ACSS1 acyl-CoA synthetase short-chain family member 1 1,67 down ARRDC1 arrest in domain containing 1 1,52 up
ACTN4 act inin, alpha 4 1,78 down ARRDC2 arrest in domain containing 2 1,70 up
ACTR1B
ARP1 act in-related protein 1 homolog B, centract in beta 
(yeast)
1,94 down ARSG arylsulfatase G 1,50 up
ACTR3 ARP3 act in-related protein 3 homolog (yeast) 1,73 up ARVCF
armadillo repeat gene deleted in velocardiofacial 
syndrome
1,82 down
ACVR2B act ivin A receptor, type IIB 1,83 down ARX aristaless related homeobox 2,65 down
ACVRL1 act ivin A receptor type II-like 1 1,54 down ASB13 ankyrin repeat and SOCS box containing 13 2,01 up
ADAD1 adenosine deaminase domain containing 1 (test is-specif ic) 1,52 down ASCL2 achaete-scute family bHLH transcript ion factor 2 1,71 up
ADAM 17 ADAM  metallopept idase domain 17 1,86 up ASPA aspartoacylase 1,64 down
ADAM 21 ADAM  metallopept idase domain 21 1,55 down ASPHD2 aspartate beta-hydroxylase domain containing 2 1,97 down
ADAM TS4
ADAM  metallopept idase with thrombospondin type 1 motif , 
4
2,08 down ASRGL1 asparaginase like 1 1,52 down
ADAM TSL1 ADAM TS-like 1 1,71 up ASTL astacin-like metallo-endopept idase (M 12 family) 1,74 down
ADAM TSL2 ADAM TS-like 2 1,53 down ASXL2 addit ional sex combs like 2 (Drosophila) 1,70 up
ADCY3 adenylate cyclase 3 1,84 up ATAD3A ATPase family, AAA domain containing 3A 1,89 down
ADD3 adducin 3 (gamma) 1,67 down ATCAY ataxia, cerebellar, Cayman type 4,80 down
ADI1 acireductone dioxygenase 1 1,81 up ATG16L1 autophagy related 16-like 1 (S. cerevisiae) 1,85 up
ADM adrenomedullin 1,51 down ATG4A autophagy related 4A, cysteine pept idase 3,06 down
ADORA3 adenosine A3 receptor 2,05 down ATG4D autophagy related 4D, cysteine pept idase 1,98 down
ADORA3 adenosine A3 receptor 1,75 down ATG7 autophagy related 7 1,53 up
ADPGK ADP-dependent glucokinase 1,57 up ATN1 atrophin 1 1,53 down
ADRA2A adrenoceptor alpha 2A 2,46 down ATOH7 atonal homolog 7 (Drosophila) 2,53 down
ADRA2B adrenoceptor alpha 2B 2,08 down ATOH8 atonal homolog 8 (Drosophila) 1,52 down
ADRBK2 adrenergic, beta, receptor kinase 2 1,52 down ATP1A4 ATPase, Na+/K+ transport ing, alpha 4 polypept ide 1,82 up
AES amino-terminal enhancer of split 2,21 up ATP1B1 ATPase, Na+/K+ transport ing, beta 1 polypept ide 2,43 up
AFG3L1P AFG3-like AAA ATPase 1, pseudogene 2,16 up ATP5E
ATP synthase, H+ transport ing, mitochondrial F1 
complex, epsilon subunit
1,77 up
AGPAT3 1-acylglycerol-3-phosphate O-acyltransferase 3 1,52 up ATP5J2
ATP synthase, H+ transport ing, mitochondrial Fo 
complex, subunit  F2
2,08 up
AGPAT4 1-acylglycerol-3-phosphate O-acyltransferase 4 1,87 down ATP6V1A
ATPase, H+ transport ing, lysosomal 70kDa, V1 
subunit  A
1,67 up
AGR2 anterior gradient 2 2,65 up ATP6V1C2
ATPase, H+ transport ing, lysosomal 42kDa, V1 
subunit  C2
3,83 down
AHCTF1 AT hook containing transcript ion factor 1 1,72 up ATP6V1G2
ATPase, H+ transport ing, lysosomal 13kDa, V1 subunit  
G2
1,77 up
AHNAK AHNAK nucleoprotein 2,21 up ATP8B1
ATPase, aminophospholipid transporter, class I, type 
8B, member 1
1,73 down
AK1 adenylate kinase 1 2,05 up ATPAF1
ATP synthase mitochondrial F1 complex assembly 
factor 1
1,54 down
AKAP17A A kinase (PRKA) anchor protein 17A 1,69 down ATRNL1 attract in-like 1 1,82 down
AKIP1 A kinase (PRKA) interact ing protein 1 1,69 up ATXN7L3 ataxin 7-like 3 1,53 down
ALDH4A1 aldehyde dehydrogenase 4 family, member A1 3,08 down AXIN1 axin 1 1,69 down
ALKBH5 alkB, alkylat ion repair homolog 5 (E. coli) 1,79 down AZIN1 antizyme inhibitor 1 1,57 up
ALOX12B arachidonate 12-lipoxygenase, 12R type 1,74 down B3GALNT1
beta-1,3-N-acetylgalactosaminyltransferase 1 
(globoside blood group)
1,60 up
ALOX15 arachidonate 15-lipoxygenase 2,17 down B3GAT2
beta-1,3-glucuronyltransferase 2 
(glucuronosyltransferase S)
1,69 up
ALOX5AP arachidonate 5-lipoxygenase-act ivat ing protein 2,28 down B4GALT1
UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, 
polypept ide 1
1,83 up
ALPL alkaline phosphatase, liver/bone/kidney 1,67 down BAALC brain and acute leukemia, cytoplasmic 1,97 up
ALYREF Aly/REF export  factor 1,91 down BAG3 BCL2-associated athanogene 3 1,57 up
AM D1 adenosylmethionine decarboxylase 1 3,50 down BAI3 brain-specif ic angiogenesis inhibitor 3 1,61 up
AM DHD1 amidohydrolase domain containing 1 1,85 up BAP1
BRCA1 associated protein-1 (ubiquit in carboxy-
terminal hydrolase)
1,60 up
AM ER3 APC membrane recruitment protein 3 1,81 down BATF3 basic leucine zipper transcript ion factor, ATF-like 3 1,51 down
AM H anti-M ullerian hormone 2,57 down BAZ2A bromodomain adjacent to zinc f inger domain, 2A 1,63 down
AM Z2 archaelysin family metallopept idase 2 1,75 up BBC3 BCL2 binding component 3 2,41 up
ANG angiogenin, ribonuclease, RNase A family, 5 1,70 up BBS2 Bardet-Biedl syndrome 2 1,62 up
ANGEL2 angel homolog 2 (Drosophila) 1,55 up BBS4 Bardet-Biedl syndrome 4 1,52 down
ANK1 ankyrin 1, erythrocyt ic 1,76 down BCAM basal cell adhesion molecule (Lutheran blood group) 1,99 up
ANKFY1 ankyrin repeat and FYVE domain containing 1 1,58 up BCAN brevican 1,88 down
ANKHD1 ankyrin repeat and KH domain containing 1 1,59 up BCAP29 B-cell receptor-associated protein 29 1,57 up
ANKRA2 ankyrin repeat, family A (RFXANK-like), 2 2,45 up BCAS3 breast carcinoma amplif ied sequence 3 1,62 down
ANKRD12 ankyrin repeat domain 12 2,28 up BCKDK branched chain ketoacid dehydrogenase kinase 1,79 up
ANKRD13B ankyrin repeat domain 13B 1,52 down BCL7A B-cell CLL/ lymphoma 7A 1,57 down
ANKRD2 ankyrin repeat domain 2 (stretch responsive muscle) 1,52 down BCL7C B-cell CLL/ lymphoma 7C 1,60 up
ANXA2 annexin A2 8,70 up BCM O1 beta-carotene 15,15'-monooxygenase 1 1,66 up
ANXA2 annexin A2 3,02 up BEGAIN brain-enriched guanylate kinase-associated 1,87 up
ANXA2P1 annexin A2 pseudogene 1 2,04 up BET1 Bet1 golgi vesicular membrane traff icking protein 1,50 down
ANXA6 annexin A6 2,34 up BGN biglycan 1,54 down
ANXA8 annexin A8 1,67 up BHLHA15 basic helix-loop-helix family, member a15 1,52 down
AOX1 aldehyde oxidase 1 1,76 up BHLHE23 basic helix-loop-helix family, member e23 2,82 down
AP2A2 adaptor-related protein complex 2, alpha 2 subunit 1,66 up BIN1 bridging integrator 1 1,53 down  
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BIRC7 baculoviral IAP repeat containing 7 1,69 down CD300E CD300e molecule 2,02 down
BLK B lymphoid tyrosine kinase 1,73 down CD300LB CD300 molecule-like family member b 2,58 down
BNIP3L BCL2/adenovirus E1B 19kDa interact ing protein 3-like 2,20 up CD3E CD3e molecule, epsilon (CD3-TCR complex) 1,59 down
BOK BCL2-related ovarian killer 1,86 down CD96 CD96 molecule 1,63 down
BPTF bromodomain PHD f inger transcript ion factor 1,95 up CDC34 cell division cycle 34 2,20 down
BRAT1 BRCA1-associated ATM  act ivator 1 1,71 up CDC34 cell division cycle 34 1,66 up
BRI3BP BRI3 binding protein 1,58 down CDC42EP1 CDC42 effector protein (Rho GTPase binding) 1 1,81 down
BRI3BP BRI3 binding protein 1,91 up CDC42EP5 CDC42 effector protein (Rho GTPase binding) 5 1,92 up
BRPF1 bromodomain and PHD f inger containing, 1 1,55 up CDH23 cadherin-related 23 1,53 down
BST2 bone marrow stromal cell ant igen 2 1,51 down CDH6 cadherin 6, type 2, K-cadherin (fetal kidney) 1,57 down
BTBD16 BTB (POZ) domain containing 16 1,89 up CDH7 cadherin 7, type 2 2,89 down
BTBD3 BTB (POZ) domain containing 3 2,41 down CDK9 cyclin-dependent kinase 9 1,58 up
BTBD7 BTB (POZ) domain containing 7 1,56 up CDKN2B
cyclin-dependent kinase inhibitor 2B (p15, inhibits 
CDK4)
1,90 down
BTF3 basic transcript ion factor 3 1,98 up CDX1 caudal type homeobox 1 1,54 down
BTG1 B-cell t ranslocat ion gene 1, ant i-proliferat ive 2,00 up CEACAM 1
carcinoembryonic ant igen-related cell adhesion 
molecule 1 (biliary glycoprotein)
2,00 up
BTK Bruton agammaglobulinemia tyrosine kinase 1,60 down CEACAM 4
carcinoembryonic ant igen-related cell adhesion 
molecule 4
1,51 down
BTN2A2 butyrophilin, subfamily 2, member A2 1,65 down CEBPA CCAAT/enhancer binding protein (C/EBP), alpha 4,04 down
BUB3 BUB3 mitot ic checkpoint protein 1,56 up CELSR2 cadherin, EGF LAG seven-pass G-type receptor 2 1,81 up
BZW1 basic leucine zipper and W2 domains 1 1,55 up CENPB centromere protein B, 80kDa 1,51 down
BZW1 basic leucine zipper and W2 domains 1 1,52 up CENPI centromere protein I 1,80 down
C11orf86 chromosome 11 open reading frame 86 1,73 down CENPN centromere protein N 1,51 down
C15orf52 chromosome 15 open reading frame 52 1,54 up CEP192 centrosomal protein 192kDa 1,54 up
C16orf92 chromosome 16 open reading frame 92 1,59 up CES2 carboxylesterase 2 1,56 down
C19orf68 chromosome 19 open reading frame 68 2,05 down CES2 carboxylesterase 2 2,26 up
C1GALT1
core 1 synthase, glycoprotein-N-acetylgalactosamine 3-beta-
galactosyltransferase, 1
2,04 down CETN1 centrin, EF-hand protein, 1 1,52 down
C1GALT1C1 C1GALT1-specif ic chaperone 1 1,82 down CHAC2 ChaC, cat ion transport  regulator homolog 2 (E. coli) 1,70 up
C1QB complement component 1, q subcomponent, B chain 1,58 down CHCHD1 coiled-coil-helix-coiled-coil-helix domain containing 1 1,83 up
C1QTNF1 C1q and tumor necrosis factor related protein 1 1,94 down CHCHD2 coiled-coil-helix-coiled-coil-helix domain containing 2 2,00 up
C2 complement component 2 2,05 up CHCHD2 coiled-coil-helix-coiled-coil-helix domain containing 2 1,84 up
C2CD4B C2 calcium-dependent domain containing 4B 2,17 down CHD9 chromodomain helicase DNA binding protein 9 1,62 up
C2orf80 chromosome 2 open reading frame 80 1,72 down CHM P6 charged mult ivesicular body protein 6 2,74 down
C5AR1 complement component 5a receptor 1 1,60 up CHRDL1 chordin-like 1 2,81 down
C5AR2 complement component 5a receptor 2 1,66 down CHRNB1 cholinergic receptor, nicot inic, beta 1 (muscle) 1,62 up
C7orf62 chromosome 7 open reading frame 62 1,89 down CHST1
carbohydrate (keratan sulfate Gal-6) sulfotransferase 
1
1,54 down
C8A complement component 8, alpha polypept ide 1,66 up CHST10 carbohydrate sulfotransferase 10 1,63 down
CA6 carbonic anhydrase VI 2,24 up CHST12 carbohydrate (chondroit in 4) sulfotransferase 12 2,27 up
CABIN1 calcineurin binding protein 1 1,66 up CHST14
carbohydrate (N-acetylgalactosamine 4-0) 
sulfotransferase 14
1,97 down
CABP1 calcium binding protein 1 1,61 down CIDECP cell death-inducing DFFA-like effector c pseudogene 1,74 up
CACNA1B calcium channel, voltage-dependent, N type, alpha 1B subunit 2,16 down CIRBP cold inducible RNA binding protein 1,98 down
CACNA1F calcium channel, voltage-dependent, L type, alpha 1F subunit 1,61 down CKAP4 cytoskeleton-associated protein 4 2,04 up
CACNG1 calcium channel, voltage-dependent, gamma subunit  1 1,61 down CLCF1 cardiotrophin-like cytokine factor 1 2,01 down
CACNG7 calcium channel, voltage-dependent, gamma subunit  7 1,94 down CLCN3 chloride channel, voltage-sensit ive 3 1,51 up
CACNG8 calcium channel, voltage-dependent, gamma subunit  8 2,45 down CLDN1 claudin 1 1,95 up
CACYBP calcyclin binding protein 1,82 up CLDN9 claudin 9 3,94 down
CACYBP calcyclin binding protein 1,57 up CLDN9 claudin 9 1,66 down
CALD1 caldesmon 1 1,92 up CLEC4A C-type lect in domain family 4, member A 1,76 down
CALD1 caldesmon 1 1,86 up CLIC4 chloride intracellular channel 4 2,01 up
CALM L6 calmodulin-like 6 1,93 down CLINT1 clathrin interactor 1 1,94 up
CALR3 calret iculin 3 1,88 up CLIP4
CAP-GLY domain containing linker protein family, 
member 4
1,57 up
CAM K2N1 calcium/calmodulin-dependent protein kinase II inhibitor 1 2,25 up CLPB ClpB caseinolyt ic pept idase B homolog (E. coli) 1,53 up
CAM SAP3
calmodulin regulated spectrin-associated protein family, 
member 3
1,70 up CLPTM 1L CLPTM 1-like 2,27 down
CAND1 cullin-associated and neddylat ion-dissociated 1 1,75 down CLTCL1 clathrin, heavy chain-like 1 1,83 down
CAND1 cullin-associated and neddylat ion-dissociated 1 1,57 down CM C1 C-x(9)-C motif  containing 1 1,65 up
CANX calnexin 1,58 up CM IP c-M af inducing protein 2,41 down
CAPS calcyphosine 1,68 down CM TM 3
CKLF-like M ARVEL transmembrane domain 
containing 3
1,97 up
CARD10 caspase recruitment domain family, member 10 1,67 down CM TM 5
CKLF-like M ARVEL transmembrane domain 
containing 5
1,52 down
CARKD carbohydrate kinase domain containing 2,76 down CNN2 calponin 2 1,89 up
CASC3 cancer suscept ibility candidate 3 1,75 down CNOT10 CCR4-NOT transcript ion complex, subunit  10 1,53 up
CASD1 CAS1 domain containing 1 1,92 down CNOT4 CCR4-NOT transcript ion complex, subunit  4 1,53 down
CASKIN1 CASK interact ing protein 1 1,97 up CNOT6 CCR4-NOT transcript ion complex, subunit  6 2,03 up
CASP2 caspase 2, apoptosis-related cysteine pept idase 1,58 up CNOT6 CCR4-NOT transcript ion complex, subunit  6 1,52 up
CASP5 caspase 5, apoptosis-related cysteine pept idase 1,78 up CNOT6L CCR4-NOT transcript ion complex, subunit  6-like 1,59 up
CATSPERB catsper channel auxiliary subunit  beta 1,54 down CNOT8 CCR4-NOT transcript ion complex, subunit  8 1,69 down
CATSPERG catsper channel auxiliary subunit  gamma 1,57 down CNP 2',3'-cyclic nucleot ide 3' phosphodiesterase 1,60 up
CAV1 caveolin 1, caveolae protein, 22kDa 2,23 up CNPY2 canopy FGF signaling regulator 2 1,53 up
CBFA2T2
core-binding factor, runt domain, alpha subunit  2; 
t ranslocated to, 2
1,55 down CNPY4 canopy FGF signaling regulator 4 1,52 up
CBS cystathionine-beta-synthase 1,83 up CNTN2 contact in 2 (axonal) 1,52 down
CBWD2 COBW domain containing 2 1,97 up CNTNAP1 contact in associated protein 1 1,80 down
CBX1 chromobox homolog 1 1,71 up CNTNAP3 contact in associated protein-like 3 1,65 down
CCDC105 coiled-coil domain containing 105 1,93 down COA6
cytochrome c oxidase assembly factor 6 homolog (S. 
cerevisiae)
1,86 up
CCDC109B coiled-coil domain containing 109B 1,58 up COBL cordon-bleu WH2 repeat protein 1,70 up
CCDC134 coiled-coil domain containing 134 1,64 up COG3 component of oligomeric golgi complex 3 1,54 up
CCDC144NL coiled-coil domain containing 144 family, N-terminal like 2,04 up COL18A1 collagen, type XVIII, alpha 1 1,67 down
CCDC151 coiled-coil domain containing 151 1,89 up COL23A1 collagen, type XXIII, alpha 1 1,61 down
CCDC43 coiled-coil domain containing 43 1,55 up COL27A1 collagen, type XXVII, alpha 1 1,94 up
CCDC57 coiled-coil domain containing 57 2,65 down COL4A1 collagen, type IV, alpha 1 1,59 down
CCDC6 coiled-coil domain containing 6 1,75 up COL4A3BP
collagen, type IV, alpha 3 (Goodpasture ant igen) 
binding protein
1,55 up
CCDC74B coiled-coil domain containing 74B 1,64 down COL9A1 collagen, type IX, alpha 1 2,28 down
CCDC8 coiled-coil domain containing 8 1,78 down COLGALT1 collagen beta(1-O)galactosyltransferase 1 1,51 up
CCDC90B coiled-coil domain containing 90B 1,65 up CORT cort istat in 1,72 up
CCL13 chemokine (C-C motif ) ligand 13 1,72 down COX11 cytochrome c oxidase assembly homolog 11 (yeast) 1,54 up
CCL15 chemokine (C-C motif ) ligand 15 1,63 down COX18 COX18 cytochrome C oxidase assembly factor 1,90 down
CCL19 chemokine (C-C motif ) ligand 19 1,76 down COX19
cytochrome c oxidase assembly homolog 19 (S. 
cerevisiae)
1,66 down
CCL20 chemokine (C-C motif ) ligand 20 1,59 down COX20 COX20 cytochrome C oxidase assembly factor 1,63 up
CCNB1 cyclin B1 1,50 up COX5A cytochrome c oxidase subunit  Va 2,26 up
CCND2 cyclin D2 1,97 up CPE carboxypept idase E 1,81 up
CCND2 cyclin D2 1,75 up CRABP1 cellular ret inoic acid binding protein 1 1,87 down
CCND3 cyclin D3 2,38 down CRAM P1L Crm, cramped-like (Drosophila) 1,99 up
CCNG1 cyclin G1 1,53 up CRB2 crumbs homolog 2 (Drosophila) 1,53 down
CCNT2 cyclin T2 1,52 up CRB3 crumbs homolog 3 (Drosophila) 1,55 down
CCR10 chemokine (C-C motif ) receptor 10 1,56 down CREB3L1 cAM P responsive element binding protein 3-like 1 3,63 down
CCR3 chemokine (C-C motif ) receptor 3 1,90 down CRHBP cort icotropin releasing hormone binding protein 1,50 down
CCSER2 coiled-coil serine-rich protein 2 1,68 up CRHR1 cort icotropin releasing hormone receptor 1 2,44 down
CCT3 chaperonin containing TCP1, subunit  3 (gamma) 1,62 down CRISP2 cysteine-rich secretory protein 2 1,94 up
CCT6P1 chaperonin containing TCP1, subunit  6 (zeta) pseudogene 1 1,57 up CRM P1 collapsin response mediator protein 1 1,62 down
CD109 CD109 molecule 1,99 up CROCC ciliary root let  coiled-coil, root let in 1,91 down
CD109 CD109 molecule 1,60 up CRTAP cart ilage associated protein 1,63 down
CD1A CD1a molecule 1,63 down CRTC1 CREB regulated transcript ion coact ivator 1 1,98 up
CD1E CD1e molecule 1,62 down CRTC2 CREB regulated transcript ion coact ivator 2 2,30 up
CD244 CD244 molecule, natural killer cell receptor 2B4 1,87 up CRYAA crystallin, alpha A 1,77 down  
110 
 
CRYBA2 crystallin, beta A2 2,33 down DRD4 dopamine receptor D4 2,36 up
CRYBG3 beta-gamma crystallin domain containing 3 1,68 up DRG1 developmentally regulated GTP binding protein 1 1,79 up
CRYBG3 beta-gamma crystallin domain containing 3 1,51 up DSC2 desmocollin 2 1,88 up
CRYGS crystallin, gamma S 1,61 up DSCR4 Down syndrome crit ical region gene 4 1,52 down
CRYZ crystallin, zeta (quinone reductase) 1,52 up DSCR4 Down syndrome crit ical region gene 4 1,66 up
CSAD cysteine sulf inic acid decarboxylase 1,54 down DSG1 desmoglein 1 2,47 up
CSF1 colony st imulat ing factor 1 (macrophage) 1,55 down DSTN destrin (act in depolymerizing factor) 2,60 up
CSF3 colony st imulat ing factor 3 (granulocyte) 1,56 down DUS1L dihydrouridine synthase 1-like (S. cerevisiae) 1,60 down
CSH2 chorionic somatomammotropin hormone 2 1,58 up DUSP15 dual specif icity phosphatase 15 2,41 down
CSNK1A1 casein kinase 1, alpha 1 1,93 up DUSP18 dual specif icity phosphatase 18 1,78 up
CSNK1D casein kinase 1, delta 1,76 up DUSP26 dual specif icity phosphatase 26 (putat ive) 1,65 down
CST1 cystat in SN 2,31 up DUSP8 dual specif icity phosphatase 8 1,63 up
CTAGE3P CTAGE family, member 3, pseudogene 1,58 down DUX4 double homeobox 4 2,81 up
CTAGE4 CTAGE family, member 4 1,64 up DVL3 dishevelled segment polarity protein 3 2,05 down
CTAGE4 CTAGE family, member 4 1,56 up DYNC1LI2 dynein, cytoplasmic 1, light intermediate chain 2 1,78 up
CTAGE4 CTAGE family, member 4 1,52 up EBF2 early B-cell factor 2 1,66 up
CTAGE7P CTAGE family, member 7, pseudogene 1,54 down EDARADD EDAR-associated death domain 1,92 up
CTBP1 C-terminal binding protein 1 1,65 down EEF1A1 eukaryot ic translat ion elongat ion factor 1 alpha 1 1,71 up
CTBP1 C-terminal binding protein 1 2,08 up EFCAB4A EF-hand calcium binding domain 4A 1,51 up
CTBP2 C-terminal binding protein 2 1,65 down EFHD2 EF-hand domain family, member D2 1,52 up
CTNNA2 catenin (cadherin-associated protein), alpha 2 1,65 down EFNB3 ephrin-B3 1,56 up
CTNNBIP1 catenin, beta interact ing protein 1 2,79 up EGFL7 EGF-like-domain, mult iple 7 1,65 down
CTNND1 catenin (cadherin-associated protein), delta 1 1,56 up EGLN1 egl-9 family hypoxia-inducible factor 1 1,55 up
CTNND2 catenin (cadherin-associated protein), delta 2 2,15 up EHM T2 euchromatic histone-lysine N-methyltransferase 2 2,45 down
CTRC chymotrypsin C (caldecrin) 2,48 down EID1 EP300 interact ing inhibitor of  dif ferent iat ion 1 2,46 up
CTSB cathepsin B 2,59 up EIF3F eukaryot ic translat ion init iat ion factor 3, subunit  F 1,72 up
CTSC cathepsin C 1,94 up EIF4A1 eukaryot ic translat ion init iat ion factor 4A1 1,69 up
CTSE cathepsin E 1,72 down EIF4B eukaryot ic translat ion init iat ion factor 4B 2,32 up
CTSE cathepsin E 1,68 down ELOVL4 ELOVL fatty acid elongase 4 2,61 up
CTU1 cytosolic thiouridylase subunit  1 1,88 down ELOVL6 ELOVL fatty acid elongase 6 2,01 up
CXADR gap junct ion protein, alpha 5, 40kDa 1,55 up ELP4 elongator acetylt ransferase complex subunit  4 2,13 up
CXADR gap junct ion protein, alpha 5, 40kDa 1,52 up ELSPBP1 epididymal sperm binding protein 1 3,24 down
CXCL16 chemokine (C-X-C motif ) ligand 16 1,52 up EM ILIN1 elast in microf ibril interfacer 1 1,77 down
CXCL2 chemokine (C-X-C motif ) ligand 2 1,79 down ENC1 ectodermal-neural cortex 1 (with BTB domain) 1,54 down
CXCR5 chemokine (C-X-C motif ) receptor 5 1,93 up ENDOV endonuclease V 1,53 down
CYB561 cytochrome b561 2,33 up ENO1 enolase 1, (alpha) 2,32 up
CYB5D2 cytochrome b5 domain containing 2 1,52 down ENPP4
ectonucleot ide pyrophosphatase/phosphodiesterase 
4 (putat ive)
1,60 up
CYB5R3 cytochrome b5 reductase 3 2,50 up ENTHD2 ENTH domain containing 2 1,99 up
CYBB cytochrome b-245, beta polypept ide 1,67 up ENTPD2 ectonucleoside triphosphate diphosphohydrolase 2 1,71 down
CYCS cytochrome c, somatic 2,11 up EPAS1 endothelial PAS domain protein 1 1,67 up
CYHR1 cysteine/hist idine-rich 1 1,54 up EPB41L4B erythrocyte membrane protein band 4.1 like 4B 1,59 up
CYP1B1 cytochrome P450, family 1, subfamily B, polypept ide 1 2,16 up EPDR1 ependymin related 1 1,60 down
CYP2R1 cytochrome P450, family 2, subfamily R, polypept ide 1 1,70 up EPHA2 EPH receptor A2 1,57 down
CYP4F2 cytochrome P450, family 4, subfamily F, polypept ide 2 1,66 down EPHA4 EPH receptor A4 1,79 up
CYP4F2 cytochrome P450, family 4, subfamily F, polypept ide 2 1,59 up EPOR erythropoiet in receptor 1,51 up
CYP51A1 cytochrome P450, family 51, subfamily A, polypept ide 1 1,56 up EPS8
epidermal growth factor receptor pathway substrate 
8
1,96 up
CYP51A1 cytochrome P450, family 51, subfamily A, polypept ide 1 1,55 up ERBB3
v-erb-b2 avian erythroblast ic leukemia viral oncogene 
homolog 3
1,88 up
CYP7B1 cytochrome P450, family 7, subfamily B, polypept ide 1 1,66 up ERCC2
excision repair cross-complementing rodent repair 
def iciency, complementat ion group 2
2,07 down
CYTH4 cytohesin 4 1,64 down ERCC6L2
excision repair cross-complementing rodent repair 
def iciency, complementat ion group 6-like 2
1,50 up
DAB2
Dab, mitogen-responsive phosphoprotein, homolog 2 
(Drosophila)
1,71 up ERG
v-ets avian erythroblastosis virus E26 oncogene 
homolog
1,57 down
DAP death-associated protein 1,68 down ERN1 endoplasmic ret iculum to nucleus signaling 1 2,65 down
DBN1 drebrin 1 1,53 down ERN1 endoplasmic ret iculum to nucleus signaling 1 1,74 up
DBN1 drebrin 1 1,88 up ESCO1
establishment of sister chromatid cohesion N-
acetyltransferase 1
1,84 up
DBP D site of albumin promoter (albumin D-box) binding protein 2,86 down ESRRA estrogen-related receptor alpha 1,60 up
DCPS decapping enzyme, scavenger 1,63 down ESRRB estrogen-related receptor beta 1,83 down
DCTD dCM P deaminase 1,63 up ESYT2 extended synaptotagmin-like protein 2 1,57 up
DDAH1 dimethylarginine dimethylaminohydrolase 1 1,92 up ETF1 eukaryot ic translat ion terminat ion factor 1 2,21 up
DDI2 DNA-damage inducible 1 homolog 2 (S. cerevisiae) 1,54 down EVL Enah/Vasp-like 2,10 up
DDO D-aspartate oxidase 1,62 down EXD2 exonuclease 3'-5' domain containing 2 1,79 down
DDX5 DEAD (Asp-Glu-Ala-Asp) box helicase 5 1,84 up EXD2 exonuclease 3'-5' domain containing 2 1,61 up
DDX50 DEAD (Asp-Glu-Ala-Asp) box polypept ide 50 1,58 down EXOC3L2 exocyst complex component 3-like 2 2,12 up
DEF8 dif ferent ially expressed in FDCP 8 homolog (mouse) 1,56 up EXOC7 exocyst complex component 7 1,78 up
DEFB103A defensin, beta 103A 1,55 up EXOSC7 exosome component 7 1,50 down
DEK DEK oncogene 1,82 up EXTL3 exostosin-like glycosyltransferase 3 1,61 down
DENND1C DENN/M ADD domain containing 1C 1,87 up EZR ezrin 2,55 up
DENND2A DENN/M ADD domain containing 2A 1,71 up FABP3
fatty acid binding protein 3, muscle and heart  
(mammary-derived growth inhibitor)
2,10 down
DERL1 derlin 1 1,78 up FABP4 fatty acid binding protein 4, adipocyte 2,29 up
DESI2 desumoylat ing isopept idase 2 1,54 down FABP5 fatty acid binding protein 5 (psoriasis-associated) 3,16 up
DEXI Dexi homolog (mouse) 2,21 up FADS2 fatty acid desaturase 2 1,60 up
DFFA DNA fragmentat ion factor, 45kDa, alpha polypept ide 1,74 up FADS3 fatty acid desaturase 3 1,58 down
DFNB31 deafness, autosomal recessive 31 2,08 down FAIM 3 Fas apoptot ic inhibitory molecule 3 1,79 down
DGKQ diacylglycerol kinase, theta 110kDa 1,77 down FAM 101B family with sequence similarity 101, member B 1,77 up
DHDDS dehydrodolichyl diphosphate synthase 1,51 up FAM 107A family with sequence similarity 107, member A 1,78 up
DHRS13 dehydrogenase/reductase (SDR family) member 13 1,80 up FAM 110B family with sequence similarity 110, member B 1,57 down
DHRS2 dehydrogenase/reductase (SDR family) member 2 2,00 down FAM 126A family with sequence similarity 126, member A 1,93 down
DHX30 DEAH (Asp-Glu-Ala-His) box helicase 30 1,67 up FAM 129B family with sequence similarity 129, member B 2,29 up
DHX34 DEAH (Asp-Glu-Ala-His) box polypept ide 34 1,81 down FAM 129C family with sequence similarity 129, member C 2,17 down
DHX58 DEXH (Asp-Glu-X-His) box polypept ide 58 1,81 up FAM 133B family with sequence similarity 133, member B 1,58 up
DIAPH2 diaphanous-related formin 2 1,56 up FAM 134A family with sequence similarity 134, member A 1,50 down
DIM T1
DIM 1 dimethyladenosine transferase 1 homolog (S. 
cerevisiae)
1,78 up FAM 160B1 family with sequence similarity 160, member B1 1,96 up
DIO2 deiodinase, iodothyronine, type II 1,52 down FAM 160B2 family with sequence similarity 160, member B2 1,58 up
DIP2A DIP2 disco-interact ing protein 2 homolog A (Drosophila) 1,64 down FAM 167B family with sequence similarity 167, member B 1,74 down
DLGAP4 discs, large (Drosophila) homolog-associated protein 4 1,74 down FAM 187B family with sequence similarity 187, member B 1,53 down
DM BX1 diencephalon/mesencephalon homeobox 1 1,58 down FAM 20B family with sequence similarity 20, member B 1,75 up
DNAH1 dynein, axonemal, heavy chain 1 1,94 down FAM 210B family with sequence similarity 210, member B 1,61 up
DNAH11 dynein, axonemal, heavy chain 11 1,77 up FAM 21C family with sequence similarity 21, member C 1,90 up
DNAH14 dynein, axonemal, heavy chain 14 1,65 down FAM 53B family with sequence similarity 53, member B 2,19 down
DNAH2 dynein, axonemal, heavy chain 2 2,11 down FAM 65A family with sequence similarity 65, member A 2,49 down
DNAH8 dynein, axonemal, heavy chain 8 1,86 down FAM 83B family with sequence similarity 83, member B 1,50 up
DNAJB1 DnaJ (Hsp40) homolog, subfamily B, member 1 1,55 up FAM 83E family with sequence similarity 83, member E 1,82 down
DNAJB11 DnaJ (Hsp40) homolog, subfamily B, member 11 1,94 up FAM 83H family with sequence similarity 83, member H 1,81 down
DNAJC27 DnaJ (Hsp40) homolog, subfamily C, member 27 1,67 up FAM 84A family with sequence similarity 84, member A 1,65 up
DNAJC8 DnaJ (Hsp40) homolog, subfamily C, member 8 1,51 up FAM 86C1 family with sequence similarity 86, member C1 1,52 up
DNASE1 deoxyribonuclease I 1,92 down FAM 90A9P
family with sequence similarity 90, member A9, 
pseudogene
1,60 down
DNM 1P35 DNM 1 pseudogene 35 2,18 up FARP1
FERM , RhoGEF (ARHGEF) and pleckstrin domain 
protein 1 (chondrocyte-derived)
2,17 up
DOCK3 dedicator of cytokinesis 3 3,04 down FARP1
FERM , RhoGEF (ARHGEF) and pleckstrin domain 
protein 1 (chondrocyte-derived)
1,84 up
DOCK6 dedicator of cytokinesis 6 1,56 down FAT2 FAT atypical cadherin 2 1,79 up
DPP6 dipept idyl-pept idase 6 2,05 down FBRSL1 fibrosin-like 1 1,88 down
DR1
down-regulator of t ranscript ion 1, TBP-binding (negat ive 
cofactor 2)
1,60 up FBXL13 F-box and leucine-rich repeat protein 13 1,83 up
DRD3 dopamine receptor D3 2,64 down FBXL17 F-box and leucine-rich repeat protein 17 1,80 down  
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FBXL7 F-box and leucine-rich repeat protein 7 1,77 up GM PPB GDP-mannose pyrophosphorylase B 1,62 up
FBXO11 F-box protein 11 1,84 up GNAI2
guanine nucleot ide binding protein (G protein), alpha 
inhibit ing act ivity polypept ide 2
1,68 up
FBXO34 F-box protein 34 1,69 up GNAL
guanine nucleot ide binding protein (G protein), alpha 
act ivat ing act ivity polypept ide, olfactory type
1,56 up
FBXO9 F-box protein 9 2,01 up GNAQ
guanine nucleot ide binding protein (G protein), q 
polypept ide
1,65 up
FCN1 ficolin (collagen/f ibrinogen domain containing) 1 1,51 down GNG12
guanine nucleot ide binding protein (G protein), 
gamma 12
1,71 up
FCRL2 Fc receptor-like 2 2,11 down GNG13
guanine nucleot ide binding protein (G protein), 
gamma 13
2,24 down
FER1L6-AS1 FER1L6 ant isense RNA 1 1,94 up GNG7
guanine nucleot ide binding protein (G protein), 
gamma 7
1,61 up
FES feline sarcoma oncogene 1,55 down GNGT1
guanine nucleot ide binding protein (G protein), 
gamma transducing act ivity polypept ide 1
1,57 down
FEZ2 fasciculat ion and elongat ion protein zeta 2 (zygin II) 1,97 down GNL2 guanine nucleot ide binding protein-like 2 (nucleolar) 1,63 up
FFAR1 free fatty acid receptor 1 1,63 down GNRH2 gonadotropin-releasing hormone 2 3,00 down
FGD6 FYVE, RhoGEF and PH domain containing 6 1,70 up GNRH2 gonadotropin-releasing hormone 2 1,75 down
FGF1 fibroblast growth factor 1 (acidic) 2,26 up GOLPH3L golgi phosphoprotein 3-like 1,56 up
FGF5 fibroblast growth factor 5 1,51 down GON4L gon-4-like (C. elegans) 1,59 up
FGFR1 fibroblast growth factor receptor 1 1,72 up GOT1 glutamic-oxaloacet ic transaminase 1, soluble 2,17 up
FGFRL1 fibroblast growth factor receptor-like 1 1,94 down GOT1 glutamic-oxaloacet ic transaminase 1, soluble 1,55 up
FHL1 four and a half  LIM  domains 1 1,50 up GP6 glycoprotein VI (platelet) 1,97 down
FHOD1 formin homology 2 domain containing 1 1,59 down GPAA1 glycosylphosphat idylinositol anchor attachment 1 1,79 down
FIBCD1 fibrinogen C domain containing 1 2,01 down GPR113 G protein-coupled receptor 113 1,64 up
FKBP1A FK506 binding protein 1A, 12kDa 1,61 down GPR115 G protein-coupled receptor 115 2,39 up
FKBP1A FK506 binding protein 1A, 12kDa 1,79 up GPR135 G protein-coupled receptor 135 1,60 down
FKBP9 FK506 binding protein 9, 63 kDa 2,42 up GPR135 G protein-coupled receptor 135 1,72 up
FLG filaggrin 2,45 up GPR15 G protein-coupled receptor 15 1,67 up
FLRT2 fibronect in leucine rich transmembrane protein 2 1,57 up GPR162 G protein-coupled receptor 162 1,68 down
FNDC3A fibronect in type III domain containing 3A 1,55 up GPR171 G protein-coupled receptor 171 1,95 up
FNDC5 fibronect in type III domain containing 5 1,67 down GPR174 G protein-coupled receptor 174 1,72 down
FNTB farnesyltransferase, CAAX box, beta 1,50 up GPR27 G protein-coupled receptor 27 1,66 down
FOS FBJ murine osteosarcoma viral oncogene homolog 1,65 down GPR3 G protein-coupled receptor 3 1,58 up
FOSB FBJ murine osteosarcoma viral oncogene homolog B 1,68 down GPR6 G protein-coupled receptor 6 1,54 down
FOXA2 forkhead box A2 1,59 up GPR62 G protein-coupled receptor 62 1,59 up
FOXA3 forkhead box A3 2,12 down GPR78 G protein-coupled receptor 78 1,81 down
FOXG1 forkhead box G1 1,84 down GPR87 G protein-coupled receptor 87 1,59 up
FOXH1 forkhead box H1 3,17 down GPX4 glutathione peroxidase 4 1,79 up
FOXJ1 forkhead box J1 1,62 down GRAP GRB2-related adaptor protein 1,90 down
FOXN2 forkhead box N2 2,26 up GRID2 glutamate receptor, ionotropic, delta 2 2,87 down
FOXN3 forkhead box N3 2,00 up GRIN2D
glutamate receptor, ionotropic, N-methyl D-aspartate 
2D
2,38 up
FOXP1 forkhead box P1 2,08 up GRK1 G protein-coupled receptor kinase 1 1,61 down
FOXP4 forkhead box P4 1,79 up GRM 4 glutamate receptor, metabotropic 4 1,89 down
FOXQ1 forkhead box Q1 2,81 up GRN granulin 2,46 down
FPGS folylpolyglutamate synthase 1,72 down GSN gelsolin 1,77 down
FPR1 formyl pept ide receptor 1 3,57 down GSTT1 glutathione S-transferase theta 1 1,61 down
FRAT2 frequent ly rearranged in advanced T-cell lymphomas 2 2,41 up GTF2A1 general t ranscript ion factor IIA, 1, 19/37kDa 1,64 up
FRM D4A FERM  domain containing 4A 2,18 down GTF2F1 general t ranscript ion factor IIF, polypept ide 1, 74kDa 2,31 up
FRM D8P1 FERM  domain containing 8 pseudogene 1 2,63 down GTF2H5 general t ranscript ion factor IIH, polypept ide 5 2,04 up
FRY furry homolog (Drosophila) 1,52 up GTF2I general t ranscript ion factor IIi 1,59 up
FRYL FRY-like 1,99 up GTF3C2
general t ranscript ion factor IIIC, polypept ide 2, beta 
110kDa
1,66 down
FSCN2
fascin homolog 2, act in-bundling protein, ret inal 
(Strongylocentrotus purpuratus)
2,21 down GTF3C4
general t ranscript ion factor IIIC, polypept ide 4, 
90kDa
1,89 up
FTSJ1 FtsJ RNA methyltransferase homolog 1 (E. coli) 1,67 down GTPBP6 GTP binding protein 6 (putat ive) 1,69 up
FTSJ1 FtsJ RNA methyltransferase homolog 1 (E. coli) 1,54 down GYG2 glycogenin 2 1,57 down
FUBP3 far upstream element (FUSE) binding protein 3 1,59 up GYPC glycophorin C (Gerbich blood group) 1,75 up
FUZ fuzzy planar cell polarity protein 1,58 down GYPE glycophorin E (M NS blood group) 2,19 down
FXN frataxin 1,67 down GZM H granzyme H (cathepsin G-like 2, protein h-CCPX) 1,59 down
FZR1 fizzy/cell division cycle 20 related 1 (Drosophila) 2,21 down GZM M granzyme M  (lymphocyte met-ase 1) 1,64 down
G6PC3 glucose 6 phosphatase, catalyt ic, 3 1,56 up HAAO 3-hydroxyanthranilate 3,4-dioxygenase 1,56 down
GAA glucosidase, alpha; acid 1,90 up HAPLN4 hyaluronan and proteoglycan link protein 4 1,77 down
GABARAPL1 GABA(A) receptor-associated protein like 1 1,83 down HAUS6 HAUS augmin-like complex, subunit  6 1,62 up
GABRB2 gamma-aminobutyric acid (GABA) A receptor, beta 2 1,57 up HAUS7 HAUS augmin-like complex, subunit  7 1,63 up
GABRP gamma-aminobutyric acid (GABA) A receptor, pi 1,86 up HBZ hemoglobin, zeta 1,92 down
GABRQ gamma-aminobutyric acid (GABA) A receptor, theta 1,57 down HCFC1 host cell factor C1 (VP16-accessory protein) 2,82 down
GALK2 galactokinase 2 2,00 down HCG18 HLA complex group 18 (non-protein coding) 1,79 up
GALNT6
UDP-N-acetyl-alpha-D-galactosamine:polypept ide N-
acetylgalactosaminyltransferase 6 (GalNAc-T6)
1,52 up HCN2
hyperpolarizat ion act ivated cyclic nucleot ide-gated 
potassium channel 2
2,30 up
GAN gigaxonin 2,18 up HCP5 HLA complex P5 (non-protein coding) 2,06 down
GAREM GRB2 associated, regulator of M APK1 1,55 up HDLBP high density lipoprotein binding protein 1,78 down
GAS6 growth arrest-specif ic 6 1,62 down HECW2
HECT, C2 and WW domain containing E3 ubiquit in 
protein ligase 2
1,51 down
GATA2 GATA binding protein 2 1,54 down HELZ2 helicase with zinc f inger 2, t ranscript ional coact ivator 1,59 down
GATA3 GATA binding protein 3 1,84 up HES4 hes family bHLH transcript ion factor 4 2,59 down
GATS GATS, stromal ant igen 3 opposite strand 1,66 up HFE hemochromatosis 1,96 down
GCK glucokinase (hexokinase 4) 1,71 down HGD homogentisate 1,2-dioxygenase 1,64 up
GCSAM L germinal center-associated, signaling and motility-like 1,63 down HGS
hepatocyte growth factor-regulated tyrosine kinase 
substrate
2,51 down
GCSH glycine cleavage system protein H (aminomethyl carrier) 1,93 up HGS
hepatocyte growth factor-regulated tyrosine kinase 
substrate
1,75 down
GDF5OS growth dif ferent iat ion factor 5 opposite strand 1,97 down HHLA3 HERV-H LTR-associat ing 3 1,51 down
GDNF glial cell derived neurotrophic factor 1,91 up HIF3A hypoxia inducible factor 3, alpha subunit 2,13 down
GDNF glial cell derived neurotrophic factor 1,70 up HIP1 hunt ingt in interact ing protein 1 1,73 down
GEM IN6 gem (nuclear organelle) associated protein 6 1,51 up HIRA histone cell cycle regulator 1,65 up
GFOD1 glucose-fructose oxidoreductase domain containing 1 2,34 up HIST1H1D histone cluster 1, H1d 2,41 up
GGA1
golgi-associated, gamma adapt in ear containing, ARF 
binding protein 1
1,71 down HIST1H1E histone cluster 1, H1e 2,55 up
GGNBP2 gametogenet in binding protein 2 1,51 up HIST1H2BE histone cluster 1, H2be 1,59 up
GGT1 gamma-glutamyltransferase 1 1,99 down HIST1H2BO histone cluster 1, H2bo 1,90 up
GGT3P gamma-glutamyltransferase 3 pseudogene 1,50 up HIST1H3A histone cluster 1, H3a 3,09 up
GGTLC2 gamma-glutamyltransferase light chain 2 1,89 up HIST1H3E histone cluster 1, H3e 2,51 up
GHDC GH3 domain containing 1,71 down HIST1H3I histone cluster 1, H3i 1,61 down
GIGYF1 GRB10 interact ing GYF protein 1 1,81 up HIST1H4E histone cluster 1, H4e 3,00 up
GIGYF2 GRB10 interact ing GYF protein 2 1,66 up HIST2H2AC histone cluster 2, H2ac 2,51 up
GIPC1 GIPC PDZ domain containing family, member 1 1,58 down HIST4H4 histone cluster 4, H4 1,74 down
GIT2 G protein-coupled receptor kinase interact ing ArfGAP 2 1,60 down HIVEP2
human immunodeficiency virus type I enhancer binding 
protein 2
1,68 down
GJB7 gap junct ion protein, beta 7, 25kDa 2,22 down HIVEP3
human immunodeficiency virus type I enhancer binding 
protein 3
1,57 up
GJC1 gap junct ion protein, gamma 1, 45kDa 2,45 down HK2 hexokinase 2 2,12 up
GJC2 gap junct ion protein, gamma 2, 47kDa 1,79 down HLA-DQB1 major histocompatibility complex, class II, DQ beta 1 2,04 down
GK2 glycerol kinase 2 1,52 down HLA-DQB2 major histocompatibility complex, class II, DQ beta 2 2,05 down
GK5 glycerol kinase 5 (putat ive) 1,60 down HLA-DRB3 major histocompatibility complex, class II, DR beta 3 1,94 down
GLB1L3 galactosidase, beta 1-like 3 1,82 down HLA-DRB3 major histocompatibility complex, class II, DR beta 3 1,59 down
GLDC glycine dehydrogenase (decarboxylat ing) 1,62 down HLA-G major histocompatibility complex, class I, G 1,59 down
GLI3 GLI family zinc f inger 3 1,62 up HLA-G major histocompatibility complex, class I, G 1,58 down
GLIPR1L1 GLI pathogenesis-related 1 like 1 1,50 down HM BOX1 homeobox containing 1 2,30 up
GLIS3 GLIS family zinc f inger 3 1,50 up HM GB1 high mobility group box 1 1,96 up
GLRX glutaredoxin (thiolt ransferase) 3,65 up HM GN1 high mobility group nucleosome binding domain 1 2,06 up
GLS glutaminase 2,27 down HM GN4 high mobility group nucleosomal binding domain 4 1,55 up
GLTSCR1 glioma tumor suppressor candidate region gene 1 1,97 down HM OX2 heme oxygenase (decycling) 2 1,93 down
GM 2A GM 2 ganglioside act ivator 1,65 up HNRNPK heterogeneous nuclear ribonucleoprotein K 1,89 up
GM CL1P1 germ cell-less, spermatogenesis associated 1 pseudogene 1 1,51 down HOXA1 homeobox A1 1,62 down
GM PPB GDP-mannose pyrophosphorylase B 2,01 down HOXA3 homeobox A3 2,67 up  
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HOXA4 homeobox A4 1,95 down KIAA0101 KIAA0101 1,56 up
HOXB9 homeobox B9 1,69 down KIAA0513 KIAA0513 1,62 up
HOXC9 homeobox C9 1,86 down KIAA0556 KIAA0556 1,51 down
HPN hepsin 2,32 down KIAA0753 KIAA0753 1,53 up
HRCT1 hist idine rich carboxyl terminus 1 1,61 down KIAA1614 KIAA1614 1,58 up
HRH3 histamine receptor H3 1,87 up KIAA1875 KIAA1875 1,69 down
HS1BP3 HCLS1 binding protein 3 1,73 down KIAA1919 KIAA1919 2,31 up
HS6ST2 heparan sulfate 6-O-sulfotransferase 2 1,80 up KIF12 kinesin family member 12 1,52 down
HSD11B2 hydroxysteroid (11-beta) dehydrogenase 2 1,92 down KIF13B kinesin family member 13B 2,13 up
HSD17B14 hydroxysteroid (17-beta) dehydrogenase 14 2,14 down KIF17 kinesin family member 17 1,85 down
HSDL1 hydroxysteroid dehydrogenase like 1 1,70 down KIF1C kinesin family member 1C 1,98 up
HSF1 heat shock transcript ion factor 1 2,82 up KIF21A kinesin family member 21A 2,15 up
HSP90AA1
heat shock protein 90kDa alpha (cytosolic), class A member 
1
1,61 up KIRREL2 kin of IRRE like 2 (Drosophila) 2,27 down
HSP90AB1
heat shock protein 90kDa alpha (cytosolic), class B member 
1
1,81 up KLF1 Kruppel-like factor 1 (erythroid) 2,69 down
HSPA12B heat shock 70kD protein 12B 2,41 down KLF16 Kruppel-like factor 16 1,94 up
HSPA5
heat shock 70kDa protein 5 (glucose-regulated protein, 
78kDa)
1,76 up KLF9 Kruppel-like factor 9 1,67 up
HSPA6 heat shock 70kDa protein 6 (HSP70B') 1,68 down KLHDC7B kelch domain containing 7B 2,01 down
HSPA8 heat shock 70kDa protein 8 1,89 up KLHL15 kelch-like family member 15 1,57 down
HSPA9 heat shock 70kDa protein 9 (mortalin) 1,55 up KLHL18 kelch-like family member 18 1,71 up
HSPB2 heat shock 27kDa protein 2 2,04 down KLHL23 kelch-like family member 23 1,79 down
HSPB9 heat shock protein, alpha-crystallin-related, B9 1,87 up KLHL8 kelch-like family member 8 1,54 up
HTR1E
5-hydroxytryptamine (serotonin) receptor 1E, G protein-
coupled
1,54 down KLK10 kallikrein-related pept idase 10 1,81 down
HTR3E 5-hydroxytryptamine (serotonin) receptor 3E, ionotropic 1,89 up KLK11 kallikrein-related pept idase 11 1,88 up
HUWE1
HECT, UBA and WWE domain containing 1, E3 ubiquit in 
protein ligase
1,51 up KLK12 kallikrein-related pept idase 12 1,96 up
IBA57 IBA57, iron-sulfur cluster assembly homolog (S. cerevisiae) 2,14 down KLK15 kallikrein-related pept idase 15 1,66 down
IBTK inhibitor of  Bruton agammaglobulinemia tyrosine kinase 1,68 up KLK2 kallikrein-related pept idase 2 1,60 down
ICAM 5 intercellular adhesion molecule 5, telencephalin 1,86 up KLK7 kallikrein-related pept idase 7 2,56 up
IDE insulin-degrading enzyme 1,84 up KLKB1 kallikrein B, plasma (Fletcher factor) 1 1,72 down
IDH3A isocitrate dehydrogenase 3 (NAD+) alpha 1,70 down KM T2A lysine (K)-specif ic methyltransferase 2A 1,64 up
IDH3B isocitrate dehydrogenase 3 (NAD+) beta 2,19 down KM T2C lysine (K)-specif ic methyltransferase 2C 1,53 up
IDI2 isopentenyl-diphosphate delta isomerase 2 1,59 up KM T2D lysine (K)-specif ic methyltransferase 2D 1,61 down
IDI2-AS1 IDI2 ant isense RNA 1 1,78 down KM T2E lysine (K)-specif ic methyltransferase 2E 2,00 up
IDO1 indoleamine 2,3-dioxygenase 1 1,60 up KREM EN2 kringle containing transmembrane protein 2 1,78 down
IDS iduronate 2-sulfatase 1,87 up KRR1
KRR1, small subunit  (SSU) processome component, 
homolog (yeast)
1,53 up
IER5L immediate early response 5-like 1,60 down KRT16 kerat in 16 2,78 up
IFI27 interferon, alpha-inducible protein 27 2,11 up KRT18P12 kerat in 18 pseudogene 12 2,46 down
IFI30 interferon, gamma-inducible protein 30 2,44 up KRT24 kerat in 24 1,50 down
IFT172 intraf lagellar t ransport  172 homolog (Chlamydomonas) 1,98 up KRT6C kerat in 6C 2,50 up
IGF1 insulin-like growth factor 1 (somatomedin C) 2,02 down KRT8P10 kerat in 8 pseudogene 10 2,13 up
IGF2BP1 insulin-like growth factor 2 mRNA binding protein 1 1,51 down KSR1 kinase suppressor of ras 1 1,86 down
IGF2BP2 insulin-like growth factor 2 mRNA binding protein 2 1,73 down KYNU kynureninase 1,64 up
IGFALS insulin-like growth factor binding protein, acid labile subunit 1,69 down L1CAM L1 cell adhesion molecule 1,90 down
IGFBP7 insulin-like growth factor binding protein 7 1,82 up L3M BTL4 l(3)mbt-like 4 (Drosophila) 1,50 down
IGFLR1 IGF-like family receptor 1 2,23 down LAM A1 laminin, alpha 1 1,56 down
IGHA1 immunoglobulin heavy constant alpha 1 1,52 down LAM A2 laminin, alpha 2 1,63 down
IGKC immunoglobulin kappa constant 1,79 down LAM A3 laminin, alpha 3 2,34 up
IGLL1 immunoglobulin lambda-like polypept ide 1 1,65 down LAM A5 laminin, alpha 5 2,81 down
IL10RA interleukin 10 receptor, alpha 1,76 down LAM B1 laminin, beta 1 1,66 up
IL16 interleukin 16 1,63 up LAM C3 laminin, gamma 3 1,61 down
IL17A interleukin 17A 1,60 down LAM P2 lysosomal-associated membrane protein 2 1,81 up
IL1R2 interleukin 1 receptor, type II 1,52 down LARP1B La ribonucleoprotein domain family, member 1B 1,68 up
IL1R2 interleukin 1 receptor, type II 1,88 up LARP4 La ribonucleoprotein domain family, member 4 2,00 up
IL2RA interleukin 2 receptor, alpha 1,61 down LATS2 large tumor suppressor kinase 2 1,83 up
ILF3 interleukin enhancer binding factor 3, 90kDa 2,00 up LBH limb bud and heart  development 3,42 down
IM PA1 inositol(myo)-1(or 4)-monophosphatase 1 1,60 down LBX1 ladybird homeobox 1 2,62 up
IM PA2 inositol(myo)-1(or 4)-monophosphatase 2 2,23 up LCN6 lipocalin 6 1,78 down
INO80 INO80 complex subunit 1,58 up LDLR low density lipoprotein receptor 1,63 up
INPP5D inositol polyphosphate-5-phosphatase, 145kDa 1,52 down LENG1 leukocyte receptor cluster (LRC) member 1 1,75 down
INPP5E inositol polyphosphate-5-phosphatase, 72 kDa 1,73 up LEPREL1 leprecan-like 1 1,73 up
INTS12 integrator complex subunit  12 1,68 up LETM D1 LETM 1 domain containing 1 1,84 up
INTS4L1 integrator complex subunit  4-like 1 1,74 up LFNG
LFNG O-fucosylpept ide 3-beta-N-
acetylglucosaminyltransferase
3,80 down
IQCD IQ motif  containing D 1,65 up LGALS9 lect in, galactoside-binding, soluble, 9 2,74 down
IQCH IQ motif  containing H 1,63 down LGALSL lect in, galactoside-binding-like 2,03 up
IQSEC3 IQ motif  and Sec7 domain 3 1,52 down LHB luteinizing hormone beta polypept ide 1,69 down
IRF1 interferon regulatory factor 1 1,74 down LHFPL1 lipoma HM GIC fusion partner-like 1 1,61 down
IRF2BP2 interferon regulatory factor 2 binding protein 2 1,65 up LIG1 ligase I, DNA, ATP-dependent 1,71 up
IRF7 interferon regulatory factor 7 1,80 down LILRA3
leukocyte immunoglobulin-like receptor, subfamily A 
(without TM  domain), member 3
1,63 down
IRS2 insulin receptor substrate 2 1,63 up LILRA4
leukocyte immunoglobulin-like receptor, subfamily A 
(with TM  domain), member 4
1,91 down
IRX3 iroquois homeobox 3 2,47 down LILRA5
leukocyte immunoglobulin-like receptor, subfamily A 
(with TM  domain), member 5
1,76 down
IRX4 iroquois homeobox 4 2,08 up LIM E1 Lck interact ing transmembrane adaptor 1 2,53 down
ISYNA1 inositol-3-phosphate synthase 1 1,58 down LIN7C lin-7 homolog C (C. elegans) 1,53 down
ITFG1 integrin alpha FG-GAP repeat containing 1 1,96 up LINC00094 long intergenic non-protein coding RNA 94 2,15 up
ITGA3
integrin, alpha 3 (ant igen CD49C, alpha 3 subunit  of  VLA-3 
receptor)
1,54 down LINC00176 long intergenic non-protein coding RNA 176 1,75 down
ITGAM
integrin, alpha M  (complement component 3 receptor 3 
subunit)
1,64 down LINC00313 long intergenic non-protein coding RNA 313 1,91 down
ITGB5 integrin, beta 5 2,26 up LINC00482 long intergenic non-protein coding RNA 482 1,57 down
ITM 2B integral membrane protein 2B 1,83 up LINC00652 long intergenic non-protein coding RNA 652 1,66 up
ITPK1 inositol-tetrakisphosphate 1-kinase 1,50 down LINC00905 long intergenic non-protein coding RNA 905 1,55 down
ITPK1 inositol-tetrakisphosphate 1-kinase 1,61 up LINC01101 long intergenic non-protein coding RNA 1101 1,68 down
ITPKB inositol-t risphosphate 3-kinase B 2,35 up LINC01106 long intergenic non-protein coding RNA 1106 2,34 down
ITPR3 inositol 1,4,5-trisphosphate receptor, type 3 1,81 up LIPH lipase, member H 1,53 up
ITPRIP inositol 1,4,5-trisphosphate receptor interact ing protein 2,23 up LM BRD2 LM BR1 domain containing 2 1,56 up
ITSN2 intersect in 2 1,63 up LM F2 lipase maturat ion factor 2 1,65 down
JADE2 jade family PHD f inger 2 1,99 down LM X1B LIM  homeobox transcript ion factor 1, beta 1,54 down
JAK3 Janus kinase 3 1,80 down LOXL3 lysyl oxidase-like 3 1,79 down
JARID2 jumonji, AT rich interact ive domain 2 2,13 up LPHN3 latrophilin 3 1,56 up
JDP2 Jun dimerizat ion protein 2 1,63 up LRFN1
leucine rich repeat and f ibronect in type III domain 
containing 1
1,95 up
KALRN kalirin, RhoGEF kinase 1,88 up LRFN3
leucine rich repeat and f ibronect in type III domain 
containing 3
1,65 down
KANK1 KN motif  and ankyrin repeat domains 1 2,34 up LRIT1
leucine-rich repeat, immunoglobulin-like and 
transmembrane domains 1
1,95 down
KCNC4
potassium voltage-gated channel, Shaw-related subfamily, 
member 4
2,11 up LRP10 low density lipoprotein receptor-related protein 10 1,74 down
KCND2
potassium voltage-gated channel, Shal-related subfamily, 
member 2
1,54 down LRP6 low density lipoprotein receptor-related protein 6 1,66 down
KCNG1 potassium voltage-gated channel, subfamily G, member 1 1,68 down LRPAP1
low density lipoprotein receptor-related protein 
associated protein 1
1,52 down
KCNH2
potassium voltage-gated channel, subfamily H (eag-related), 
member 2
2,99 down LRRC1 leucine rich repeat containing 1 1,56 up
KCNH6
potassium voltage-gated channel, subfamily H (eag-related), 
member 6
2,56 down LRRC4C leucine rich repeat containing 4C 1,52 down
KCNJ5 potassium inwardly-rect ifying channel, subfamily J, member 5 1,80 up LRRC61 leucine rich repeat containing 61 2,02 down
KCNK3 potassium channel, subfamily K, member 3 3,74 down LRRC73 leucine rich repeat containing 73 1,54 down
KCNN2
potassium intermediate/small conductance calcium-act ivated 
channel, subfamily N, member 2
1,89 up LRRN4 leucine rich repeat neuronal 4 1,57 down
KCNQ4
potassium voltage-gated channel, KQT-like subfamily, 
member 4
2,40 down LRSAM 1 leucine rich repeat and sterile alpha motif  containing 1 1,74 down
KCTD12 potassium channel tetramerizat ion domain containing 12 1,52 down LRTOM T
leucine rich transmembrane and O-methyltransferase 
domain containing
1,66 up
KCTD17 potassium channel tetramerizat ion domain containing 17 1,96 down LSM 12 LSM 12 homolog (S. cerevisiae) 1,89 up
KIAA0101 KIAA0101 1,82 down LSP1 lymphocyte-specif ic protein 1 1,93 down  
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LTB4R2 leukotriene B4 receptor 2 3,33 down M TRF1L mitochondrial t ranslat ional release factor 1-like 1,57 down
LTBP2 latent transforming growth factor beta binding protein 2 1,87 down M UC17 mucin 17, cell surface associated 1,57 up
LTBP4 latent transforming growth factor beta binding protein 4 1,58 down M UC3A mucin 3A, cell surface associated 2,73 down
LTC4S leukotriene C4 synthase 1,87 down M UC5B mucin 5B, oligomeric mucus/gel-forming 2,36 down
LTK leukocyte receptor tyrosine kinase 1,95 down M USK muscle, skeletal, receptor tyrosine kinase 1,63 down
LUZP1 leucine zipper protein 1 1,98 down M UTYH mutY homolog 1,53 down
LY6H lymphocyte ant igen 6 complex, locus H 2,20 down M VP major vault  protein 1,95 down
LY6K lymphocyte ant igen 6 complex, locus K 1,58 down M XD1 M AX dimerizat ion protein 1 1,61 up
LYRM 2 LYR motif  containing 2 1,71 up M XRA5 matrix-remodelling associated 5 1,91 up
LYZ lysozyme 1,68 down M YBL1
v-myb avian myeloblastosis viral oncogene homolog-
like 1
1,66 down
LZIC leucine zipper and CTNNBIP1 domain containing 1,72 up M YBPH myosin binding protein H 1,67 down
M ADD M AP-kinase act ivat ing death domain 1,88 down M YD88 myeloid dif ferent iat ion primary response 88 1,67 down
M AFG
v-maf avian musculoaponeurot ic f ibrosarcoma oncogene 
homolog G
2,01 down M YF5 myogenic factor 5 1,57 down
M AGEA11 melanoma ant igen family A, 11 1,50 down M YH15 myosin, heavy chain 15 1,59 down
M AGEH1 melanoma ant igen family H, 1 2,02 up M YL3 myosin, light chain 3, alkali; ventricular, skeletal, slow 1,70 up
M AGIX M AGI family member, X-linked 1,59 up M YL9 myosin, light chain 9, regulatory 1,63 up
M AGOHB mago-nashi homolog B (Drosophila) 2,00 up M YLK myosin light chain kinase 1,69 up
M ALAT1
metastasis associated lung adenocarcinoma transcript  1 (non-
protein coding)
2,71 up M YO1A myosin IA 1,51 down
M AM DC4 M AM  domain containing 4 2,54 down M YO1C myosin IC 1,88 up
M AN2A2 mannosidase, alpha, class 2A, member 2 1,52 down M YO6 myosin VI 1,99 up
M AP2K7 mitogen-act ivated protein kinase kinase 7 1,99 down M YOF myoferlin 1,62 up
M AP3K11 mitogen-act ivated protein kinase kinase kinase 11 1,88 down NAA38 N(alpha)-acetylt ransferase 38, NatC auxiliary subunit 1,71 up
M AP3K6 mitogen-act ivated protein kinase kinase kinase 6 1,92 up NAA38 N(alpha)-acetylt ransferase 38, NatC auxiliary subunit 1,62 up
M AP4K1 mitogen-act ivated protein kinase kinase kinase kinase 1 1,59 up NADSYN1 NAD synthetase 1 1,89 up
M APK15 mitogen-act ivated protein kinase 15 1,90 up NAGPA
N-acetylglucosamine-1-phosphodiester alpha-N-
acetylglucosaminidase
1,55 down
M APK8IP1 mitogen-act ivated protein kinase 8 interact ing protein 1 1,72 up NAGS N-acetylglutamate synthase 2,00 up
M APK8IP3 mitogen-act ivated protein kinase 8 interact ing protein 3 1,99 down NANOS3 nanos homolog 3 (Drosophila) 1,89 up
M APRE2 microtubule-associated protein, RP/EB family, member 2 1,50 up NAP1L3 nucleosome assembly protein 1-like 3 1,66 down
M ARCKS myristoylated alanine-rich protein kinase C substrate 2,53 up NAPRT1
nicot inate phosphoribosyltransferase domain 
containing 1
3,64 down
M ARCO macrophage receptor with collagenous structure 1,64 down NAPRT1
nicot inate phosphoribosyltransferase domain 
containing 1
1,51 down
M ARK2 M AP/microtubule aff inity-regulat ing kinase 2 2,03 up NAPSA napsin A aspart ic pept idase 2,46 down
M ARK3 M AP/microtubule aff inity-regulat ing kinase 3 1,71 up NBL1 neuroblastoma 1, DAN family BM P antagonist 1,82 down
M ARS methionyl-tRNA synthetase 1,96 up NBPF14 neuroblastoma breakpoint family, member 14 2,49 up
M AT1A methionine adenosyltransferase I, alpha 3,73 down NBPF15 neuroblastoma breakpoint family, member 15 1,53 up
M AT2B methionine adenosyltransferase II, beta 1,73 up NBPF3 neuroblastoma breakpoint family, member 3 3,52 up
M ATR3 matrin 3 1,79 up NCKIPSD NCK interact ing protein with SH3 domain 1,51 down
M AU2 M AU2 sister chromatid cohesion factor 2,24 up NCL nucleolin 1,72 up
M AX M YC associated factor X 1,75 up NCOR1 nuclear receptor corepressor 1 1,79 up
M AZ
M YC-associated zinc f inger protein (purine-binding 
transcript ion factor)
1,52 down NDC1 NDC1 transmembrane nucleoporin 1,63 up
M B myoglobin 1,82 down NDEL1 nudE neurodevelopment protein 1-like 1 1,77 up
M BL1P mannose-binding lect in (protein A) 1, pseudogene 1,79 down NDRG2 NDRG family member 2 1,58 up
M BOAT2 membrane bound O-acyltransferase domain containing 2 1,79 up NDST1
N-deacetylase/N-sulfotransferase (heparan 
glucosaminyl) 1
1,83 down
M BTPS1 membrane-bound transcript ion factor pept idase, site 1 1,55 down NDST2
N-deacetylase/N-sulfotransferase (heparan 
glucosaminyl) 2
2,29 down
M BTPS1 membrane-bound transcript ion factor pept idase, site 1 1,68 up NDUFA3
NADH dehydrogenase (ubiquinone) 1 alpha 
subcomplex, 3, 9kDa
1,94 down
M CFD2 mult iple coagulat ion factor def iciency 2 1,53 up NDUFA6
NADH dehydrogenase (ubiquinone) 1 alpha 
subcomplex, 6, 14kDa
1,64 up
M CM 2 minichromosome maintenance complex component 2 1,63 down NDUFAF2
NADH dehydrogenase (ubiquinone) complex I, 
assembly factor 2
1,58 up
M ECR mitochondrial t rans-2-enoyl-CoA reductase 1,59 down NDUFAF7
NADH dehydrogenase (ubiquinone) complex I, 
assembly factor 7
1,67 up
M ED13L mediator complex subunit  13-like 3,49 up NDUFB7
NADH dehydrogenase (ubiquinone) 1 beta 
subcomplex, 7, 18kDa
1,62 down
M EF2B myocyte enhancer factor 2B 1,86 down NDUFB9
NADH dehydrogenase (ubiquinone) 1 beta 
subcomplex, 9, 22kDa
2,42 up
M EF2C myocyte enhancer factor 2C 1,52 down NEAT1
nuclear paraspeckle assembly transcript  1 (non-
protein coding)
2,09 up
M EIS3 M eis homeobox 3 2,13 down NEB nebulin 1,56 down
M ESDC2 mesoderm development candidate 2 1,51 down NEFM neurof ilament, medium polypept ide 1,66 up
M ESP1 mesoderm posterior 1 homolog (mouse) 1,80 up NEK9 NIM A-related kinase 9 1,61 up
M ETAP2 methionyl aminopept idase 2 1,54 up NES nest in 1,85 up
M ETRN meteorin, glial cell dif ferent iat ion regulator 1,53 down NEU4 sialidase 4 1,68 down
M ETTL1 methyltransferase like 1 1,89 down NF1 neurof ibromin 1 1,68 down
M ETTL13 methyltransferase like 13 1,80 up NFIB nuclear factor I/B 1,69 up
M ETTL15 methyltransferase like 15 2,32 up NFKBIB
nuclear factor of kappa light polypept ide gene 
enhancer in B-cells inhibitor, beta
1,72 down
M ETTL18 methyltransferase like 18 1,56 down NFYC nuclear transcript ion factor Y, gamma 1,61 up
M ETTL9 methyltransferase like 9 1,54 up NHLH2 nescient helix loop helix 2 1,53 down
M FGE8 milk fat  globule-EGF factor 8 protein 1,51 down NIPAL2 NIPA-like domain containing 2 1,90 up
M FN1 mitofusin 1 2,67 up NIPBL Nipped-B homolog (Drosophila) 2,78 down
M FN1 mitofusin 1 1,95 up NIPBL Nipped-B homolog (Drosophila) 1,57 up
M FSD12 major facilitator superfamily domain containing 12 2,19 down NIT1 nitrilase 1 3,52 down
M FSD9 major facilitator superfamily domain containing 9 1,95 down NKAPP1 NFKB act ivat ing protein pseudogene 1 2,34 down
M ICALL2 M ICAL-like 2 2,09 up NLGN2 neuroligin 2 2,48 down
M IR22HG M IR22 host gene (non-protein coding) 2,77 down NLRP12 NLR family, pyrin domain containing 12 1,64 down
M KL1 megakaryoblast ic leukemia (translocat ion) 1 1,52 down NLRP2 NLR family, pyrin domain containing 2 1,55 down
M KRN1 makorin ring f inger protein 1 2,10 down NM B neuromedin B 1,97 up
M LLT1
myeloid/ lymphoid or mixed-lineage leukemia (trithorax 
homolog, Drosophila); t ranslocated to, 1
1,85 up NM T1 N-myristoyltransferase 1 1,79 up
M LLT10
myeloid/ lymphoid or mixed-lineage leukemia (trithorax 
homolog, Drosophila); t ranslocated to, 10
1,63 down NM UR2 neuromedin U receptor 2 1,58 up
M LXIPL M LX interact ing protein-like 2,92 down NOL6 nucleolar protein 6 (RNA-associated) 1,59 down
M M P27 matrix metallopept idase 27 1,54 down NOLC1 nucleolar and coiled-body phosphoprotein 1 1,57 up
M M S19 M M S19 nucleot ide excision repair homolog (S. cerevisiae) 1,86 up NOLC1 nucleolar and coiled-body phosphoprotein 1 1,56 up
M OB1A M OB kinase act ivator 1A 1,53 up NOP2 NOP2 nucleolar protein 1,79 up
M ON1A M ON1 secretory traf f icking family member A 1,50 down NOTCH2NL notch 2 N-terminal like 1,85 up
M ORC1 M ORC family CW-type zinc f inger 1 1,62 up NOTCH3 notch 3 1,85 down
M ORC2 M ORC family CW-type zinc f inger 2 1,57 up NOTCH4 notch 4 1,75 down
M PRIP myosin phosphatase Rho interact ing protein 1,62 up NOTCH4 notch 4 2,02 up
M PZL1 myelin protein zero-like 1 1,76 up NOV nephroblastoma overexpressed 1,52 up
M PZL2 myelin protein zero-like 2 2,05 up NOXA1 NADPH oxidase act ivator 1 2,04 down
M RFAP1 M orf4 family associated protein 1 1,66 up NOXO1 NADPH oxidase organizer 1 2,62 down
M RGPRX2 M AS-related GPR, member X2 1,58 down NPAS3 neuronal PAS domain protein 3 2,18 down
M RPL35 mitochondrial ribosomal protein L35 1,53 up NPCDR1 nasopharyngeal carcinoma, down-regulated 1 1,61 up
M RPL43 mitochondrial ribosomal protein L43 1,78 down NPDC1 neural proliferat ion, dif ferent iat ion and control, 1 1,60 down
M RPL9 mitochondrial ribosomal protein L9 2,22 up NPFFR2 neuropept ide FF receptor 2 1,82 up
M RPS15 mitochondrial ribosomal protein S15 1,65 up NPHP3 nephronophthisis 3 (adolescent) 2,22 up
M RPS6 mitochondrial ribosomal protein S6 1,80 up NPHS2 nephrosis 2, idiopathic, steroid-resistant (podocin) 1,93 up
M SANTD2 M yb/SANT-like DNA-binding domain containing 2 1,52 down NPTN neuroplast in 1,76 up
M SLN mesothelin 1,67 down NPW neuropept ide W 2,31 down
M SM B microseminoprotein, beta- 1,52 up NR1D1 nuclear receptor subfamily 1, group D, member 1 1,78 up
M T1M metallothionein 1M 2,04 up NR1H2 nuclear receptor subfamily 1, group H, member 2 4,46 down
M TERFD2 M TERF domain containing 2 1,76 up NR2C2 nuclear receptor subfamily 2, group C, member 2 1,65 up
M THFD1
methylenetetrahydrofolate dehydrogenase (NADP+ 
dependent) 1, methenyltetrahydrofolate cyclohydrolase, 
formyltetrahydrofolate synthetase
1,63 up NR2C2AP nuclear receptor 2C2-associated protein 2,89 up
M THFD1L
methylenetetrahydrofolate dehydrogenase (NADP+ 
dependent) 1-like
1,71 down NR4A2 nuclear receptor subfamily 4, group A, member 2 1,77 down
M TM R1 myotubularin related protein 1 1,55 up NRAP nebulin-related anchoring protein 1,54 down
M TM R11 myotubularin related protein 11 1,66 up NRIP3 nuclear receptor interact ing protein 3 1,57 up
M T-ND1 mitochondrially encoded NADH dehydrogenase 1 1,69 up NRL neural ret ina leucine zipper 1,75 down
M T-ND2 mitochondrially encoded NADH dehydrogenase 2 1,88 up NRSN2 neurensin 2 1,88 down
M TPN myotrophin 1,53 up NRTN neurturin 1,59 down  
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M TRF1L mitochondrial t ranslat ional release factor 1-like 1,57 down NSA2 NSA2 ribosome biogenesis homolog (S. cerevisiae) 1,66 up
M UC17 mucin 17, cell surface associated 1,57 up NSUN5P2 NOP2/Sun domain family, member 5 pseudogene 2 1,81 up
M UC3A mucin 3A, cell surface associated 2,73 down NT5DC3 5'-nucleot idase domain containing 3 1,54 down
M UC5B mucin 5B, oligomeric mucus/gel-forming 2,36 down NTN3 netrin 3 3,21 down
M USK muscle, skeletal, receptor tyrosine kinase 1,63 down NUAK1 NUAK family, SNF1-like kinase, 1 1,91 up
M UTYH mutY homolog 1,53 down NUCKS1
nuclear casein kinase and cyclin-dependent kinase 
substrate 1
2,04 up
M VP major vault  protein 1,95 down NUDC nudC nuclear distribut ion protein 1,70 down
M XD1 M AX dimerizat ion protein 1 1,61 up NUDT4
nudix (nucleoside diphosphate linked moiety X)-type 
motif  4
1,57 up
M XRA5 matrix-remodelling associated 5 1,91 up NUM BL numb homolog (Drosophila)-like 1,95 up
M YBL1 v-myb avian myeloblastosis viral oncogene homolog-like 1 1,66 down NUP205 nucleoporin 205kDa 1,72 up
M YBPH myosin binding protein H 1,67 down OBFC1
oligonucleot ide/oligosaccharide-binding fold 
containing 1
2,03 up
M YD88 myeloid dif ferent iat ion primary response 88 1,67 down OBP2A odorant binding protein 2A 1,56 down
M YF5 myogenic factor 5 1,57 down OCLM oculomedin 1,76 down
M YH15 myosin, heavy chain 15 1,59 down OFCC1 orofacial clef t  1 candidate 1 1,58 down
M YL3 myosin, light chain 3, alkali; ventricular, skeletal, slow 1,70 up OGFOD2
2-oxoglutarate and iron-dependent oxygenase 
domain containing 2
1,76 down
M YL9 myosin, light chain 9, regulatory 1,63 up OGG1 8-oxoguanine DNA glycosylase 1,56 up
M YLK myosin light chain kinase 1,69 up OLFM 1 olfactomedin 1 2,73 down
M YO1A myosin IA 1,51 down OPN1LW opsin 1 (cone pigments), long-wave-sensit ive 2,01 down
M YO1C myosin IC 1,88 up OPN1M W opsin 1 (cone pigments), medium-wave-sensit ive 2,62 down
M YO6 myosin VI 1,99 up OPTC opticin 1,50 up
M YOF myoferlin 1,62 up OR10G8 olfactory receptor, family 10, subfamily G, member 8 1,83 down
NAA38 N(alpha)-acetylt ransferase 38, NatC auxiliary subunit 1,71 up OR10H1 olfactory receptor, family 10, subfamily H, member 1 1,50 down
NAA38 N(alpha)-acetylt ransferase 38, NatC auxiliary subunit 1,62 up OR10H2 olfactory receptor, family 10, subfamily H, member 2 2,25 down
NADSYN1 NAD synthetase 1 1,89 up OR10P1 olfactory receptor, family 10, subfamily P, member 1 1,74 up
NAGPA
N-acetylglucosamine-1-phosphodiester alpha-N-
acetylglucosaminidase
1,55 down OR10T2 olfactory receptor, family 10, subfamily T, member 2 2,08 up
NAGS N-acetylglutamate synthase 2,00 up OR1D2 olfactory receptor, family 1, subfamily D, member 2 1,54 up
NANOS3 nanos homolog 3 (Drosophila) 1,89 up OR2V2 olfactory receptor, family 2, subfamily V, member 2 1,79 down
NAP1L3 nucleosome assembly protein 1-like 3 1,66 down OR4D5 olfactory receptor, family 4, subfamily D, member 5 1,60 down
NAPRT1 nicot inate phosphoribosyltransferase domain containing 1 3,64 down OR5P2 olfactory receptor, family 5, subfamily P, member 2 1,51 down
NAPRT1 nicot inate phosphoribosyltransferase domain containing 1 1,51 down OR7A5 olfactory receptor, family 7, subfamily A, member 5 1,56 down
NAPSA napsin A aspart ic pept idase 2,46 down OR7E13P
olfactory receptor, family 7, subfamily E, member 13 
pseudogene
1,63 up
NBL1 neuroblastoma 1, DAN family BM P antagonist 1,82 down OR7E24 olfactory receptor, family 7, subfamily E, member 24 2,27 up
NBPF14 neuroblastoma breakpoint family, member 14 2,49 up OR7G3 olfactory receptor, family 7, subfamily G, member 3 2,26 down
NBPF15 neuroblastoma breakpoint family, member 15 1,53 up ORAI1 ORAI calcium release-act ivated calcium modulator 1 2,06 up
NBPF3 neuroblastoma breakpoint family, member 3 3,52 up OS9
osteosarcoma amplif ied 9, endoplasmic ret iculum 
lect in
2,07 up
NCKIPSD NCK interact ing protein with SH3 domain 1,51 down OSBPL1A oxysterol binding protein-like 1A 1,93 up
NCL nucleolin 1,72 up OXA1L oxidase (cytochrome c) assembly 1-like 1,59 up
NCOR1 nuclear receptor corepressor 1 1,79 up P2RX4 purinergic receptor P2X, ligand-gated ion channel, 4 1,58 down
NDC1 NDC1 transmembrane nucleoporin 1,63 up P2RX5 purinergic receptor P2X, ligand-gated ion channel, 5 1,55 down
NDEL1 nudE neurodevelopment protein 1-like 1 1,77 up P2RY10 purinergic receptor P2Y, G-protein coupled, 10 1,53 down
NDRG2 NDRG family member 2 1,58 up P2RY4 pyrimidinergic receptor P2Y, G-protein coupled, 4 2,34 down
NDST1 N-deacetylase/N-sulfotransferase (heparan glucosaminyl) 1 1,83 down PA2G4 proliferat ion-associated 2G4, 38kDa 2,58 up
NDST2 N-deacetylase/N-sulfotransferase (heparan glucosaminyl) 2 2,29 down PABPC3 poly(A) binding protein, cytoplasmic 3 1,87 up
NDUFA3
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 3, 
9kDa
1,94 down PABPN1 poly(A) binding protein, nuclear 1 2,25 up
NDUFA6
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 6, 
14kDa
1,64 up PADI4 pept idyl arginine deiminase, type IV 1,63 up
NDUFAF2
NADH dehydrogenase (ubiquinone) complex I, assembly 
factor 2
1,58 up PAEP progestagen-associated endometrial protein 1,51 up
NDUFAF7
NADH dehydrogenase (ubiquinone) complex I, assembly 
factor 7
1,67 up PAFAH2 platelet-act ivat ing factor acetylhydrolase 2, 40kDa 1,53 down
NDUFB7
NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 7, 
18kDa
1,62 down PAIP2 poly(A) binding protein interact ing protein 2 1,74 up
NDUFB9
NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 9, 
22kDa
2,42 up PAK2 p21 protein (Cdc42/Rac)-act ivated kinase 2 1,87 up
NEAT1
nuclear paraspeckle assembly transcript  1 (non-protein 
coding)
2,09 up PAK3 p21 protein (Cdc42/Rac)-act ivated kinase 3 1,99 down
NEB nebulin 1,56 down PAK4 p21 protein (Cdc42/Rac)-act ivated kinase 4 3,46 down
NEFM neurof ilament, medium polypept ide 1,66 up PAK7 p21 protein (Cdc42/Rac)-act ivated kinase 7 1,54 down
NEK9 NIM A-related kinase 9 1,61 up PANK3 pantothenate kinase 3 1,62 up
NES nest in 1,85 up PANX2 pannexin 2 2,05 down
NEU4 sialidase 4 1,68 down PAPOLA poly(A) polymerase alpha 2,19 up
NF1 neurof ibromin 1 1,68 down PAPPA pregnancy-associated plasma protein A, pappalysin 1 1,60 up
NFIB nuclear factor I/B 1,69 up PAPSS1 3'-phosphoadenosine 5'-phosphosulfate synthase 1 1,59 up
NFKBIB
nuclear factor of kappa light polypept ide gene enhancer in B-
cells inhibitor, beta
1,72 down PARP10 poly (ADP-ribose) polymerase family, member 10 2,82 down
NFYC nuclear transcript ion factor Y, gamma 1,61 up PARP10 poly (ADP-ribose) polymerase family, member 10 1,90 up
NHLH2 nescient helix loop helix 2 1,53 down PASK PAS domain containing serine/threonine kinase 1,56 up
NIPAL2 NIPA-like domain containing 2 1,90 up PATZ1 POZ (BTB) and AT hook containing zinc f inger 1 1,63 down
NIPBL Nipped-B homolog (Drosophila) 2,78 down PAX4 paired box 4 1,80 up
NIPBL Nipped-B homolog (Drosophila) 1,57 up PBX2 pre-B-cell leukemia homeobox 2 1,55 up
NIT1 nitrilase 1 3,52 down PCAT4
prostate cancer associated transcript  4 (non-protein 
coding)
1,52 down
NKAPP1 NFKB act ivat ing protein pseudogene 1 2,34 down PCDH15 protocadherin-related 15 1,59 down
NLGN2 neuroligin 2 2,48 down PCDHA1 protocadherin alpha 1 1,50 down
NLRP12 NLR family, pyrin domain containing 12 1,64 down PCDHA5 protocadherin alpha 5 1,69 down
NLRP2 NLR family, pyrin domain containing 2 1,55 down PCDHB7 protocadherin beta 7 1,64 up
NM B neuromedin B 1,97 up PCDHB9 protocadherin beta 9 1,59 up
NM T1 N-myristoyltransferase 1 1,79 up PCDHGC4 protocadherin gamma subfamily C, 4 1,57 down
NM UR2 neuromedin U receptor 2 1,58 up PCGF1 polycomb group ring f inger 1 1,56 up
NOL6 nucleolar protein 6 (RNA-associated) 1,59 down PCGF2 polycomb group ring f inger 2 1,82 down
NOLC1 nucleolar and coiled-body phosphoprotein 1 1,57 up PCSK1N proprotein convertase subt ilisin/kexin type 1 inhibitor 2,21 down
NOLC1 nucleolar and coiled-body phosphoprotein 1 1,56 up PCSK4 proprotein convertase subt ilisin/kexin type 4 2,49 down
NOP2 NOP2 nucleolar protein 1,79 up PCSK5 proprotein convertase subt ilisin/kexin type 5 1,54 up
NOTCH2NL notch 2 N-terminal like 1,85 up PCSK7 proprotein convertase subt ilisin/kexin type 7 1,69 up
NOTCH3 notch 3 1,85 down PDE2A phosphodiesterase 2A, cGM P-st imulated 1,52 down
NOTCH4 notch 4 1,75 down PDE6B phosphodiesterase 6B, cGM P-specif ic, rod, beta 1,57 down
NOTCH4 notch 4 2,02 up PDIA2 protein disulf ide isomerase family A, member 2 1,58 down
NOV nephroblastoma overexpressed 1,52 up PDIA3 protein disulf ide isomerase family A, member 3 2,22 up
NOXA1 NADPH oxidase act ivator 1 2,04 down PDIA3 protein disulf ide isomerase family A, member 3 1,85 up
NOXO1 NADPH oxidase organizer 1 2,62 down PDK4 pyruvate dehydrogenase kinase, isozyme 4 1,66 down
NPAS3 neuronal PAS domain protein 3 2,18 down PDLIM 5 PDZ and LIM  domain 5 1,73 up
NPCDR1 nasopharyngeal carcinoma, down-regulated 1 1,61 up PDS5B
PDS5, regulator of cohesion maintenance, homolog B 
(S. cerevisiae)
2,11 up
NPDC1 neural proliferat ion, dif ferent iat ion and control, 1 1,60 down PDZD2 PDZ domain containing 2 1,65 up
NPFFR2 neuropept ide FF receptor 2 1,82 up PDZD7 PDZ domain containing 7 1,89 up
NPHP3 nephronophthisis 3 (adolescent) 2,22 up PDZD8 PDZ domain containing 8 1,60 up
NPHS2 nephrosis 2, idiopathic, steroid-resistant (podocin) 1,93 up PEAK1 pseudopodium-enriched atypical kinase 1 1,67 up
NPTN neuroplast in 1,76 up PELI3 pellino E3 ubiquit in protein ligase family member 3 1,66 down
NPW neuropept ide W 2,31 down PEPD peptidase D 2,24 up
NR1D1 nuclear receptor subfamily 1, group D, member 1 1,78 up PER2 period circadian clock 2 1,55 up
NR1H2 nuclear receptor subfamily 1, group H, member 2 4,46 down PEX10 peroxisomal biogenesis factor 10 1,90 down
NR2C2 nuclear receptor subfamily 2, group C, member 2 1,65 up PEX11A peroxisomal biogenesis factor 11 alpha 1,56 down
NR2C2AP nuclear receptor 2C2-associated protein 2,89 up PEX19 peroxisomal biogenesis factor 19 1,61 up
NR4A2 nuclear receptor subfamily 4, group A, member 2 1,77 down PEX2 peroxisomal biogenesis factor 2 1,52 up
NRAP nebulin-related anchoring protein 1,54 down PEX5 peroxisomal biogenesis factor 5 1,77 down
NRIP3 nuclear receptor interact ing protein 3 1,57 up PFKFB1
6-phosphofructo-2-kinase/fructose-2,6-
biphosphatase 1
1,69 down
NRL neural ret ina leucine zipper 1,75 down PFKL phosphofructokinase, liver 2,51 down
NRSN2 neurensin 2 1,88 down PFN1P2 prof ilin 1 pseudogene 2 1,58 up
NRTN neurturin 1,59 down PGC progastricsin (pepsinogen C) 1,51 down  
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PGD phosphogluconate dehydrogenase 2,49 up PRR7 proline rich 7 (synapt ic) 1,87 up
PGM 5 phosphoglucomutase 5 2,61 down PRRC1 proline-rich coiled-coil 1 1,64 up
PGRM C2 progesterone receptor membrane component 2 2,68 up PRRG1 proline rich Gla (G-carboxyglutamic acid) 1 1,56 up
PHACTR3 phosphatase and act in regulator 3 1,54 down PRRG2 proline rich Gla (G-carboxyglutamic acid) 2 2,24 down
PHF2 PHD f inger protein 2 1,61 up PRSS42 protease, serine, 42 1,63 up
PHF20 PHD f inger protein 20 1,51 down PRSS53 protease, serine, 53 1,60 up
PHIP pleckstrin homology domain interact ing protein 1,62 up PSD3 pleckstrin and Sec7 domain containing 3 1,56 up
PHKA2 phosphorylase kinase, alpha 2 (liver) 1,61 up PSM C2
proteasome (prosome, macropain) 26S subunit , 
ATPase, 2
1,87 up
PHKB phosphorylase kinase, beta 1,65 up PSM C5
proteasome (prosome, macropain) 26S subunit , 
ATPase, 5
1,51 up
PHLDA1 pleckstrin homology-like domain, family A, member 1 1,71 down PSM G2
proteasome (prosome, macropain) assembly 
chaperone 2
1,88 up
PIAS2 protein inhibitor of  act ivated STAT, 2 1,54 up PSTPIP1
proline-serine-threonine phosphatase interact ing 
protein 1
3,00 down
PID1 phosphotyrosine interact ion domain containing 1 1,51 up PTAR1
protein prenyltransferase alpha subunit  repeat 
containing 1
1,85 up
PIGG phosphat idylinositol glycan anchor biosynthesis, class G 1,58 up PTBP3 polypyrimidine tract binding protein 3 2,92 up
PIGG phosphat idylinositol glycan anchor biosynthesis, class G 1,54 up PTCH2 patched 2 1,98 down
PIGT phosphat idylinositol glycan anchor biosynthesis, class T 1,85 up PTCRA pre T-cell ant igen receptor alpha 1,73 down
PIGY phosphat idylinositol glycan anchor biosynthesis, class Y 1,66 up PTDSS2 phosphat idylserine synthase 2 1,73 up
PIK3CD
phosphat idylinositol-4,5-bisphosphate 3-kinase, catalyt ic 
subunit  delta
1,65 down PTEN phosphatase and tensin homolog 1,79 up
PIK3IP1 phosphoinosit ide-3-kinase interact ing protein 1 1,53 down PTGDR prostaglandin D2 receptor (DP) 2,01 up
PIK3IP1 phosphoinosit ide-3-kinase interact ing protein 1 1,55 up PTGER4 prostaglandin E receptor 4 (subtype EP4) 1,53 up
PIN1P1
peptidylprolyl cis/ trans isomerase, NIM A-interact ing 1 
pseudogene 1
1,94 down PTGES3 prostaglandin E synthase 3 (cytosolic) 1,52 up
PIN1P1
peptidylprolyl cis/ trans isomerase, NIM A-interact ing 1 
pseudogene 1
1,80 up PTM A prothymosin, alpha 1,94 up
PIP5K1A phosphat idylinositol-4-phosphate 5-kinase, type I, alpha 1,51 up PTM A prothymosin, alpha 1,67 up
PITPNC1 phosphat idylinositol t ransfer protein, cytoplasmic 1 1,62 down PTN pleiotrophin 2,19 up
PKD1L2 polycyst ic kidney disease 1-like 2 1,61 down PTPDC1 protein tyrosine phosphatase domain containing 1 1,60 down
PKD2L1 polycyst ic kidney disease 2-like 1 1,61 down PTPLAD2
protein tyrosine phosphatase-like A domain 
containing 2
1,55 down
PKD2L2 polycyst ic kidney disease 2-like 2 1,61 up PTPN11 protein tyrosine phosphatase, non-receptor type 11 1,59 up
PKP2 plakophilin 2 1,70 up PTPN2 protein tyrosine phosphatase, non-receptor type 2 1,69 up
PLA2G16 phospholipase A2, group XVI 1,74 down PTPN5
protein tyrosine phosphatase, non-receptor type 5 
(striatum-enriched)
1,52 down
PLA2G2F phospholipase A2, group IIF 1,56 down PTPRH protein tyrosine phosphatase, receptor type, H 1,58 down
PLAC1 placenta-specif ic 1 1,87 up PUM 2 pumilio RNA-binding family member 2 1,84 up
PLCB2 phospholipase C, beta 2 1,61 up PVALB parvalbumin 1,99 down
PLD1 phospholipase D1, phosphat idylcholine-specif ic 1,99 up PVRL2
poliovirus receptor-related 2 (herpesvirus entry 
mediator B)
1,88 up
PLEKHA6 pleckstrin homology domain containing, family A member 6 2,51 down PYCRL pyrroline-5-carboxylate reductase-like 1,68 up
PLEKHF1
pleckstrin homology domain containing, family F (with FYVE 
domain) member 1
1,87 down PYDC1 PYD (pyrin domain) containing 1 1,51 up
PLEKHG4B
pleckstrin homology domain containing, family G (with 
RhoGef domain) member 4B
1,66 down PYGB phosphorylase, glycogen; brain 1,98 down
PLEKHM 1P
pleckstrin homology domain containing, family M  (with RUN 
domain) member 1 pseudogene
2,54 down PYGO1 pygopus family PHD f inger 1 1,58 up
PLIN3 perilipin 3 1,75 up QPRT quinolinate phosphoribosyltransferase 2,03 up
PLIN4 perilipin 4 1,53 down QSOX2 quiescin Q6 sulfhydryl oxidase 2 1,63 down
PLK2 polo-like kinase 2 2,00 up R3HDM 2 R3H domain containing 2 1,97 up
PLOD3 procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3 2,50 down RAB22A RAB22A, member RAS oncogene family 2,12 up
PLXDC2 plexin domain containing 2 1,85 up RAB2A RAB2A, member RAS oncogene family 1,60 up
PLXNA4 plexin A4 1,64 up RAB36 RAB36, member RAS oncogene family 1,62 down
PLXND1 plexin D1 1,74 down RAB3D RAB3D, member RAS oncogene family 1,75 up
PM 20D1 peptidase M 20 domain containing 1 1,51 down RAB42 RAB42, member RAS oncogene family 1,75 down
PM EPA1 prostate transmembrane protein, androgen induced 1 1,86 down RAB43 RAB43, member RAS oncogene family 1,58 down
PM FBP1 polyamine modulated factor 1 binding protein 1 1,69 up RAB4B RAB4B, member RAS oncogene family 1,50 down
PM P2 peripheral myelin protein 2 2,05 down RAB7B RAB7B, member RAS oncogene family 1,79 up
PM P22 peripheral myelin protein 22 2,29 up RABGAP1 RAB GTPase act ivat ing protein 1 1,52 up
PNKD paroxysmal nonkinesigenic dyskinesia 1,59 up RABGEF1 RAB guanine nucleot ide exchange factor (GEF) 1 1,55 up
PNM A3 paraneoplast ic M a ant igen 3 1,60 down RABIF RAB interact ing factor 1,80 up
PNM A6A paraneoplast ic M a ant igen family member 6A 1,71 down RABL6 RAB, member RAS oncogene family-like 6 2,49 down
PNM AL1 paraneoplast ic M a ant igen family-like 1 2,08 down RAD23B RAD23 homolog B (S. cerevisiae) 1,53 up
PNPLA8 patat in-like phospholipase domain containing 8 1,68 up RAD51C RAD51 paralog C 1,58 up
POC1A POC1 centriolar protein A 1,68 down RAI1 ret inoic acid induced 1 1,53 up
POLA1 polymerase (DNA directed), alpha 1, catalyt ic subunit 1,51 up RANBP2 RAN binding protein 2 1,58 up
POLD2 polymerase (DNA directed), delta 2, accessory subunit 1,55 down RANBP3 RAN binding protein 3 1,69 up
POLE2 polymerase (DNA directed), epsilon 2, accessory subunit 2,30 down RAPGEF1 Rap guanine nucleot ide exchange factor (GEF) 1 1,73 up
POLE3 polymerase (DNA directed), epsilon 3, accessory subunit 2,34 up RARRES2
ret inoic acid receptor responder (tazarotene induced) 
2
1,54 up
POLL polymerase (DNA directed), lambda 1,68 down RASGEF1A RasGEF domain family, member 1A 1,55 up
POLQ polymerase (DNA directed), theta 1,70 down RASGEF1C RasGEF domain family, member 1C 1,87 down
POLR1C polymerase (RNA) I polypept ide C, 30kDa 1,54 up RASGRP2
RAS guanyl releasing protein 2 (calcium and DAG-
regulated)
1,61 down
POLR2B polymerase (RNA) II (DNA directed) polypept ide B, 140kDa 1,81 up RASGRP4 RAS guanyl releasing protein 4 1,62 up
PON3 paraoxonase 3 2,10 up RAX2 ret ina and anterior neural fold homeobox 2 2,09 up
POU5F1 POU class 5 homeobox 1 1,51 up RBBP4 ret inoblastoma binding protein 4 3,09 up
PPAN peter pan homolog (Drosophila) 1,68 down RBM 15B RNA binding motif  protein 15B 1,74 up
PPCS phosphopantothenoylcysteine synthetase 1,56 up RBM 17 RNA binding motif  protein 17 2,20 up
PPFIA1
protein tyrosine phosphatase, receptor type, f  polypept ide 
(PTPRF), interact ing protein (liprin), alpha 1
1,57 down RBM 17 RNA binding motif  protein 17 1,57 up
PPFIA4
protein tyrosine phosphatase, receptor type, f  polypept ide 
(PTPRF), interact ing protein (liprin), alpha 4
1,66 down RBM 28 RNA binding motif  protein 28 1,76 down
PPIA pept idylprolyl isomerase A (cyclophilin A) 1,59 up RBM 39 RNA binding motif  protein 39 1,62 up
PPIAL4A peptidylprolyl isomerase A (cyclophilin A)-like 4A 2,05 up RBM 41 RNA binding motif  protein 41 1,80 up
PPIAL4A peptidylprolyl isomerase A (cyclophilin A)-like 4A 1,96 up RBM X2 RNA binding motif  protein, X-linked 2 1,57 down
PPIAL4A peptidylprolyl isomerase A (cyclophilin A)-like 4A 1,90 up RCOR2 REST corepressor 2 2,27 up
PPIAL4A peptidylprolyl isomerase A (cyclophilin A)-like 4A 1,82 up RFESD Rieske (Fe-S) domain containing 1,52 down
PPOX protoporphyrinogen oxidase 1,97 down RFX2
regulatory factor X, 2 (inf luences HLA class II 
expression)
2,25 up
PPP1R35 protein phosphatase 1, regulatory subunit  35 1,73 up RFX7 regulatory factor X, 7 1,57 up
PPP1R3C protein phosphatase 1, regulatory subunit  3C 1,95 up RGAG4 retrotransposon gag domain containing 4 1,80 down
PPP1R3D protein phosphatase 1, regulatory subunit  3D 1,80 up RGCC regulator of cell cycle 1,53 up
PPP2CA protein phosphatase 2, catalyt ic subunit , alpha isozyme 1,55 up RGS19 regulator of G-protein signaling 19 2,02 down
PPP2CB protein phosphatase 2, catalyt ic subunit , beta isozyme 1,81 up RHBDD2 rhomboid domain containing 2 2,24 up
PPP2R2D protein phosphatase 2, regulatory subunit  B, delta 1,61 up RHBDL3 rhomboid, veinlet-like 3 (Drosophila) 2,07 up
PPP2R5D protein phosphatase 2, regulatory subunit  B', delta 1,53 down RHOA ras homolog family member A 1,93 up
PPP4R4 protein phosphatase 4, regulatory subunit  4 1,62 down RHOD ras homolog family member D 1,58 up
PPP6R2 protein phosphatase 6, regulatory subunit  2 1,54 down RHOT2 ras homolog family member T2 1,77 down
PPP6R3 protein phosphatase 6, regulatory subunit  3 1,57 down RHPN1 rhophilin, Rho GTPase binding protein 1 1,65 down
PPRC1
peroxisome proliferator-act ivated receptor gamma, 
coact ivator-related 1
1,91 up RHPN2 rhophilin, Rho GTPase binding protein 2 1,51 up
PRAF2 PRA1 domain family, member 2 1,60 down RLTPR
RGD motif , leucine rich repeats, t ropomodulin domain 
and proline-rich containing
1,97 down
PRAM 1 PM L-RARA regulated adaptor molecule 1 1,60 down RNF112 ring f inger protein 112 1,98 down
PRCD progressive rod-cone degenerat ion 1,72 up RNF113A ring f inger protein 113A 2,03 up
PRDM 11 PR domain containing 11 1,51 up RNF114 ring f inger protein 114 1,70 up
PRDM 8 PR domain containing 8 1,70 up RNF151 ring f inger protein 151 3,33 down
PRICKLE4 prickle homolog 4 (Drosophila) 1,65 down RNF152 ring f inger protein 152 1,66 up
PRKAA2 protein kinase, AM P-act ivated, alpha 2 catalyt ic subunit 1,52 down RNF216 ring f inger protein 216 1,51 up
PRKAG2
protein kinase, AM P-act ivated, gamma 2 non-catalyt ic 
subunit
1,95 up RNF39 ring f inger protein 39 2,59 up
PRKD3 protein kinase D3 1,60 up RNH1 ribonuclease/angiogenin inhibitor 1 2,15 down
PRKRA
protein kinase, interferon-inducible double stranded RNA 
dependent act ivator
1,54 up ROR2 receptor tyrosine kinase-like orphan receptor 2 1,74 down
PRLHR prolact in releasing hormone receptor 2,30 down RPAP1 RNA polymerase II associated protein 1 1,71 up
PRM T7 protein arginine methyltransferase 7 1,87 up RPIA ribose 5-phosphate isomerase A 1,61 up
PROM 1 prominin 1 1,54 down RPL10 ribosomal protein L10 2,01 down
PROP1 PROP paired-like homeobox 1 4,39 down RPL12 ribosomal protein L12 2,29 up
PRR5 proline rich 5 (renal) 1,70 up RPL17 ribosomal protein L17 2,00 up  
116 
 
RPL18 ribosomal protein L18 2,43 up SLC25A36
solute carrier family 25 (pyrimidine nucleot ide carrier 
), member 36
1,67 up
RPL21 ribosomal protein L21 2,46 up SLC25A47 solute carrier family 25, member 47 1,82 down
RPL21 ribosomal protein L21 2,01 up SLC25A52 solute carrier family 25, member 52 1,91 down
RPL21 ribosomal protein L21 1,83 up SLC2A4
solute carrier family 2 (facilitated glucose 
transporter), member 4
1,67 down
RPL21 ribosomal protein L21 1,58 up SLC2A4RG SLC2A4 regulator 1,92 down
RPL22 ribosomal protein L22 1,55 up SLC2A8
solute carrier family 2 (facilitated glucose 
transporter), member 8
1,56 up
RPL23 ribosomal protein L23 3,03 up SLC30A1 solute carrier family 30 (zinc transporter), member 1 1,67 up
RPL29 ribosomal protein L29 2,07 up SLC30A8 solute carrier family 30 (zinc transporter), member 8 1,96 up
RPL38 ribosomal protein L38 4,08 up SLC31A1
solute carrier family 31 (copper transporter), member 
1
1,61 up
RPL7A ribosomal protein L7a 2,32 up SLC35E3 solute carrier family 35, member E3 1,67 up
RPL9 ribosomal protein L9 1,72 up SLC35E4 solute carrier family 35, member E4 2,23 up
RPN2 ribophorin II 1,61 up SLC35F2 solute carrier family 35, member F2 1,58 up
RPP14 ribonuclease P/M RP 14kDa subunit 1,56 up SLC36A3 solute carrier family 36, member 3 1,52 up
RPP25 ribonuclease P/M RP 25kDa subunit 2,11 down SLC36A4
solute carrier family 36 (proton/amino acid 
symporter), member 4
1,58 up
RPP38 ribonuclease P/M RP 38kDa subunit 1,98 up SLC38A2 solute carrier family 38, member 2 1,92 up
RPS10 ribosomal protein S10 2,88 up SLC38A5 solute carrier family 38, member 5 1,82 down
RPS13 ribosomal protein S13 4,78 up SLC38A7 solute carrier family 38, member 7 1,87 down
RPS26 ribosomal protein S26 2,64 up SLC39A5 solute carrier family 39 (zinc transporter), member 5 1,67 down
RPS2P45 ribosomal protein S2 pseudogene 45 1,72 down SLC45A4 solute carrier family 45, member 4 1,67 down
RPS6 ribosomal protein S6 7,71 up SLC48A1 solute carrier family 48 (heme transporter), member 1 2,12 down
RPS6KA1 ribosomal protein S6 kinase, 90kDa, polypept ide 1 1,57 up SLC48A1 solute carrier family 48 (heme transporter), member 1 1,99 up
RPS6KA3 ribosomal protein S6 kinase, 90kDa, polypept ide 3 1,81 up SLC4A11
solute carrier family 4, sodium borate transporter, 
member 11
2,99 down
RTDR1 rhabdoid tumor delet ion region gene 1 1,53 up SLC4A5
solute carrier family 4 (sodium bicarbonate 
cotransporter), member 5
1,63 up
RTEL1 regulator of telomere elongat ion helicase 1 2,02 down SLC5A1
solute carrier family 5 (sodium/glucose 
cotransporter), member 1
1,85 up
RWDD2A RWD domain containing 2A 1,54 down SLC5A10
solute carrier family 5 (sodium/sugar cotransporter), 
member 10
1,69 up
RXFP4 relaxin/ insulin-like family pept ide receptor 4 1,76 up SLC6A14
solute carrier family 6 (amino acid transporter), 
member 14
1,55 up
RXRA ret inoid X receptor, alpha 1,66 down SLC6A19
solute carrier family 6 (neutral amino acid 
transporter), member 19
2,88 down
RYBP RING1 and YY1 binding protein 1,94 up SLC6A6
solute carrier family 6 (neurotransmit ter t ransporter), 
member 6
1,98 up
S1PR3 sphingosine-1-phosphate receptor 3 1,61 down SLC8A2
solute carrier family 8 (sodium/calcium exchanger), 
member 2
1,57 down
SAM D1 sterile alpha motif  domain containing 1 1,61 up SLCO4C1
solute carrier organic anion transporter family, 
member 4C1
1,57 down
SAM D4A sterile alpha motif  domain containing 4A 1,52 down SLFNL1 schlafen-like 1 1,69 down
SAP30L SAP30-like 1,98 up SLIRP SRA stem-loop interact ing RNA binding protein 1,83 up
SAR1B SAR1 homolog B (S. cerevisiae) 1,93 up SM AD7 SM AD family member 7 1,71 down
SASS6 spindle assembly 6 homolog (C. elegans) 1,80 down SM AP1 small ArfGAP 1 1,54 up
SATB1 SATB homeobox 1 1,85 up SM ARCA4
SWI/SNF related, matrix associated, act in dependent 
regulator of chromatin, subfamily a, member 4
1,84 up
SC5D sterol-C5-desaturase 1,93 up SM ARCC1
SWI/SNF related, matrix associated, act in dependent 
regulator of chromatin, subfamily c, member 1
2,15 up
SCAF11 SR-related CTD-associated factor 11 2,04 up SM ARCD1
SWI/SNF related, matrix associated, act in dependent 
regulator of chromatin, subfamily d, member 1
1,87 up
SCAND2P SCAN domain containing 2 pseudogene 1,63 down SM ARCD2
SWI/SNF related, matrix associated, act in dependent 
regulator of chromatin, subfamily d, member 2
1,81 up
SCD5 stearoyl-CoA desaturase 5 2,00 down SM ARCE1
SWI/SNF related, matrix associated, act in dependent 
regulator of chromatin, subfamily e, member 1
2,26 up
SCG3 secretogranin III 1,53 down SM G1 SM G1 phosphat idylinositol 3-kinase-related kinase 2,37 up
SCM H1 sex comb on midleg homolog 1 (Drosophila) 1,66 up SM OC1 SPARC related modular calcium binding 1 1,87 up
SCN3A sodium channel, voltage-gated, type III, alpha subunit 1,50 up SM OC2 SPARC related modular calcium binding 2 1,88 up
SCN3B sodium channel, voltage-gated, type III, beta subunit 1,84 down SM PDL3B sphingomyelin phosphodiesterase, acid-like 3B 2,00 up
SCN4B sodium channel, voltage-gated, type IV, beta subunit 1,69 up SM URF1 SM AD specif ic E3 ubiquit in protein ligase 1 1,54 up
SCNN1G sodium channel, non-voltage-gated 1, gamma subunit 1,80 down SNAI1 snail family zinc f inger 1 2,12 down
SCRT1 scratch family zinc f inger 1 4,49 down SNAP25 synaptosomal-associated protein, 25kDa 1,62 up
SCTR secret in receptor 2,05 down SNAP29 synaptosomal-associated protein, 29kDa 1,98 up
SCYL2 SCY1-like 2 (S. cerevisiae) 2,63 up SNCG synuclein, gamma (breast cancer-specif ic protein 1) 1,68 down
SDC3 syndecan 3 1,52 down SND1-IT1 SND1 intronic transcript  1 (non-protein coding) 2,23 down
SDC4 syndecan 4 1,57 down SND1-IT1 SND1 intronic transcript  1 (non-protein coding) 2,02 down
SDHAF2 succinate dehydrogenase complex assembly factor 2 2,07 up SNURF SNRPN upstream reading frame 1,57 down
SDHD
succinate dehydrogenase complex, subunit  D, integral 
membrane protein
2,02 up SNX13 sort ing nexin 13 1,51 up
SDK1 sidekick cell adhesion molecule 1 2,52 down SNX19 sort ing nexin 19 1,59 up
SEC14L1 SEC14-like 1 (S. cerevisiae) 1,82 up SNX3 sort ing nexin 3 1,52 up
SEL1L sel-1 suppressor of lin-12-like (C. elegans) 1,61 up SOCS7 suppressor of cytokine signaling 7 1,76 down
SEM A4C
sema domain, immunoglobulin domain (Ig), t ransmembrane 
domain (TM ) and short  cytoplasmic domain, (semaphorin) 
4C
1,54 up SOGA1 suppressor of glucose, autophagy associated 1 1,54 down
SEM A6C
sema domain, t ransmembrane domain (TM ), and cytoplasmic 
domain, (semaphorin) 6C
1,56 down SORBS1 sorbin and SH3 domain containing 1 1,68 up
SEPT12 sept in 12 1,97 up SORBS2 sorbin and SH3 domain containing 2 1,70 up
SEPT5 sept in 5 1,53 down SOWAHD sosondowah ankyrin repeat domain family member D 2,27 down
SEPT7 sept in 7 2,10 up SOX12 SRY (sex determining region Y)-box 12 2,11 down
SEPT7 sept in 7 1,87 up SOX17 SRY (sex determining region Y)-box 17 1,65 down
SERF2 small EDRK-rich factor 2 4,39 up SOX21 SRY (sex determining region Y)-box 21 1,87 down
SERINC3 serine incorporator 3 1,64 up SOX3 SRY (sex determining region Y)-box 3 2,53 up
SERPINB13 serpin pept idase inhibitor, clade B (ovalbumin), member 13 1,53 up SP5 Sp5 transcript ion factor 2,02 down
SERPINB2 serpin pept idase inhibitor, clade B (ovalbumin), member 2 2,27 up SPAG9 sperm associated ant igen 9 1,51 up
SERTAD2 SERTA domain containing 2 1,51 up SPANXB2 SPANX family, member B2 1,58 up
SESN2 sestrin 2 1,65 down SPATA2 spermatogenesis associated 2 1,51 up
SETD4 SET domain containing 4 1,75 up SPATA25 spermatogenesis associated 25 2,06 down
SETD8 SET domain containing (lysine methyltransferase) 8 1,57 up SPATA32 spermatogenesis associated 32 1,68 up
SETD9 SET domain containing 9 1,53 up SPATC1L spermatogenesis and centriole associated 1-like 1,95 down
SF3A1 splicing factor 3a, subunit  1, 120kDa 2,00 up SPHAR S-phase response (cyclin related) 1,79 up
SF3B1 splicing factor 3b, subunit  1, 155kDa 2,36 up SPN sialophorin 1,64 up
SFI1 Sfi1 homolog, spindle assembly associated (yeast) 1,67 up SPRN shadow of prion protein homolog (zebraf ish) 1,64 down
SFT2D3 SFT2 domain containing 3 1,90 down SPRR2B small proline-rich protein 2B 2,66 down
SFTPA1 surfactant protein A1 1,56 down SPTB spectrin, beta, erythrocyt ic 1,74 down
SH2D3A SH2 domain containing 3A 1,58 down SPTLC3 serine palmitoyltransferase, long chain base subunit  3 1,60 up
SH2D3C SH2 domain containing 3C 1,70 down SQLE squalene epoxidase 1,58 up
SH3BP5 SH3-domain binding protein 5 (BTK-associated) 2,08 up SRF
serum response factor (c-fos serum response element-
binding transcript ion factor)
1,85 down
SH3RF2 SH3 domain containing ring f inger 2 1,71 up SRI sorcin 1,50 up
SHB Src homology 2 domain containing adaptor protein B 1,84 up SRP14P1
signal recognit ion part icle 14kDa (homologous Alu 
RNA binding protein) pseudogene 1
1,64 up
SHH sonic hedgehog 2,23 down SRP72 signal recognit ion part icle 72kDa 1,58 up
SHM T1 serine hydroxymethyltransferase 1 (soluble) 1,61 down SRP9 signal recognit ion part icle 9kDa 1,57 up
SHPK sedoheptulokinase 2,06 up SRPK1 SRSF protein kinase 1 1,86 up
SIGIRR
single immunoglobulin and toll-interleukin 1 receptor (TIR) 
domain
1,56 down SRRM 1 serine/arginine repet it ive matrix 1 1,58 up
SIGLEC5 sialic acid binding Ig-like lect in 5 2,09 down SRRM 2 serine/arginine repet it ive matrix 2 1,80 down
SIL1 SIL1 nucleot ide exchange factor 1,94 down SRRT
serrate RNA effector molecule homolog 
(Arabidopsis)
1,87 up
SIM 1 single-minded family bHLH transcript ion factor 1 1,77 down SRSF11 serine/arginine-rich splicing factor 11 1,88 up
SIX2 SIX homeobox 2 1,85 down SRSF2 serine/arginine-rich splicing factor 2 1,54 down
SLC12A2
solute carrier family 12 (sodium/potassium/chloride 
transporter), member 2
1,53 up SRSF8 serine/arginine-rich splicing factor 8 1,58 up
SLC12A7
solute carrier family 12 (potassium/chloride transporter), 
member 7
1,51 up SSB Sjogren syndrome ant igen B (autoant igen La) 1,95 up
SLC15A3 solute carrier family 15 (oligopept ide transporter), member 3 2,17 up SSBP2 single-stranded DNA binding protein 2 2,28 up
SLC16A1
solute carrier family 16 (monocarboxylate transporter), 
member 1
1,77 up SSNA1 Sjogren syndrome nuclear autoant igen 1 1,99 up
SLC16A8
solute carrier family 16 (monocarboxylate transporter), 
member 8
2,84 down ST13
suppression of tumorigenicity 13 (colon carcinoma) 
(Hsp70 interact ing protein)
1,57 up
SLC17A6
solute carrier family 17 (vesicular glutamate transporter), 
member 6
1,51 down ST6GALNAC2
ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-
1,3)-N-acetylgalactosaminide alpha-2,6-
sialylt ransferase 2
2,03 up
SLC1A7 solute carrier family 1 (glutamate transporter), member 7 1,91 down ST6GALNAC3
ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-
1,3)-N-acetylgalactosaminide alpha-2,6-
sialylt ransferase 3
1,88 down
SLC22A10 solute carrier family 22, member 10 2,00 down STAG2 stromal ant igen 2 1,53 up
SLC22A14 solute carrier family 22, member 14 1,61 down STEAP3 STEAP family member 3, metalloreductase 1,62 up
SLC23A3 solute carrier family 23, member 3 1,53 down STK25 serine/threonine kinase 25 1,60 down
SLC25A26
solute carrier family 25 (S-adenosylmethionine carrier), 
member 26
1,80 up STK39 serine threonine kinase 39 1,55 up
SLC25A32
solute carrier family 25 (mitochondrial folate carrier), member 
32
1,81 up STM N3 stathmin-like 3 1,71 down  
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STM N3 stathmin-like 3 1,56 down TM EM 150A transmembrane protein 150A 4,31 down
STOM stomatin 1,87 up TM EM 151A transmembrane protein 151A 2,48 down
STOM L2 stomatin (EPB72)-like 2 1,76 up TM EM 158 transmembrane protein 158 (gene/pseudogene) 1,80 up
STOX2 storkhead box 2 2,73 up TM EM 169 transmembrane protein 169 1,54 down
STRBP spermatid perinuclear RNA binding protein 1,80 up TM EM 200C transmembrane protein 200C 3,08 down
STRC stereocilin 1,52 up TM EM 209 transmembrane protein 209 1,55 up
STX12 syntaxin 12 1,64 up TM EM 214 transmembrane protein 214 1,87 up
STX1A syntaxin 1A (brain) 1,64 up TM EM 223 transmembrane protein 223 1,64 up
STX6 syntaxin 6 1,72 up TM EM 237 transmembrane protein 237 1,78 up
SUB1 SUB1 homolog (S. cerevisiae) 1,95 up TM EM 259 transmembrane protein 259 1,92 down
SULT1B1 sulfotransferase family, cytosolic, 1B, member 1 1,66 down TM EM 33 transmembrane protein 33 1,74 up
SULT4A1 sulfotransferase family 4A, member 1 1,64 up TM EM 35 transmembrane protein 35 1,72 down
SUPT4H1 suppressor of Ty 4 homolog 1 (S. cerevisiae) 2,66 up TM EM 52 transmembrane protein 52 1,75 down
SUZ12 SUZ12 polycomb repressive complex 2 subunit 1,98 up TM EM 55A transmembrane protein 55A 1,84 up
SWSAP1 SWIM -type zinc f inger 7 associated protein 1 1,77 down TM EM 70 transmembrane protein 70 1,72 up
SYAP1 synapse associated protein 1 1,52 up TM EM 86B transmembrane protein 86B 2,52 down
SYK spleen tyrosine kinase 1,79 up TM EM 92 transmembrane protein 92 1,77 down
SYNC syncoilin, intermediate f ilament protein 1,64 up TM EM 97 transmembrane protein 97 1,61 up
SYNCRIP synaptotagmin binding, cytoplasmic RNA interact ing protein 1,95 up TM PRSS6 transmembrane protease, serine 6 1,87 down
SYNCRIP synaptotagmin binding, cytoplasmic RNA interact ing protein 1,72 up TM SB4X thymosin beta 4, X-linked 2,31 up
SYNGR3 synaptogyrin 3 1,95 down TM TC3
transmembrane and tetratricopept ide repeat 
containing 3
1,88 up
SYNPO2L synaptopodin 2-like 1,57 down TM UB1 transmembrane and ubiquit in-like domain containing 1 1,60 down
SYT12 synaptotagmin XII 1,50 down TM X2 thioredoxin-related transmembrane protein 2 1,96 down
SYT6 synaptotagmin VI 1,85 down TM X4 thioredoxin-related transmembrane protein 4 1,53 up
SYT8 synaptotagmin VIII 1,62 up TNFAIP8 tumor necrosis factor, alpha-induced protein 8 1,90 up
SZT2 seizure threshold 2 homolog (mouse) 1,54 up TNFAIP8L3 tumor necrosis factor, alpha-induced protein 8-like 3 1,53 down
TACR1 tachykinin receptor 1 1,85 down TNFRSF18
tumor necrosis factor receptor superfamily, member 
18
1,93 down
TAF1C
TATA box binding protein (TBP)-associated factor, RNA 
polymerase I, C, 110kDa
1,54 up TNFRSF21
tumor necrosis factor receptor superfamily, member 
21
2,15 up
TAF1L
TAF1 RNA polymerase II, TATA box binding protein (TBP)-
associated factor, 210kDa-like
2,50 down TNFRSF6B
tumor necrosis factor receptor superfamily, member 
6b, decoy
1,69 down
TAF2
TAF2 RNA polymerase II, TATA box binding protein (TBP)-
associated factor, 150kDa
1,52 up TNFSF14 tumor necrosis factor (ligand) superfamily, member 14 1,57 down
TAF9
TAF9 RNA polymerase II, TATA box binding protein (TBP)-
associated factor, 32kDa
1,65 up TNIP2 TNFAIP3 interact ing protein 2 1,69 down
TAF9
TAF9 RNA polymerase II, TATA box binding protein (TBP)-
associated factor, 32kDa
1,52 up TNK2 tyrosine kinase, non-receptor, 2 1,89 down
TANGO2 transport  and golgi organizat ion 2 homolog (Drosophila) 1,66 down TNKS
tankyrase, TRF1-interact ing ankyrin-related ADP-
ribose polymerase
1,87 up
TAOK2 TAO kinase 2 2,70 down TNNI2 troponin I type 2 (skeletal, fast) 2,01 down
TAS2R4 taste receptor, type 2, member 4 3,33 down TNNT1 troponin T type 1 (skeletal, slow) 1,59 down
TATDN1 TatD DNase domain containing 1 1,57 down TNPO1 transport in 1 2,09 up
TBC1D20 TBC1 domain family, member 20 2,13 up TNPO2 transport in 2 1,79 up
TBC1D2B TBC1 domain family, member 2B 1,88 down TNRC18 trinucleot ide repeat containing 18 4,28 down
TBCD tubulin folding cofactor D 1,65 down TNRC18 trinucleot ide repeat containing 18 2,38 down
TBKBP1 TBK1 binding protein 1 2,44 down TNS1 tensin 1 1,58 down
TBL1XR1 transducin (beta)-like 1 X-linked receptor 1 2,19 up TNXB tenascin XB 2,50 down
TBL3 transducin (beta)-like 3 1,67 down TOB1 transducer of ERBB2, 1 2,34 up
TBPL1 TBP-like 1 1,58 up TONSL tonsoku-like, DNA repair protein 1,68 down
TBX21 T-box 21 1,55 down TOR3A torsin family 3, member A 1,50 up
TBX3 T-box 3 1,69 up TP53I11 tumor protein p53 inducible protein 11 1,67 down
TCEA3 transcript ion elongat ion factor A (SII), 3 1,77 up TP53I13 tumor protein p53 inducible protein 13 1,50 down
TCEAL1 transcript ion elongat ion factor A (SII)-like 1 1,74 up TP53INP2 tumor protein p53 inducible nuclear protein 2 2,04 up
TCEAL5 transcript ion elongat ion factor A (SII)-like 5 1,62 up TP53TG1 TP53 target 1 (non-protein coding) 1,51 up
TCEAL6 transcript ion elongat ion factor A (SII)-like 6 1,94 up TPCN1 two pore segment channel 1 1,81 up
TCEAL8 transcript ion elongat ion factor A (SII)-like 8 2,11 up TPCN2 two pore segment channel 2 1,74 down
TCEB3B
transcript ion elongat ion factor B polypept ide 3B (elongin 
A2)
1,60 down TPM 1 tropomyosin 1 (alpha) 1,55 up
TCF12 transcript ion factor 12 1,67 up TPM 1 tropomyosin 1 (alpha) 1,51 up
TCL1A T-cell leukemia/ lymphoma 1A 2,71 down TPM 3 tropomyosin 3 2,41 up
TCL6 T-cell leukemia/ lymphoma 6 (non-protein coding) 1,56 down TPM 4 tropomyosin 4 1,75 up
TCP11L2 t-complex 11, test is-specif ic-like 2 1,51 up TPR translocated promoter region, nuclear basket protein 1,60 up
TCTE3 t-complex-associated-test is-expressed 3 1,54 up TPRX1 tetra-pept ide repeat homeobox 1 1,64 down
TCTN2 tectonic family member 2 2,03 down TRA T cell receptor alpha locus 1,58 down
TDP1 tyrosyl-DNA phosphodiesterase 1 1,85 up TRAF2 TNF receptor-associated factor 2 1,87 down
TEAD4 TEA domain family member 4 1,68 up TRAF3IP1
TNF receptor-associated factor 3 interact ing protein 
1
1,53 up
TENC1 tensin like C1 domain containing phosphatase (tensin 2) 1,59 down TRAIP TRAF interact ing protein 1,85 down
TENM 1 teneurin transmembrane protein 1 1,63 up TRAK1 traff icking protein, kinesin binding 1 2,13 up
TEPP test is, prostate and placenta expressed 1,50 down TRAPPC8 traff icking protein part icle complex 8 1,66 up
TERT telomerase reverse transcriptase 1,58 down TREM L1 triggering receptor expressed on myeloid cells-like 1 1,89 down
TET2 tet methylcytosine dioxygenase 2 1,61 up TRH thyrotropin-releasing hormone 2,29 down
TEX261 test is expressed 261 1,80 down TRIL TLR4 interactor with leucine-rich repeats 1,50 down
TEX261 test is expressed 261 1,80 up TRIM 11 tripart ite motif  containing 11 1,92 up
TEX37 test is expressed 37 1,64 up TRIM 13 tripart ite motif  containing 13 1,65 up
TFAP2B
transcript ion factor AP-2 beta (act ivat ing enhancer binding 
protein 2 beta)
2,76 up TRIM 33 tripart ite motif  containing 33 1,74 up
TFCP2L1 transcript ion factor CP2-like 1 1,55 up TRIM 35 tripart ite motif  containing 35 2,06 up
TFF2 trefoil factor 2 1,77 up TRIM 45 tripart ite motif  containing 45 1,79 up
TFG TRK-fused gene 2,18 up TRIM 56 tripart ite motif  containing 56 1,73 down
TFIP11 tuftelin interact ing protein 11 2,20 down TRIM 62 tripart ite motif  containing 62 1,73 up
TFPI
t issue factor pathway inhibitor (lipoprotein-associated 
coagulat ion inhibitor)
2,75 down TRIM 7 tripart ite motif  containing 7 2,63 down
TFPT TCF3 (E2A) fusion partner (in childhood Leukemia) 1,60 down TRIM 72 tripart ite motif  containing 72 2,64 down
TGFBRAP1
transforming growth factor, beta receptor associated 
protein 1
1,63 up TRIM 72 tripart ite motif  containing 72 1,52 down
TGS1 trimethylguanosine synthase 1 1,55 down TRIM 74 tripart ite motif  containing 74 1,73 down
THAP3 THAP domain containing, apoptosis associated protein 3 1,57 down TRM T1 tRNA methyltransferase 1 homolog (S. cerevisiae) 1,77 down
THBS2 thrombospondin 2 1,80 up TRM T2B tRNA methyltransferase 2 homolog B (S. cerevisiae) 1,68 up
THEG theg spermatid protein 1,89 down TRM T5 tRNA methyltransferase 5 1,82 up
THRAP3 thyroid hormone receptor associated protein 3 1,51 up TRM T6 tRNA methyltransferase 6 homolog (S. cerevisiae) 1,69 up
THRSP thyroid hormone responsive 1,68 up TRM U
tRNA 5-methylaminomethyl-2-thiouridylate 
methyltransferase
1,70 down
TIGD7 tigger transposable element derived 7 1,75 down TRPC2
transient receptor potent ial cat ion channel, subfamily 
C, member 2, pseudogene
1,80 down
TIM M 10
translocase of inner mitochondrial membrane 10 homolog 
(yeast)
1,53 up TRPM 2
transient receptor potent ial cat ion channel, subfamily 
M , member 2
1,54 down
TIM M 8A
translocase of inner mitochondrial membrane 8 homolog A 
(yeast)
1,67 up TRPM 5
transient receptor potent ial cat ion channel, subfamily 
M , member 5
1,51 down
TIM P3 TIM P metallopept idase inhibitor 3 2,67 up TRPV1
transient receptor potent ial cat ion channel, subfamily 
V, member 1
1,78 up
TJP1 tight junct ion protein 1 1,89 up TRPV2
transient receptor potent ial cat ion channel, subfamily 
V, member 2
1,58 down
TJP2 tight junct ion protein 2 1,73 down TSC1 tuberous sclerosis 1 1,68 down
TLL2 tolloid-like 2 1,87 up TSEN2 TSEN2 tRNA splicing endonuclease subunit 1,51 up
TM 4SF5 transmembrane 4 L six family member 5 1,92 down TSG101 tumor suscept ibility 101 2,17 up
TM 9SF3 transmembrane 9 superfamily member 3 1,71 up TSHZ1 teashirt  zinc f inger homeobox 1 1,50 up
TM BIM 1 transmembrane BAX inhibitor motif  containing 1 1,87 up TSPAN32 tetraspanin 32 1,60 down
TM BIM 4 transmembrane BAX inhibitor motif  containing 4 1,57 up TSPAN33 tetraspanin 33 1,92 down
TM CO1 transmembrane and coiled-coil domains 1 1,75 up TSPYL2 TSPY-like 2 1,80 down
TM CO1 transmembrane and coiled-coil domains 1 1,52 up TSPYL4 TSPY-like 4 1,73 up
TM ED10P1
transmembrane emp24-like traf f icking protein 10 (yeast) 
pseudogene 1
1,58 up TSSC1 tumor suppressing subtransferable candidate 1 1,57 down
TM ED2 transmembrane emp24 domain traf f icking protein 2 1,53 up TSSK1B test is-specif ic serine kinase 1B 1,69 up
TM ED4
transmembrane emp24 protein transport  domain containing 
4
1,69 up TTC28 tetratricopept ide repeat domain 28 1,66 down
TM EM 109 transmembrane protein 109 1,61 down TTC3 tetratricopept ide repeat domain 3 1,95 up
TM EM 121 transmembrane protein 121 1,51 down TTC33 tetratricopept ide repeat domain 33 1,51 down
TM EM 125 transmembrane protein 125 2,28 down TTC39A tetratricopept ide repeat domain 39A 2,63 down  
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TTI1 TELO2 interact ing protein 1 1,51 down ZM IZ2 zinc f inger, M IZ-type containing 2 1,67 up
TTLL5 tubulin tyrosine ligase-like family, member 5 2,31 down ZM YM 3 zinc f inger, M YM -type 3 1,54 down
TTTY14 test is-specif ic t ranscript , Y-linked 14 (non-protein coding) 1,82 down ZNF148 zinc f inger protein 148 2,02 up
TUB tubby bipart ite transcript ion factor 1,88 down ZNF154 zinc f inger protein 154 2,06 up
TUBA3D tubulin, alpha 3d 2,63 down ZNF226 zinc f inger protein 226 1,73 up
TUBB tubulin, beta class I 2,60 up ZNF253 zinc f inger protein 253 1,61 up
TUBB3 tubulin, beta 3 class III 1,56 up ZNF254 zinc f inger protein 254 3,34 up
TUBB4B tubulin, beta 4B class IVb 1,69 up ZNF292 zinc f inger protein 292 1,51 up
TUBGCP2 tubulin, gamma complex associated protein 2 1,75 up ZNF300 zinc f inger protein 300 1,55 down
TUBGCP5 tubulin, gamma complex associated protein 5 1,51 down ZNF333 zinc f inger protein 333 1,63 up
TUSC1 tumor suppressor candidate 1 1,53 up ZNF346 zinc f inger protein 346 1,57 up
TUT1 terminal uridylyl t ransferase 1, U6 snRNA-specif ic 2,01 down ZNF365 zinc f inger protein 365 1,53 up
TXNDC2 thioredoxin domain containing 2 (spermatozoa) 2,33 down ZNF394 zinc f inger protein 394 1,56 up
TXNL4A thioredoxin-like 4A 1,68 up ZNF423 zinc f inger protein 423 1,51 up
U2SURP U2 snRNP-associated SURP domain containing 2,65 up ZNF430 zinc f inger protein 430 2,58 up
UBA2 ubiquit in-like modif ier act ivat ing enzyme 2 1,55 up ZNF440 zinc f inger protein 440 1,77 up
UBD ubiquit in D 2,04 down ZNF446 zinc f inger protein 446 2,13 down
UBE2D4 ubiquit in-conjugat ing enzyme E2D 4 (putat ive) 2,32 up ZNF449 zinc f inger protein 449 1,74 down
UBE2L3 ubiquit in-conjugat ing enzyme E2L 3 1,70 up ZNF467 zinc f inger protein 467 1,92 down
UBE2N ubiquit in-conjugat ing enzyme E2N 1,99 up ZNF467 zinc f inger protein 467 1,91 down
UBE4B ubiquit inat ion factor E4B 1,75 up ZNF467 zinc f inger protein 467 1,73 up
UBQLN1 ubiquilin 1 2,37 up ZNF488 zinc f inger protein 488 1,73 down
UBXN6 UBX domain protein 6 1,80 up ZNF493 zinc f inger protein 493 1,75 up
UGGT2 UDP-glucose glycoprotein glucosyltransferase 2 1,87 up ZNF532 zinc f inger protein 532 1,69 up
UHRF1BP1 UHRF1 binding protein 1 1,59 up ZNF559 zinc f inger protein 559 1,53 down
ULBP3 UL16 binding protein 3 1,60 down ZNF572 zinc f inger protein 572 1,51 down
ULK2 unc-51 like autophagy act ivat ing kinase 2 2,13 down ZNF575 zinc f inger protein 575 1,58 down
UM OD uromodulin 1,83 up ZNF581 zinc f inger protein 581 2,00 up
UNC13B unc-13 homolog B (C. elegans) 1,57 down ZNF587 zinc f inger protein 587 1,68 up
UNC5A unc-5 homolog A (C. elegans) 1,58 down ZNF587 zinc f inger protein 587 1,61 up
UNC5B unc-5 homolog B (C. elegans) 2,31 up ZNF600 zinc f inger protein 600 1,92 up
UNC93B1 unc-93 homolog B1 (C. elegans) 3,40 down ZNF626 zinc f inger protein 626 1,94 up
UNG uracil-DNA glycosylase 1,82 down ZNF641 zinc f inger protein 641 1,75 down
UNKL unkempt family zinc f inger-like 1,99 up ZNF644 zinc f inger protein 644 1,69 up
UPB1 ureidopropionase, beta 2,43 down ZNF66 zinc f inger protein 66 2,81 up
UPF1 UPF1 regulator of nonsense transcripts homolog (yeast) 1,71 up ZNF675 zinc f inger protein 675 1,80 up
UPK1A uroplakin 1A 2,01 down ZNF681 zinc f inger protein 681 2,18 up
URM 1 ubiquit in related modif ier 1 2,22 down ZNF682 zinc f inger protein 682 1,86 down
USHBP1 Usher syndrome 1C binding protein 1 1,99 down ZNF683 zinc f inger protein 683 1,57 up
USP14
ubiquit in specif ic pept idase 14 (tRNA-guanine 
transglycosylase)
1,70 up ZNF697 zinc f inger protein 697 2,37 down
USP31 ubiquit in specif ic pept idase 31 1,85 up ZNF708 zinc f inger protein 708 2,35 up
USP35 ubiquit in specif ic pept idase 35 1,90 up ZNF708 zinc f inger protein 708 1,51 up
USP54 ubiquit in specif ic pept idase 54 2,30 up ZNF713 zinc f inger protein 713 1,97 up
UTF1 undif ferent iated embryonic cell t ranscript ion factor 1 2,51 down ZNF714 zinc f inger protein 714 1,71 up
UTS2R urotensin 2 receptor 1,76 down ZNF738 zinc f inger protein 738 1,62 up
VASH1 vasohibin 1 1,76 down ZNF746 zinc f inger protein 746 2,02 up
VEGFA vascular endothelial growth factor A 1,58 up ZNF761 zinc f inger protein 761 1,64 up
VGLL4 vest igial like 4 (Drosophila) 1,84 up ZNF767 zinc f inger family member 767 1,51 up
VHL
von Hippel-Lindau tumor suppressor, E3 ubiquit in protein 
ligase
2,84 up ZNF789 zinc f inger protein 789 1,55 down
VIL1 villin 1 1,61 down ZNF792 zinc f inger protein 792 1,60 up
VIPR2 vasoact ive intest inal pept ide receptor 2 1,64 up ZNF92 zinc f inger protein 92 2,20 up
VPS11 vacuolar protein sort ing 11 homolog (S. cerevisiae) 1,70 up ZSCAN10 zinc f inger and SCAN domain containing 10 2,13 down
VPS16 vacuolar protein sort ing 16 homolog (S. cerevisiae) 2,01 up ZXDC ZXD family zinc f inger C 1,65 up
VPS9D1 VPS9 domain containing 1 1,53 down ZYG11B zyg-11 family member B, cell cycle regulator 1,57 down
VRTN vertebrae development associated 1,52 down 1. Information from HGNC (HUGO Gene Nomenclature Committee; www.genenames.org).
WDR1 WD repeat domain 1 1,89 up 2. Type of regulat ion.
WDR1 WD repeat domain 1 1,79 up
WDR24 WD repeat domain 24 2,34 down
WDR26 WD repeat domain 26 1,50 up
WDR48 WD repeat domain 48 1,89 up
WDR63 WD repeat domain 63 1,52 down
WDR70 WD repeat domain 70 1,55 up
WDR76 WD repeat domain 76 1,53 down
WDR82 WD repeat domain 82 1,52 up
WDR89 WD repeat domain 89 1,57 up
WDR90 WD repeat domain 90 2,05 down
WFDC10B WAP four-disulf ide core domain 10B 1,57 up
WFDC2 WAP four-disulf ide core domain 2 1,62 down
WHSC1 Wolf-Hirschhorn syndrome candidate 1 1,52 down
WNT7A wingless-type M M TV integrat ion site family, member 7A 1,63 down
WRB tryptophan rich basic protein 1,55 down
WWP1 WW domain containing E3 ubiquit in protein ligase 1 1,63 up
XIST X inact ive specif ic t ranscript  (non-protein coding) 2,22 up
XKR8
XK, Kell blood group complex subunit-related family, 
member 8
1,88 up
XRCC5
X-ray repair complementing defect ive repair in Chinese 
hamster cells 5 (double-strand-break rejoining)
1,62 up
YAP1 Yes-associated protein 1 1,81 up
YARS tyrosyl-tRNA synthetase 2,14 down
YBEY ybeY metallopept idase (putat ive) 1,60 up
YBX1 Y box binding protein 1 2,21 up
YBX3 Y box binding protein 3 1,95 up
YIPF5 Yip1 domain family, member 5 1,99 down
YPEL1 yippee-like 1 (Drosophila) 1,96 up
YWHAE
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase 
act ivat ion protein, epsilon
1,78 up
YWHAZ
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase 
act ivat ion protein, zeta
2,11 up
YWHAZ
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase 
act ivat ion protein, zeta
1,93 up
YWHAZ
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase 
act ivat ion protein, zeta
1,90 up
YWHAZ
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase 
act ivat ion protein, zeta
1,70 up
ZAN zonadhesin (gene/pseudogene) 3,79 down
ZBTB10 zinc f inger and BTB domain containing 10 1,68 down
ZC3H12A zinc f inger CCCH-type containing 12A 1,83 up
ZCCHC17 zinc f inger, CCHC domain containing 17 1,94 up
ZDHHC21 zinc f inger, DHHC-type containing 21 1,52 up
ZDHHC23 zinc f inger, DHHC-type containing 23 1,72 down
ZDHHC4 zinc f inger, DHHC-type containing 4 1,87 up
ZFAND5 zinc f inger, AN1-type domain 5 2,14 up
ZFHX2 zinc f inger homeobox 2 1,55 down
ZFP62 ZFP62 zinc f inger protein 2,02 up
ZFYVE26 zinc f inger, FYVE domain containing 26 1,82 up
ZKSCAN1 zinc f inger with KRAB and SCAN domains 1 2,36 up
ZKSCAN1 zinc f inger with KRAB and SCAN domains 1 1,59 up
1. Information from HGNC (HUGO Gene Nomenclature Committee; www.genenames.org).
2. Type of regulat ion.
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Table S3. Characterization of the secondary volunteer panel for real-time qPCR validation. 
V olunt eer N umber A ge ( Y ears Old ) Skin Phot o t ype
1
Skin Type
2
Et hnic Group
3
1 20 II Normal Polish
2 21 II Normal Polish
3 22 III Not declared Not declared
4 23 III Not declared Not declared
5 24 II Not declared Not declared
6 25 III Not declared Not declared
7 25 II Not declared Not declared
8 25 III Combinat ion African/German
9 27 II Not declared Not declared
10 29 II Not declared Not declared
11 29 III Normal Italian/Libanese/Spanish
12 30 II Normal Italian
13 50 II Not declared Not declared
14 51 II Not declared Not declared
15 52 II Normal Polish
16 52 III Oily African
17 53 III Oily Italian
18 54 III Normal African
19 54 III Normal Spanish
20 55 III Not declared Not declared
21 56 II Dry Polish
22 58 II Normal Italian
1. Classif icat ion according to Fitzpatrick phototyping scale
2. Personal declarat ion of predominant skin type in the body according to sebum production
3. Personal declarat ion of ethnic groups  
 
Table S4. KEGG pathways modulated in sun-exposed epidermal aging considering p-value cut-off 
0.01. 
KEGG pat hway name KEGG code N umber o f  D EGs
1
Systemic lupus erythematosus hsa05322 72
Neuroact ive ligand-receptor interact ion hsa04080 37
M APK signaling pathway hsa04010 33
Focal adhesion hsa04510 27
Small cell lung cancer hsa05222 16
Ribosome hsa03010 15
Endocytosis hsa04144 23
Base excision repair hsa03410 9
ECM -receptor interact ion hsa04512 14
Axon guidance hsa04360 18
Chemokine signaling pathway hsa04062 23
Hypertrophic cardiomyopathy (HCM ) hsa05410 14
Insulin signaling pathway hsa04910 18
mTOR signaling pathway hsa04150 10
Wnt signaling pathway hsa04310 19
Phosphat idylinositol signaling system hsa04070 12
Notch signaling pathway hsa04330 9
RNA degradat ion hsa03018 10
Antigen processing and presentat ion hsa04612 13
Dilated cardiomyopathy hsa05414 13
Pathogenic Escherichia coli infect ion hsa05130 10
Renal cell carcinoma hsa05211 11
Protein export  hsa03060 6
Regulat ion of act in cytoskeleton hsa04810 22
Arrhythmogenic right ventricular cardiomyopathy (ARVC) hsa05412 11
Inositol phosphate metabolism hsa00562 9
Basal t ranscript ion factors hsa03022 7
Cytokine-cytokine receptor interact ion hsa04060 25
Calcium signaling pathway hsa04020 19
1. DEGs, dif ferent ially expressed genes.  
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Table S5. Epidermal age-modulated genes in plucked hair shaft shared with previous study using 
tape strip. 
HGNC 
Appr ov e d 
S y mbol 1
HGNC Appr ov e d Na me 1
HGNC Appr ov e d 
S y mbol 1
HGNC Appr ov e d Na me 1
ABCC6 ATP-binding casset t e, sub-f amily C (CFTR/ MRP), member 6 CYHR1 cyst eine/ hist idine-r ich 1
ABCE1 ATP-binding casset t e, sub-f amily E (OABP), member 1 CYP4F2 cyt ochrome P450, f amily 4, subf amily F, polypept ide 2
ABHD1 abhydrolase domain cont aining 1 DAB2 Dab, mit ogen-responsive phosphoprot ein, homolog 2 (Drosophila)
ACBD4 acyl-CoA binding domain cont aining 4 DBN1 drebrin 1
ACTR1B ARP1 act in-relat ed prot ein 1 homolog B, cent ract in bet a (yeast ) DBP D sit e of  albumin promot er (albumin D-box) binding prot ein
ADD3 adducin 3 (gamma) GC group-specif ic component  (vit amin D binding prot ein)
ADRBK2 adrenergic, bet a, recept or kinase 2 HSD17B4 hydroxyst eroid (17-bet a) dehydrogenase 4
AES amino-t erminal enhancer of  split DENND1C DENN/ MADD domain cont aining 1C
AFG3L1P AFG3-like AAA ATPase 1, pseudogene DESI2 desumoylat ing isopept idase 2
AGPAT4 1-acylglycerol-3-phosphat e O-acylt ransf erase 4 DFFA DNA f ragment at ion f act or, 45kDa, alpha polypept ide
ALOX5AP arachidonat e 5- lipoxygenase-act ivat ing prot ein DHX34 DEAH (Asp-Glu-Ala-His) box polypept ide 34
AMDHD1 amidohydrolase domain cont aining 1 DMBX1 diencephalon/ mesencephalon homeobox 1
ANKFY1 ankyrin repeat  and FYVE domain cont aining 1 DNAH11 dynein, axonemal, heavy chain 11
ANXA8 annexin A8 DNAH2 dynein, axonemal, heavy chain 2
AP2A2 adapt or-relat ed prot ein complex 2, alpha 2 subunit DNAJB11 DnaJ (Hsp40) homolog, subf amily B, member 11
APH1B APH1B gamma secret ase subunit DNM1P35 DNM1 pseudogene 35
APLP2 amyloid bet a (A4) precursor- like prot ein 2 DOCK3 dedicat or of  cyt okinesis 3
APPBP2 amyloid bet a precursor prot ein (cyt oplasmic t ail)  binding prot ein 2 DRD4 dopamine recept or D4
AQP2 aquaporin 2 (collect ing duct ) DSC2 desmocollin 2
ARF1 ADP-ribosylat ion f act or 1 DSC3 desmocollin 3
ARHGEF25 Rho guanine nucleot ide exchange f act or (GEF) 25 DUX4 double homeobox 4
ARHGEF3 Rho guanine nucleot ide exchange f act or (GEF) 3 DVL3 dishevelled segment  polar it y prot ein 3
ARID5B AT r ich int eract ive domain 5B (MRF1-like) EFHD2 EF-hand domain f amily, member D2
ARL3 ADP-ribosylat ion f act or- like 3 ELOVL6 ELOVL f at t y acid elongase 6
ARL6IP1 ADP-ribosylat ion f act or- like 6 int eract ing prot ein 1 EMILIN1 elast in microf ibr il int erf acer 1
ARRDC1 arrest in domain cont aining 1 ENC1 ect odermal-neural cort ex 1 (wit h BTB domain)
ATCAY at axia, cerebellar, Cayman t ype ENPP4 ect onucleot ide pyrophosphat ase/ phosphodiest erase 4 (put at ive)
ATG16L1 aut ophagy relat ed 16-like 1 (S. cerevisiae) EPAS1 endot helial PAS domain prot ein 1
ATOH7 at onal homolog 7 (Drosophila) EPB41L4B eryt hrocyt e membrane prot ein band 4.1 like 4B
ATP1A4 ATPase, Na+/ K+ t ransport ing, alpha 4 polypept ide EPHA4 EPH recept or A4
ATP6V1A ATPase, H+ t ransport ing, lysosomal 70kDa, V1 subunit  A ERCC6L2
excision repair  cross-complement ing rodent  repair  def iciency, 
complement at ion group 6- like 2
BCAM basal cell adhesion molecule (Lut heran blood group) ERG v-et s avian eryt hroblast osis virus E26 oncogene homolog
BCAT2 branched chain amino-acid t ransaminase 2, mit ochondrial ERN1 endoplasmic ret iculum t o nucleus signaling 1
BCAN brevican EXOC3L2 exocyst  complex component  3- like 2
BCKDK branched chain ket oacid dehydrogenase kinase FABP3
f at t y acid binding prot ein 3, muscle and heart  (mammary-derived 
growt h inhibit or)
BCL7A B-cell CLL/ lymphoma 7A FADS2 f at t y acid desat urase 2
BHLHE23 basic helix- loop-helix f amily, member e23 FAIM3 Fas apopt ot ic inhibit ory molecule 3
BHLHE23 basic helix- loop-helix f amily, member e23 FAM101B f amily wit h sequence similar it y 101, member B
BNIP3L BCL2/ adenovirus E1B 19kDa int eract ing prot ein 3- like FAM129B f amily wit h sequence similar it y 129, member B
BPTF bromodomain PHD f inger t ranscript ion f act or FAM129C f amily wit h sequence similar it y 129, member C
BRAT1 BRCA1-associat ed ATM act ivat or 1 FAM21C f amily wit h sequence similar it y 21, member C
BTF3 basic t ranscript ion f act or 3 FAT2 FAT at ypical cadherin 2
BTN3A3 but yrophilin, subf amily 3, member A3 FBXL17 F-box and leucine-r ich repeat  prot ein 17
BTG1 B-cell t ranslocat ion gene 1, ant i-prolif erat ive FBXL7 F-box and leucine-r ich repeat  prot ein 7
C2 complement  component  2 FBXO9 F-box prot ein 9
C5AR1 complement  component  5a recept or 1 FCN1 f icolin (collagen/ f ibr inogen domain cont aining) 1
CABIN1 calcineurin binding prot ein 1 FER1L6-AS1 FER1L6 ant isense RNA 1
CACNA1B calcium channel, volt age-dependent , N t ype, alpha 1B subunit FGD6 FYVE, RhoGEF and PH domain cont aining 6
CACNG7 calcium channel, volt age-dependent , gamma subunit  7 FGF5 f ibroblast  growt h f act or 5
CASD1 CAS1 domain cont aining 1 FKBP1A FK506 binding prot ein 1A, 12kDa
CASP5 caspase 5, apopt osis-relat ed cyst eine pept idase FOXG1 f orkhead box G1
CAV1 caveolin 1, caveolae prot ein, 22kDa FOXJ1 f orkhead box J1
CBS cyst at hionine-bet a-synt hase FOXN3 f orkhead box N3
CCDC134 coiled-coil domain cont aining 134 FOXP1 f orkhead box P1
CCDC144NL coiled-coil domain cont aining 144 f amily, N-t erminal like FOXQ1 f orkhead box Q1
CCDC90B coiled-coil domain cont aining 90B FRMD4A FERM domain cont aining 4A
CCND2 cyclin D2 FUBP3 f ar upst ream element  (FUSE) binding prot ein 3
CCND3 cyclin D3 FXN f rat axin
CD109 CD109 molecule FZR1 f izzy/ cell division cycle 20 relat ed 1 (Drosophila)
CD1E CD1e molecule GALNT6
UDP-N-acet yl-alpha-D-galact osamine:polypept ide N-
acet ylgalact osaminylt ransf erase 6 (GalNAc-T6)
CD244 CD244 molecule, nat ural killer cell recept or 2B4 GDNF glial cell der ived neurot rophic f act or
CDC42EP1 CDC42 ef f ect or prot ein (Rho GTPase binding) 1 GFOD1 glucose-f ruct ose oxidoreduct ase domain cont aining 1
CEACAM1
carcinoembryonic ant igen-relat ed cell adhesion molecule 1 (biliary 
glycoprot ein)
GGT1 gamma-glut amylt ransf erase 1
CEACAM4 carcinoembryonic ant igen-relat ed cell adhesion molecule 4 GGT3P gamma-glut amylt ransf erase 3 pseudogene
CEBPA CCAAT/ enhancer binding prot ein (C/ EBP), alpha GGTLC2 gamma-glut amylt ransf erase light  chain 2
CHAC2 ChaC, cat ion t ransport  regulat or homolog 2 (E. coli) GIT2 G prot ein-coupled recept or kinase int eract ing Arf GAP 2
CHRDL1 chordin- like 1 GJC2 gap junct ion prot ein, gamma 2, 47kDa
CIDECP cell deat h- inducing DFFA-like ef f ect or c pseudogene GLDC glycine dehydrogenase (decarboxylat ing)
CIRBP cold inducible RNA binding prot ein GLIS3 GLIS f amily zinc f inger 3
CLCF1 cardiot rophin- like cyt okine f act or 1 GLRX glut aredoxin ( t hiolt ransf erase)
CLINT1 clat hr in int eract or 1 GM2A GM2 ganglioside act ivat or
CLPTM1L CLPTM1-like GNG13 guanine nucleot ide binding prot ein (G prot ein), gamma 13
CMIP c-Maf  inducing prot ein GPR115 G prot ein-coupled recept or 115
CNOT4 CCR4-NOT t ranscript ion complex, subunit  4 GPR62 G prot ein-coupled recept or 62
CNOT6 CCR4-NOT t ranscript ion complex, subunit  6 GRIN2D glut amat e recept or, ionot ropic, N-met hyl D-aspart at e 2D
COL18A1 collagen, t ype XVIII, alpha 1 GTF3C4 general t ranscript ion f act or IIIC, polypept ide 4, 90kDa
CORT cort ist at in GYPC glycophorin C (Gerbich blood group)
CRABP1 cellular ret inoic acid binding prot ein 1 HAPLN4 hyaluronan and prot eoglycan link prot ein 4
CRHR1 cort icot ropin releasing hormone recept or 1 HCP5 HLA complex P5 (non-prot ein coding)
CRTC1 CREB regulat ed t ranscript ion coact ivat or 1 CYCSP5 cyt ochrome c, somat ic pseudogene 5
CRTC2 CREB regulat ed t ranscript ion coact ivat or 2 HGD homogent isat e 1,2-dioxygenase
CSAD cyst eine sulf inic acid decarboxylase HGS hepat ocyt e growt h f act or-regulat ed t yrosine kinase subst rat e
CTNND2 cat enin (cadherin-associat ed prot ein), delt a 2 HIF3A hypoxia inducible f act or 3, alpha subunit
CTSB cat hepsin B HIP1 hunt ingt in int eract ing prot ein 1
CYB5R3 cyt ochrome b5 reduct ase 3 HIST1H2BE hist one clust er 1, H2be  
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HIST1H4E hist one clust er 1, H4e NPHS2 nephrosis 2, idiopat hic, st eroid-resist ant  (podocin)
HIVEP3 human immunodef iciency virus t ype I enhancer binding prot ein 3 NPTN neuroplast in
HLA-DQB1 major hist ocompat ibilit y complex, class II, DQ bet a 1 NRAP nebulin-relat ed anchoring prot ein
HMGN1 high mobilit y group nucleosome binding domain 1 NOL6 nucleolar prot ein 6 (RNA-associat ed)
HRH3 hist amine recept or H3 NRSN2 neurensin 2
HS1BP3 HCLS1 binding prot ein 3 NUCKS1 nuclear casein kinase and cyclin-dependent  kinase subst rat e 1
HSD17B14 hydroxyst eroid (17-bet a) dehydrogenase 14 OGFOD2
2-oxoglut arat e and iron-dependent  oxygenase domain cont aining 
2
IDI2 isopent enyl-diphosphat e delt a isomerase 2 OGG1 8-oxoguanine DNA glycosylase
IFI27 int erf eron, alpha-inducible prot ein 27 OLFM1 olf act omedin 1
IFI30 int erf eron, gamma-inducible prot ein 30 OPTC opt icin
IGHA1 immunoglobulin heavy const ant  alpha 1 OR10H2 olf act ory recept or, f amily 10, subf amily H, member 2
IL10RA int er leukin 10 recept or, alpha OR10P1 olf act ory recept or, f amily 10, subf amily P, member 1
IL17A int er leukin 17A OR1D2 olf act ory recept or, f amily 1, subf amily D, member 2
IMPA1 inosit ol(myo)-1(or 4)-monophosphat ase 1 OR7E13P olf act ory recept or, f amily 7, subf amily E, member 13 pseudogene
IMPA2 inosit ol(myo)-1(or 4)-monophosphat ase 2 OR7E24 olf act ory recept or, f amily 7, subf amily E, member 24
IRX4 iroquois homeobox 4 OSBPL1A oxyst erol binding prot ein- like 1A
KALRN kalir in, RhoGEF kinase PADI4 pept idyl arginine deiminase, t ype IV
KCNG1 pot assium volt age-gat ed channel, subf amily G, member 1 PARP10 poly (ADP-r ibose) polymerase f amily, member 10
KCNH2
pot assium volt age-gat ed channel, subf amily H (eag-relat ed), 
member 2
PBX2 pre-B-cell leukemia homeobox 2
KIAA0513 KIAA0513 PBX2P1 pre-B-cell leukemia homeobox 2 pseudogene 1
KIAA0753 KIAA0753 PCDHA1 prot ocadherin alpha 1
KIAA1614 KIAA1614 PCDHB9 prot ocadherin bet a 9
KIAA1875 KIAA1875 PCDHGC4 prot ocadherin gamma subf amily C, 4
KIAA1919 KIAA1919 PCGF1 polycomb group r ing f inger 1
KIF1C kinesin f amily member 1C PCSK1N proprot ein convert ase subt ilisin/ kexin t ype 1 inhibit or
KLHL15 kelch-like f amily member 15 PDE6B phosphodiest erase 6B, cGMP-specif ic, rod, bet a
KLHL18 kelch-like f amily member 18 PDIA3 prot ein disulf ide isomerase f amily A, member 3
KLK10 kallikrein-relat ed pept idase 10 PEAK1 pseudopodium-enriched at ypical kinase 1
KLK15 kallikrein-relat ed pept idase 15 PER2 period circadian clock 2
KLK2 kallikrein-relat ed pept idase 2 PEX10 peroxisomal biogenesis f act or 10
KLK7 kallikrein-relat ed pept idase 7 PEX2 peroxisomal biogenesis f act or 2
KLK6 kallikrein-relat ed pept idase 6 PFKFB1 6-phosphof ruct o-2-kinase/ f ruct ose-2,6-biphosphat ase 1
KMT2C lysine (K)-specif ic met hylt ransf erase 2C PFKL phosphof ruct okinase, liver
KSR1 kinase suppressor of  ras 1 PGRMC2 progest erone recept or membrane component  2
L1CAM L1 cell adhesion molecule PID1 phosphot yrosine int eract ion domain cont aining 1
LAMA1 laminin, alpha 1 PIGG phosphat idylinosit ol glycan anchor biosynt hesis, class G
LARP1B La r ibonucleoprot ein domain f amily, member 1B PIGT phosphat idylinosit ol glycan anchor biosynt hesis, class T
LATS2 large t umor suppressor kinase 2 PIGY phosphat idylinosit ol glycan anchor biosynt hesis, class Y
LBH limb bud and heart  development PKD2L2 polycyst ic kidney disease 2- like 2
C6orf 1 chromosome 6 open reading f rame 1 PLAC1 placent a-specif ic 1
LFNG LFNG O-f ucosylpept ide 3-bet a-N-acet ylglucosaminylt ransf erase PLD1 phospholipase D1, phosphat idylcholine-specif ic
LINC00094 long int ergenic non-prot ein coding RNA 94 PCLD polycyst ic liver disease
LRP10 low densit y lipoprot ein recept or-relat ed prot ein 10 PLEKHF1
pleckst r in homology domain cont aining, f amily F (wit h FYVE 
domain) member 1
LRTOMT
leucine r ich t ransmembrane and O-met hylt ransf erase domain 
cont aining
PNMA3 paraneoplast ic Ma ant igen 3
LY6H lymphocyt e ant igen 6 complex, locus H PNPLA8 pat at in- like phospholipase domain cont aining 8
LY6K lymphocyt e ant igen 6 complex, locus K POC1A POC1 cent r iolar prot ein A
MAGOHB mago-nashi homolog B (Drosophila) PON3 paraoxonase 3
MALAT1
met ast asis associat ed lung adenocarcinoma t ranscript  1 (non-
prot ein coding)
POU5F1 POU class 5 homeobox 1
MAN2A2 mannosidase, alpha, class 2A, member 2 PPFIA1
prot ein t yrosine phosphat ase, recept or t ype, f  polypept ide 
(PTPRF), int eract ing prot ein ( lipr in), alpha 1
MAPK15 mit ogen-act ivat ed prot ein kinase 15 PPIA pept idylprolyl isomerase A (cyclophilin A)
MAPK8IP1 mit ogen-act ivat ed prot ein kinase 8 int eract ing prot ein 1 PPP1R3C prot ein phosphat ase 1, regulat ory subunit  3C
MARCKS myrist oylat ed alanine-r ich prot ein kinase C subst rat e PPP2CB prot ein phosphat ase 2, cat alyt ic subunit , bet a isozyme
MAU2 MAU2 sist er chromat id cohesion f act or PPP6R3 prot ein phosphat ase 6, regulat ory subunit  3
MCFD2 mult iple coagulat ion f act or def iciency 2 PRAF2 PRA1 domain f amily, member 2
MED13L mediat or complex subunit  13-like PRDM11 PR domain cont aining 11
MEF2B myocyt e enhancer f act or 2B PRKAG2 prot ein kinase, AMP-act ivat ed, gamma 2 non-cat alyt ic subunit
METTL15 met hylt ransf erase like 15 PRLHR prolact in releasing hormone recept or
MFN1 mit of usin 1 PROP1 PROP paired-like homeobox 1
MFSD12 major f acilit at or superf amily domain cont aining 12 PRR5 proline r ich 5 (renal)
MIR22HG MIR22 host  gene (non-prot ein coding) PRR7 proline r ich 7 (synapt ic)
MLXIPL MLX int eract ing prot ein- like PRSS42 prot ease, ser ine, 42
MOB1A MOB kinase act ivat or 1A PRSS53 prot ease, ser ine, 53
MPRIP myosin phosphat ase Rho int eract ing prot ein PTBP3 polypyrimidine t ract  binding prot ein 3
MRPL35 mit ochondrial r ibosomal prot ein L35 PUM2 pumilio RNA-binding f amily member 2
MSANTD2 Myb/ SANT-like DNA-binding domain cont aining 2 PYGO1 pygopus f amily PHD f inger 1
MSMB microseminoprot ein, bet a- QPRT quinolinat e phosphoribosylt ransf erase
MTPN myot rophin QSOX2 quiescin Q6 sulf hydryl oxidase 2
MTRF1L mit ochondrial t ranslat ional release f act or 1- like RAB22A RAB22A, member RAS oncogene f amily
MUC5B mucin 5B, oligomeric mucus/ gel- f orming RAB43 RAB43, member RAS oncogene f amily
MXRA5 mat r ix-remodelling associat ed 5 RABIF RAB int eract ing f act or
MYBL1 v-myb avian myeloblast osis viral oncogene homolog-like 1 RABL6 RAB, member RAS oncogene f amily- like 6
MYD88 myeloid dif f erent iat ion pr imary response 88 RAD23B RAD23 homolog B (S. cerevisiae)
MYL3 myosin, light  chain 3, alkali; vent r icular, skelet al, slow RAPGEF1 Rap guanine nucleot ide exchange f act or (GEF) 1
MYO1C myosin IC RASGEF1A RasGEF domain f amily, member 1A
MYO1E myosin IE RASGRP2 RAS guanyl releasing prot ein 2 (calcium and DAG-regulat ed)
MYO6 myosin VI RASGRP4 RAS guanyl releasing prot ein 4
NADSYN1 NAD synt het ase 1 RBM15B RNA binding mot if  prot ein 15B
NAGS N-acet ylglut amat e synt hase RFX2 regulat ory f act or X, 2 ( inf luences HLA class II expression)
NCKIPSD NCK int eract ing prot ein wit h SH3 domain RHBDL3 rhomboid, veinlet - like 3 (Drosophila)
NCL nucleolin RHOA ras homolog f amily member A
NDC1 NDC1 t ransmembrane nucleoporin RHOA ras homolog f amily member A
NDRG2 NDRG f amily member 2 RHPN1 rhophilin, Rho GTPase binding prot ein 1
NDST1 N-deacet ylase/ N-sulf ot ransf erase (heparan glucosaminyl)  1 RHPN2 rhophilin, Rho GTPase binding prot ein 2
NDST2 N-deacet ylase/ N-sulf ot ransf erase (heparan glucosaminyl)  2 RNH1 ribonuclease/ angiogenin inhibit or 1
NDUFA3 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 3, 9kDa RNASEH1P1 ribonuclease H1 pseudogene 1
NDUFAF7 NADH dehydrogenase (ubiquinone) complex I, assembly f act or 7 RPL22 ribosomal prot ein L22
NDUFB7 NADH dehydrogenase (ubiquinone) 1 bet a subcomplex, 7, 18kDa RPL23 ribosomal prot ein L23
NEK9 NIMA-relat ed kinase 9 RPL17 ribosomal prot ein L17
NES nest in RPL29 ribosomal prot ein L29
NFIB nuclear f act or I/ B RPL7A ribosomal prot ein L7a
NMT1 N-myrist oylt ransf erase 1 RPP25 ribonuclease P/ MRP 25kDa subunit
NMUR2 neuromedin U recept or 2 RPS13 ribosomal prot ein S13
NOL6 nucleolar prot ein 6 (RNA-associat ed) RPS26 ribosomal prot ein S26
NOTCH4 not ch 4 RPS6 ribosomal prot ein S6
NOV nephroblast oma overexpressed RPS6KA1 ribosomal prot ein S6 kinase, 90kDa, polypept ide 1
RPL10 ribosomal prot ein L10 RXFP4 relaxin/ insulin- like f amily pept ide recept or 4
PLXNA1 plexin A1 SAMD4A st erile alpha mot if  domain cont aining 4A
NPAS3 neuronal PAS domain prot ein 3 SC5D st erol-C5-desat urase
NPFFR2 neuropept ide FF recept or 2 SCAND2P SCAN domain cont aining 2 pseudogene
NPHP3 nephronopht hisis 3 (adolescent ) SCN3A sodium channel, volt age-gat ed, t ype III, alpha subunit  
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SDHAF2 succinat e dehydrogenase complex assembly f act or 2 TMEM169 t ransmembrane prot ein 169
SDHD
succinat e dehydrogenase complex, subunit  D, int egral membrane 
prot ein
TMEM209 t ransmembrane prot ein 209
SEMA4C
sema domain, immunoglobulin domain (Ig), t ransmembrane domain 
(TM) and short  cyt oplasmic domain, (semaphorin) 4C
TMEM214 t ransmembrane prot ein 214
SEPT12 sept in 12 TMEM237 t ransmembrane prot ein 237
SERF2 small EDRK-rich f act or 2 TMEM55A t ransmembrane prot ein 55A
SERTAD2 SERTA domain cont aining 2 TMEM97 t ransmembrane prot ein 97
SETD4 SET domain cont aining 4 TMPRSS6 t ransmembrane prot ease, ser ine 6
SETD8 SET domain cont aining ( lysine met hylt ransf erase) 8 TNFRSF21 t umor necrosis f act or recept or superf amily, member 21
SETD9 SET domain cont aining 9 TNRC18 t r inucleot ide repeat  cont aining 18
SH3BP5 SH3-domain binding prot ein 5 (BTK-associat ed) TNS1 t ensin 1
SHB Src homology 2 domain cont aining adapt or prot ein B TNXB t enascin XB
SHPK sedohept ulokinase TP53I11 t umor prot ein p53 inducible prot ein 11
SLC16A1 solut e carr ier f amily 16 (monocarboxylat e t ransport er), member 1 TPCN1 t wo pore segment  channel 1
SLC23A3 solut e carr ier f amily 23, member 3 TPM1 t ropomyosin 1 (alpha)
SLC25A52 solut e carr ier f amily 25, member 52 TRAK1 t raf f icking prot ein, kinesin binding 1
SLC2A8 solut e carr ier f amily 2 ( f acilit at ed glucose t ransport er), member 8 TREML1 t r iggering recept or expressed on myeloid cells- like 1
SLC31A1 solut e carr ier f amily 31 (copper t ransport er), member 1 TRIM33 t r ipart it e mot if  cont aining 33
SLC35E3 solut e carr ier f amily 35, member E3 TRIM35 t r ipart it e mot if  cont aining 35
SLC5A1 solut e carr ier f amily 5 (sodium/ glucose cot ransport er), member 1 TRIM62 t r ipart it e mot if  cont aining 62
SLC6A6 solut e carr ier f amily 6 (neurot ransmit t er t ransport er), member 6 TRMT2B t RNA met hylt ransf erase 2 homolog B (S. cerevisiae)
SMARCC1
SWI/ SNF relat ed, mat r ix associat ed, act in dependent  regulat or of  
chromat in, subf amily c, member 1
TRMT6 t RNA met hylt ransf erase 6 homolog (S. cerevisiae)
SMARCD1
SWI/ SNF relat ed, mat r ix associat ed, act in dependent  regulat or of  
chromat in, subf amily d, member 1
TRPV1 t ransient  recept or pot ent ial cat ion channel, subf amily V, member 1
SMARCD2
SWI/ SNF relat ed, mat r ix associat ed, act in dependent  regulat or of  
chromat in, subf amily d, member 2
TRPV2
t ransient  recept or pot ent ial cat ion channel, subf amily V, member 
2
SMG1 SMG1 phosphat idylinosit ol 3-kinase-relat ed kinase TSSK1B t est is-specif ic ser ine kinase 1B
SMPDL3B sphingomyelin phosphodiest erase, acid- like 3B TUBB4B t ubulin, bet a 4B class IVb
SND1-IT1 SND1 int ronic t ranscript  1 (non-prot ein coding) U2SURP U2 snRNP-associat ed SURP domain cont aining
SNX13 sort ing nexin 13 UBA2 ubiquit in- like modif ier act ivat ing enzyme 2
SOGA1 suppressor of  glucose, aut ophagy associat ed 1 UHRF1BP1 UHRF1 binding prot ein 1
SORBS1 sorbin and SH3 domain cont aining 1 UMOD uromodulin
SOX12 SRY (sex det ermining region Y)-box 12 USP54 ubiquit in specif ic pept idase 54
SOX17 SRY (sex det ermining region Y)-box 17 UTF1 undif f erent iat ed embryonic cell t ranscript ion f act or 1
SOX3 SRY (sex det ermining region Y)-box 3 UTS2R urot ensin 2 recept or
SP5 Sp5 t ranscript ion f act or VEGFA vascular endot helial growt h f act or A
SPAG9 sperm associat ed ant igen 9 VIPR2 vasoact ive int est inal pept ide recept or 2
SPATA32 spermat ogenesis associat ed 32 VPS11 vacuolar prot ein sort ing 11 homolog (S. cerevisiae)
SPRR2B small proline-r ich prot ein 2B WDR90 WD repeat  domain 90
SPTLC3 serine palmit oylt ransf erase, long chain base subunit  3 WHSC1 Wolf -Hirschhorn syndrome candidat e 1
SRSF11 serine/ arginine-r ich splicing f act or 11 YBEY ybeY met allopept idase (put at ive)
SSB Sjogren syndrome ant igen B (aut oant igen La) YBX1 Y box binding prot ein 1
SSBP2 single-st randed DNA binding prot ein 2 YWHAE
t yrosine 3-monooxygenase/ t rypt ophan 5-monooxygenase 
act ivat ion prot ein, epsilon
STEAP3 STEAP f amily member 3, met alloreduct ase YWHAZ
t yrosine 3-monooxygenase/ t rypt ophan 5-monooxygenase 
act ivat ion prot ein, zet a
STOM st omat in ZDHHC21 zinc f inger, DHHC-t ype cont aining 21
STOML2 st omat in (EPB72)- like 2 ZDHHC4 zinc f inger, DHHC-t ype cont aining 4
STX12 synt axin 12 ZFAND5 zinc f inger, AN1-t ype domain 5
SULT4A1 sulf ot ransf erase f amily 4A, member 1 ZFHX2 zinc f inger homeobox 2
SYNC syncoilin, int ermediat e f ilament  prot ein ZFYVE26 zinc f inger, FYVE domain cont aining 26
SZT2 seizure t hreshold 2 homolog (mouse) ZNF226 zinc f inger prot ein 226
TACR1 t achykinin recept or 1 ZNF333 zinc f inger prot ein 333
TBC1D20 TBC1 domain f amily, member 20 ZNF346 zinc f inger prot ein 346
TCEA3 t ranscript ion elongat ion f act or A (SII) , 3 ZNF440 zinc f inger prot ein 440
TCL6 T-cell leukemia/ lymphoma 6 (non-prot ein coding) ZNF467 zinc f inger prot ein 467
TCTE3 t -complex-associat ed-t est is-expressed 3 ZNF532 zinc f inger prot ein 532
TENC1 t ensin like C1 domain cont aining phosphat ase (t ensin 2) ZNF581 zinc f inger prot ein 581
TEX261 t est is expressed 261 ZNF644 zinc f inger prot ein 644
TFPI
t issue f act or pat hway inhibit or ( lipoprot ein-associat ed coagulat ion 
inhibit or)
ZNF681 zinc f inger prot ein 681
THRAP3 t hyroid hormone recept or associat ed prot ein 3 ZNF697 zinc f inger prot ein 697
TIMM8A t ranslocase of  inner mit ochondrial membrane 8 homolog A (yeast ) ZNF761 zinc f inger prot ein 761
TMCO1 t ransmembrane and coiled-coil domains 1 ZNF767 zinc f inger f amily member 767
TMED2 t ransmembrane emp24 domain t raf f icking prot ein 2 ZYG11B zyg-11 f amily member B, cell cycle regulat or
1. Inf ormat ion f rom HGNC (HUGO Gene Nomenclat ure Commit t ee; www.genenames.org). 1. Inf ormat ion f rom HGNC (HUGO Gene Nomenclat ure Commit t ee; www.genenames.org).  
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Abstract 
 
One of the major unanswered questions regarding the morphological 
characteristics of the skin during the aging process is whether the thickness of its 
main layers is altered. Some studies propose that stem cells are responsible for 
maintaining the proliferative potential of the epidermis in vivo, while others argue 
that this potential is lost during the aging process. In this study, we compare 
keratinocytes from neonatal and 26-, 36- and 48-year-old groups to evaluate their 
proliferative and differentiation potential, both in monolayer cultures and in skin 
reconstituted in vitro. Cells isolated from neonatal donors show higher expression 
levels of Ki67 and keratins 10 and 14. Furthermore, the number of neonatal cells in 
the G2/M phase of the cell cycle was strikingly higher. To determine the number of 
stem cells present in this population, we used the β1 and α6 integrins as molecular 
markers. Interestingly, we did not observe any differences among these cells in 
culture. In the reconstituted skin model, the cells isolated at different ages were 
able to undergo epidermal proliferation and differentiation in a similar manner. The 
expression of Ki67 and of keratins 10 and 14 were also higher in skin reconstituted 
with cells isolated from neonatal donors. In conclusion, cultured neonatal cells 
have a higher proliferative capacity and differentiation potential relative to adult 
cells isolated at different donor ages, as revealed by the markers tested. The 
monolayer and reconstituted skin models generated from cultured cells represent 
important alternative methods to investigate the process of skin aging.  
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Introduction 
 
All cells and organs of the body age gradually, and the skin can be used as 
a marker of this inevitable process. Skin is the largest organ of the human body 
and is a self-renewable tissue that is responsible for numerous physiological 
functions such as thermoregulation, protection against pathogens and ultraviolet 
radiation, tactile sensations, secretions, and excretion of toxins (Geusau et al., 
2001; Yamaguchi et al., 2006; Kirschner et al., 2013; Polak et al., 2013). Moreover, 
it is the first organ that shows the health and well-being of the individual and 
reflects numerous aesthetic parameters. 
 The skin consists of two compartments: the epidermis and the dermis 
(Gangatirkar et al., 2007). The epidermis is a stratified tissue that is histologically 
composed of four layers: the basal layer, containing epidermal stem cells (SC) and 
a population of transient amplifying cells (TA); the spinous layer, containing 
differentiating cells; the granular layer, containing cells that have already 
differentiated; and the stratum corneum, which is populated by dead cells (Rizvi 
and Wong, 2005; Gangatirkar et al., 2007).  
 Aged skin is thinner and has a lower healing potential compared with 
youthful skin. Nevertheless, it is still able to heal and regenerate its epithelium, 
showing that it retains, at least partially, cell renewal potential (Webb and Kaur, 
2006; Racila and Bickenbach, 2009; Winter and Bickenbach; 2009). Numerous 
studies in the literature have addressed whether the characteristics of skin cells are 
related to the anatomical morphology of the skin. One of the major points 
discussed in these studies is the thickness of the epidermal layer. Many studies 
describe a flattening at the epidermal-dermal junction and a decrease in the 
thickness of these layers in aged skin (Fenske and Lober 1986; Fenske and 
Conard, 1988). However, some authors still argue against these points, showing 
that there is no consensus on this topic. Different studies have reported large 
variations in the epidermal and dermal thickness during the aging process. 
However, it is important to note that these studies have compared different 
parameters, such as the anatomical sites and phenotypic features of the 
126 
 
individuals examined (Ya-Xian et al., 1999; Nozdrin et al., 2011; Baroni et al., 
2012; Crisan et al., 2012; Waaijer et al., 2012; Tsugita et al., 2013; Shlivko et al., 
2013).  
 One explanation for the decreased epidermal thickness is related to the 
decreased proliferative potential of its main cell type, the keratinocyte, during the 
aging process. Grove and Kligman (1983) evaluated cell renewal in the human 
epidermis using a fluorescent marker. These authors reported that the dye 
disappeared from the stratum corneum at 20 days in young adults, while it 
persisted for up to 30 days in older adults. However, these authors note that the 
number of layers of horny cells did not change with increasing age. This finding 
was proposed to result from a decreased proliferation of epidermal cells. This study 
also reported that cells maintain a constant renewal rate in the early years of life 
that decreases over time, with a dramatic reduction after 50 years (Grove and 
Kligman, 1983). Subsequent studies have attempted to explain possible 
differences in the thickness of the epithelium in vivo by correlating the presence of 
SC with the proliferative capacity of keratinocytes in vitro. Stem cells derived from 
adult tissues in some regions of the body are defined as rare and relatively 
quiescent, with the capacity to constantly self-renew and regenerate tissues during 
homeostasis. Some authors claim that epidermal SC appears to resist aging. They 
do not show age-related changes in gene expression, cell number and telomere 
length, thus maintaining the capacity to respond to environmental changes. In 
addition, these cells do not show defects associated with increasing levels of 
reactive oxygen species encountered during the process of cellular aging (Li et al., 
2004; Racila and Bickenbach, 2009). However, other studies suggest that the 
transient amplifying cells also possess multipotency and an extensive capacity for 
tissue regeneration (Clayton et al., 2007; Schlüter et al., 2011). Another important 
issue to note is that some authors claim that it is more difficult to isolate and to 
maintain cultured keratinocytes from elderly donors compared with young or 
neonatal donors. Youn et al. (2004) reported that this can be explained by cellular 
senescence, chronological aging, or repeated sub-culture that induces the loss of 
SC in keratinocyte cultures and in vitro reconstituted epidermis models.  
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 By comparing the literature, we have observed that the many different 
findings may correlate, and depend upon, the experimental model used in each 
study. Our study focuses on in vitro models, which are extensively used due to 
their ease of production, practicality and reproducibility. Therefore, we compare 
keratinocytes from neonatal and 26-, 36- and 48-year-old groups in this study to 
determine the differences in their proliferative capacity and differentiation potential, 
both in a monolayer model as well as in an in vitro reconstituted skin model. We 
also determined the number of stem cells (SC) and transient amplifying cells (TA) 
present in each of these populations. The data presented here confirm that the 
proliferation capacity and differentiation potential of neonatal and adult cells is 
significantly different for all conditions examined, while the cells isolated from adult 
donors do not show striking differences in vitro. 
 
Materials and methods 
 
Cell culture 
 
The primary cells used in this work were obtained from Cascade Biologics 
(Portland, OR, USA). The keratinocytes used were isolated at different donor ages: 
neonatal and 26, 34, 36 and 48 years old (lots 979196, 950451, 952853, 1030541, 
1249380 and 1139070, respectively). Fibroblasts were isolated from a 37-year-old 
donor (lot 759506). Fibroblasts were grown in Dulbecco’s modified Eagle’s medium 
(DMEM) (Gibco, Grand Island, NY, USA) supplemented with 10% fetal bovine 
serum (FBS, Gibco), 50 U/mL penicillin and 50 µg/mL streptomycin (Gibco). 
Keratinocytes were maintained in Epilife media (SKU # M-EPICF-500, Cascade 
Biologics) supplemented with Human Keratinocyte Growth Supplement (HKGS, 
SKU # S-001, Cascade Biologics). All cells were maintained at 37°C under 5% 
CO2.  
 
 
 
128 
 
Fluorescence microscopy 
 
Keratinocyte monolayer cultures derived from donors of different ages were 
plated in 96-well plates. After the incubation period, the cells were fixed with 
methanol (Sigma, St. Louis, MO, USA) for ten minutes followed by three washes 
with PBS (Sigma, diluted 10x). The primary antibody staining was performed 
overnight at 4°C. The antibodies used were Ki-67 (clone B56, BD Pharmingen, 
Biosciences, Bedford, MA, USA), keratin 10 MAb Ms (Abcam, ab9026; Cambridge, 
Cambridgeshire, England) and keratin 14 MAb Ms (Abcam, ab7800). The 
antibodies were diluted in PBS containing 2% BSA (Sigma, 9576). Following the 
primary antibody incubation, the cells were washed with PBS and incubated with 
the secondary antibodies, Alexa Fluor 488 goat anti-mouse (Molecular Probes, 
Eugene, OR, USA; A11029) or Alexa Fluor 488 goat anti-rabbit (Molecular Probes, 
A11034), diluted in PBS containing 1% BSA and 0.1% Tween 20 for one hour 
(Amersham Biosciences, Uppsala, Uppsala Country, Sweden,17-1316-01). The 
cells were washed with the same buffer, and then fixed with NucBlue cell stain 
(Molecular Probes, R37606) for nuclear staining. All images were acquired using 
an Image Xpress Micro microscope (Molecular Devices). The fluorescence 
intensity analyses were performed with the MetaXpress 4.0 software.  
 
Cell cycle analysis 
 
DAPI, which binds stoichiometrically to DNA, was used to quantitatively 
assess DNA content. Seventy thousand cells were centrifuged at 1000 rpm for 5 
min at 4°C. The pelleted cells were fixed in ice-cold 70% ethanol for 30 minutes 
and washed twice in PBS. Cells were subsequently incubated for 1 h at room 
temperature with DAPI, and then evaluated by a FACS Aria I flow cytometer using 
the DIVA software (Becton Dickinson, San Diego, CA, USA). Ten thousand events 
were analyzed per experiment. The processed single cells were plotted on gated 
histograms to calculate the number of cells in the G1, S and G2/M phases.  
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Determination of stem cells in the cultures isolated from donors of different ages 
 
To determine the percentage of KSC in the samples isolated from donors of 
different ages, 105 cells from each individual donor were used. Following 
trypsinization and washing with PBS, the cells were blocked with 500 μL of BSA 
Stain Buffer (BD, 554657) and double-stained with the following antibodies: CD29 
(BD, 555443) and CD49f (BD, 551129). After 30 minutes of labeling at 4°C in the 
dark, the cells were centrifuged at 6300 rpm for 3 minutes, resuspended in PBS 
and kept at 4°C until analysis on a FACS Aria I flow cytometer (Becton Dickinson). 
Ten thousand events were acquired per experiment. The data were analyzed using 
the DIVA software. 
 
In vitro skin reconstitution 
 
The skin reconstitution model was adapted from Gangatirkar et al. (2007). 
Briefly, the dermal equivalent was prepared using 6x104 fibroblasts embedded in a 
type I collagen matrix (BD). After polymerization of the dermal equivalent, 1.2x105 
keratinocytes isolated from donors of different ages (neonatal and 26, 34, 36 and 
48 years old) purchased from Cascade Biologics or freshly isolated were plated 
above the dermal layer. After 24 hours, the equivalent was kept on an air-liquid 
interface while maintaining contact with the differentiation medium consisting of 
15% of DME (Gibco, 12800-017), 5% Ham's F12 (Gibco, 114971), 2% Fetal 
Bovine Serum (Gibco, F0926), 0.5 μg/mL Transferrin (T-8158, Sigma), 5 μg/mL 
Insulin (I-9278, Sigma) and 10 ng/mL EGF (human epidermal growth factor, 
53003-18, Gibco). After 10 days on the air-liquid interface, the reconstituted skin 
was fixed in 4% formaldehyde (Sigma, F8775). 
 
Immunostaining 
 
After deparaffinization and rehydration, antigen retrieval was performed in 
Tris- EDTA, pH 9.0 (S3307, Dako, Carpinteria, CA, USA), using a water bath 
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heated with steam and maintained at 97°C for 30 minutes. The slides were cooled 
to room temperature for 20 minutes and then washed with distilled water and TBST 
buffer (Tris-buffered saline with 0.01% Tween-20, 3306, Dako). The slides were 
blocked with 2% BSA for 2 hours at 37°C. Immunohistochemical analyses were 
performed with the following primary antibodies: Ki-67 (clone B56, BD Pharmingen, 
556027), keratin 10 MAb Ms (Abcam, ab9026) and keratin 14 mAb Ms (Abcam, 
ab7800) ARK (Animal Research Kit, K3954, Dako). The primary antibody was 
omitted in the negative controls. 
 
Statistical analyses 
 
Cell cycle and fluorescence microscopy analyses are expressed as means ± 
SEM. The Graph Pad Prism 6 (version 6.00 for Windows Vista, Graph Pad 
Software, San Diego, CA, USA) software and a two way ANOVA test were used to 
perform statistical analyses. A one-way ANOVA with multiple comparison test 
(Tukey–Kramer Multiple Comparisons Test) was used for data analyses. We used 
correlation analysis to identify potentially causal associations between variables.  
 
Results 
 
Cell differentiation and proliferation in monolayer cultures 
 
To assess the differences among keratinocytes isolated from donors of 
different ages, monolayer cultures of cells isolated from neonatal and from 26-, 36- 
and 46-year-old donors were stained with a nuclear marker of cell proliferation, 
Ki67, and markers of cell differentiation, keratin 10 and 14. As shown in Figure 1, 
the neonatal cells display both an increased number of Ki67-labeled nuclei and a 
more pronounced staining with this cell proliferation marker, indicating higher 
expression levels of Ki67 in the neonatal cells. A quantification of the fluorescence 
intensity of Ki67 staining revealed a significant difference between the neonatal 
and adult cells (p<0.05). Higher expression levels were also observed for the 
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differentiation markers keratin 10 (p<0.01) and keratin 14 (p<0.05) in neonatal 
keratinocytes compared with adult keratinocytes. However, no differences were 
observed among the keratinocytes isolated from the adults of different ages. 
 
Cell cycle analyses 
 
Because Ki67 expression analyses in monolayers revealed an increased 
expression of this proliferation marker in neonatal cells (Figure 1), we performed 
cell cycle analyses to determine whether there is indeed a difference in cell cycle 
phases among cells isolated from donors of different ages. The cell cycle analyses 
were performed by flow cytometry, using DAPI staining of the DNA content to 
differentiate between the cell cycle phases. Figure 2a shows the histograms 
obtained from these analyses. This figure shows the distribution of the number of 
cells in each cell cycle phase for the four ages analyzed. Figure 2b shows that the 
neonatal cultures exhibit a significant decrease in the number of cells in the G0/G1 
phase (p <0.01) and a striking increase in the number of cells in the G2/M phase (p 
<0.001) compared with adult cells. The only difference detected among the adult 
cells was a reduction in the number of S phase cells from the 48-year-old donor (p 
<0.05); no significant differences were observed in the other phases analyzed. 
 
Analysis of keratinocyte stem cells 
 
To determine whether the differences in cell proliferation were related to 
changes in the number of KSC (keratinocyte stem cell) present in the neonatal and 
adult cell populations, we tested two typical markers of KSC: the β1 and α6 
integrin. The KSC population should be double positive for the β1 (CD29) and α6 
integrin (CD49f) markers. The KSCs are distinguished from the transient amplifying 
cells (TAs) by exhibiting a strong, bright signal for β1 integrin, whereas TA cells 
exhibit a dim signal. The α6 integrin signal is bright for both populations. Both cell 
types can be accordingly identified as KSCβ1bri,α6 bri differentiating cells and 
TAβ1dim,α6 bri differentiated keratinocytes (Kaur and Li, 2000). 
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Figure 1. Fluorescence microscopy analysis of proliferation (Ki67) or differentiation (keratin 10 and 14) markers and their respective negative 
controls. Cells isolated from neonatal or 26-, 36- and 48-year-old adult donors were used in these analyses. The graphs on the right hand side 
show the ratio of fluorescence intensity per total cell number for the three marker proteins tested. A significantly higher number of neonatal cells 
(p <0.05) demonstrate positive staining for the three markers tested compared with adult cells. Magnification 20x 
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Figure 2. Cell cycle analyses of keratinocytes isolated from donors of different ages. (A) The histograms show the cell cycle distribution 
according to the DNA content for each age tested. G0/G1, S and G2/M indicate the cell cycle phases. (B) The graphs show the percentage of 
cells in each cell cycle phase for the four ages tested. Note that the neonatal cells have a smaller number of cells in the G0/G1 (p <0.01) and a 
strikingly large number of cells in the G2/M proliferative phase (p <0.001). On the other hand, the 48-year-old cells show a significant reduction in 
the number of S phase cells (p <0.05). 
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As shown in Figure 3, it was not possible to detect KSCs in any of the cells 
analyzed because the populations were very homogenous and stained brightly for 
both the β1 and α6 integrins. No differences were observed among the adult cells 
isolated from donors of different ages (data not shown).  
 
 
Figure 3. The dotplot and histograms show the β1 and α6 integrin staining in neonatal and 48 year-
old donor cells. All cells are positive for both markers. Only one population detected shows that 
cells in culture form a homogenous population, as determined by the expression of the β1 and α6 
integrin markers. 
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Skin reconstitution using cells from donors of different ages 
 
To examine keratinocyte proliferation and differentiation in a model that 
mimics human skin, cells isolated from donors of different ages were used to 
reconstitute skin in vitro. As shown in Figure 4, all cells were able to differentiate 
and form a multi-layered epithelium containing the four main layers of the 
epidermis (basal, spinous, granular and stratum corneous; HandE staining). As in 
the monolayer model, more intense Ki67 labeling and an increased number of 
Ki67-labeled nuclei (indicated by arrows) were observed in the skin reconstituted 
with neonatal cells relative to skin reconstituted with aged cells. Higher expression 
levels of keratin 14, a marker for basal cells, were also present in the skin 
reconstituted with neonatal derived cells. A similar increase in the expression 
levels of keratin 10, a marker of differentiated cells was observed in the skin 
reconstituted with neonatal cells; however, it was less pronounced than the 
increased expression of Ki67 and keratin 14. 
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Figure 4. Analysis of skin reconstituted in vitro. Keratinocytes isolated from different age groups were used to show the proliferation and 
differentiation potential in a three-dimensional model. The H&E staining shows that all cells have a similar potential to form the main layers of the 
epidermis. However, neonatal cells show a stronger signal than adult cells for Ki67, keratin 10 and keratin 14 staining. The negative controls for 
immunostaining are shown. Magnification 20x. 
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Discussion 
 
One of the most controversial issues in the literature describing the 
morphological characteristics of skin aging is the proliferation and differentiation of 
keratinocytes. Some authors claim that there is a decrease in the proliferative 
potential of these cells during aging, while others argue that there are no 
detectable differences in the thickness of the epidermis at different ages. Ya-Xian 
et al. (1999) determined the number of cell layers in the stratum corneum of normal 
skin at different anatomical locations in the body of 301 volunteers of various ages. 
These authors reported large variations in the number of cell layers that depended 
on two factors: body location and genetic variability. In contrast, Baroni et al. 
(2012) reported no significant age associated differences in the thickness of the 
epidermal and dermal layers in a study including 218 Caucasian women. However, 
in a study of 286 Dutch individuals from middle-aged offspring with siblings older 
than 90 years, and therefore, a genetic predisposition to longevity, and their 
partners without this favorable genetic condition, Waaijer et al. (2012) 
demonstrated that epidermal thickness is reduced during the aging process. 
Furthermore, there were no differences between the genetically privileged and 
non-privileged individuals. We presumed that the variations among the 
experimental models used in these studies might explain the different conclusions 
reached by the investigators. Thus, we compared keratinocytes cultures derived 
from donors of different ages in this study to evaluate the effects of culture 
conditions on keratinocyte proliferation and differentiation.  
To understand how the experimental conditions affect the proliferative 
capacity and differentiation potential of keratinocytes, we tested different markers 
identifying these processes in monolayer and reconstituted skin cultures using cells 
isolated from donors of different ages (Figure 1). Ki67 is a nuclear antigen present 
in proliferating cells, but absent from cells in the S phase of the cell cycle (Gerdes 
et al., 1983; Rahmanzadeh et al., 2010). A previous study of scalps isolated during 
the autopsies of males between 7 months and 75 years of age (Nozdrin et al., 
2011), analyzed the expression of p53, Ki67 and involucrin and determined their 
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relationship to the proliferative layers of the epidermis. This report found that the 
epidermis was thinner in children with low p53 and Ki67 expression. This study 
also reported that the maximum proliferative activity was obtaining in skin isolated 
from 19- to 21-year-old individuals. Aging was associated with a reduction in the 
proliferation rate and, consequently, a thinning of the epidermis and an increase in 
the number of p53-positive cells. No changes were detected in the expression of 
involucrin. Contrary to the results described by Nozdrin et al. (2011), the neonatal 
cells cultured in vitro in this study exhibited higher expression levels of Ki67 
compared with adult cells isolated from donors of different ages, both in the 
monolayer model (Figure 1) and in the in vitro reconstructed skin model (Figure 4).  
Keratins are major structural proteins synthesized by keratinocytes (Prokshk 
et al., 2008). Keratinization is the terminal differentiation process of epidermal 
keratinocytes from the basal layer to the stratum corneum, forming a three-
dimensional network and a highly dynamic cytoskeleton that is essential for the 
mechanical stability of epithelial tissues (Arin, 2009; Ramot et al., 2009). During 
this process, pairs of keratins are expressed in a highly specific manner for each 
dynamic stage of epithelial differentiation (Moll et al., 2008; Arin, 2009). The keratin 
family consists of 54 functional genes that have different modes of expression in 
different skin layers and in different organs, representing physiological and 
pathological states of epithelial cells and epidermal cells (Ramot et al., 2009). In 
the epidermis, the transition of keratinocytes from the proliferative basal layer to 
the spinous layer during the terminal differentiation process is characterized by 
changes in keratin expression. This involves a change in expression from the basal 
keratins (keratins 5, 14 and 15) to the suprabasal keratins (type II keratin 1 and 
subsequently type I keratin 10) (Moll et al., 2008; Arin et al., 2009). 
The data presented here show that all cultured keratinocytes, regardless of 
age, are capable of passing through terminal differentiation as demonstrated by the 
stratification observed in the in vitro reconstituted skin model (Figure 4, HandE). 
However, neonatal keratinocytes exhibit higher expression levels of keratin 10 and 
14, both in monolayer cultures (Figure 1) and in reconstituted skin (Figure 4), 
although keratin 10 does not seem to be expressed at the same levels as keratin 
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14. Together, these results reveal that a larger number of neonatal cells have 
proliferative potential compared with adult cells. 
Numerous analyses of epithelial cell kinetics in vivo suggest that the 
sustained cell renewal of the epidermis can be attributed to long-lived SC because 
the life expectancy of the majority of proliferating epidermal cells (transient 
amplifying cells) is short, and a rapid loss of those cells occurs due to terminal 
differentiation within a period of weeks (Morris et al., 1985; Bickenbach et al., 1986, 
Li et al., 2004). The growth capacity exhibited by the cultured epidermal cells is 
attributed to the activity of stem cells; once transplanted, cells maintain the ability 
to renew the epithelium over a longer period of time (Pellegrini et al. 1999; Li et al., 
2004).  
Epidermal stem cells or keratinocyte stem cells (KSCs) are unique among 
somatic stem cells because, regardless of the age of the skin, the epidermis must 
be replaced continuously, requiring these cells to function correctly (Webb and 
Kaur, 2006; Racila and Bickenbach 2009). As their name indicates, KSCs are pre-
keratinocyte. The cell division of KSCs gives rise to a new population of 
keratinocytes in culture (Papini et al., 2003). Moreover, after isolation and 
selection, KSC cultures produce keratinocytes that will differentiate and give rise to 
the three populations of transiently amplified and differentiated keratinocytes.  
Several enrichment protocols have been reported in the literature for the 
separation of the basal layer of KSC or progenitors (TA), including the use of β1 
integrin (Jones et al., 1995; Kaur and Li, 2000), integrin α6 and transferrin receptor 
CD71 (Li et al., 1998; Tani et al., 2000). Thus, we examined the KSC and TA 
populations present in keratinocyte cultures from donors of different ages (Figure 
3). Interestingly, no differences were detected among the cells isolated from 
donors of different ages, as it was not possible to differentiate the KSCβ1bri,α6 bri from 
the TAβ1dim,α6 bri populations in cultured keratinocytes. One explanation for this 
result is that these are cultured, and not freshly isolated cells. Kaur et al. (2004) 
note the importance of working with freshly isolated cells rather than cultured cells 
to identify and isolate epidermal stem cells. They claim that the expression of the 
main markers present in vivo may be altered following in vitro culturing. In our lab, 
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we have observed that it is possible to separate the KSC population and to obtain 
thicker epithelia in skin reconstructed in vitro (data not shown) by using freshly 
isolated samples. In addition, the higher expression levels of the keratin 10 
differentiation marker observed in the cultured cells could explain the lack of a KSC 
population (Webb et al., 2004). Another possibility is that the isolation of adult 
keratinocytes and, therefore, separation of KSC, is more complex compared with 
neonatal keratinocytes. A study by Gragnani et al. (2008) examined primary 
keratinocytes isolated from the skin of 22 patients with ages ranging between 0 
and 15 years and found that the highest number of single cells was obtained in the 
0- to 3-year-old group, with approximately 4 x 106 cells. The number of single cells 
isolated falls to 106 in the oldest ages, and a direct inverse relationship was 
observed between age and the number of isolated cells: as age increased, the 
number of isolated cells decreased. 
In conclusion, this work shows that in vitro models are promising tools for 
studying the epidermal aging process, although some issues, such as the 
reprogramming of gene expression and the selection of cell subpopulations, still 
need to be considered. Cultured neonatal cells have a higher proliferative capacity 
and differentiating potential compared with adult cells. The adult cells derived from 
donors of different ages did not exhibit differences in their proliferation capacity or 
differentiation potential in either the monolayer or reconstructed skin models, as 
determined by Ki67 or keratin 10 and 14 labeling, respectively. KSCs should be 
studied in freshly isolated cell preparations because reliable markers for KSC 
identification are still lacking, and the integrins used to enrich stem cell populations 
are upregulated when keratinocytes are cultured. Finally, this work shows that 
cultured cells can be used as an alternative method to understanding the 
differences in the proliferation and differentiation processes between neonatal and 
adult cells. Future studies are needed to verify whether there are the differences in 
adult cells freshly isolated from donors of different ages cultured in vitro. 
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4. DISCUSSÃO GERAL 
 
Com base na análise global da expressão de genes, o presente trabalho 
indica evidências para a regulação molecular associada ao processo de 
envelhecimento epidermal, mais especificamente de regiões continuamente 
expostas à radiação solar. O estudo experimental inicial, baseado na avaliação da 
epiderme obtida com fitas adesivas, evidenciou a regulação de processos 
biológicos de diferenciação e atividade dos queratinócitos. Processos como 
proliferação celular não foram enriquecidos, possivelmente porque as células da 
camada basal da epiderme não puderam ser coletadas devido a limitações da 
técnica empregada. Considerando amostras coletadas do dorso das mãos, este 
trabalho representou o primeiro estudo com foco na avaliação do transcriptoma 
epidermal humano de região exposta ao sol. 
É importante notar que alguns estudos já avaliaram os efeitos do 
envelhecimento em pele humana completa, contendo epiderme e derme. 
Entretanto, a maioria tem provado dificuldades de interpretação frente à 
heterogeneidade das amostras biológicas, tanto em termos de varialibidade 
interindividual como também com relação à complexidade tecidual (Gromov et al., 
2003). Visando superar tal dificuldade, as análises de expressão gênica global em 
nosso trabalho foram conduzidas apenas com material de origem epidermal e com 
um tamanho amostral significativo, possibilitando um delineamento experimental 
reforçado e favorecendo o enriquecimento de listas de genes diferencialmente 
expressos. Além disso, buscando completar as informações já existentes na 
literatura científica, utilizamos um painel experimental de amplo espectro com 
relação às faixas etárias avaliadas, segmentado a cada década entre 20 e 80 
anos.  
Inicialmente, buscando estabelecer comparativos com a grande maioria dos 
estudos, realizamos uma análise prévia com os indivíduos organizados em dois 
grupos polarizados quanto ao envelhecimento: abaixo de 50 anos ou jovens e 
acima de 50 anos ou idosos. Dentre os processos biológicos que apresentaram 
regulação significativa com o avanço da idade, alguns complementam achados 
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prévios da literatura, como a indução de apoptose na epiderme fotoenvelhecida, 
marcada pela presença de queratinócitos apoptóticos (Leyden, 2001; Van 
Laethem et al., 2005). Um estudo recente avaliou mudanças relacionadas à idade 
na composição do envelope córneo na pele humana (Rinnerthaler et al., 2013). 
Corroborando com nossos achados, os autores observaram alterações 
significativas na expressão dos genes envolvidos nas etapas iniciais de montagem 
do estrato córneo. Por outro lado, nossos dados mostraram padrões distintos na 
expressão de genes como loricrina, sugerindo características específicas da 
regulação gênica epidermal em tecido exposto ao sol. Tal ocorrência poderia 
ajudar a explicar mudanças clínicas só observadas na pele fotoexposta, como o 
espessamento epidermal (Leyden, 2001; El-Domyati et al., 2002), que não 
acomete regiões fotoprotegidas (Lock-Andersen et al., 1997; Makrantonaki e 
Zouboulis, 2007). Ainda, também evidenciamos modulações em vias metabólicas 
relacionadas à sinalização de cálcio e sinalização do citoesqueleto de actina, 
podendo contribuir na elucidação de mecanismos moleculares envolvidos na 
perda do gradiente epidermal de cálcio (Denda et al., 2003) ou em alterações 
morfológicas que acometem queratinócitos envelhecidos, que apresentam forma 
irregular, alargada e achatada (Soroka et al., 2008). Dessa maneira, nossos 
resultados sugerem um mecanismo diferenciado do envelhecimento epidermal em 
regiões de pele fotoexposta, incluindo distúrbios na formação do estrato córneo, 
ainda sem descrição na literatura e com potencial desdobramento em estudos 
futuros. 
Além dos resultados já destacados, utilizamos uma abordagem diferenciada 
para análise do envelhecimento em nosso modelo experimental. Com base na 
proposição de que o envelhecimento é um processo contínuo e cumulativo, 
também realizamos análises com voluntários agrupados em diferentes décadas de 
vida. Em cada década, utilizamos como critério de inclusão dos voluntários uma 
variação reduzida ao redor da idade média desejada, como nos grupos de 20 ± 1 
ano ou 30 ± 1 ano, por exemplo, visando restringir possíveis componentes de 
variabilidade individual intragrupo. Por outro lado, a diferença entre as idades 
médias de cada grupo, de 10 anos, foi mantida constante. Tais definições foaram 
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adotadas no estudo visando facilitar a identificação de características comuns 
dentro de uma faixa etária específica e que pudessem apresentar variação entre 
as diferentes idades. Calculando a diferença entre o número de genes com 
aumento de expressão e aqueles com diminuição de expressão em cada década, 
observamos um perfil oscilatório ao longo das idades, remetendo à idéia de um 
equilíbrio dinâmico de regulação constante como o que ocorre em respostas 
compensatórias de restabelecimento homeostático. Ainda, uma análise adicional 
foi realizada para identificar genes que tendem a mudar sua expressão de forma 
contínua ao longo da vida. 
 No segundo trabalho experimental da tese, uma nova análise de expressão 
gênica global aplicando microarranjos de DNA foi utilizada para avaliar 
modulações transcricionais associadas ao envelhecimento da epiderme, desta vez 
coletada a partir de bulbos de folículos pilosos da região das sobrancelhas. A 
análise do envelhecimento foi determinada comparando mulheres adultas 
distribuídas em dois grupos de idade, com menos de 50 anos ou jovens e mais de 
50 anos ou idosas, divididas de acordo com o critério biológico da ocorrência de 
menopausa ao redor dos 50 anos da mulher. Interessantemente, o agrupamento 
hierárquico espontâneo das amostras biológicas evidenciou uma repartição em 
dois grupos muito similares ao que se esperava obter com a proposição dos 
grupos pré e pós-menopausa, reforçando a significância da ocorrência da 
menopausa na mulher como agente desencadeante de uma mudança sistêmica 
com grande impacto sobre a pele (Raine-Fenning et al., 2003). 
Uma diferença importante que deve ser destacada ao compararmos nossos 
resultados obtidos a partir da epiderme derivada de fitas adesivas ou folículos 
pilosos: as camadas ou mesmo os tipos celulares coletados a partir de cada uma 
das técnicas são significativamente distintos. Enquanto o material proveniente de 
fitas adesivas deve ser enriquecido em queratinócitos em estágio final de 
diferenciação das camadas espinhosa ou granulosa (principalmente), o material 
dos folículos pilosos deve ser rico em células epidermais não diferenciadas ou em 
estágio inicial de diferenciação, representando nichos biológicos com 
particularidades funcionais e moleculares (Blanpain and Fuchs, 2009). Além disso, 
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o processo de diferenciação destas células presentes no folículo piloso é distinto 
da diferenciação epidermal prevista para regiões interfoliculares, provavelmente 
envolvendo a ocorrência de eventos moleculares independentes que culminam 
com a expressão de diferentes tipos de queratina, dentre outros (Schweizer et al., 
2007; Jiang et al., 2010; Mascré et al., 2012).  
 Diferentemente dos resultados obtidos com fitas adesivas, as análises do 
material epidermal proveniente de pelos de sobrancelhas revelou resultados 
difíceis de correlacionar com aspectos clínicos e morfológicos do envelhecimento 
epidérmico. De fato, observou-se uma prevalência de processos biológicos de 
largo espectro ou generalistas, tais como metabolismo celular, processos 
biossintéticos e regulação da expressão gênica ou transcrição. Além disso, a 
modulação de diversas vias de sinalização foi uma característica marcante do 
envelhecimento deste tipo de material biológico, incluindo genes representativos 
como proteínas do tipo zinc finger e elementos associados. De acordo com um 
recente trabalho de Tevy et al. (2013), por razões ainda desconhecidas, há um 
declínio no ritmo circadiano com a idade. A temporização da divisão e 
diferenciação de células proliferativas na epiderme do folículo piloso, por sua vez, 
depende de um controle associado ao ritmo circadiano, de forma que 
camundongos com ritmo circadiano perturbado apresentam envelhecimento 
epidermal prematuro e predisposição à tumorigênese (Janich et al., 2011). Assim, 
estudos futuros poderiam ser conduzidos para estabelecer uma ligação entre a 
ocorrência de um ritmo circadiano perturbado com a regulação do comportamento 
de células proliferativas na epiderme do folículo piloso com a idade. Considerando 
nossos resultados, a desregulação da sinalização celular na epiderme folicular 
com o envelhecimento pode ser um dos caminhos decisivos para o melhor 
entendimento destes aspectos. 
 No terceiro trabalho experimental, buscamos estabelecer um comparativo 
entre características do envelhecimento epidermal in vivo e modelos que aplicam 
culturas in vitro de queratinócitos. Para isso, trabalhamos com células adquiridas 
comercialmente e isoladas de doadoras de diferentes faixas etárias, avaliando 
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características como potencial proliferativo, expressão de marcadores de 
diferenciação epidermal e capacidade de originar epiderme reconstituída in vitro. 
 A literatura científica não é homogênea quanto ao potencial proliferativo dos 
queratinócitos com o envelhecimento. Ya-Xian et al. (1999) determinou o número 
de camadas celulares no estrato córneo de 301 voluntários de várias idades, 
relatando variações que dependem da localização do corpo e fatores genéticos. 
Baroni et al. (2012) não relataram diferenças significativas na espessura das 
camadas epidérmicas com a idade em 218 mulheres caucasianas. Por sua vez, 
Waaijer et al. (2012) demonstraram que a espessura da epiderme é reduzida com 
o envelhecimento em 286 indivíduos de descendência holandesa. 
 Em nossos ensaios in vitro, as células de doadores de diferentes idades 
foram capazes de originar epidermes reconstituídas, indicando um potencial 
proliferativo e de diferenciação preservados com o avanço da idade. Entretanto, a 
expressão dos marcadores moleculares de proliferação e diferenciação foi 
significativamente maior nas células derivadas de neonatos, em comparação com 
as demais faixas etárias avaliadas que variavam de 20 a 50 anos, 
aproximadamente. Tal ocorrência foi observada para a expressão de Ki67, um 
antigénio nuclear marcador de proliferação, e queratinas, incluindo os tipos 10 e 
14, tanto no modelo de cultivo em monocamada quanto na pele reconstituída. 
Como não foi possível detectar diferenças entre as faixas etárias adultas, ao 
contrário do que já foi observado in vivo para marcadores como o Ki67 (Nozdrin et 
al., 2011), nossos resultados sugerem limitações do modelo in vitro para 
determinados estudos de envelhecimento cutâneo. Como foi possível diferenciar 
ao menos a expressão dos marcadores nas células de neonatos, acreditamos que 
os modelos in vitro consigam preservar e evidenciar mudanças moleculares que 
caracterizam o envelhecimento epidermal. Entretanto, mudanças mais tênues 
podem ser perdidas ao longo da manutenção das células in vitro, podendo ser 
este um ponto de atenção para tais modelos de estudo. 
O tema de manutenção da atividade de células-tronco epidermais ao longo 
do envelhecimento é bastante discutido. Há trabalhos relatando ausência de 
alterações na atividade das células-tronco da epiderme, com mudanças no 
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controle das chamadas células amplificadoras transientes (Liang et al., 2004; 
Stern e Bickenbach, 2007; Charruyer et al., 2009). Buscando uma melhor 
compreensão desta questão, outro ensaio realizado em nosso trabalho com 
queratinócitos in vitro foi avaliar marcadores de superfície celular capazes de 
diferenciar populações de células-tronco ou células amplificadoras transientes. 
Curiosamente, não foram detectadas diferenças quanto à expressão destes 
marcadores entre as células de doadores de diferentes idades. Novamente, o uso 
de células cultivadas durante algum período, e não recém-isoladas, pode ter 
comprometido a detecção de diferenças associadas ao envelhecimento. Kaur et 
al. (2004) observaram que a expressão dos principais marcadores presentes in 
vivo pode ser alterada ao longo da manutenção de culturas in vitro. Em ensaios 
anteriores, observamos que é possível obter epidermes reconstituídas mais 
espessas ao utilizar células recém-isoladas. Além disso, o isolamento de células-
tronco de adultos, e até mesmo queratinócitos, é mais complexo. Gragnani et al. 
(2008) observaram uma relação inversa entre o aumento da idade dos doadores e 
o número de células isoladas. De maneira geral, percebemos que os modelos in 
vitro podem representar ferramentas promissoras para estudo do envelhecimento 
epidemal, embora algumas questões, tais como a reprogramação da expressão 
gênica e a seleção de subpopulações celulares ainda precisam ser mais bem 
avaliadas.
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5.  CONCLUSÕES 
 
 De forma geral, os resultados encontrados neste trabalho reafirmam a 
epiderme como um componente ativo da pele, cujas funções biológicas são 
significativamente afetadas pelo envelhecimento. 
 Especificamente, pode-se concluir que: 
 Alterações possivelmente associadas à desregulação homeostática 
acometem a epiderme ao longo do envelhecimento, sugerindo uma perda 
gradativa na capacidade do tecido epidermal de responder a elementos externos 
que desafiam o equilíbrio cutâneo. 
 Apesar de diversas variações, alguns genes demonstraram tendência clara 
de aumento ou redução contínua ao longo do envelhecimento da epiderme. 
Dentre eles, foram identificados marcadores com envolvimento na função de 
barreira, como SPPR2G (small proline-rich protein 2G) e o componente de 
envelope córneo LCE1 (late cornified envelope 1A). 
 A avaliação global de transcritos associados ao envelhecimento da 
epiderme humana em amostras de pele fotoexpostas permitiu a identificação de 
processos moleculares que podem auxiliar no entendimento de características 
clínicas ou morfológicas. A regulação do gene da actina beta (ACTB), por 
exemplo, pode estar relacionada à ocorrência de ceratose hiperproliferativa.  
 Há diferenças significativas na interpretação do envelhecimento epidermal 
de acordo com a técnica empregada para amostragem. Em nosso caso, as coletas 
de fitas adesivas ou de pelos de sobrancelha apontaram para a regulação de 
processos ou vias biológicas distintas, evidenciando nichos biológicos com 
particularidades funcionais e moleculares nas regiões folicular ou interfolicular da 
epiderme. 
 Maior capacidade de proliferação e diferenção foram observadas para 
queratinócitos in vitro isolados de doadores neonatos quando comparados a 
doadores adultos de entre 20 e 50 anos, aproximadamente.  
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Abstract 
 
 As the outer layer of the skin, epidermis plays multiple essential protective 
roles; the transitory nature of epidermal layers implies a continuous supply of new 
cells to maintain a multilayered tissue that undergoes permanent homeostasis 
throughout life. However, like any biological system, epidermis has an imperfect 
balance. Thus, epidermal homeostasis progressively deteriorates with aging, which 
is reflected in loss of the ability of the epidermis to give stability to its major 
molecules and cells, and consequently to preserve its own organizational and 
functional integrity. The bathtub elegantly illustrates the “modus operandi” of the 
epidermis, because the model is perfectly compatible with current biological 
findings: 1) tap flow has been enriched by the boom in epidermal stem cell 
research – fundamental for a comprehensive view of epidermal renewal dynamics; 
2) bath volume has grown with the discovery of molecular pathways involved in 
epidermal stratification, differentiation, and cell signaling through a complex 
regulatory network; and finally 3) plug-hole has been refined with the discovery of 
details on important biochemical and physicochemical properties of the stratum 
corneum, as well as on its genesis and subsequent desquamation. Furthermore, 
age-related intrinsic and extrinsic components have considerable effects on 
epidermal machinery, leading to disturbances in skin physiology and possible 
impairments in the quality of life of elderly people. This work presents an overview 
of the structure and function of epidermis, by refilling the old bath model with the 
results of recent advances to provide an integrative perspective, and discusses the 
main epidermal changes that come with aging, suggesting new opportunities for 
future studies and/or possible dermatological therapies. 
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Introduction 
 
Epidermis – the outer layer of the skin – represents a functional barrier in 
the control of substances that can be released from or absorbed into the body 
(Sotoodian and Maibach, 2012) and plays an important role in the prevention of 
water and nutrient loss, while performing multiple essential protective functions 
against environmental insults, such as toxins, pathogens, chemicals, pollution, 
mechanical stress and solar ultraviolet (UV) radiation (Simpson et al., 2011; 
Ramos-e-Silva and Jacques, 2012). As the most exposed body part, epidermis is 
also an important indicator of skin health, which has significant psychosocial 
implications (Farage et al., 2008c and 2010a). Skin imperfections have a negative 
influence on self-esteem and can cause considerable emotional distress. 
Outweighing the aesthetic importance, some diseases or disturbances specifically 
affecting epidermal organization, such as vitiligo or psoriasis, interfere considerably 
with the quality of life of the patients by causing anxiety, depression, and social 
withdrawal (Bilgiç et al., 2011; Jobling and Naldi, 2006; Sotoodian and Maibach, 
2012). 
Although aging is a natural process, it is also a factor that significantly 
affects epidermal tissue. Over time, cumulative exposures to external aggressors 
wear down the machinery of the human body, leading to functional deterioration 
and changes in biological structures. Considering that the population is aging 
rapidly, the skin is a portal of knowledge on aging, and the body of knowledge is 
burgeoning on this subject, Farage et al. (2010b) organized a comprehensive 
textbook that covers details in respect to structure and function, cellular and 
molecular mechanisms, and the latest bioengineering instruments used to assess 
age-related changes in the skin. As for the epidermis, aging causes disturbances in 
its barrier function. Aged skin tends to have an overall drier, duller and tired aspect, 
and is more predisposed to wrinkling. A common clinical sign in the elderly is 
xerosis – i.e., abnormal dryness of skin (Durai et al., 2008). It is usually a source of 
discomfort, either because of the unsightly aspect of increased skin flaking or 
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because of the annoying pruritus, of which excessive dryness is the most common 
cause in older adults (White-Chu and Reddy, 2011).  
Specifically on the subject of aged epidermal permeability barrier, a review 
by Elias and Ghadially in 2002 focused on the basis of functional abnormalities. 
Since then, increasing numbers of scientific publications related to the subject have 
emerged. A search in the Pubmed literature base (www.pubmed.com) using the 
words “epidermis” and “aging” shows that the total number of citations from 1954 to 
2002 was 556, a figure that had almost doubled, to 1176, by the end of 2012. More 
than looking at recent researches merely from a quantitative perspective, it is 
important to consider the qualitative approach taken in such works with respect to 
the technological advances and innovative areas that evolved over the last decade. 
Some of these developments appeared during the boom in stem cell research 
(including stem cells present in the skin and particularly in epidermis) (Castilho et 
al., 2009; Fuchs, 2008); others gave rise to the emergence of new fields derived 
from cell and molecular biology (such as “omics” and high throughput analyses, 
development of reliable alternative methods based on 3D reconstructed models, 
description of new signaling pathways, and others) (Blumenberg, 2012; Boulter et 
al., 2013; Brohem et al., 2011; Castilho et al., 2009).  
This review summarizes recent biological findings and functional 
mechanisms related to epidermal aging from an integrative perspective, rethinking 
the bath model as an opportunity to discuss scientific works that have been 
published since one of the first propositions for the “modus operandi” of epidermis 
was put forward. 
 
Epidermal structure and bath model 
 
More than a physical structure, epidermis is a highly specialized epithelium 
that undergoes a continuous renewal process and is characterized by overlapped 
cells that form a stratified barrier on the surface of the body to protect it against 
external aggressions and maintain its required balance of fluids and ions. A variety 
of cell types are found in epidermis: keratinocytes (corresponding to 80-95% of the 
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epidermal cells), melanocytes (that produce melanin for skin pigmentation), 
Langerhans cells (antigen presenting cells for immunosurveillance), and Merkel 
cells (capable of synthesizing catecholamines and thought to act as tactile 
receptors). Four main cell strata are distinguished according to the level of 
keratinocyte maturation: basal layer (BL; cells with a high proliferative capacity), 
spinous layer (SL; desmosome-enriched, thorny-looking cells), granular layer (GL; 
cells abundant in lipid and protein granules), and stratum corneum (SC; dead, 
enucleated and flattened cells, also called corneocytes, interspersed with 
intercellular lipids). BL is the inner layer and its proliferative cells are responsible 
for constant epidermal replenishment. They migrate toward the skin surface, 
crossing both SL and GL, until their complete differentiation in SC. The process 
occurs every four weeks throughout the lifetime. In some anatomic regions where 
skin is especially thick, such as the soles and palms, it is possible to differentiate a 
fifth layer between SC and GL: the stratum lucidum, designed to help the body 
handle friction (Brohem et al., 2011; Fuchs and Raghavan, 2002; Simpson et al., 
2011). 
“Epidermal engine” was the term defined by Marks (1986) in his paper on 
epidermal complexity and dynamics. The “epidermal bath model” was used as a 
practical analogy in which the size of the cell population was likened to the bath 
volume, and the rates of inflow from the tap and outflow from the plughole were 
taken to resemble epidermopoiesis and desquamation, respectively (Figure 1). 
Dynamic balance presupposes a perfect reposition system, by which the 
proliferation of cells is activated inside the epidermis as other cells are lost outside 
it. The basis of this system is similar to that of homeostasis, defined by O’Neill 
(1997) as the ability of a living organism to control its internal conditions in spite of 
fluctuations in the external environment. In terms of energy balance, however, 
living organisms are not perfect systems, and constant exposure to external 
insults, associated with a preprogrammed resistance of internal genetic-based 
components, leads to a continuous systemic degeneration. 
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Figure 1. Epidermal bath model, originally proposed by Marks (1986). The model consists of three 
main components: (1) tap, which represents epidermopoiesis or cell renewal that results from 
constant proliferation in the layer connected to basement membrane (BM); (2) bath volume, which 
corresponds to the size of epidermal cell population; and (3) plughole, which stands for the 
desquamation process of continuous corneocyte release due to physical stressors. Keratinocyte 
flow is indicated by blue arrows, including the direction of their differentiation process, which drives 
them from the inside to the outside toward the body surface and through different epidermal layers, 
in the following sequence: basal layer (BL), spinous layer (SL), granular layer (GL) and stratum 
corneum (SC). 
  
Aging and loss of homeostasis capacity 
 
Aging – a key concept in explaining homeostasis failures during life – is a 
highly complex biological process involving cumulative changes that affect the 
ability of the organism to respond adaptively to stress (Gilhar et al., 2004; 
Kirkwood, 2005). Impact of aging can be perceived in different parts of the 
organism, where it promotes loss of function and affects the self-adaptive capacity 
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of the system to maintain optimal internal conditions. Progressive deterioration of 
the ability of cells and tissues to preserve the stability in some of their biological 
molecules, such as nucleic acids or proteins, that comes with age also contributes 
to the functional loss (Garinis et al., 2008; Koga et al., 2011). Overall system failure 
in controlling homeostasis results from the sum of interdependent occurrences. 
Since the human body is an integrated system, disturbances in the original function 
of specific components are expected to reflect on others in a domino effect. Aging 
leads to physiological and metabolic failures in systems of temperature control, 
intra- and extracellular ion level regulation (especially for sodium and potassium), 
and water and hormone balance (Copinschi and Caufriez, 2013; O’Neill, 1997). All 
these changes may impact the skin. 
Elderly seem more susceptible to hypo- or hyperthermia when exposed to 
thermal stress, which can cause cell death or DNA damage (Anderson et al., 1996; 
Roti Roti, 2008). Keratinocyte response to hyperthermia shows intriguing results, 
such as the development of heat tolerance and UVB resistance (Kane and Maytin, 
1995; Maytin, 1992; Maytin et al., 1993 and 1994), or apoptosis induction and 
micronuclei formation (Hintzsche et al., 2012; Wang et al., 2009). However 
different the experimental designs, the activation of cellular anti-stress systems is a 
common feature, sometimes marked by the expression of heat shock proteins 
(HSP). Independently of protective or damaging responses, any deviation in 
physiological patterns leads the cells to turn on warning signals mediated by 
consistent epidermal mechanisms of tissue recovery. Still, according to Maytin 
(1992), changes in the expression of many stress-inducible genes often occur 
under conditions ultimately lethal to the cells, calling into question their adaptive 
significance. 
Regarding hormonal imbalance with aging, postmenopausal women usually 
have reduced levels of estrogens; this accelerates the decline in the appearance of 
the skin by affecting several of its functions, such as hair growth and the 
pigmentation, vascularity, elasticity, and water-holding capacity of the skin (Shu 
and Maibach, 2011; Verdier-Sévrain et al., 2006; Zouboulis et al., 2007). In 
addition, skin collagen content decreases at a rate of 2% per year (Brincat et al., 
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1987; Shah and Maibach, 2001). In men, aging-induced reductions in androgen 
levels correlate to decreased skin thickness and body hair (Wespes and Schulman, 
2002; Zouboulis et al., 2007). Such findings substantiate the fact that age-related 
systemic homeostasis failures cause significant structural changes in the skin and 
diminish its capability to regenerate its original, or younger, organization. 
Homeostasis presupposes the need of an organism to sense and respond to 
environmental changes by setting in motion mechanisms to restore its previous 
state of balance (O’Neill, 1997). Skin plays a fundamental role in the interaction 
with the external environment: it acts as a selective barrier and a major sensory 
organ of the body. Consequently, aged skin might have a cumulative impact on the 
entire aged organism, since its diminished internal capacity to adjust to 
environmental changes is further reduced by a compromised protective barrier that 
may fail to capture outside signals (Benedetto, 1998; Dufour and Candas, 2007; 
Farage et al., 2008b; Farage et al., 2009) (Figure 2). Epidermis, in particular, is the 
first line of contact with the surroundings, which increases the significance of a 
better understanding of the impacts of aging on this element of the skin (De Luca 
and Valacchi, 2010). Denda’s group, a specialized team working on epidermal 
issues, hypothesizes that an information-processing function may exist in the 
epidermis, particularly because of its ectoderm-derived origin – the same as the 
nervous system – and also because of the expression of neurotransmitter 
receptors in different cells (Boulais and Misery, 2008; Denda and Tsutsumi, 2011). 
Basically, Merkel cells form an enigmatic skin cell population, found at the 
epidermal/dermal border, synaptic-connected with sensory terminals. Merkel cells 
are proposed to be mechanotransducers related to light touch responses. 
However, exactly how Merkel cells transduce mechanical signals remains unknown 
(Maricich et al., 2009; Reed-Geaghan and Maricich, 2011). A recent review 
suggested that the acid-sensing ion channels (ASICs), expressed in Merkel cell-
neurite complexes, might be a possible component that would help to elucidate 
mechanotransduction pathways in the skin (Chen and Wong, 2013).  
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Figure 2. Epidermal mechanisms for capturing of external signals and regulation of homeostasis. 
(1) An important component of the ability of the organism to sense external environment, it allows 
different signals to be detected by epidermis, including temperature variations, mechanical stress 
and chemical stimuli. (2) Transient receptor potential channels (TRP) are ionic channels located in 
the membrane of free nerve endings and keratinocytes, and constitute an epidermal sensitive 
mechanism. Primarily related but not restricted to thermal oscillations, various environmental factors 
are sensed by TRP receptors, and their signals are transferred to peripheral sensory nerve fibers. 
(3)  Merkel receptors are described as part of the cutaneous sensory system, composed of Merkel 
cells (containing numerous neuropeptides inside dense core neurosecretory granules) and sensory 
afferents (with structures known as tactile discs), which are connected to periphery nerve fibers. 
Exact way by which Merkel cells work is still object of debate, but some authors consider them as 
excitable neurone-like cells that may respond to various stimuli, and recent findings proved their 
essential contribution to light touch responses. (4) In view of the crucial role of epidermis as a 
sensory tissue, epidermal homeostasis has direct implications in the overall homeostasis of the 
organism. Aging affects the epidermal balance between cell renewal and desquamation, much as it 
affects several internal organs, which experience loss of functional properties. Thus, reduced ability 
of aged epidermis to deploy best internal defenses against environmental aggressors may be 
further compounded by its diminished ability to sense external signals. This extends the cumulative 
impact of epidermal aging to homeostasis of the whole organism. 
166 
 
In addition to terminal sensory nerves and Merkel cells, keratinocytes have 
also been recently described as sensitive cells. Recent studies have been 
specifically targeted to determine the sensitive properties of keratinocytes, and the 
superfamily of transient receptor potential channels (TRPs) has emerged (Denda 
and Tsutsumi, 2011). TRPs are non-selective cation channels expressed 
throughout the body and regulated by stimuli; they are subdivided into seven 
families: TRPA (ankyrin), TRPC (canonical), TRPM (melastatin), TRPML 
(mucolipin), TRPN (no mechanoreceptor potential C), TRPP (polycystin), and 
TRPV (vanilloid) (Fernandes et al., 2012; Steinhoff and Bíró, 2009). Since TRPV1 
was identified in epidermal keratinocytes, the involvement of TRP in epidermal 
tissue has significantly changed (Denda et al., 2001b). After TRPV1, TRPV3 was 
found to mediate a cell autonomous response in keratinocytes upon exposure to 
heat (Peier et al. 2002). Subsequently, other channels have been shown to play a 
temperature regulatory role in keratinocytes, such as TRPV-4 (sensitive to heat) 
and TRPA1 (sensitive to cold) (Atoyan et al., 2009; Denda et al., 2007; Fernandes 
et al., 2012; Lee and Caterina, 2005). Temperature-sensitive ion channels affect 
other functions and skin processes as well, including cellular differentiation and 
proliferation, water flow control, reinforcement of cell junctions and 
mechanosensory properties (Akazawa et al., 2013; Bíró and Kovács, 2009; Denda 
and Tsutsumi, 2011; O'Neil and Heller, 2005; Steinhoff and Bíró, 2009;). 
 
How skin undergoes aging and epidermal organization impact 
 
Aging is a complex and multifactorial phenomenon, composed of intrinsic 
and extrinsic factors, defined respectively by individual genetic constitution and 
external insults. In humans, aging is said to be directly influenced by lifestyle and, 
according to Farage et al. (2007 and 2008a), the intrinsic rate of skin aging in any 
individual can also be dramatically influenced by personal, socioeconomic and 
environmental factors. Nevertheless, as the lifetime of an individual unfolds, a 
particular set of genetically programmed events drive the changes that take place 
in all tissues and lead to the aging of the whole organism (Makrantonaki et al., 
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2012; Zouboulis and Makrantonaki, 2011). Aging skin undergoes progressive 
degenerative changes; constant exposure of the skin to environmental aggressors 
contributes to accelerating or intensifying the process (Farage et al., 2009). 
According to the micro-inflammatory model, UV radiation skin exposure promotes 
migration of macrophages and production of free radicals affecting resident cells, 
such as fibroblasts or keratinocytes. Neo-synthesis of adhesion molecules is 
stimulated in endothelial cells by recruiting new inflammatory cells, thus closing the 
cycle of self-maintained micro-inflammation, which results in the disruption of skin 
tissue and the ensuing loss of volume and elasticity (Giacomoni and Rein, 2004). 
From the clinical viewpoint, skin aging is characterized by wrinkling, flabbiness, 
increased fragility, blister formation, impaired wound healing, dryness, 
pigmentation changes, and increased risk of cancer (Farage et al., 2007, 2008b 
and 2009). Deeper wrinkles and a leathery appearance result from extensive 
sunlight exposure (Scharffetter-Kochanek et al., 2000). Clinical signs reflect 
internal and structural changes extensively reviewed by Waller and Maibach (2005 
and 2006), including diminished blood flow, reduced thickness of different skin 
layers, disorganized collagen and elastic fiber patterns, reduced activity of 
enzymes involved in post-translational modification processes, protein aggregate 
formation, changes in deposition of glycosaminoglycans (GAGs) which then tend to 
interact less with water molecules, and changes in the lipid content of the skin. 
Even with the numerous dermal aging studies based mainly on the 
supportive function and fiber-enriched structure of the dermis, the epidermis has 
recently been receiving more attention. Although epidermal machinery becomes 
less efficient with age, the balance between cell production and cell loss may 
change over the entire lifetime (Gilhar et al., 2004). Several studies suggest that, 
much more than just undergoing minor functional abnormalities, the epidermal 
structure in fact suffers multiple impacts from intrinsic and extrinsic aging (Table 1). 
Many other mechanisms have been identified since the 1980’s to complement the 
epidermal bath model, and many studies explain the more significant changes that 
affect the aging epidermis. Discovery of new molecules and the identification of 
new biological functions make it important to rethink and complement the three 
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main steps of the epidermal bath model in light of recent advances in cell and 
molecular biology. 
 
Table 1. Structural changes in epidermis with aging. 
Affected 
characteristic 
Observed effect of aging 
Skin 
condition* 
Reference 
Epidermal surface 
Increase in number of pores PP 
Rawlings, 2006 
Deterioration of fine reticular patterning in 
the SC surface  
PP/PE 
Shekar et al., 2005 
Deteriorated surface appearance and 
weakening in the adhesion of 
keratinocytes to SC, especially in 
photoaging 
PP/PE 
Chu and Kollias, 
2011 
Change in the rhomboidal epidermal 
furrow pattern to a linear appearance 
PE 
Longo et al., 2013 
Epidermal 
thickness 
Decrease in thickness of viable cellular 
epidermis, without changes in SC 
PP 
Lock-Andersen et 
al., 1997 
Thinning epidermis by 10-50% between 
30 and 80 years 
PP 
Makrantonaki and 
Zouboulis, 2007 
SL atrophy  PP 
Zouboulis and 
Makrantonaki, 
2011 
Constant mean epidermal thickness from 
6-84 years in sun-exposed and protected 
skin, showing thicker epidermis in facial in 
comparison with abdominal skin 
PP/PE 
El-Domyati et al., 
2002 
Decrease in epidermal thickness and in 
the amount of viable cell layers from 17 to 
81 years 
PP/PE 
Levakov et al., 
2012 
Thickening of the SC with faulty 
degradation of desmosomes, dehydration 
and microfissures 
PE 
Leyden, 2001 
Reduced epidermal thickness by 30% in 
individuals older than 65 years, despite a 
slight increase in middle-aged subjects 
PE 
Longo et al., 2013 
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Epidermal 
shrinkage 
Decrease in epidermal shrinkage by 22% 
in superficial layers and 6% in the lower 
epidermis 
PP 
Moragas et al., 
1993 
Dermo-epidermal 
junction 
organization 
Flattening of the dermo-epidermal 
junction, with 36.3% decrease in the rete 
peg-related roughness index, mainly 
between 40 and 60 years 
PP 
Moragas et al., 
1993 
Flattening of dermal-epidermal junction 
from 17 to 81 years 
PP/PE 
Levakov et al., 
2012 
Reduced collagen type VII containing 
anchoring fibrils, while collagen IV might 
be also degraded 
PE 
Scharffetter-
Kochanek et al., 
2000 
Cellular 
morphology and 
distribution 
Expanded intercellular space throughout 
epidermis 
PP 
Minematsu et al., 
2011 
Increased heterogeneity in basal cell size, 
decreased mitotic activity, 
increased duration of cell cycle and 
migration time of keratinocytes, slow 
replacement of lipids in the SC, decrease 
and heterogeneity of melanocytes, 
decrease of Langerhans cells 
PP 
Zouboulis and 
Makrantonaki, 
2011 
Increase in the amount of keratohyalin 
granules from 17 to 81 years 
PP/PE 
Levakov et al., 
2012 
Appearance of "sunburn" cells 
(keratinocyte apoptotic cells), DNA 
damage to basal keratinocytes, increased 
numbers of melanocytes and melanocytic 
hyperplasia, and Langerhans cell 
depletion 
PE 
Leyden, 2001 
Impaired adhesion, proliferation and 
differentiation of keratinocytes 
PE 
Makrantonaki and 
Zouboulis, 2007 
Presence of irregularly shaped 
keratinocytes, irregular honeycomb 
pattern and areas with unevenly 
distributed pigmentation 
PE 
Longo et al., 2013 
*PP: photo-protected; PE: photo-exposed. 
 
Opening the tap flow: cell renewal dynamics in BL 
 
The first step illustrated in the epidermal bath model (Figure 1) refers to tap 
flow, focused on the cell renewal dynamics that occurs in the BL. A massive 
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amount of recent studies related to epidermal stem cells accounts for the 
elucidation of epidermopoietic regulation. The BL contains a heterogeneous 
proliferative cell population and also cells committed to terminal differentiation 
(Fuchs, 2008). Basically, tissue renewal depends on epidermal stem cells with a 
high-proliferation capacity and a low terminal-differentiation probability. 
Characteristically, such stem cells express relatively higher levels of γ-catenin and 
β1 integrins and lower levels of E-cadherin and β-catenin than other basal 
keratinocytes (Molès and Watt, 1997). Proliferative populations also express 
keratin 5 (K5) and K14, as well as p63, an important molecule working as a 
gatekeeper of proliferation in epithelial stem cells (Fuchs, 2008; Senoo et al., 
2007). In addition, many studies recognize that the stem cells engender transit-
amplifying cells designed to undergo terminal differentiation after a few rounds of 
division, about five times before reducing its adhesiveness to the underlying BM 
and delaminating (Fuchs, 2008). Although there are heterogeneous concepts 
about the exact function of proliferating cells in the BL, as well as about the 
epidermal proliferative unit organization, a consensus has, nevertheless, been 
reached about BM as a niche for epidermal progenitors, and displacement is likely 
to play a significant role in cell fate (Ray and Lechler, 2011). In BL, a fine regulation 
occurs to maintain the renewal cycle of the epidermis, with two main classes of cell 
division – symmetric and asymmetric – and different possibilities of spindle 
orientation (Figure 3). 
Occurrence of asymmetrical divisions provides a different view of how a 
basal stem cell and a committed cell might arise. In the first of the studies on this 
subject, epidermal stem cells were shown to shift from a lateral to a more 
perpendicular spindle orientation to undergo asymmetrical divisions, which account 
for 70% of total basal cell mitoses, while 30% of the cell mitoses remained 
symmetric (Lechler and Fuchs, 2005). Clayton et al. (2007) demonstrated that 
most asymmetrical divisions in epidermis leave both daughter cells adhering to 
BM, with the committed cells inheriting a stronger Notch signal as a key 
transcriptional determinant of the spinous cell fate. An additional consideration is 
that distinct patterns of cell division and proliferation can operate in different life 
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stages. During early stages of embryonic skin development, most cell divisions are 
symmetric and parallel to BM, which ensures the growth of the surface with the 
epithelium as a single layer. During epidermal stratification, the majority of cell 
divisions become asymmetric, such that the mitotic spindle aligns perpendicularly 
to the BM in order to allow the quick development of suprabasal cells, which 
differentiate terminally and form stratified layers. In adult skin, predominant plane 
of asymmetric divisions is parallel to the BM, such that one daughter cell remains a 
stem cell, while the other is committed to terminal differentiation and probably 
undergoes delamination to reach the suprabasal layers (Blanpain and Fuchs, 
2009). 
 
Figure 3. Epidermal cell renewal. Epidermopoiesis depends on proliferative cells present in the 
basal layer (BL). Stem cells (STC) generate transit amplifying cells (TAC), which have been 
postulated to divide four to five times, and/or spinous cells (SPC) committed to terminal 
differentiation. There are two main classifications for cell divisions: (1) symmetric, when both 
daughters adopt the same fate, or (2) asymmetric, when there is unequal segregation of a cell fate 
determinant, or when one of the daughters strays from the STC niche, resulting in daughters with 
distinct fates. The cell division plane can be parallel or perpendicular to the basement membrane 
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(BM). When spinous cells committed to terminal differentiation are originated in contact with the BM, 
a reduction of the adhesiveness to the substratum is needed for delamination (blue arrows), which 
allows cell migration and differentiation. 
 
Specific markers have been identified as important controllers for the 
orientation of the division in basal cells; examples of such markers are the 
differential segregation of integrins, growth factor receptors, and the more recently 
described apical positioning of Par complex associated with the mInsc/LGN/NuMA 
complex for the anchorage of dynein and microtubules (Blanpain and Fuchs, 2009; 
Ray and Lechler, 2011). Recent studies on the maintenance of proper balance 
between stem cell quiescence and proliferation over the lifetime of the organism 
uncovered new regulatory networks for the control of the proliferation and terminal 
differentiation of epidermal stem cells, such as the regulation of Yap (Yes-
associated protein) – a transcriptional effector of Hippo growth pathway – by the 
adherens junction component α-catenin (Flores and Halder, 2011; Schlegelmilch et 
al., 2011; Zhang et al., 2011). 
Regarding the effect of aging under the conditions imposed by the dynamics 
of cell renewal in BL, thinning of the epidermis and its diminished self-healing 
capacity were at first associated with decreasing numbers of, or functional changes 
in, epidermal stem cells (Winter and Bickenbach, 2009). But this topic remains 
under discussion in the scientific community. Giangreco et al. (2010) observed, 
especially in subjects over 60 years, a significant reduction in rete ridge height and 
basal cell density, as well as a lower expression of two markers of human 
interfollicular epidermal stem cells: melanoma chondroitin sulfate proteoglycan 
(MCSP) and β1 integrins. There is a decline in the regenerative potential of tissue 
with age, which could be ascribed to intrinsic aging of stem cells and/or of the 
microenvironment of the tissue lodging the stem cells (Rando, 2006). Using a 
murine model, Liang and coworkers (2004) demonstrated that aged and young 
stem cells show similar plasticity response when placed in the developmental 
environment of a blastocyst, as well as similar gene and protein expression 
profiles. Stern and Bickenbach (2007) did not find significant differences in the 
epidermal stem cell number per unit area of the epidermis of footpads of young 
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and old adult mice. Moreover, they found similar characteristics in cell cultures 
from each of the two groups, including the same lengths for the telomeres and 
similar results for gene expressions related to cell cycling, apoptosis, stress 
response, and stem cell dynamics (no differences in the 422 tested genes, when 
comparing freshly isolated young and old epidermal stem cells). These results led 
the authors to conclude that epidermal stem cells are resistant to cellular aging. 
Both studies conducted by Liang et al. (2004) and Stern and Bickenbach (2007), 
suggest that the ability of stem cells to respond to environmental influences might 
not diminish with age. In support of this hypothesis, Giangreco and coworkers 
(2008) showed that epidermal stem cells are retained by the organism throughout 
its lifetime despite significant age-associated changes in dermal thickness, 
epidermal proliferation, and peripheral immune cell abundance, suggesting that 
local environmental or dermal factors, rather than stem-cell-intrinsic factors, 
influence skin aging. How stem cells preserve this capacity throughout lifetime 
remains unclear, but it may be due to an intrinsic set of stem cell genes, which are 
to be determined. In a study with stem cells from the bulge of skin hair follicles of 
young and aged human skin, the results found by Rittié et al. (2009) were similar to 
those observed in mice: aging did not alter the expression or location of hair follicle 
stem cell markers, and there were no significant differences in hair follicle density 
or bulge cell numbers between young and aged human scalp skin. Regarding the 
mechanisms of stem cell retention in the skin, the authors noted that hedgehog 
(Hh) signaling is activated in human bulge cells in vivo and down-regulated in 
differentiated hair follicule keratinocytes, both in young and aged skin. Some 
controversial results notwithstanding, increased telomerase expression and activity 
in epidermal basal cells may represent another possible mechanism for preserving 
the stem cell potential (Buckingham and Klingelhutz, 2011). 
Even so, if the number and functionality of epidermal stem cells are not 
affected by aging, the question remains: what causes the structural changes 
observed in the elderly epidermis. Transit amplifying cells seem to play a key part 
in the answer. Even the authors, who did not detect differences in stem cells of the 
young and old, were able to identify some particularities in the characteristics of 
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transit amplifying cells (Giangreco et al., 2008; Liang et al., 2004; Stern and 
Bickenbach, 2007). Charruyer et al. (2009) demonstrated that transit amplifying cell 
frequency and cell cycle kinetics are altered in the aged epidermis. They used in 
vivo transplantation of green fluorescent protein-labeled epidermal cells to evaluate 
the formation of replicating units (RUs) from stem cells (long-term RUs, survived 
more than 9 weeks) or transit amplifying cells (short-term RUs, lost before 9 
weeks). No differences were observed in the number of long-term RUs when 
comparing young and old keratinocytes, which indicated that the number of stem 
cells is relatively constant in aged and young epidermis. However, fewer short-term 
RUs were found after transplantation of young cells in comparison with 
transplantation of old cells, which seemed contradictory. The answer for this 
intriguing question was provided by a complementary discovery: the increased cell 
cycle duration in the aged cells. In their comments on the study, Winter and 
Bickenbach (2009) compared the findings described by Charruyer et al. (2009) to a 
crowded freeway: when the vehicles travel at lower speeds, overall result is more 
vehicles on the road at any given time, which could be an analogy to more transit 
amplifying cells in the aged epidermis. Increased number of transit amplifying cells 
in the aged epidermis might be a means of compensating their decreasing activity 
with age. Although the number of long-term RUs containing stem cells is similar in 
young and in aged epidermis, aging skin heals more slowly or is thinner because of 
a reduction in the efficiency of regeneration from transit amplifying cells. 
When evaluating the effect of photoaging in epidermal proliferative 
populations, Kwon et al. (2008) found less keratinocyte stem cells and more transit 
amplifying cells in photoaged than in chronologically aged skin. In keratinocyte 
cultures, replicative senescence is a gradual process that occurs only when all 
stem cells have completed their clonal evolution and give rise to terminal transit 
amplifying cells, named paraclones. Cordisco and coworkers (2010) observed that 
human keratinocyte replicative senescence is associated with a progressive 
increase in the expression of p16INK4a, whose expression is also detectable in 
primary keratinocytes from elderly subjects; p16INK4a is in particular constantly 
present in individuals of more than 70 years of age. Remarkably, first-passage 
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keratinocyte cultures show a strong positive correlation between stem cell 
depletion and early p16INK4a expression, indicating the presence of senescent cells 
in the epidermis from old donors. Presence of higher paraclone percentages and 
p16INK4a levels in keratinocyte cultures from old photoexposed skin, as compared 
with non-photoexposed skin, indicated that chronic UV exposure contributes to 
keratinocyte senescence. Moreover, the authors assigned the downregulation of 
Bmi-1, a p16INK4a repressor, a key role in the enforcement of primary human 
keratinocyte aging. 
Although many studies corroborate the importance of transit amplifying cells, 
some authors understand that these cells might not be required for epidermal 
homeostasis; they favor, instead, a single proliferative progenitor cell population to 
sustain epithelial renewal (Clayton et al., 2007). To clarify this issue and prove 
existence of transit amplifying cells, Mascré et al. (2012) conducted an elegant 
study based on the application of two Cre recombinase-oestrogen receptor (Cre-
ER) transgenic mice that target interfollicular epidermis progenitors: Cre-ER under 
the control of the K14 promoter (K14-Cre-ER) and Cre-ER under the control of the 
involucrin promoter (Inv-Cre-ER); both allowing lineage tracing experiments by 
analyses of tamoxifen-induced fluorescence. Inv-Cre-ER targets committed 
progenitors (or transit amplifying cells) while K14-Cre-ER targets long-lived stem 
cells. Pattern of growth of individual clones targeted by the Inv-Cre-ER indicated 
that, following the divisions of committed progenitors (about 1 division per week), 
80% resulted in asymmetric fate (leading to one dividing and one differentiated 
cell) with the remainder leading to symmetric duplication or differentiation with 
approximately equal probability. Dynamics of the clones targeted by K14-Cre-ER 
followed a quite different pattern, with an initial abrupt expansion followed by 
deceleration over the first few weeks, which indicates that, after division, stem cells 
re-enter a quiescent phase whereas their progeny go on to proliferate and 
differentiate. With a slower division rate (4 to 6 divisions per year), 80 ± 10% of 
stem cell divisions result in asymmetric fate (one stem cell and one committed 
progenitor cell), whereas the remaining divisions are equally balanced between 
stem cell duplication and symmetrical differentiation into two committed progenitor 
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cells (Figure 3). Mascré et al. (2012) also performed a molecular characterization 
of the cells, proving the existence, as much as the hierarchical organization and 
proliferation dynamics, of two distinct types of progenitors involved in epidermal 
homeostasis and repair. 
Even without characterizing different progenitor cell lines, Doles and 
coworker (2012) showed changes in hair follicle stem cells during skin aging; such 
changes included increased cell numbers, decreased cell function, and an inability 
of cells to tolerate stress. This study shows that aging epidermis plays a part in the 
disruption of cytokine and stem cell homeostasis; this is characterized by an 
imbalance in the epidermal Jak-Stat signaling, which could easily be adjusted to fit 
the micro-inflammatory model (Giacomoni and Rein, 2004). Decline in epidermal 
functionality was interpreted as a mechanism for suppression of tumors that might 
occur with age. Castilho et al. (2009) used a murine transgenic model to evaluate 
the consequences of persistently expressing Wnt1 on epidermal stem cells. Rapid 
growth of the hair follicles caused epithelial cell senescence, disappearance of the 
epidermal stem cell compartment by the persistent activation of mTOR, and 
progressive hair loss. While the exhaustion of stem cells may act as a protective 
mechanism, helping to maintain the genetic integrity of the stem cell population 
and suppressing tumor formation, persistent activation of mTOR may contribute to 
cell senescence and, consequently, accelerate aging. Absence of the vitamin D 
receptor also leads to a reduction in the number of keratinocyte stem cells and 
impair their function, both in vivo and in vitro, disturbing the cyclic regeneration of 
the hair follicle (Luderer and Demay, 2010). Some authors believe that the aging-
induced delay in epidermal turnover is related to a decrease in the energy 
metabolism of epidermal basal cells, suggesting that adenosine 5’-monophosphate 
(AMP) may accelerate the epidermal turnover delayed by aging (Furukawa et al., 
2008). Janich et al. (2011) described a circadian molecular clock in a murine model 
that creates epidermal stem cell heterogeneity, with coexisting populations of cells 
at opposite phases of the clock, like dormancy and activation. Core clock protein 
aryl hydrocarbon receptor nuclear translocator-like (Arntl or Bmal1) modulates the 
expression of stem cell regulatory genes in an oscillatory manner, to create 
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populations that are either predisposed or less prone to activation. Janich et al. 
(2011) also found that stem cell arrhythmia can lead to premature epidermal aging. 
Most studies on the source of epidermal renewal focus the cellular 
properties of keratinocytes in BL, but other cells types and the supportive structure 
of BM also seem affected. Proliferative cells must be maintained in a specific 
microenvironment to preserve renewal potential. Therefore, age-associated effects 
of the structural organization of this niche may impact the maintenance of 
proliferative cells over life. Relatively high incidence of anti-BM antibodies 
observed in serum samples from elderly subjects exemplifies this and, in fact, 
highlights occurrence of a specific immune defect in elderly individuals; this 
probably contributes to the reduction of the rete ridge height of aged epidermis, 
which, in turn, could lead to a decreasing exchange of nutrients between the 
epidermis and dermis (Hachisuka et al., 1996). BM of sun-exposed skin becomes 
damaged and multilayered, and partly disrupted in comparison with the BM of sun-
protected skin; BM fragmentation includes the participation of matrix 
metalloproteinases (MMPs) and plasmin (Amano, 2009). 
As for the different proliferative cells types in epidermal BL, Steingrímsson et 
al. (2005) reviewed the subject of melanocyte stem cells and their impact on hair 
graying, and discussed importance of paired box 3 (Pax3) transcription factor and 
of microphthalmia-associated transcription factor (Mitf) as key molecules that help 
to regulate the balance between maintenance and differentiation of melanocyte 
stem cells. Pax3 works simultaneously to initiate a melanogenic cascade while 
acting downstream to prevent terminal differentiation. Pax3 activates Mitf 
expression and at the same time prevents Mitf from activating downstream genes, 
by competing for enhancer occupancy. Thus, Mitf accumulates until the Pax3-
mediated repression is relieved by external stimuli, when the cellular dormant state 
is broken and differentiation occurs rapidly (Lang et al., 2005). Using the Mitf 
presence as a typical marker of proliferative melanocytes, Nishimura et al. (2005) 
evaluated the presence of these cells in aging human hair follicles and identified 
Bcl-2 as a critical molecule for the preservation of melanocyte stem cells – 
specifically for their entry into dormancy. While melanocyte stem cells were 
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abundant in follicles from young (20-30 year-old) subjects, which represented 2 to 
3% of the total basal keratinocytes in the bulge area, the numbers of melanocyte 
stem cells were lower in middle-age (40-60 year-old) individuals and absent in 
most hair follicles of old (70-90 year-old) subjects. Briefly, there is a loss of 
melanocyte stem cells with age, which temporally precedes loss of differentiated 
melanocytes in hair matrix. 
 
Describing bath volume: differentiation and signaling mechanisms  
 
 Bath Volume represents the second step of the epidermal bath model that is 
here refilled in detail (Figure 1). Several molecular pathways are involved in 
regulation of processes creating the stratified epidermal structure. The multilayer 
organization contains cells with different profiles, which go through a course of 
continuous differentiation that is governed by a complex network of signaling 
mechanisms. As such, epidermal bath volume represents a complex and 
integrated biological system to be explored especially in regard to dynamic 
changes related to aging (Figure 4). 
Calcium is a good example of ions involved in the control of epidermal 
structure and functionality. Calcium is differentially distributed among cell layers, as 
an essential element for keratinocyte differentiation, and for maintaining skin 
barrier homeostasis (Elias et al., 2002). The distribution of calcium in the epidermis 
varies with age (Denda et al. 2003). In young and healthy skin, there is a calcium 
gradient characterized by low concentration levels in inner layers, such as BL and 
SL, and by an increasing availability of extra and intracellular calcium, which is 
reached at its highest levels of concentration in GL. In skin samples of older 
individuals, however, calcium is distributed equally among all epidermal layers, 
without forming the gradients observed in young skin (Denda et al. 2003). Although 
direct evidence for this difference in calcium distribution is lacking, it is probably 
related to structural changes and clinical disorders that affect aged epidermis.  
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Figure 4. Refilling bath volume with the major cell and molecular changes involved in epidermal 
aging. Several mechanisms and pathways describe the effects of aging on epidermis. The vast 
majority of literature focuses on keratinocyte-related changes, but investigations of other epidermal 
cells and of the epidermal extracellular matrix organization have also yielded interesting findings. 
AQP3 (aquaporin 3), Bcl-2 (apoptosis protein B-cell lymphoma 2), BM (basement membrane), Bmi-
1 (polycomb ring finger oncogene BMi-1), CD1d (cluster of differentiation 1d), ECM1 (extracellular 
matrix protein 1), Fas (cluster of differentiation 95), FasL (cluster of differentiation 95 ligand), FliI 
(flightless 1), GAG (glycosaminoglycan), HA (hyaluronic acid), HSP-27 (heat shock protein 27), Il-
1α (interleukin 1α), IL-1RII (interleukin 1 receptor type II), K33 (keratin 33), K34 (keratin 34), KAP4 
(keratin-associated proteins group 4), Ki-67 (nuclear protein Ki-67), MC-1R (melanocortin receptor 
1), MC-2R (melanocortin receptor 2), MOR-1 (μ-opiate receptor 1), NMFs (natural moisturizing 
factors), p53 (protein 53), POMC (pro-opiomelanocortin), RACK-1 (receptor for activated C kinase 
1), Smad7 (intracellular protein mothers against decapentaplegic homolog 7), S100A8 (S100 
calcium binding protein 8), SC (stratum corneum), TLR3 (toll-like receptor 3), TNF-α (tumor 
necrosis factor α), TRPV1 (transient receptor potential cation channel subfamily V member 1). 
 
Using a mouse model, Denda et al. (2001a) showed that the skin surface 
potential is affected by the ion flow between the outside and the inside of 
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keratinocytes. When calcium or magnesium ions move toward the bottom of the 
epidermis, skin surface potential becomes negative. Whether potential itself has a 
role in the epidermal function requires investigation, but it has already been 
reported to induce keratinocyte migration, accelerate wound healing, and influence 
skin metabolism or homeostasis (Denda et al., 2001a; Nuccitelli, 2003; Sheridan et 
al., 1996; Weiss et al., 1990). Thus, an inadequate calcium distribution in aged 
epidermis may contribute to damage the regeneration capacity of the skin – a 
typical clinical sign in elderly. Another consequence of the altered calcium 
gradation in epidermis of older subjects is an increase in exocytosis of lamellar 
bodies (Menon et al., 1994). Lamellar body secretion and lipid structure is 
abnormal in the epidermis of patients with Netherton syndrome, a skin disorder 
characterized by chronic inflammation and universal pruritus (Fartasch et al., 
2009). Pruritus is common in older adults and possibly associated with changes in 
the nerve fibers of aged skin. TRPV1, an ion channel permeable to calcium 
expressed in keratinocytes and free epidermal nerve endings, has recently been 
reported to be increasingly expressed under conditions of intrinsic aging and 
photoaging (Lee et al., 2009a; Lee et al., 2012). While increased TRPV1 
expression in nerve fibers in aged skin suggests an important role of this ion 
channel in the pathophysiology of itchy skin in elderly subjects, it also points to a 
possible cause for the age-disrupted epidermal calcium gradient. Until now, the few 
publications in this field do not provide a robust model for ion dynamics at the 
cellular level of aged epidermis; an overall dysfunction in pumps, ion channels or 
ionotropic receptors, however, might be a reliable candidate to explain altered 
dispersion of calcium and consequent morphologic and functional abnormalities 
seen in older individuals (Denda et al., 2003). Since monosaccharides are capable 
of regulating calcium pump function, it is possible that abnormal distribution of 
calcium in aged epidermis may be related to the reduced presence of 
monosaccharides at the surface of epidermal cells (Georgiou et al., 2005; 
González Flecha et al., 1999; Tengholm et al., 2001). A study analyzing the 
influence of age on the carbohydrate residue composition of keratinocyte plasma 
membranes in human sun-protected skin detected no changes in the concentration 
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and distribution of β-D-galactose, D-galactose-β-(1,3 N-acetylo-D-galactosamine), 
β-(1,4-D-N-acetylo-βD-glucosamine) and α-D-N-acetylo-D-galactosamine at the 
cell surface with age, while the expression of α-D-mannose, α-D-glucose and α-L-
fucose at the cell surface reveals marked reductions in the groups of people over 
50 years of age (Georgiou et al., 2005). 
Other findings point to molecules or mechanisms related to increased 
difficulty of the epidermis to sense external signs, protect the interior of the body 
and/or eliminate damage caused by aggressors, when comparing samples from 
individuals of different age groups. Overall, the effect of increasing age on 
keratinocyte response both to exogenous and endogenous mitogens is striking and 
marked by a significant decrease in mitogenic responsiveness and colony-forming 
potential (Gilchrest and Yaar, 1992). Ki-67 is a nuclear protein that is associated 
with, and may be necessary for, cellular proliferation. Staining of Ki-67, an 
indication of proliferation index in young epidermis, was approximately twice as 
strong in younger than in older epidermis (Gilhar et al., 2004). HSP-27 decreases 
in the epidermis with age, which might impair keratinocyte differentiation (Jonak et 
al., 2006; Jonak et al., 2011). A gradually decreasing level of CD1d protein 
production in human epidermis with age was also reported, suggesting a lowering 
of the immune response. CD1d belongs to a family of antigen-presenting 
molecules that are structurally related to the classic major histocompatibility 
complex (MHC) class I proteins; in normal human skin, CD1d protein production is 
confined to keratinocytes immediately beneath the lipid-rich stratum corneum (Adly 
et al., 2006). The 20S proteasome shows an age-related decline in activity that is 
associated with changes in its subunits, suggesting impairment of the epidermal 
proteolytic system, which should be responsible for the removal of abnormal and 
oxidatively damaged proteins (Bulteau et al., 2000). 
A key element of innate protection is the recognition of pathogen-associated 
molecular patterns (PAMPs) by Toll-like receptors (TLRs) expressed by several 
cell types, including skin keratinocytes. TLR3, specifically related to antiviral 
defense, exhibited enormous differences in the magnitude of expression and 
function, including enhanced secretion of cytokines (such as CXCL8/IL8, 
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CXCL10/IP-10 and TNF-α) in epidermal keratinocytes, before and after birth, when 
compared with adults, suggesting the existence of age-specific responses (Iram et 
al., 2012). In assessing the ability of keratinocytes to respond to hormonal 
stimulation according to the aging status, Pain et al. (2010) studied pro-
opiomelanocortin (POMC) and related receptors, such as melanocortin receptors 2 
and 1 (MC-2R and MC-1R) and μ-opiate receptor 1 (MOR-1) for 
adrenocorticotrophic hormone (ACTH), α-melanocyte stimulating hormone (α-
MSH), and β-endorphin, respectively. Gene and protein expression of MC-1R, MC-
2R and MOR-1 dramatically decreased with age, whereas POMC increased five-
fold. Results were more significant around 50 years of age, which could include 
menopausal women, suggesting a significant contribution of menopause to 
changes in epidermal physiology with aging. Ye et al. (2002) addressed the 
hypothesis that cytokine dysregulation may cause permeability barrier abnormality 
in aged epidermis, mainly as a result of altered expression of interleukin 1 (IL-1) 
family of cytokines and receptors, which could help to explain decreasing 
mitogenesis and lipid synthesis with epidermal aging. Gene and protein expression 
of aquaporin 3 (AQP3), involved in the transport of water and glycerol to hydrate 
the skin, decreases with increasing age in human epidermis and isolated 
keratinocytes; this decrease is probably involved in the development of xerosis (Li 
et al., 2010). In a study with knockout mice, Rezvani et al. (2011) identified a 
significant role of the hypoxia-inducible factor 1a (HIF-1a) in epidermal 
homeostasis, because the downregulation of HIF-1a lead to decreased expression 
of α6 integrin and β1 integrin, diminished keratinocyte- colony-forming efficiency, 
and arrested cell cycle progression, which, acting together, could contribute to 
epidermal aging and pronounced failure in epidermal reconstruction. 
Aging in hair follicles is associated with a decline of structural proteins such 
as certain keratins and keratin-associated proteins (KAP). While the expression of 
K31, K32, K36, K85 and K86 is unaffected by aging, K33A, K34 and the group of 
KAP4 genes produce a statistically significant decline in gene activity above 50 
years of age (Giesen et al., 2011). Aging additionally leads to a diminished 
epidermal content in specific polysaccharides, such as hyaluronic acid (HA) and 
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GAGs usually attached to extracellular matrix proteins to form proteoglycans (PG). 
Oh et al. (2011) described the age-promoted reduction in epidermal HA and 
heparan sulphate content, determined as an isolated GAG or composing different 
PGs such as perlecan and syndecan-1. According to Stern and Maibach (2008), 
although dermal HA is responsible for most skin HA, epidermal cells are also able 
to synthesize HA, mainly located in the upper SL and GL, where most of it is 
extracellular; BL also has HA, but it is predominantly intracellular. Proportion of 
total GAG synthesis devoted to HA is greater in the epidermis than in the dermis 
and, in senile skin, HA is still present in the dermis, whereas the HA of the 
epidermis seems to disappear with unknown reasons (Meyer and Stern, 1994; 
Stern and Maibach, 2008). An increase in the content of keratan sulphate 
beginning at age 50 and a decrease in chondroitin 6-sulphate after age 60 were 
observed in human epidermis (Willen et al., 1991). These changes may indicate 
declining skin physiologies, including epidermal proliferation, cell adhesion, 
migration and various cellular signalings (Bourguignon et al., 2006; Lundqvist et al., 
2001; Parish, 2006; Tkachenko et al., 2005). 
Epigenetics is also part of the age-affected mechanisms in epidermis. 
Proteins of the Polycomb group (PcG) are epigenetic suppressors that act by 
modifying histones to change the structure of chromatin and modulate gene 
expression and cell behavior. These proteins are found in a wide variety of cells in 
the progenitor, BL and suprabasal layers of the epidermis, where they regulate the 
keratinocyte cell-cycle progression, apoptosis, senescence, and differentiation 
(Eckert et al., 2011). PcG protein expression, such as Bmi-1, declines in aging 
epidermis, which shows that a loss of PcG protein expression is associated with 
keratinocyte senescence both in vivo and in cell culture models (Cordisco et al., 
2010; Eckert et al., 2011). The presence of the β6 integrin subunit in epidermis 
helps to explain the significant delay that occurs in the wound healing of elderly 
people (AlDahlawi et al., 2006). In addition to the decreasing numbers of structural 
molecules, inhibitory elements of epidermal renewal are up-regulated with age; one 
such element is the actin-remodeling protein Flightless I (FliI), an important 
mediator of wound repair by inhibiting cell proliferation and motility (Adams et al., 
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2008). Skin immunosenescence refers to a functional immune impairment with 
age. In the epidermis, it is associated with decreased expression of the receptor for 
activated C kinase (RACK-1), defective protein kinase C (PKC) translocation, and 
reduced tumor necrosis factor (TNF-α) (Corsini et al., 2009). Formation of 
advanced glycation end products (AGEs) is the result of a chemical reaction 
between reducing sugars and amino acids of proteins, and is related to skin aging. 
AGE accumulation has been extensively studied in dermal proteins, but the 
presence of NƐ-(Carboxymethyl) lysine was recently described in the human 
epidermis as affecting specifically K10 (Kawabata et al., 2011). 
Impact of UV light on human skin is a particular source of epidermal 
dysfunction throughout life. Yamada et al. (2006) found that the removal of 
pyrimidine dimers induced by UVB occurs more slowly in the epidermis of older 
individuals. Time for complete removal of dimers was 4 days in the 22- to 26-year-
old group, while 14 days were needed in the 70- to 78-year-old group. DNA 
damage induced by generation of free radicals can be yet another pathway 
involved in skin photoaging. In photoaged skin, a significant depletion of 
antioxidant enzyme expression, including copper-zinc superoxide dismutase and 
catalase, was observed inside the SC and in viable epidermis (Sander et al., 
2002). Transforming growth factor-beta (TGF-β) signaling in the epidermis – 
important for cell growth and collagen regulation – is also affected by UV-induced 
photoaging. Upon activation, TGF-β receptors (TβR) propagate a signal 
downstream to intracellular proteins termed Smads. Han et al. (2005) 
demonstrated that the UV-induced down-regulation of TβRII and the concerted 
over-expression of Smad7 in aged and photoaged epidermis may trigger the 
inhibition of the TGF-β-induced phosphorylation of Smad2, suggesting an active 
role of the epidermal compartment in the induction of age-related dermal collagen 
damage. S100 calcium-binding proteins are highly conserved, low-molecular-
weight, acidic proteins with important regulatory functions in calcium buffering, 
regulation of kinases and phosphatases, cell proliferation, differentiation, energy 
metabolism, cytoskeletal-membrane interactions, embryogenesis, cell migration, 
and inflammation (Donato, 2001). Lee et al. (2009b) studied changes in S100A8 
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expression in UV-irradiated and aged human skin in vivo, finding increased mRNA 
and protein in the sun-protected epidermis of elderly people in comparison with 
youth. Additionally, in the same elderly individuals, sun-exposed skin expressed 
more S100A8 than sun-protected areas, evincing the intrinsic involvement of 
S100A8 in both the aging and the photoaging processes of the epidermis. 
Another example of a molecular mechanism affected in the epidermis by 
UV-induced aging is the regulation of alternative splicing, as in the case of the 
primary transcript of elastin. Elastin transcript containing exon 26A was found 
upregulated in keratinocytes of photoaged forearm skin compared with intrinsically 
aged buttock skin in the same elderly individuals, which can affect normal elastic 
fiber formation and contribute to the development of solar elastosis (Chen et al., 
2009). Several publications point to UV-induced photoaging as an exacerbation of 
the signs of intrinsic aging. However, mainly at the molecular level, the result of 
cumulative UV exposure sometimes differs from the effect of intrinsic aging. 
Expression of extracellular matrix protein 1 (ECM1) in BL and upper epidermal cell 
layers in aged skin, for example, is significantly lower than in young skin. In 
contrast, and similarly to solar elastosis in the dermis, photoaging shows an 
increased epidermal expression of ECM1. More than impairing the regular 
dynamics of keratinocyte proliferation and/or differentiation, ECM1 has a key 
interaction with BM perlecan, and an affected ECM1 expression may impact the 
dermal-epidermal junction physiology (Sander et al., 2006). 
Terminal differentiation of keratinocytes is marked by cell death that typically 
occurs in GL to originate corneocytes in the composition of the SC. There is 
controversy as to whether the terminal differentiation of keratinocytes is a variant of 
apoptosis. Both processes share activation of endonucleases and degradation of 
DNA. However, apoptosis differs from terminal differentiation in other respects. 
When comparing sun-protected skin of two groups of people with a mean age of 70 
years and 23 years respectively, epidermal thinning with age was associated with a 
decrease in the proliferative capacity and an increase in the rate of apoptosis of 
keratinocytes below GL, along with a higher expression of Fas (CD95) and Fas 
ligand (FasL). In contrast, keratinocytes showing DNA strand breaks, which occur 
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at the GL as part of normal keratinocyte differentiation, do not appear related to 
Fas (Gilhar et al., 2004). 
Since cellular senescence and apoptosis occur together in aging tissues, it 
is important to understand their mutual relationships in aging. Wang et al. (2004) 
found increased senescence-associated β-galactosidase activity in aging 
keratinocyte cultures as well as in epidermal in vivo aging. In parallel, they 
observed increased levels of Fas and different components of the Fas-mediated 
pathway of apoptosis (such as Fas-L, FAAD adaptor and caspase-8 – all 
contributors to the death-inducing signaling complex, or “DISC”), higher levels of 
p53 (a tumor suppressor protein that can promote either apoptosis or transient 
growth arrest and cellular senescence), and lower levels of Bcl-2 (a mitochondrial 
component and crucial inhibitor of the intrinsic pathway of apoptosis) under the 
same conditions, both in vitro and in vivo. Moreover, when the Fas receptor was 
activated by antibody binding, or when the culture medium was exhausted (a 
possible cause of death signal induction), apoptotic cells appeared in larger 
numbers in senescent keratinocytes, showing that the Fas-dependent apoptotic 
machinery was indeed potentiated in keratinocytes at senescence. Considering the 
existence of distinct apoptotic pathways and of results that vary with the different 
experimental models, Wang et al. (2004) concluded that it was reasonable to 
assume that in senescent keratinocytes, the Fas-mediated pathway can be readily 
activated, while the p53-dependent pathway is kept in a stand-by state. 
In addition to the changes affecting keratinocytes with aging, there are 
modifications associated with distinct epidermal cell types, such as a reduction in 
number of melanocytes, and a decline in the amount of Langerhans cells (which 
may impair the immune protection against radiation). There are also changes in the 
structural organization of Merkel cells (Bergman et al., 2000; Ortonne, 1990; Wulf 
et al., 2004). With aging, melanocytes become unevenly distributed in epidermis, 
which affects the interaction between keratinocytes and melanocytes (Ortonne, 
1990). The number of functional melanocytes in nonexposed human skin 
decreases with age, at a rate of 8-20% each decade. However, in UV-irradiated 
skin there are approximately twice as many melanocytes as in unexposed areas, 
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but there is still a comparable decrease in melanocytes with age (Costin and 
Hearing, 2007). Secretion of melanocyte-stimulating cytokines was impaired in old 
donors (Okazaki et al., 2005). mRNA expression and activity of nicotinamide 
adenine dinucleotide (NADH) dehydrogenase decreases in late passage cultures 
of keratinocytes, suggesting reduction in enzyme production with epidermal aging 
(Nakama et al., 2012). Furthermore, inhibition of NADH dehydrogenase induces 
production of reactive oxygen species (ROS) in mammalian tissue (Paradies et al., 
2004). As positive feedback, increased levels of ROS induce the production of IL-
1α and endothelin 1 (EDN1), upregulation of tyrosinase expression, and 
acceleration of skin melanogenesis (Hughes et al., 1996; Karg et al., 1993; 
Nakama et al., 2012). Consequently, age-related decrease in NADH 
dehydrogenase might be directly involved in the regulation of keratinocyte-
melanocyte signaling, and lead to increased skin pigmentation. Mouse models also 
indicate age-dependent reduction in Langerhans cell frequency without affecting 
their survival and proliferation in epidermis, suggesting either a deficiency in bone 
marrow-derived Langerhans cell progenitors, or a less responsive profile to signals 
known to be required for the recruitment of these progenitors into skin. 
Functionally, the capacity of aged Langerhans cells to induce T cell priming is 
impaired. Moreover, expression of microRNAs (miRNAs) in aged epidermal 
Langerhans cells shows an altered profile in comparison with that of a young 
epidermis, a condition that is especially noteworthy in miRNAs related to the 
downregulation of TGF-β signaling pathway, which affects the development of 
Langerhans cells (Xu et al., 2012). TNF-α-induced migration of Langerhans cells 
appears reduced in elderly (Bhushan et al., 2002). However, another study 
concluded that phenotype and function of monocyte-derived Langerhans cells are 
not altered by aging, and that changes in the epidermal environment are likely to 
be more important (Ogden et al., 2011). Notwithstanding a few differing opinions, in 
the photoaging of human skin, the numbers of Langerhans cells are inversely 
proportional to photodamage severity: cells are reduced by up to 50% in UV-
exposed skin areas in comparison with UV-protected skin areas (Grewe, 2001). 
Regarding the effect of aging on the epidermal sensorial system, a decrease in the 
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target neurotrophin (NT) expression has been demonstrated, particularly in NT3 
and NT4, which results in a site-specific loss of sensory terminals with a reduction 
in the number of Merkel cell-neurite complexes (Bergman et al., 2000). 
 
Unstopping the plughole: biological and physicochemical properties and SC 
desquamation 
 
The third step of the bath model, desquamation (Figure 1), emphasizes SC 
structure and organization. Basically, SC is composed of two compartments: intact, 
lipid-depleted and protein-enriched corneocytes, which represent the “bricks” 
embedded in a continuous, lipid-enriched (mainly ceramides, cholesterol and free 
fatty acids) extracellular matrix that is organized into functional membrane bilayers 
representing the ‘‘mortar’’ (Michaels et al., 1975). The construction of competent 
epidermal lipid bilayers takes place according to the following sequence: lipid 
synthesis, secretion of lamellar body lipids at the GL-SC interface, and extracellular 
processing of secreted polar lipid precursors into a hydrophobic mixture that forms 
functionally competent lamellar membranes (Choi et al., 2007). In fact, corneocytes 
in the SC are dead cells, but this does not make it an inert layer. On the contrary: 
SC is metabolically active and interactive with the underlying nucleated cell layers 
of the epidermis (Elias and Ghadially, 2002). Changes that the SC suffers with 
aging have a great impact on the epidermal permeability barrier, damaging the 
basic composition of the “brick and mortar” model (Figure 5). 
Xerosis is an uncomfortable manifestation of aged skin, which may result 
from a decrease in lipid synthesis (Akimoto et al., 1993). Schmuth et al. (2005) 
showed differences in production of fatty acid transport proteins between 
embryonic and adult epidermal tissues, indicating that a dynamic regulation of 
these constituents is active throughout the development stages of an individual. 
Ghadially et al. (1995) found a reduction in the delivery of secreted lipids to the SC, 
resulting in less extracellular lamellar bilayers. There is an overall reduction in aged 
SC lipids that totals about one third less lipid weight percentage than in young SC, 
suggesting that aged epidermis possibly has a more porous extracellular matrix 
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than the young one (Elias and Ghadially, 2002). In addition, several molecular 
pathways involved in SC lipid metabolism are down-regulated at the level of gene 
expression in the aging skin and probably contribute to the decreased capacity of 
aged skin to maintain and repair the epidermal barrier (Jarrold et al., 2009). 
Decreased levels of IL-1α with chronologic aging must be associated with a 
decreased production of epidermal lipids (Ye et al., 1999). According to Ghadially 
et al. (1996), cholesterol seems the most age-affected class of lipids in the SC, 
which shows a reduced deposition of cholesterol molecules and a decreased 
activity of its rate-limiting enzyme, 3-hydroxy-3-methylglutaryl-coenzyme A 
reductase. Several studies show that different classes of SC lipids are differently 
affected by aging. 
 
Figure 5. Stratum corneum (SC) organization. (1) “Brick and mortar model” proposed by Michaels 
et al. (1975) highlights the main components of SC structure: the “bricks” are lipid-depleted and 
protein-enriched dead corneocytes embedded in the “mortar”, which is composed of a continuous, 
lipid-enriched (mostly by ceramides, cholesterol and free fatty acids) extracellular matrix organized 
into functional membrane bilayers. Extracellular pH is neutral up to the transition between granular 
layer (GL) and SC. Then it turns more acidic and reaches approximately 4.5 up to the skin surface, 
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where there is a hydrolipidic or acid mantle composed of a mixture of sebum, sweat, corneocyte 
debris and constituents of natural moisturizing factors. (2) Corneodesmosomes – structures derived 
from desmosomes – are responsible for securing the cohesion of intercorneocytes, and are present 
at the cell edges on the skin surface. Corneodesmosomes are incorporated into the cell membrane 
or cornified envelope and are composed of several cytoplasmic (plakoglobins, desmoplakins and 
plakophilins), transmembrane (desmogleins and desmocollins) and extracellular proteins 
(corneodesmosin). Corneodesmosin bonds to desmosomes to form corneodesmosomes. During 
corneocyte maturation, corneodesmosomes are progressively degraded by several serine, cysteine 
and aspartic enzymes, including kallikrein-related peptidases and cathepsins. This facilitates the 
desquamation process which is characterized by the release of corneocytes from the skin surface 
by friction forces. 
 
Epidermal ceramides are obtained by hydrolysis of sphingomyelin or else by 
means of a synthesis from sphingosin and fatty acids, and are degraded by 
ceramidase. Sphingomyelinase activity declines with age: 80-year-old individuals 
have 25% of the activity found in 20-year-olds (Yamamura and Tezuka, 1990). 
Denda et al. (1993) demonstrated age- and sex-dependent change in SC 
sphingolipids, by evaluating ceramides 1-6. No differences were found in men, 
while women showed significant modifications: from prepubertal age to adulthood, 
ceramides 1 and 2 increased while ceramides 3 and 6 decreased; after reaching 
maturity, ceramide 2 decreased and ceramide 3 increased with age. These results 
suggest a significant influence of female hormones on SC sphingolipid 
composition. De Paepe et al. (2004) found sex-related differences at the level of 
total ceramide concentration: there were higher ceramide concentrations in men as 
compared with age-matched females. Effect of aging was significant only for a 
decrease in cholesterol sulfate and cholesterol concentrations in the abdominal 
skin. However, evaluations of the total amounts of lipids showed no changes due 
to sex or aging, which calls into question the high intervariability of the studies of 
lipids in the human SC, because of the different origins of the skin samples and 
variety of extraction methods currently in use. Jensen et al. (2005) used a mice 
model to identify the age-related reduction in acid sphingomyelinase (A-SMase) 
and ceramide synthase activities, but the changes were observed only in the inner 
layers of epidermis, not the SC. 
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Regarding SC free fatty acid composition, Kim et al. (2010a; 2010b) studied 
the effect of aging in photoprotected and photoexposed areas of the skin. Levels of 
palmitic acid, stearic acid, linoleic acid and 11,14,17-eicosatrienoic acid (ETA) 
decreased in aged skin by 15%, 31%, 7%, and 56%, respectively, in comparison 
with levels of the same acids in young skin. In contrast, palmitoleic acid and oleic 
acid levels increased in aged skin by 67% and 22%, respectively. Levels of palmitic 
acid and stearic acid in photoaged forearm epidermis decreased by 11% and 23%, 
respectively, compared with levels of these acids in the buttock skin of the same 
elderly individuals. Conversely, amounts of linoleic acid and ETA in photoaged 
forearm epidermis increased by 19% and 69%, respectively. The authors 
emphasized the results for ETA, an omega-3 polyunsaturated acid, which 
increased significantly in photoaged human epidermis in vivo, but decreased 
significantly in intrinsically aged epidermis. They also demonstrated that ETA 
inhibited MMP-1 expression after UV-irradiation, which may suggest the existence 
of a photoprotective effect for human skin. In general, Kim et al. (2010a; 2010b) 
concluded that the amounts of free fatty acids and triglycerides decreased 
significantly in the epidermis of photoaged human SC. Moreover, the expression of 
genes related to lipid synthesis, including acetyl-CoA carboxylase (ACC), fatty acid 
synthase (FAS), stearoyl-CoA desaturase (SCD), sterol regulatory element binding 
proteins (SREBPs), and peroxisome proliferation-activated receptors (PPARγ) 
decreased markedly with photoaging. 
Although several studies focus on differences in the composition of lipids 
and on the regulatory mechanisms related to lipid synthesis, secretion and 
processing of lipids are crucial steps in construction of an efficient epidermal 
barrier. Secretion is regulated by changes in extracellular calcium and potassium 
concentrations (Mauro et al., 1998a and b; Menon et al., 1985). Association of 
calcium with lamellar body disc membranes and contents suggests that it may 
contribute to lamellar body secretion as well as to the formation of intercorneocyte 
membrane bilayers (Menon et al., 1985). In addition, selective obliteration of the 
epidermal calcium gradient by means of sonophoresis enhanced lamellar body 
secretion (Menon et al., 1994). As previously mentioned, aging hinders the 
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formation of calcium gradients in epidermis (Denda et al. 2003). It can therefore be 
said that age-induced changes in the distribution of calcium in the epidermis may 
have an impact on the SC formation in elderly individuals. While lipid secretion is 
strongly influenced by ions, lipid processing is controlled by the pH of the 
extracellular spaces and requires two acidity-dependent lipid hydrolases: β-
glucocerebrosidase (BCG) and A-SMase (Hachem et al., 2005). SC normally has a 
low pH value, which favors the enzymatic activity necessary for its formation. 
However, changes in pH values may cause modifications in the enzymatic 
dynamics of the SC; again, aging is a relevant factor in the control of the pH on the 
skin surface. Choi et al. (2007) demonstrated that SC acidification is already 
weakened in moderately aged human and murine skin, showing that pH value rises 
progressively in aged humans beginning at about age 50. Prolonged SC 
neutralization causes profound abnormalities in SC function, due to the activity of 
pH-induced high serine proteases, which, in turn, degrade lipid processing 
enzymes, such as BCG and aSM’ase (Hachem et al., 2005). Investigating the 
molecular regulation of pH changes in the SC, Choi et al. (2007) found a 
diminished Na+/H+ antiporter (NHE1) expression that lead to increased pH values 
in the SC and, consequently, to defective processing of lipids and delayed 
maturation of lamellar membranes. 
Nevertheless, divergences should be noted in results regarding continuous 
pH increase with aging. Luebberding et al. (2013) evaluated 150 women aged 18 
to 80 years and found decreased surface pH associated with a continuous decline 
in sebum production with age. Interestingly, pH decrease was not observed in 
moderately aged, 50-60 year-old women, who showed slightly increased pH 
values. In a large Chinese panel consisting of 713 subjects, skin surface forehead 
pH of males and females over the age of 70 was higher than in younger groups 
(Man et al., 2009). These differences could, of course, be attributed to different 
experimental designs and applied techniques, but they are in agreement with the 
finding of impaired acidification in moderately aged epidermis. According to Choi et 
al. (2007), advanced aging is likely to reveal a combination of abnormalities in the 
synthesis and processing of lipids; however, at least in moderately aged epidermis, 
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barrier dysfunction due to an impaired acidification of the SC leads, not to an 
abnormal synthesis, but to a diminished processing of lipids. 
Antimicrobial protection depends on the maintenance of an acid pH in the 
SC to create an ecological milieu that is simultaneously hostile to microbial 
pathogens and favorable to the growth of the normal flora. Rodriguez-Martin et al. 
(2011) evaluated antimicrobial peptides in a mouse model for aging and found 
reduced levels of cathelicidin antimicrobial peptide (CAMP) and increased levels of 
β-defensin 3 (BD3) and of the neuroendocrine peptide catestatin (Cst). Whether 
further abnormalities in antimicrobial defense mechanisms occur in moderately 
aged and/or more-advanced aged and/or photoaged epidermis is not known. 
However, taken together, these findings suggest that antimicrobial protective 
function of SC might become impaired relatively early in older people. Mixture of 
sebum and small amounts of lipids, produced by keratinizing epidermal cells 
(mainly corneocytes), forms the skin surface lipids (SSL) that mantle human 
epidermis, and thus constitutes a protection of the body against exogenous 
oxidative insults (Passi et al., 2002). Total SSL vary according to sex and age: they 
are higher in males than in females, peak at maturity and diminish with age 
because of a reduction in the activity of sebaceous glands (Cotterill et al., 1972). 
Different fatty acids of triglycerides seem to follow the activity of the sebaceous 
glands: they are higher at maturity than in childhood and advancing age; while 
squalene, vitamin E and Coenzyme Q10 increase from childhood to maturity to 
decrease again significantly in old age (Passi et al., 2002). These results suggest 
important changes at the top of SC with aging, which may be indicators of lowered 
protection against exogenous oxidative insults, particularly from harmful UV rays. 
Mixture of SSL, from sebum and corneocyte debris, with water, and from sweat 
and substances derived from protein degradation such as NMFs, compose the 
hydrolipidic or acid mantle (Shetage et al., 2013). 
Regarding protein component of SC as part of its “bricks”, Takahashi and 
Tezuka (2004) observed reduction in protein level of filaggrin in older epidermis, 
while the mRNA level was not affected by age, and formation of natural 
moisturizing factors (NMF) derived from enzymatic degradation of filaggrin 
194 
 
increased in elderly individuals. Consequently, the reduction in the protein level of 
filaggrin might be caused not only by changes affecting gene expression, but also 
by intensified proteolytic activity, which may degrade epidermal filaggrin before it 
can form large molecules (Takahashi and Tezuka, 2004). It is also essential to look 
at the organization of corneodesmosomes – the modified desmosomes that are 
present in corneocytes to keep them attached to each other. Corneodesmossomes 
are major determinants of SC cohesiveness; they are lodged in the edges of the 
cells on the surface of the skin, incorporated in the cell membrane or cornified 
envelope, and composed of several cytoplasmic (plakoglobins, desmoplakins and 
plakophilins), transmembrane (desmogleins and desmocollins) and extracellular 
proteins (corneodesmosins) (Chapman et al., 1991; Ishida-Yamamoto et al., 2011; 
Rawlings, 2003). During corneocyte maturation, corneodesmosin is progressively 
proteolyzed (Ishida-Yamamoto et al., 2011). Both exogenous and endogenous 
proteases are involved in the cleavage of the corneodesmosome junctions. Among 
endogenous proteases, there are several serine, cysteine and aspartic enzymes, 
including kallikrein-related peptidases (KLK) and cathepsins, both produced by 
keratinocytes (Ishida-Yamamoto et al., 2011; Rawlings, 2003). The pH-induced 
high serine protease activity caused by impaired acidification of the SC with aging 
also degrades corneodesmosome proteins, such as desmoglein 1 (Hachem et al., 
2005). This complements the finding that corneocyte detachment becomes more 
prevalent with age, and helps to explain the prevalence of xerosis and pruritus in 
the elderly (Chu and Kollias, 2011; White-Chu and Reddy, 2011). 
Usually, changes that are seen in chronologically aged skin are further 
aggravated (by about 20%) in human skin areas with superimposed photoaging 
(Elias and Ghadially, 2002; Reenstra et al., 1996). Shekar et al. (2005) applied 
microtopography to show that deterioration of fine reticular patterning of the SC, 
also referred to as skin pattern on the Beagley-Gibson scale, occurs over time. In 
an elegant study, they estimated the extent to which changes are due to genetic or 
environmental influences by analyzing nuclear twin families. Variation in skin 
pattern was due to genetic influences in the proportion of 86% at age 12, 75% at 
age 14, 72% at age 16, and 62% in an adult sample aged between 32 and 86 
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years. While the genetic influence decreased with aging, environmental factors 
appeared to have a growing and cumulative impact throughout the lifetime. 
Analyses of the adult group showed that extrinsic components were related to a 
more extensive deterioration in the skin pattern but, surprisingly, caused very little 
variation in the adult skin pattern (less than 2%), which was explained by the 
inability to tan and prolonged outdoor work. The results corroborated previous 
data, and also concluded that the variation in stratum corneum patterning was 
indicative of intrinsic skin aging rather than photoaging (Seddon et al., 1992). 
Subsequently, Shekar et al. (2006) conducted the first genome-wide linkage scan 
study of epidermal reticular patterning with adolescent twins and siblings, and 
found a suggestive linkage at chromosomal markers such as 12p13.31 and 4q23. 
Identified regions in chromosomes probably correspond to genetic factors 
associated with the structure or regulation of the epidermis, like MMP and protease 
inhibitor α-2-macroglobulin, as well as the subunit 1 of NF-κB involved in regulating 
keratinocyte differentiation and proliferation. 
 
Concluding remarks and future perspectives 
 
Increasing number of studies related to the epidermis is a clear indication of 
its importance as a dynamic structure in the control of skin and organism 
homeostasis. Recent cell biology studies provide consistent evidence to propose a 
working model for renewal of the epidermis, based mainly on the emerging 
researches on epidermal proliferative cells, which allow discussing the new 
significant findings about epidermal development and aging. An innovative in silico 
study was developed to model long-term colony dynamics in the epidermis, as a 
complement to experimental studies (Li et al., 2013). Different models were 
challenged using the in silico approach, and hypothesis of populational asymmetry 
with stem cells (Mascré et al., 2012) provided the best mechanism for sustained 
tissue regeneration and homeostasis. 
Cell signaling studies also indicate great opportunities to discover the major 
pathways related to the physiology and aging of the epidermis. This has been 
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significantly accelerated with the application of new “omics” techniques based on 
global analyses and associated with the birth of bioinformatics technologies. The 
term “skinomics”, for example, was applied to define the transcriptional profiling in 
dermatology and skin biology (Blumenberg, 2012). A number of studies have been 
conducted to understand global mRNA or protein expression of human epidermis, 
which harbors a wealth of information about the genes involved in skin function and 
genetic skin disorders (Jansen and Schalkwijk, 2003). An extensive study using 
DNA microarrays quantified and described considerable differences in the 
transcriptional profiling of epidermal keratinocytes, by comparing the gene 
expression in skin, cultured keratinocytes, and reconstituted epidermis (Gazel et 
al., 2003). An Investigation of the transcriptome of accelerated and replicatively 
senescent keratinocytes revealed links to differentiation, interferon signaling, and 
Notch related pathways (Perera et al., 2006). Despite their important contributions 
to the understanding of epidermal physiology, the above-cited works were not 
directly intended to explain the effects of aging on epidermis. Several conclusions 
on epidermal aging could of course be drawn from analyses of senescent 
keratinocytes, but important considerations must be taken into account when 
comparing cell biology mechanisms of in vitro senescence with those of in vivo 
aging (Hwang et al., 2009). Other studies used in vivo human biopsy samples for 
global molecular analyses of skin aging; these studies, however, fail to supply 
specific information about how epidermis ages, since skin biopsies also contain 
(confounding) dermal material (Laimer et al., 2010; Lener et al., 2006). Gromov et 
al. (2003) conducted the only work that targeted analysis of in vivo epidermal aging 
by adopting an “omics” approach. By isolating an enriched epidermis portion of 
skin biopsies from young and old individuals, they analyzed protein profiling of the 
human epidermis from elderly persons and substantiated the argument that aging 
is associated with increased severe oxidative stress and alterations in the signaling 
of apoptosis. Therefore, platforms based on global analyses at different molecular 
levels represents a promising alternative to define new pathways inscribed in the 
aging of the epidermis. In addition, mechanisms other than the regulation of 
epidermal process, such as differentiation and cornification, have begun to be 
197 
 
understood and interconnected with functional and/or clinical signs in the elderly. 
Specifically for this purpose, study of premature aging and associated 
comorbidities, such as the Hutchinson-Gilford progeria syndrome and the Werner 
syndrome, offers an alternative for understanding key molecular components in the 
aging process (Capell et al., 2009; Coppedè, 2013; Navarro et al., 2006). 
Effects of physical, chemical and biological agents on the aging of the 
epidermis might provide a powerful way to find new therapeutic opportunities that 
are more effective and directed to specific pathways or molecular targets. 
Epidermal keratinocytes are complex cells that create a unique three-dimensional 
structure, which differentiates through a multistage process and responds to 
environmental and extracellular stimuli from nearby cells (Gazel et al., 2003). In 
addition, epidermal keratinocytes have been the target of many studies because 
they respond to a rich variety of inflammatory and immunomodulating cytokines, 
hormones, vitamins, ultraviolet (UV) light, toxins, and physical injury (Blumenberg, 
2006). Modulation of gene expression, and possibly of many other molecular 
levels, is a reality that can be applied to fight aging effects on skin tissue 
(Talbourdet et al. 2007). Expression of molecules related to the ability of skin to 
sense the external environment was identified out of neuronal cells, such as TRV 
channels in the cell membrane of keratinocytes, suggesting new routes to sensitive 
properties of epidermis (Denda et al., 2001b). Moreover, a thorough understanding 
of molecular skin aging may, in a not-too-distant future, permit the efficient 
application of pharmacogenomics using individualized drug therapies based on 
genomic biomarker identification, which would avoid potential side effects while 
maximizing therapeutic response (Greenfield and Maibach, 2012; Rizzo and 
Maibach, 2012). In this sense, increasing knowledge about epidermal aging, which 
has a direct influence on response to topic treatments, should result in 
considerable gains in the field of personalized medicine and drug delivery 
optimization.  
Dynamics of aged skin barrier shows particularities to such an extent that 
drug pharmacokinetics and pharmacodynamics may be altered in the elderly 
(Flammiger and Maibach, 2006). Maibach’s group has extensively studied 
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percutaneous drug absorption, including changes promoted by an altered barrier 
function in aged epidermis (Harvell and Maibach, 1994; Konda et al., 2012a and 
2012b; Roskos et al., 1986, 1989 and 1990). It is a common misconception, for 
example, that older skin has a diminished barrier capacity, and that percutaneous 
absorption is therefore greater (Oriba et al., 1996). A better understanding of the 
changes affecting epidermal barrier with age is fundamental for the development of 
more efficient treatments and reduction of dermatotoxicological effects in elderly 
individuals (Ngo and Maibach, 2010). 
Challenges that face elucidation of complex epidermal interactions and even 
the understanding of functional signaling in the epidermis with aging are far from 
complete. Several possibilities emerge for future perspectives, including 
development of functional assays to identify key protein players in epidermal stem 
cell proliferation and differentiation; of cell sorting and gene expression studies to 
shed light on age-related changes in homeostasis for each epidermal cell type; and 
perhaps of an investigation of functional interplay between different cells in 
epidermis. Epidermal bath model should be continuously revisited and refilled with 
recent scientific data, not only as a framework for understanding mechanisms 
involved in skin aging, but also as a helpful tool for the development of improved 
therapies to improve, reinforce and/or restore the function of healthy skin. 
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7.3. Aprovação do Comitê de Ética em Pesquisa 
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7.4. Produtividade técnico-científica do aluno ao longo do curso de 
Doutorado 
 
Patentes 
 
1) Título: Process for preparing a plant extract of Passiflora alata and use of said extract in 
cosmetic and pharmaceutical compositions 
Inventores: Ana Paula Pedroso de Oliveira, Cintia Rosa Ferrari, Elaine Cristina de Oliveira, Gilson 
Paulo Manfio, Jean-Luc Gesztesi, João Batista Calixto, Márcio Lorencini, Patricia da Luz Moreira, 
Rodrigo Collina Romanhole, Sandra Patricia Hurtado Medina, Sergio Delarcina Junior, Simone 
Soares Esteves, Thiago Braz 
Código: FR07/06151 / Abrangência: França / Data depósito: 03/09/2007 / Publicação: não 
publicada 
Código: WO/2009/030008 / Abrangência: Mundial / Data depósito: 03/09/2008 / Publicação: 
12/03/2009 
Código: EP2185166 / Abrangência: Europa / Data depósito: 03/09/2008 / Publicação: 
19/05/2010 
Código: CA2696566 / Abrangência: Canadá / Data depósito: 15/02/2010 / Publicação: não 
publicada 
Depositante: Natura Cosméticos S.A., Universidade Federal de Santa Catarina 
Resumo: The present invention relates to the use of plant extracts of Passiflora alata as an anti-
inflammatory agent in cosmetic and pharmaceutical compositions. The present invention further 
relates to a process for obtaining a plant extract of Passiflora alata comprising the steps of 
submitting the leaves of the Passiflora alata plants to an extraction with water to obtain an aqueous 
extract and submitting the aqueous extract thus obtained to at least one elution with an aqueous 
solution of ethanol in a specific column and later drying of said extract by spray-drying. 
 
2) Título: Cosmetic composition comprising siliconed sapucainha ester and a cosmetic 
product comprising said composition 
Inventores: Daisy de Fátima Scarparo de Sanctis, Débora Figueiredo Beda, Érica Dadario 
Brugnollo, Leandra Moraes Santos, Márcio Lorencini, Vanessa de Moura Sá Rocha 
Código: US20110097290 / Abrangência: Estados Unidos / Data depósito: 27/10/2009 / 
Publicação: 28/04/2011 
Código: EP2493448 / Abrangência: Europa / Data depósito: 27/08/2010 / Publicação: 
05/09/2012 
Código: WO/2011/050433 / Abrangência: Mundial / Data depósito: 27/10/2010 / Publicação: 
05/05/2011 
Código: US20120328547 / Abrangência: Estados Unidos / Data depósito: 26/03/2012 / 
Publicação: 27/12/2012 
Código: CA2779151 / Abrangência: Canadá / Data depósito: 27/04/2012 / Publicação: não 
publicada 
Depositante: Natura Cosméticos S.A. 
Resumo: The present invention relates to a cosmetic composition comprising siliconed sapucainha 
ester, compound which can be used as a cosmetic excipient replacing silicones for several 
applications. The present invention further relates to cosmetic products comprising said 
composition. 
 
3) Título: Process for obtaining a standardised extract of quercetin and 3-0-methylquercetin 
from flowers of macela (Achyrocline satureioides), and cosmetic and pharmaceutical compositions 
comprising said extract 
Inventores: Alan Passero, Débora Figueiredo Beda, Márcio Lorencini, Sergio Delarcina Junior, 
Tiago Costa Beber, Vanessa de Moura Sá Rocha 
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Código: FR09/59012 / Abrangência: França / Data depósito: 15/12/2009 / Publicação: não 
publicada 
Código: WO/2011/073961 / Abrangência: Mundial / Data depósito: 06/01/2011 / Publicação: 
23/06/2011 
Código: EP2512495 / Abrangência: Europa / Data depósito: 06/01/2011 / Publicação: 
24/10/2012 
Código: US20130012577 / Abrangência: Estados Unidos / Data depósito: 06/01/2011 / 
Publicação: 10/01/2013 
Depositante: Natura Cosméticos S.A. 
Resumo: It describes an extraction process for obtaining a standardized extract of quercetin and 3-
0-methylquercetin from inflorescences of macela-do-campo (Achyrocline satureioides) 
characterized by comprising of the following steps: A) grinding the inflorescences of Achyrocline 
satureioides to obtain a material of ground plant; B) submitting the ground plant to at least four 
sequential stages of hydro-alcoholic extraction at a temperature from 60°C to 80°C1 for 3 to 4 hours 
for each stage, in order to obtain 4 intermediary hydro-alcoholic extracts; C) combining the 4 
intermediary hydro-alcoholic extracts; D) concentrating the intermediary hydro-alcoholic extracts 
mixture; in order to obtain up to a maximum of 20% of the initial mass of the intermediary hydro-
alcoholic extracts; E) drying the material obtained in (D). It also describes cosmetic, pharmaceutical 
and veterinary compositions containing the aforesaid extract of macela-do-campo, destined for the 
prevention and treatment of the damages arising from inflammatory, microbial and 
oxidation/lypoperoxidation reactions. The use and method of application of the aforesaid extract of 
macela are also described. 
 
4) Título: Composição antienvelhecimento e formulação cosmética e/ou dermatológica 
contendo a mesma 
Inventores: Carlos Eduardo de Oliveira Praes, Marcela Contador Baptista, Márcio Lorencini, 
Ruandro Victor Knapik 
Código: PI 1005274-7 A2 / Abrangência: Brasil / Data depósito: 15/12/2010 / Publicação: 
publicada em 09/04/2013 
Depositante: Botica Comercial Farmacêutica Ltda. 
Resumo: Descreve-se a presente invenção como uma composição antienvelhecimento e 
formulação cosmética e/ou dermatológica contendo a mesma que, de acordo com as suas 
características gerais, propicia uma composição antienvelhecimento a partir de uma combinação 
de otimizada de ingredientes contendo sais minerais, com vistas a propiciar por meio da 
combinação otimizada destes ingredientes um aumento da produção de colágeno e, por 
conseguinte, a firmeza da pele, de modo a promover a minimização de rugas e linhas da pele e 
uma melhora efetiva do aspecto geral da pele, ambos obtidos diretamente pela ação balanceada 
destes ingredientes ricos em sais minerais. 
 
5) Título: Composição farmacêutica para aplicação na pele 
Inventores: Alessandro Afornali, Camila Miranda de Carvalho, Carlos Eduardo de Oliveira Praes, 
Fernanda Lourenço Angelucci, Márcio Lorencini, Priscila Fernanda Campos de Menezes, Ruandro 
Victor Knapik 
Código: PI 1010479-8 / Abrangência: Brasil / Data depósito: 27/12/2010 / Publicação: 
notificação de depósito de pedido de patente em 15/05/2012 
Depositante: Botica Comercial Farmacêutica Ltda. 
Resumo: Conteúdo ainda não publicado pelo INPI. 
 
6) Título: Composição cosmética e/ou dermatológica e formulação cosmética e/ou 
dermatológica contendo a referida composição 
Inventores: Alessandro Afornali, Camila Miranda de Carvalho, Carlos Eduardo de Oliveira Praes, 
Márcio Lorencini, Priscila Fernanda Campos de Menezes 
Código: PI 1005496-0 A2 / Abrangência: Brasil / Data depósito: 29/12/2010 / Publicação: 
publicada em 16/04/2013 
Depositante: Botica Comercial Farmacêutica Ltda. 
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Resumo: A presente invenção refere-se a uma composição antienvelhecimento e formulação 
cosmética e/ou dermatológica contendo a referida composição. Esta mistura otimizada de 
ingredientes ativos é capaz de atuar positivamente sobre processos biológicos relacionados ao 
envelhecimento da pele, conferindo proteção e minimização dos sinais do relevo cutâneo. Este 
conjunto de características é obtido pela combinação de dois peptídeos e um polissacarídeo. 
 
7) Título: Ingrediente cosmético e/ou dermatológico e formulação cosmética e/ou 
dermatológica contendo o mesmo 
Inventores: Alessandro Afornali, Alexandre Roberto Silva, Bruna Bastos Swinka, Camila Miranda 
de Carvalho, Carlos Eduardo de Oliveira Praes, Luiza Fernanda Schier, Márcio Lorencini, Priscila 
Fernanda Campos de Menezes 
Código: PI 1102721-5 A2 / Abrangência: Brasil / Data depósito: 10/06/2011 / Publicação: 
publicada em 16/07/2013 
Depositante: Botica Comercial Farmacêutica Ltda. 
Resumo: A presente invenção refere-se a um ingrediente e formulação cosmética e/ou 
dermatológica que apresenta ações de preservação da longevidade de células dérmicas 
(fibroblastos) e células-tronco adultas, de aumento do metabolismo celular, sustentação e adesão 
das células da pele e melhoria da função barreira, garantindo assim uma atividade 
antienvelhecimento diferenciada, com minimização dos sinais de envelhecimento da pele. Este 
conjunto de benefícios é proporcionado por uma fração obtida a partir de Malus sp. 
 
8) Título: Composição nutritiva e formulação cosmética e/ou dermatológica contendo a 
mesma 
Inventores: Alessandro Afornali, Alexandre Roberto Silva, Camila Miranda de Carvalho, Carlos 
Eduardo de Oliveira Praes, Márcio Lorencini, Priscila Fernanda Campos de Menezes, Ruandro 
Victor Knapik, Vanessa Vitoriano da Silva  
Código: PI 1104880-8 / Data depósito: 27/10/2011 / Abrangência: Brasil / Publicação: 
notificação de depósito de pedido de patente em 14/08/2012 
Depositante: Botica Comercial Farmacêutica Ltda. 
Resumo: Conteúdo ainda não publicado pelo INPI. 
 
9) Título: Ingrediente protetor da barreira cutânea e formulação cosmética e/ou dermatológica 
contendo o mesmo 
Inventores: Alessandro Afornali, Bruna Bastos Swinka, Carla Abdo Brohem, Gustavo de Campos 
Diaemant, Israel Henrique Stokfisz Feferman, Marcela Contador Baptista, Márcio Lorencini, Tammy 
Proença Zagonel Nichele 
Código: BR 10 2012 032898 4 / Data depósito: 21/12/2012 / Abrangência: Brasil / Publicação: 
notificação de depósito de pedido de patente em 11/06/2013 
Depositante: Botica Comercial Farmacêutica Ltda. 
Resumo: Conteúdo ainda não publicado pelo INPI. 
 
Artigos Científicos 
 
1) Silva JA, Lorencini M, Reis JR, Carvalho HF, Cagnon VH, Stach-Machado DR. The 
influence of type I diabetes mellitus in periodontal disease induced changes of the gingival 
epithelium and connective tissue. Tissue Cell. 2008 Aug;40(4):283-92. 
 
2) Lorencini M, Silva JA, Almeida CA, Bruni-Cardoso A, Carvalho HF, Stach-Machado DR. A 
new paradigm in the periodontal disease progression: gingival connective tissue remodeling 
with simultaneous collagen degradation and fibers thickening. Tissue Cell. 2009 Feb;41(1):43-
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3) Lorencini M, Silva JA, de la Hoz CL, Carvalho HF, Stach-Machado DR. Changes in MMPs 
and inflammatory cells in experimental gingivitis. Histol Histopathol. 2009 Feb;24(2):157-66. 
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4) Peroni LA, Lorencini M, dos Reis JR, Machado MA, Stach-Machado DR. Differential 
diagnosis of Brazilian strains of Citrus tristeza virus by epitope mapping of coat protein 
using monoclonal antibodies. Virus Res. 2009 Oct;145(1):18-25. 
 
5) Roesler R, Lorencini M, Pastore GM. Brazilian cerrado antioxidant sources: cytotoxicity 
and phototoxicity in vitro. Ciênc Tecnol Aliment. 2010 Jul-Sep;30(3):814-821. 
 
6) Carvalho CM, Menezes PF, Letenski GC, Praes CE, Feferman IH, Lorencini M. In vitro 
induction of apoptosis, necrosis and genotoxicity by cosmetic preservatives: application of 
flow cytometry as a complementary analysis by NRU. Int J Cosmet Sci. 2012 Apr;34(2):176-82. 
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IHS, Fabrício L, Lorencini M. Triple nanoemulsion potentiates the effects of topical treatments 
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